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Recently a new Flavivirus, GB Virus C also referred to as Hepatitis G virus (GBV-
CIHGV) was identified in humans with indeterminate hepatitis . Whilst in non-African
countries this discovery led to an enormous enthusiasm to elucidate an association with
liver disease, very little was known about the prevalence and pathogenicity of GBV-
CIHGV infection in KwaZulu Natal, South Africa, where Hepatitis B Virus (HBV)
infection is endemic and infection with the Human immunodeficiency virus (IDV) is a
catastropic health problem.
Sera from patients with liver disease (chronic liver disease [n = 98]; alcoholic liver disease
[n = 50]); high risk groups (haemodialysis patients [n = 70]; mv positive mothers and
their babies [n = 75]) and control groups (alcoholics without liver disease [n = 35] and
blood donors from the four racial groups [n = 232]) were screened for OBV-CIHGV RNA
and Anti-E2 antibodies by reverse transcription polymerase chain reaction (RT-PCR) and
an enzyme linked immunosorbent assay (ELISA) , respectively. Overall 43.9% (43/98) of
patients with chronic liver disease; 60 % (30/50) of patients with alcoholic liver disease;
47.1% (33/70) of haemodialysis patients; 60% (21/35) of alcoholics without liver disease
and 31.9% (74/232) of blood donors (Africans] 44/76; 5.9%); Asians (5/52; 9.6%); Whites
(15/49; 30.6%) and "Coloureds"[mixed origin] (9/54; 16.6%)]) were exposed to GBV-
CIHGV infection as determined by the detection of Anti-E2 &/or RNA ·in serum. There
was a significant difference in the prevalence of GBV-CIHGV infection (RNA &/or anti-
E2) between African blood donors and the other racial groups (p < 0.001), between blood
donors and haemodialysis patients (p =0.02) and or patients with chronic liver disease (p =
xxx
0.04). There was no significant difference in the prevalence of GBV-CIHGV between
Afiican blood donors (45/76,59.2%) and alcoholics with and without liver disease (30/50,
60% and 21135, 60%, respectively). Anti-E2 antibodies and GBV-CIHGV RNA were
almost mutually exclusive. GBV-CIHGV infected dialysis patients tended to have had
more transfusions (p = 0.03) and had a longer duration of dialysis than non infected
patients, indicating that the majority of patients on maintenance haemodialysis acquire
their GBV-CIHGV infection through the transfusions they receive. There was no evidence
for in utero and/or intrapartum transmission of GBV-CIHGY. However, there is some
mother-to-infant transmission of GBV-CIHGV, though it is very probable that in KZN
GBV-CIHGV is transmitted by as yet undefined non-parenteral routes.
Sequence and phylogenetic analysis of the 5' non-coding region (5' NCR) and E2 gene
segments of the GBV-CIHGV genome identified an additional "genotype" (Group 5) of
GBV-CIHGV that is distinct from all other known GBV-CIHGV sequences (Groups 1-4).
Although there is a high prevalence of Group 5 GBV-CIHGV isolates in KZN, there was
no significant difference in liver biochemistry between GBV-CIHGV infected and non-
infected patients with liver disease or between blood donors in each of the four racial
groups. There was no significant differences in CD4 (461.12 ± 163.28 vs 478.42 ± 181.22)
and CD8 (680.83 ± 320.36 vs 862.52 ± 354.48) absolute cell counts between IllV positive
patients eo-infected with GBV-CIHGV and those not infected with GBV-CIHGV
. ,
respectively. However, significantly higher relative CD3 [80.0 ± 4.17% vs 70.99 ±
19.79%] (p = 0.015), gamma delta T cells (YOT) [3.22± 1.30% vs 2.15 ± 29.12%] (p =
xxxi
0.052) and lower CD 30 [35.45 ± 17.86% vs 50.59 ± 9.20%] (p = 0.041) status were
observed in GBV-CIHGV positive compared to GBV-CIHGV negative mv infected
patients, respectively.
Although there is a high prevalence of novel Group isolates of GBV-CIHGV in KZN, the
lack of elevated liver enzymes and clinical hepatitis in blood donors and haemodialysis
patients suggests that GBV-CIHGV is not associated with liver disease. HBV and not
GBV-CIHGV modifies the course of alcoholic liver disease. The relatively higher number
of CD3 cells and increased roT expression, together with a decrease in CD 30 cells tends
to suggest an association with protection and·or delayed progression of HfV disease in
GBV-CIHGV infected patients. Whilst GBV-CIHGV is not associated with liver disease, it





The first reference to hepatitis was ascribed to Hippocrates. The earliest reference to
hepatitis in Western Europe was in a letter written in 751 AD by Pope Zacharias to St
Boniface, Archbishop ofMainz. Although hepatitis was known as an infectious disease, the
current knowledge of human hepatitis began with observational studies of epidemics during
World Wars I and IT and the demonstration later by transmission studies with bacteria free
filtrates that the disease was cuased by a virus (Zuckerman, 1977). The lack of animal
models of infection and in vitro systems for propagating hepatic viruses hindered much of
the early work on the causative agents of viral hepatitis in humans. The first successful
transmission of viral hepatitis from humans to non-human primates was achieved by
Deinhardt et al (1967), when serum from a 34 year-old surgeon (whose initials were GB)
with acute hepatitis was inoculated into tamarins (Saguinus spp). Animals inoculated with
GB serum developed hepatitis, as did animals inoculated with sera of tamarins with GB
serum-induced hepatitis. In the 1970s two types of hepatitis transmissions were
differentiated on the basis of epidemiological observations. Type A (Hepatitis A virus) was
transmitted faecal-orally and Type B (Hepatitis B virus) was transmitted parenterally. The
discoveries of hepatitis A virus (HAV) and hepatitis B virus (HBV) as candidates for non -
A, non - B (NANB) human hepatitis in the 1970s led to a waning in the interest of the GB
agent, but indicated the existence offurther forms ofhepatitis (non-A, non-B [NANB]).
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In the late 1980s and 1990s, two NANB agents, Hepatitis C Virus (HCV) (Choo et al, 1989;
Kuo et al, 1989) and Hepatitis E Virus [HEV](Reyes et al, 1990; Dawson et al, 1992) were
established as principle etiologic agents in NANB hepatitis. Hepatitis F Virus (HFV), a new
entericalIy transmitted virus which is hepatotropic was implicated as an additional agent in
NANB hepatitis, but these findings were not substantiated (ArankalIe et al, 1994, Deka et al,
1994). Despite the development of very sensitive and specific assays to detect viral proteins
and antibodies to these proteins or nucleic acids, it became apparent that approximately 15-
20% of parenterally transmitted cases of NANB hepatitis and 10-15% of community
acquired hepatitis cases could not be attributed to either of these viruses (Alter and Bradley,
1995). After exclusion ofknown viruses and rigorous application ofcriteria to exclude drug
exposure, alcohol abuse, auto immune diseases and other conditions that cause liver damage,
the evidence strongly suggested that yet another hepatitis virus or viruses may be responsible
for these cases ofnon-A, non-B, non-C, non-E (NANE) hepatis. To examine this possibility,
recombinant DNA technology was used to identify a novel virus from the serum or plasma
of patients with non-A-E hepatitis.
1.1 Discovery of GB Virus -C (GBV-C)
Tamarins clearly developed hepatitis after inoculation with the GB serum, after extensive
serial passage of the agent in these animals, a question was raised about the human origin of
the hepatitis-causing agent in them (parks and Melnick, 1969). Additional passage and cross-
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challenge experiments indicated that the GB agent was distinct from any known human
hepatitis viruses (Karayiannis et al, 1989; Deinhardt et al, 1975).
A modified version of the polymerase (PCR) technique known as representational difference
analysis (RDA) (Lisitsyn et al, 1993) was used to selectively amplify unique nucleotide
sequences present in one complex source (in this case, a pool of known infectious tamarin
GB plasma at the eleventh passage) and absent in another (plasma taken from the same
animals before inoculation) (Simons et al, 1995a). Genomic representations of the related
source material were generated by PCR amplification of the restriction-digested DNA to
which specific oligonucleotide primers were ligated. Through a series of subsequent
subtractive hybdrization and selective amplification steps, the unique sequences present in
one representation were exponentially amplified, while the sequences held in common with a
second representation were linearly amplified. The enriched DNA was then cloned and
analysed. Simons et al (1995b) identified and cloned as complementary DNA (cDNA), two
RNAs with features of flavivirus RNAs in tamarin GB plasma and named these RNAs,
hepatitis GB viruses A (GBV-A) and B (GBV-B) . Both apparent viral genomes have an
overall organization similar to the genomes ofHCV and other flaviviruses, and have limited
nucleotide sequence homology with one another and with HCV (Muerhoff et al, 1995).
GBV-A and GBV-B have not been found in humans, although GBV-B was serially
transmitted in tamarins and caused hepatitis, GBV-A could not be readily transmitted to
tamarins (Schaluder et al, 1995). Whether either is the causative agent of hepatitis in the
original human patient, GB, remains unproven.
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Following cloning of GBV-A and GBV-B from tamarin serum, a related virus was
discovered in serum ofa human in West Africa (Simons et ai, 1995b). Serum samples from
numerous patients living in this region were first screened for antibodies against recombinant
proteins encoded by GBV-A and GBV-B (Pilot-Matias et ai, 1996a); immunoreactive
samples were further screened for RNA by reverse transcription (RT)-PCR, using degenerate
primers derived from the homologous sequences shared by GBV-A, GBV-B and HCV from
the NS3/helicase region of these viruses. Amplification products were obtained from
immunoreactive sera whose sequences were different from the other viruses (Simons et ai,
1995c). Sequence and phylogenetic analysis of the PCR products from GBV-A, GBV-B and
HCV together with additional members of the Flaviviridae, were consistent with this
sequence being derived from a virus which is more closely related to GBV-A than to GBV-
B, or any ofthe HCV genotypes. The new virus was named GBV-C (Simons et ai, 1995c).
1.2 Discovery of Hepatitis G Virus (HGV)
The independent discovery of another human virus, named hepatitis G virus (HGV) which
is almost identical to GBV-C, was more straightforward than that of GBV-C.
Independently, in an effort to identify additional agents for post-transfusion NANB
hepatitis, Linnen et al (1996a) performed molecular cloning with plasma from a patient
designated PNF2161 . This patient was originally believed not to be infected with HCV
(based on a negative test for serum antibody to HCV with a first-generation immunoassay).
Subsequent testing with a second-generation immunoassay for anti-HCV and PCR assay
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(for the 5' nontranslated region of HCY) for HCV RNA in serum demonstrated that this
patient was chronically infected with HCV. The extracted viral RNA was reverse
transcribed with random primers to prepare cDNA and subsequently amplified following a
sequence-independent single-primer amplification (SISPA) strategy, .that was designed to
amplify any double-stranded DNA. The amplified product was used to construct a Agt11
library, which was then immunoscreened with serum from the patient, and a single
immunoreactive clone was identified. An anchor PCR was employed to generate multiple
overlapping clones whose sequences were combined to produce the 9392 nucleotide (nt)
long HGV genome (Linnen et al, 1996a). In this way, a virus like RNA sequence was
identified and designated as HGV.
When HGV sequences were compared to GBV-A and GBV-B, these viruses were found to
be significantly similar. Comparison ofHGV with the original 311 nucleotide (nt) reported
for GBV-C (Simons et al, 1995b) found that these sequences were nearly identical (85%
and 100% at the nucleotide and amino acid levels, respectively) suggesting that these
viruses were closely related (Linnen et al, 1996a). Comparisons of the full-length
sequences of GBV-C and HGV revealed that both these viruses were indeed independent
isolates of the same virus (Zuckerman, 1996). The nt sequence comparisons between HGV
and GBV-C and other members of the Flaviviridae showed intermediate homologies
between GBV-C and GBV-A (48%), and between GBV-C and HGV (43%) compared to
the lower homology found between any other two GBV-CIHGV clones (26%-32%) (Table
1.1).
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Table 1.1 Amino acid sequence homology (%) between HGV and
GBV-C and other members of the Flaviviridae
(Linnen et al 1996a; Leary et al, 1996a,b)
GBV-A GBV-B GBV-C HGV
GBV-B 27
GBV-C 48 28
HGV 43 28 100 (NS3)
HCV 26 32 29 27
GBV-GB Virus A, B,and C; HGV-Hepatitis G Virus; HCV-HepatitisC Virus
1.3 Molecular Analysis ofGBV-CIHGV
1.3.1 Genomic organisation
The genomic organisation of GBV-C/HGV and HCV is similar and both viruses belong to
the Flaviviridae family. The genome of the virus consists of single stranded RNA and has
a positive polarity. Similar to other members of the Flaviviridae, GBV-C/HGV genome is
approximately 9500 nt (Table 1.2 and Fig. 1.1) in length and contains a single open reading
frame (ORF) that encodes the viral polyprotein.
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Table 1.2 Comparison of the genomic organisation ofGBV-C and HGV with
other members of the Flavivirdae [adapted from Linnen et al
(1996a) and Simmons et al (1996)]
GBV-A GBV-B GBV-C RCV
Genome 9653 9143 9103-9395 9401
5' NCR(nt) 594 445 281-551 341
3' NCR (nt) 198 83 313-315 72
Polyprotein 2954 2864 2842-2933 3011
Core absent present absent present
Host tarnarins tamarins humans humans
.. ..
GBV-GB VIrus A, B, and C; HGV- Hepatitis G VIrus ; HCV- Hepatitis C VIrus
5 ' NCR-5 prime non-coding region; nt-nucleotide
Based on amino-acid sequence homology, characteristic amino-acid motifs and
hydrophobicity/hydrophilicity plots, homologues of nearly all HCV proteins have been
found in GBV-C/HGV (Linnen et al, 1996a; Leary et ai, 1996b). The viral polyproptein is
preceded by a 5' non-coding region (5' NCR), followed by a long open reading frame
(ORP) terminating with 3' NCR (Fig.1.1) (Linnen et al, 1996a). The polyprotein IS
cleaved into smaller viral proteins necessary to complete the viral life cycle with different
functions by host-encoded signal peptidases and viral proteases. Polyprotein cleavage was
studied by expressing GBV-C/HGV cDNA constructs in mammalian cells using vaccina
virus or baculovirus (Kim and Fray, 1998). These fragments include the envelope proteins
(El and E2) at the amino or N-terminal end followed by nonstructural (NS) proteins (NS2,





l l l? ? ?
5'NCR El E2 NS2 NS3 NS5a NS5b 3'NCR
GENES
458b a ib 315b
!
PROTEIN
(10?) 20 70 (11?) 28 55 57 SIZE (Kd)
+ + + +
?Core Envelope Protease Protease! NS3 RNA-dependent FUNCTIOl'
Glycoprotein Helicase Co-factor RNA-polymerase
Fig.1.1 HGV (pNF2161) genome..Proteolytic processing and functions of the structural
and non-structural proteins (nt-nucleotide; NCR-non coding region; E-envelope
genes; NS - non-structural genes) [adapted from Kim and Fry, 1998)
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1.3.2 Sequence characteristics
The GBV-C/HGV genome is unusual. The region between the 5' NCR and the envelope
proteins is absent or truncated [Fig.1.1] (Leary et al, 1996b, Linnen et al, 1996a; Simons et
al, 1995a). This region normally encodes the nucleocapsid or core protein that encases the
viral genome. Nucleotide sequence alignments from the middle of the 5' NCR to within
the El encoding region show that the deduced amino-acid sequences upstream ofEl varied
in length. Close scrutiny shows that all isolates examined so far share a consensus
initiation codon 14 amino-acids upstream ofEl (Muerhoff et al, 1996; Linnen et al, 1996a;
1997; Kim et al, 1997; Okamoto et al, 1997; Pickering et aI, 1997), which represents the
shortest peptide encoded by some isolates. In order to determine the site of polyprotein
initiation, Simons et al. (1996) performed in vitro translation experiments using constructs
in which the 5' NCR sequences, which included coding sequences also, were fused in
frame with chloramphenicol acetyltransferase (CAT). CAT activity was abolished when
the AUG nearest to El was rendered inactive. Similarly, truncation of sequences upstream
of El that removed this initiation codon had a similar effect. These experiments established
that the AUG nearest to El is the authentic initiation codon for polyprotein synthesis and
confirmed the absence of a nucleocapsid protein. The only other flavivirus without an
obvious core gene is GBV-A (Simons et al, 1996). Other Flaviviruses have an initiator
methionine at the first amino acid of a basic core protein.
Thermodynamic modelling to determine the secondary RNA structure of the 5' NCR
shows that this region has a complex structure consisting ofa number of stem-loops
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suggestive of a regulatory function (Simons et al, 1996; Pickering et al, 1997). Translation
of bicistronic RNAs containing 5' NCR sequences within the intercistronic space was
consistent with the presence of a weakly active internal ribosome entry site (IRES) not
only in HGV, GBV-C, but also in GBV-A (Simons et al, 1996).
The NS2 protein is a zinc protease that cleaves the polyprotein at the NS2INS3 junction.
The activity of the protein was abolished when the two conserved amino-acids histidine
and cysteine associated with this activity were mutated (Kim et al, 1997). The N-terminal
end of NS3 encodes a protein which functions as a chymotrypsin-like serine protease and
contains the characteristic conserved catalytic triad of the three amino-acids H,D and S,
(Leary et al, 1996b; Linnen et al, 1996a; Kim et al, 1997). The carboxyl end of the NS3
region encodes a protein with motifs associated with helicase activity, whilst the NS5
region of the gene contains the GDD motif characteristic of RNA-dependent RNA
polymerases. Finally, the envelope glycoproteins of the virus bear little similarity to those
of HCV and are less heavily glycosylated. Such observations suggest either that GBV-
CffiGV is a core-less virus, or that a core-like structure is appropriated from cellular
proteins or a eo-infecting viruses. The 3' UTR of HGV is 350 nt long, thus, longer than
that ofHCV. It does not have a poly-A tract or a poly-V-tail (Tanaka et al, 1995). Neither
the 5' nor the 3' UTR bear any identity to those ofHCV.
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1.3.3. Phylogenetic relationships
1.3.3.1. Relatedness to the Flaviviridae
Phylogeneticanalysis take into account the number of genetic changes that have occurred
to change one amino acid sequence into another. The larger the number of changes, the
further the genetic distance between the two sequences. If differences between multiple
sequences are compared, sequences that share groups of similar changes as. compared to
the other sequences will be closer to each other than those that do not contain shared
changes. The relative evolutionary distances between GB viruses and other members of
the Flaviviridae are readily apparent on analysis of the unrooted phylogenetic tree in which
the length of the traced path from one sequence to the next represents the amount of
genetic distance between the sequences (Fig.1.2). Phylogenetic analysis ofFlaviviridae
polyproteins shows that HGV and GBV-C are more similar to the tarmarin GBV-A than
either HCV or GBV-B which are about equally distant (Fig 1.2). Even more distant are
members of the flaviviruses (yellow fever and dengue 1) and the pestiviruses (Linnen et ai,
1996a; Leary et ai, 1996b) (Fig 1.2). The divergence between GBV-A, GBV-B and GBV-
C and other Flaviviridae members, including HCV group, demonstrates that GBV-CIHGV
cannot be considered genotypes ofHCV. This analysis suggests that the GB agents may be
classified into separate genera within the Flaviviridae or into subgenera in a genus
including HCV. However the lack of a core protein in GBV-A and GBV-C could















Fig. 1.2 Unrooted phylogenetic tree of the NS3 RNA helicase domains of the GB viruses
and other members of the Flaviviridae. Flaviviruses: Japanese Encephalitis virus
(JEV), West Nile virus (\VNV), Yellow Fever virus (YFV) and Dengue virus type
1 and 2.Pestiviruses: Hog cholera virus (HCHV), Bovine Viral Diarrhoea virus




Initial studies on the phylogenetic structure of GBV-CIHGV were based on the sequence
analysis of short fragments of the NS3 (~1l8nt) and or the NS5b (~354nt) regions of the
genome, where the initial PCR primers for the detection of this virus were located (Simons et
ai, 1995b Leary et ai, 1996b; Linnen et ai, 1996a). Congruent phylogenetic trees were not
noted between isolates from different parts of the world in these studies (Berg et ai, 1996a;
Kao et ai, 1996; Schreier et ai, 1996; Tsuda et ai, 1996; Kinoshita et ai, 1997; Pickering et ai,
1997; Viazov et ai, 1997a).
Previous studies have identified three (Okamoto et ai, 1997; Susuki et ai, 1999) four (Charrel
et ai, 1999) or five (Takahashi et ai, 1997) phylogenetic groupings of GBV-CIHGV, although
some of these groupings are weak and inconsistent between different studies. Whereas HCV
genotypes can be distinguished by phylogenetic analysis of a variety of sub-genomic regions
as small as .222 nt, variants of GBV-CIHGV can not be reliably identified in this way.
Systematic analysis of six complete GBV-CIHGV genome sequences revealed that congruent.
phylogenetic relationships were obtained for only a minority of 300, 600 and 1200 nt
fragments, and that the optimal region was all or part of the 5' NCR (Muerhoff et ai, 1997
Smith et ai, 1997a). Based on the assumption that the sequence analysis of the 5' NCR was
predictive of the analysis of the complete genome sequence, sequence analysis of 5' NCR
provided limited evidence that GBV-CIHGV can be separated into three major groups that
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correlated with the geographic origin of the isolates (Muerhoff et aI, 1996, 1997; Smith et aI,
1997a). The evolutionary relationship between some ofthese isolates is presented graphically
in Fig. 1.3. Group 1 consists of isolates from West and Central Africa and includes the original
GBV-C isolate. Group 3 isolates have been found predominantly in South-East Asia and
Japan. Group 2 isolates have found in Europe and North America (HGV like), but also
includes isolates from Japan, Pakistan arid East Africa. In addition Group 2 can be subdivided
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Fig.1.3 Consensus phylogenetic tree of the 5'NCR of geographically disparate
isolates ofGBV-CIHGV. The tree was generated by comparison of positions
-366 to -235 of the 5'NCR. The percentage of bootstrap replicates in which
major groupings were observed amongst 500 replicates is indicated.
Sequences are identified by accession numbers or by the prefixes Pak for
Pakistan, Ed for Edinburgh and Zai for Zaire. The geographical origin for
each sequence is indicated at the right (Smith et al, 1997a).
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1.4 Biophysical and biochemical characteristics of GBV-CIHGV
Biophysical and biochemical characterisation of GBV-CIHGV has been hampered by the lack
of adequate cell culture or animal models to generate large amounts of highly purified virions.
Currently, human plasma is the best source of GBV-C/HGV Because viral titers are < 109/ml.
Viral RNA is detected by RT-PCR Flaviviruses are characterised physically by a lipid-
containing envelope and core proteins that surround and protect the RNA viruses from serum
RNases (Westaway et ai, 1985). The lipid envelopes ofFlaviviruses are sensitive to disruption
by chloroform and by ionic and non-ionic detergents. Chloroform has been reported to reduce
infectivity ofHCV (Bradley et al, 1~83) . In addition chloroform has been used to reveal HCV
nucleocapsids (Hijikata et al, 1993). Several biological detergents (e.g. sodium deoxycholate,
Brij-58, NP-40, Triton X-lOO and Tween-80) have been used to reveal nucleocapsids of
Flaviviruses as indicated by a shift in detectable RNA to higher buoyant densities (Miyamoto
etal, 1992; Takahashietal, 1992).
The presence and/or absence of core protein in GBV-C/HGV has been debatable. The length
of the GBV-C/HGV ORF upstream of the El protein is truncated or absent in some isolates.
The distribution of genetic polymorphisms among various isolates suggests that the region is
not a coding region (Okamoto et ai, 1997). In vitro translation data suggest that only the AUG
at position 552 is capable of initiating translation (Simons et ai, 1996). It has been suggested
that either the virus does not have a nucleocapsid, or that it uses a unique capsid protein,
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perhaps obtained from another virus with which the infected person is eo-infected, or even a
cellulargene product (Simons et al, 1996).
Immunoprecipitation experiments suggest that GBV-CIHGV is associated with low density
lipoproteins in plasma but not human antibodies because anti-lipoprotein Al and anti-
apolipoprotein B antibodies shift PCR signal to the precipitate while anti-human IgG antibody
does not (Hijikata et aI, 1996; Sato et al, 1996). Xiang et al (1998) using sucrose gradient
centrifugation, isopycnic banding in caesium chloride, and saline density flotation
centrifugation demonstrated extremely-low-density GBV-CIHGV virion particles (1.07 to 1.09
g/ml) and a nucleocapsid density of approximately 1.18 g/ml, similar to HCY. One major
difference between the particle types was that GBV-CIHGV was consistently more stable in
cesium chloride than HCY. An observed shift in RNA buoyant density in sucrose gradients
following treatment with Tween-80 in the presence of RNase inhibitor (Sato et aI, 1996)
provided additional physical evidence of a GBV-CIHGV nucleocapsid. Lectin columns bind
GBV-CffiGV consistently with the presence of envelope glycoproteins (Sato et aI, 1996). In
their more recent study Xiang etal (1999) evaluated the buoyant density ofGBV-CIHGV, and
found very low density particles consistent with virions, and intermediate density particles
consistent with nucleocapsids in GBV-CffiGV infected patients. In addition, for the first time,
Xiang et aI, (1999) using electron microscopy demonstrated an apparent nucleocapsid within
an enveloped particle. .To assess the origin of the protein content of this particle, patient
plasma was evaluated for reactivity with a synthetic oligopeptide representing a conserved
18
region near the amino terminus of the predicted ORF (Xiang et aI, 1999). Specific antibody
was detected in some individuals, similar to the data presented by Feucht et al (1997a) who
identified antibody against a recombinant core protein in GBV-CffiGV-infected patients.
These data indicate that GBV-CIHGV particles contain nucleocapsids. In some isolates, the
region upstream of the GBV-CIHGV El protein coding region appears to be expressed, and
this region may represent the structural protein of the nucleocapsid. Sequential filtration and
RNA titration studies suggest that the GBV-CIHGV virion is between 50-100nm in diameter,
being unchanged after passing through a 100nm filter and being reduced to 10-1000 fold after
passing through a 50nm filter (Melvin et aI, 1998).
For HCV, the free nucleocapsid is detected by the PCR signal to an increased buoyant density
after detergent treatment (Melvin et aI, 1998). The peak of GBV-CIHGV RNA in sucrose
gradients was observed at a buoyant density of 1.05-1.13g!ml (Melvin et aI, 1998). GBV-
CIHGV RNA was reduced following treatment with chloroform or with five detergents
indicating that GBV-CIHGV has a lipid-containing envelope (Melvin et aI, 1998). Sucrose
gradients and self-forming caesium chloride gradients of detergent-treated GBV-CIHGV
showed a shift in the RNA peak to heavier buoyant density only when RNasin and high
detergent concentrations were present (Melvin et aI, 1998). The treated material was non
filterable and RNA had density of> 1.5g!ml (Melvin et aI, 1998). These results indicate that
GBV-CIHGV is a small, lipid-enveloped RNA virus, and that the GBV-CIHGV RNA was
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present in an extended or aggregated form and do not support the existence of a nucleocapsid
structure in the GBV-C/HGV virion (Melvin et ai, 1998).
Until additional biochemical studies are undertaken to identify the amino terminus of the
proteins contained in the nucleocapsid structures shown on the electronmicrographs (Xiang et
ai, 1999), the origin of these structures will remain debatable.
1.5 Diagnosis of GBV-CIHGV
In contrast to what is found for HCV, the identification of serological markers indicative of
ongoing GBV-C/HGV infection have not been successful to-date. Thus, the identification of
viraemic samples has relied on the detection of viral RNA. Several nucleic acid-based assays
have been developed for this purpose. Although labour-intensive, many of these assays are
sensitive and specific. An antibody marker ofviral clearance has been identified.
1.5.1. Detection ofRibonucleic acid (RNA)
The reverse-transcription polymerase chain reaction (RT-PCR) is the only diagnostic tool
available to detect current GBV-C/HGV infection in human serum, plasma, or tissues. Several
of the assays start with the synthesis of complementary DNA (cDNA) using random
hexameres with reverse transcriptase; the purpose of which was to generate relatively large
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number of DNA sequences to which GBV-CIHGV specific primers would anneal. The cDNA
then could be efficiently amplified with thermostable DNA polymerase. Because some of the
genomic regions were not well conserved among various GBV-CIHGV isolates, degenerate
primers (primers with bases containing more than one nucleotide at a certain position) were
used. To increase the specificity of the annealing between mismatched nucleotide sequences, a
thermal cycling strategy named "touchdown" PCR was used. The annealing temperature is
incrementally decreased with each PCR cycle, preferentially allowing the best matched primer
template to form (Leary et al, 1996b).
There are also assays that use primers targeting the NS5B replicase region of the GBV-
CIHGV genome (Genelabs Technologies INC, USA~ Boehringer Mannheim, Germany). The
PCR product is detected by dot blot hybridisation using a riboprobe or an enzyme-linked test
(semiquantitative Enzyrnun-Test) . Another strategy depends on the PCR amplification of two
target regions (5' NCR and NS5A) from the same clinical specimen (Schlueter et aI, 1996).
This technique is applicable for routine screening in clinical laboratories.
The first generation RT-PCR assays utilised primers from the NS3 and NS5 (Simons et al,
1995b~ Linnen et aI, 1996a) regions of the genome to detect viral RNA. However, because the
targets of these assays are coding regions, silent mutations noted in the various GBV-CIHGV
isolates resulted in a number of false-negative results. The second generation RT-PCR assays
target highly conserved regions within the NS5A (Linnen et aI, 1996a) or 5' UTR (Schlueter et
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aI, 1996); the latter region appears to be more sensitive and more widely used in this respect
(Kao et aI, 1997a). These assays are more sensitive and specific than the first generation
assays. However, both the first and second generation assays rely on Southern hybridisation
for the detection of GBV-CIHGV PCR products . The inclusion of Southern hybridisation
results in assays that are tedious, labour-intensive and time consuming.
Kao et al (1997a) compared sensitivity and specificity of PCR assays using primers 'from
different regions of viral genome, viz. 5' NCR, E2 and NS3: The positive rates by 5' NCR,
NS3 and E2 primers were 100%, 98% and 84%, respectively, and the sensitivity of the PCR
assays using 5' NCR primers were 10-100 times more likely to detect GBV-CIHGVRNA than.
that of NS3 and E2 primers. These results were confirmed by other investigators (Bhardwaj et
aI, 1997; Cantaloube et aI, 1997).
Because GBV -CIHGV was detected in blood donors, the question arose whether blood banks
should include GBV-CIHGV in their screening. Screening of blood donations is only feasible
with serological tests, not with PCR Third generation RT-PCR assays have been developed
which permit a higher level of throughput, in conjunction with ease of use. In these assays
GBV-CIHGV specific PCR products are captured by oligomer hybridisation for the detection
of sequences within the 5' NCR The assay described by Schlueter et al (1996) utilises a two
step RT-PCR assay in which digoxigenin-labelled dUTP is incorporated during .the PCR
amplification. A biotinylated capture oligomer hybridises with all GBV-CIHGV specific
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products that may be present. The GBV-C/HGV oligomer complex is captured on a
streptavidin-coated surface. After extensive washing, captured PCR product is detected
immunologically using an anti-digoxigenin-peroxidase conjugate (Schlueter et ai, 1996)
[Boehringer Mannheim,Germany].
Abbott Laboratories described a single tube assay that only requires the addition of serum-
derived nucleic acid to pre-aliquoted reaction vials. Reverse transcription, PCR amplification
and oligomer hybridisation occur in the same tube containing recombinant Thennus
theromphilus (rTth) polymerase, adamantine-labeled sense and anti-sense oligonucleotide
primers for the 5' NCR of GBV-C/HGV, and carbazole-labelled capture oligomer. Detection
of GBV-C/HGV product employs the automated LCx detection system (Abbott Laboratories,
Abbott Park, TI..-, USA) utilising a microparticle enzyme immunoassay (MIA). These third
generation assays provide data within 5 hours (hr) as opposed to the 2 days minimumrequired
for the first- or second- generation RT-PCRs.
Apart from detection of GBV-C/HGV RNA based on RT-PCR, branched chain DNA (bDNA)
signal amplification has been developed. Although convenient, it is not as sensitive as RT-
PCR assays. While RT-PCR remains the "gold standard" for detecting GBV-C/HGV, its
sensitivity is not fully resolved.
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1.5.2. Detection of antiviral antibodies (Anti-E2)
Five different prokaryotically expressed recombinant GBV-C/HGV proteins were employed
for serological studies utilising ELISA and Western blot (Dawson et aI, 1996; Pilot-Matias et
al, 1996b). Although some regions of GBV-C/HGV have been identified as immunogenic,
efforts to develop a screening immunoassay for the detection of GBV-C/HGV antibodies have
been unsuccessful because only 15% of GBV-C/HGV infected individuals develop antibodies
to these prokaryotically-expressed proteins. Most of the seropositive individuals produce
antibodies against only a single antigen, and no single antigen has been identified thus far that
is consistently recognised by individuals exposed to GBV-C/HGV (Dawson et aI, 1996).
The phylogenetic relationship between GBV-C/HGV and HCV suggested that useful markers
of GBV-C/HGV exposure might be found in regions homologous to those identified for HCY.
With this in mind, an antibody response to GBV-C/HGV directed against the envelope
glycoprotein, El, has been detected following its expression as a recombinant protein in
Chinese hamster ovary cells (Pilot-Matias et al, 1996b; Tacke et aI, 1997a). The secreted El
protein has been purified and used in a solid phase enzyme-linked immunosorbent assay
(ELlSA) for the detection of anti-El (Dille et aI, 1997). Interestingly, almost all sera positive
for anti-El are negative for viral RNA, and vice versa, implying that anit-El is associated with
virus clearance and is perhaps, protective or neutralising (Pilot-Matias et aI, 1996b; Tacke et
aI, 1997). However, the specificity for anti-El has not been established.
1.5.2.1
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GBV-CIHGVAnti-E2. A protective and or neutralising antibody and a
marker for recovery ?
Analysis of serial samples for both RNA and anti-E2 suggests that GBV-C/HGV infection
follows one of two paths; acute infection followed by recovery (appearance of GBV-C/HGV
E2 antibody), or acute infection progressing to chronicity (persistence of GBV-C/HGV RNA).
Follow-up of 16 post transfusion patients for up to 16 years revealed that individuals who
develop an anti-E2 response become GBV-C/HGV-RNA-negative, while those who do not
develop anti-E2 are persistently infected (Tacke et aI, 1997b). The presence of anti-E2 and
the subsequent loss of viraemia have been confirmed by other investigators (Dille et aI, 1997;
Gutierrez et aI, 1997; Hassoba et aI, 1997). Anti-E2 appears to be a long-lasting circulating
antibody and once acquired generally tends to persist (Masuko et aI, 1996, Lefrere et al,
1997).
In chronic HCV infection the co-existence of E2/NS1 antibody and viraemia suggests that
anti-E2 is not a neutralising/protective antibody, but serves as a marker of active HCV
replication (Yuki et aI, 1996). GBV-C/HGV Anti-E2 on the other hand, has been described as
a marker of viral clearance and is considered to be protective against GBV-C/HGV
reinfection In 54 recipients who underwent orthotopic liver transplantation (OLT) the
presence of anti-E2 pre-transplant was associated with a relatively low rate (15%) of post
transplantation GBV-C/HGV infection compared to 46% in anti-E2 negative (pre transplant)
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patients (Hassoba et aI, 1998). Post transplantation immune suppression apparently had only a
minor effect on the prevalence of anti-E2 in patients who were anti-E2 positive prior to
transplantation (Hassoba et aI, 1998). A negative association between the presence of GBV-
CIHGV RNA and the presence of anti-E2 was found in all patients tested pre- and post
transplantation, suggesting viral clearance (Hassoba et aI, 1998). Anti-E2 appears to be a
neutralizing antibody whose presence at the time of liver transplantation protects against
acquisition of GBV-CIHGV infection post-OLT (Bizollon et aI, 1998; Hassoba et aI, 1998;
Tillman et ai, 1998; Silini et ai, 1998). No new GBV-CffiGV infections were noted among
subjects with anti-E2, despite ongoing drug use (Thomas et aI, 1998). These data suggest that
anti-E2 is a protective or neutralising antibody. Because high titres of GBV-CIHGV anti-E2
antibodies appear to be protective in humans, the possibility of using human or animal
immune serum globulin for prophylactic purposes is intriguing. Other possibilities such as use
of recombinant GBV-CffiGV E2 glycoprotein or synthetic subunit vaccines should be
explored if GBV-CffiGV is proven to be a public hazard.
1.6 Routes of GBV-CIHGV transmission
Since the discovery of GBV-CffiGV, attempts have been made to clarify its principle mode of
transmission. In non-African countries the predominant route of transmission of GBV-CffiGV
is parenteral. (Sathar et al, 2000) A high prevalence of GBV-eIHGV has been found in
subjects with frequent parenteral exposure and in groups at high risk of exposure to blood and
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blood products, including intravenous drug abusers (IVDA), patients on maintenance
haemodialysis, multi-transfused individuals and haemophiliacs (Sathar et ai, 2000). The high
prevalence in blood donors worldwide, suggests that the principle route of transmission is via
. contaminated blood and blood products. However, maintenance of the virus at high levels in
blood donors and the general population requires an effective non-parenteral route of
transmission Blood donors, however, are not representative of the general population since
they are highly selective.
Various studies have pointed to the important role of sexual exposure as a likely route of
transmission of GBV--CIHGV, in both non-HIV infected subjects without the risk for
parenteral transmission (IVDU and multi-transfused individuals including haemophiliacs)
(Kao et ai, 1997b; Scallan et ai, 1998; Sawayama et ai, 1999) and HfV infected individuals
with the risk for parenteral and sexual transmission (homosexuals, heterosexual and
prostitutes) (Nubling et ai, 1997; Ibanez et ai, 1998; Nerurkar et ai, 1998; Bourlet et ai, 1999).
. Infection with GBV-CIHGV appears to be more frequent in patients with a sexual risk than
those with parenteral exposure (Ibanez et ai, 1998; Bourlet et ai, 1999). In a study of 600
antenatal patients there was an overall prevalence (GBV-CIHGV RNA and/or Anti-E2
positive) of 11.8%. Since this group represents a young, sexually active population, the
authors concluded that sexual or close contact might play a role in the transmission of GBV-
CIHGV (Skidmore & Collingharn 1999). Rubio et al (1997) reported . a GBV-CIHGV
prevalence of21.7% among heterosexual partners of 150 index cases. Strak et al (1996) found
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GBV-CIHGV prevalence of 10.9% among non-drug injecting homosexual and bisexual men
Scallan et al (1998) found a high prevalence of markers for GBV-CIHGV in non-intravenous
drug using prostitutes (40%) and male homosexuals (47%). A positive correlation was
demonstrated between GBV-CIHGV infection in prostitutes and the number of years of
prostitution (Kao et aI, 1997b; Sawayama et al, 1999) and the high frequency of paid sex (Wu
et ai, 1997). The near absence of GBV-C/RGV infection among heterosexual men (4%) and
the comparatively higher prevalence among heterosexual women (15%) suggests that, as in
HIV infection, the receptive partner is at high risk for acquiring GBV-CIHGV (Nerurkar et aI,
1998). Interspousal transmissions of GBV-C/HGV have been reported (Kao et aI, 1997c;
Sarrazin et ai, 1997). Whilst the role of semen in the transmission of GBV-CIHGV is
controversial (Semprini et ai, 1997; Hollingsworth et aI, 1998; Eugenia et aI, 2001), recent
reports have suggested that human saliva may contribute to the spread of GBV-CIHGV RNA
(Chen et ai, 1997; Seemayer et aI, 1998; Eugenia et aI, 2001). Tucker et al (2000) did not
detect GBV-CIHGV replicative intermediaries in the cadaver biopsies. Tucker et al (2000)
looked in salivary glands and the gonads of GBV-CffiGV positive patients. Their results
suggest that the virus may be present in the saliva and semen of infected individuals, but not
transmitted by these routes. Despite the evidence for increased frequencies of GBV-CIHGV
infection in association with sexual exposure, the mechanism of transmission remains unclear.
There is a higher risk of mother to infant transmission in high"risk groups (Feucht et aI, 1996;
Viazov et aI, 1997b; Fiscler et aI, 1997; Zanetti et aI, 1997; Wejstal et al, 1999). However, it
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is not clear whether eo-infection with HCV, HIV-1 or both or IVDU are the underlying cause
for transmission of GBV-CIHGV from mother to infant. Nor is it clear as to whether
transmission of GBV-CffiGV is influenced by breast-feeding or by the mode of delivery
(Zanetti et al, 1997; Wejstal et al, 1999). Although the rate of perinatal transmission of GBV-
CIHGV exceeds that ofHCV, in most studies GBV-CIHGV did not induce liver disease in the
infants studied (Zanetti et al, 1997; Viazov et al, 1997b; Wejstal et al, 1999).
Among 220 cases of needle-stick injuries, GBV-C/HGV RNA was detected in 21 (9.5%)
donors (Shibuya et al, 1998). At the time of injury none of the 21 recipients was positive for
GBV-C/HGV RNA or anti-E2, only 1/14 (7.1%) recipients became positive for GBV-C/HGV .
RNA which persisted for approximately 3 years without any evidence of liver disease
(Shibuya et ai, 1998). It has been suggested that iatrogenic transmission of GBV-C/HGV
could possibly occur as a result of insufficient sterilization of needles and syringes (Ohshima
et al, 2000). Confirmation that GBV-C/HGV is indeed an occupational hazard in hospital
employees (Gartner et ai, 1999; Schaade et ai, 2000) will require more comprehensive
longitudinalstudies.
1.7 Prevalence of GBV-CIHGV infection
The prevalence of GBV-C/HGV infection in selected groups of subjects from some published
studies are listed in tables 1.3 - 1.6. The frequency ofpositivity for RNA or anti-E2. varies
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among groups, depending on the subjects' origins and the methods used to detect GBV-
CIHGV markers. Generally, infection with GBV-CIHGV is significantly associated with a
history of IVDA, exposure to blood transfusions, dialysis and with HCV infection. There is a
higher prevalence of GBV-CIHGV RNA in blood donors and the general population of
African countries (10-19%) compared to non-African countries (1-6%) (Table 1.3). The high
prevalence in commercial blood donors (5-26%) (Table lA) is probably due to the increased
risk ofparenetral acquisition in this group. The prevalence ofGBV-CIHGV anti-E2 antibodies
in healthy individuals ranges from 3% -15.1% (Table 1.6).
The simultaneous detection of anti-E2 greatly extends the ability of RT-PCR to define the
epidemiology of GBV-CIHGV (Table 1.6). For example, in non-African countries, 1-2.5% of
blood donors is GBV-CIHGV RNA positive. Using anti-E2 assays, the same population of
blood donors showed 3-9% seroprevalence. The overall prevalence of GBV-CIHGV in non-
African blood donors was 4 -16%, compared to 20-30% in Africa (Table 1.6). In the high risk
group of patients the overall prevalence of GBV-CIHGV infection ranged from 20-89% (Table
1.6). The combined overall prevalence of GBV-CIHGV infection is higher in African
countries compared to non-African countries (Table 1.6). The simultaneous detection of GBV-
CIHGV RNA and anti-E2 may represent the seroconversion state.
Thus, the total exposure to GBV-CIHGV should take into account both the number of PCR
positive samples (i.e. viraemic/RNA positive) and anti-E2 positive samples (i.e. previously
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infected but cleared) in a given population. GBV-CIHGV infection appears to be a common ·
infection globally. The reason for the high prevalence of GBV-CIHGV in blood donors
worldwide and the basis for the racial differences in GBV-CIHGV infection in blood donor
populations are not known. Whether socio-economic factors are associated with prevalence of
GBV-CIHGV is not known for certain, although a relationship was noted between GBV-
CIHGV infection and the lack of water-borne sewage (Tucker et aI, 1997). The differences in
the prevalence of detecting GBV-CIHGV infection (Tables 1.3-1.6) may be due to the
differences in the sensitivity of the various PCR protocoIs and primers (derived from various
regions of the genome) used by various investigators; pre selection of patients in terms of
status for other viral markers as well as different patient histories. Further investigations are
required to determine whether genetically distinct isolates from different geographical regions
of the world escape detection by current PCR methods and anti-E2 assays.
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Table 1.3 Reported prevalence of GBV-C/HGV RNA in blood donors
Continent Country n RNA+(%) References
N America USA 769 13 (1.7) (Linnen et al,1996a,b)
S America Brazil 11 2 (1.8) (Lampe et aI, 1997)
Africa Egypt 82 16 (12.2) (EI-Zayadi et al, 1999)
South Africa 248 32 (12.9) (Mphahlele et aI, 1998)
South Africa 249 26 (1004) (Tucker et al, 1997)
South Africa 167 21 (12.6) (Lightfoot et aI, 1997)
South Africa 532 59(11.1) (Castelling et al, 1998)
South Africa 232 44 (18.9) (Sathar et aI, 1999a)
Caribbean Martinique 221 9 (4. 1) (Cesaire et al, 1999)
Asia Japan 448 4 (0.9) (Masuko et aI, 1996)
China 205 2 (1) (Wang et aI, 1997a,b)
Thailand 69 3 (4.3) (Raengsakulrarch et aI, 1997)
Vietnam 890 11 (1.2) (Kakumu et aI, 1998)
Nepal 181 4 (2) (Shrestha et aI, 1997)
Mongolia 121 8 (6.6) (Kondo et al, 1997)
Australia 120 5 (4) (Moaven et al, 1996)
Europe Austria 92 3 (3) (Schlueter et al, 1996)
Germany 1048 14 (1.34) (Roth et aI, 1997)
Germany 106 59 (4.7) (Heringlake et al, 1996a)
UK 125 4 (3.2) (Jarvis et aI, 1996)
Italy . 100 1 (1) (Fiordalisi et al, 1996)
Spain 200 6 (3) (Saiz et al, 1997)
n-number; %-per cent; +-positive
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Table 1.4 Reported prevalences ofGBV-CIHGV RNA in high risk groups
Clinical Grou Count RNA+n % References
n-nwnber; %-per cent; +-positive; IVDU-intravenous drug user
(El-Zayadi et al., 1999)
(Linnen et al, 1996b)
(Sathar et al. , 1999a)
(Lampe et al., 1997)
(Wang et al , 1997a)
(De Lamballerie et al , 1996)
(Masuko et al., 1996)
(Tsuda et al., 1996)
(Jarvis et al., 1996)
(Linnen et al, 1996a)
(Gerolami et al. , 1997)
(Kinoshita et al., 1997)
(Gonzales-Prez et al., 1997)
(Castelling et al., 1998)
(Anastassopoulou et al., 1998)
(Dille et al., 1997)
(Gutierrez et al., 1997)
(Shev et al., 1998)
(Linnen et al, 1996a)
(Tacke et al., 1997a)
(Aikawa et al, 1996)
(Roth et al., 1997)
(Dille et al. , 1997)
(Pilot-Matias et al, 1996b)
(Gutierrez et al. , 1997)
(El-Zayadi et al., 1999)
(Shrestha et al., 1997)
(Scallan et al. , 1998)
(WU et al. , 1997)
(Scallan et al., 1998)








































Table 1.5 Reported prevalences of GBV-e/HGV RNA in patients with
liver diseases
n- number; % - percent; + positive
Clinical Group Country RNA+n (%) References
Acute/Chronic HBV Europe 72 (9.7) (Linnen et a11996a)
Egypt 63(11,1) (EI-Zayadi et al., 1999)
Japan 83 (4) (Sugai et al., 1997)
US 100 (32) (Alter et al, 1997a)
South Africa 106 (26.4) (Mphahlele et al., 1998)
Acute/Chronic HCV Egypt 100 (14) (EI-Zayadi et al., 1999)
Germany 100 (9) (Schleicher et al., 1996)
Italy 83 (26.5) (Francesconi, 1997)
Japan 88 (8) (Sugai et al., 1997)
Russia 22 (41) (Yashina et al., 1997)
Spain 143 (5.6) (Saiz et al., 1997)
Taiwan 52 (10) (Hwang et al., 1997)
US 116 (20) (Alter et al, 1997a)
South Africa 82 (30.5) (Mphahlele et al., 1998)
Acute/Chronic HAV Japan 21 (0) (Nakatsuji et aI., 1996)
US 100 (25) (Alter et al, 1997a)
Non A-E hepatitis China 108 (16.7) (Wang & Jin, 1997)
Japan 43 (0) (Nakatsuji et al., 1996)
Russia 28 (3.6) (Yashina et aI., 1997)
US 149 (8.7) (Dawson et aI., 1996)
Chronic Liver Disease Indonesia 149 (5) (Tsuda et al., 1996)
Nepal 145 (3) (Shrestha et al., 1997)
South Africa 92 (12) (Sathar et aI., 1999a)
Japan 226 (7.5) (Nakatsuji et al., 1996)
US 326 (12.2) (Linnen et al, 1996a)
Italy 36 (39) (Fiordalisi et aI., 1996)
Hepatocellular Carcinoma Japan 111 (10) (Kanda et aI., 1997)
Japan 109 (10) (Nishiyama et al., 1999)
Thailand 101 (6) (Tangkijvanich et al., 1999)
China 114 (14,9) (Cao et al., 1998)
Europe 57 (7) (Brechot et al., 1998)
South Africa 135 (14) (Lightfoot et al., 1997)
Fulminant hepatitis Japan 6 (50) (Yoshiba et al., 1995)
Japan 10 (0) (Kanda et al., 1997)
Germany 22 (50) (Heringlake et aI., 1996)
UK 23 (21.7) (Haydon et al., 1997)
UK 20 (0) (Sallie et al., 1996)
US 36 (38.8) (Munoz S.J. et al., 1999)
Taiwan 32 (9) (Liuet al., 1999)..
Table 1.6 Reported prevalences ofGBV-C/HGV RNA and Anti-E2 antibodies in blood donors, high risk groups and patients
with liver disease
Clinical Group Country n RNA+(%) Anti-E2+ (%) Exposure- References
(%)
Blood Donors Japan 200 2 (1) 10 (5) 12 (6) (Tanaka et al., 1998)
Germany 200 5 (2.5) 7 (9) 33 (16.5) (Tacke et al., 1997a)
US 199 3 (1.5) 9 (4.5) 11 (5.5) (Gutierrez et al., 1997)
US 100 1 (1) 3 (3) 4 (4) (Dille et al., 1997)
Spain 200 5 (2.5) 28 (14) 32 (16) (Tacke et al., 1997b)
South Africa 248 32 (12.9) 30 (12.1) 52 (21.1) (Mphahlele et al., 1999)
South Africa 232 44 (18.9) 35 (15.1) 74 (31.9) (Sathar et al., 1999a)
Commercial Donors US 711 93 (13.1) 195 (27.4) 288 (40.5) (Gutierrez et al., 1997)
Plasmapheresis Donors US 50 13 (26) 17 (34) 30 (60) (Dille et al., 1997)
West Africa 30 10 (33.3) 4 (13.3) 14 (46.7) (Dille et al., 1997)
IVDU Germany 99 38 (38) 41 (41) 75 (75) (Tacke et aI., 1997a)
US 27 1 (3.7) 23 (85.2) 24 (88.9) (Dille et al., 1997).
US 102 15 (14.7) 76 (74.5) 91 (89.2) (Gutierrez et al., 1997)
Haemophliacs Spain 62 22 (34) 20 (32) 33 (53) (Tacke et al., 1997b)
France 92 16(17.4) 33 (35) 47 (51) (Gerolami et al., 1997)
Haemodialysis South Africa 70 17 (24.3) 18 (25.7) 33 (47.1) (Sathar et al., 1999a)
Renal Transplant Germany 221 31 (14) 89 (40) 118 (53) (Stark et al., 1997)
Chronic liver disease South Africa 98 12 (12.2) 32 (32.7) 33 (47.1) (Sathar et al., 1999a)




1.8 Site(s) of GBV-CIHGV replication
A true hepatotropic virus replicates in the liver. GBV-CIHGV is a flavivirus with a
positive stranded RNA genome that is similar to HCV, as such replication should proceed
via a negative strand RNA intermediate, the detection of which should be possible in the
liver.
GBV-C/HGV RNA has been detected by RT-PCR in washed hepatocytes in 9 of 58
(15%) children with chronic viral hepatitis (Lopez-Alcorocho et aI, 1997). Madejon et al
(1997) and Saito et al (1997) detected GBV-CIHGV antigenomic RNA in 12 of 13 livers
and in peripheral blood mononuclear cells (PBMCs) of one of the same 13 patients
examined. Because hepatocytes and PBMCs are bathed in blood, it is possible that the
PCR signal noted may have been due to cell-bound virus rather than active replication
occurring in these cells (Laras et aI, 1999). Using RT-PCR with tagged primers and
southern blot analysis, antigenomic GBV-CIHGV RNA was detected in 4 of 6 liver
specimens; using in situ hybridisation in two such specimens GBV-CIHGV infection was
restricted to hepatocytes (Seipp et aI, 1999). Using RT-PCR with tagged primers and in
vitro derived templates, MelIor et al (1998) was unable to detect antigenomic GBV-
CIHGV RNA in the liver biopsies nor in the PBMCs of 20 GBV-C/HGV infected
individuals. Radkowski et al (1998) suggested that PBMCs may not be the replication
site of GBV-C/HGY. In 5 of 17 patients undergoing liver transplant, GBV-C/HGV RNA
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was detected in sera and not in the liver on repeated testing for viral RNA from different
portions of the liver (Fan et al, 1999). In patients eo-infected with GBV-CIHGV and
HCV, the hepatotropism ofHCV and not GBV-CIHGV was consistently proven (Kudo et
al, 1997; Laskus et al, 1997; Pessoa et al, 1998).
In vitro studies have provided evidence that GBV-CIHGV is able to infect and replicate
in established cell lines of haematopoietic origin, vascular endothelial cells and human
hepatoma cell lines (Ikeda et al, 1997; Seippet al, 1999; Fogeda et al, 1999). In contrast,
contradictory results have been reported with respect to the detection of GBV-CIHGV in
liver and PMBC samplesfrom chronically infected patients (Laskus et al, 1997; Pessoa et
al, 1998; Fan et al, 1999). Some of the these discrepancies between different studies may
be due to either the existence of GBV-CIHGV variants with different cell tropism
(Fogeda et al, 2000) or differences in the inoculums used as a source of the virus.
Patients with GBV-CIHGV are often eo-infected with HCV, and since HCV infects and
replicates in both the liver and PMBC, HCV may influence the tropism of GBV-CIHGV
variants by facilitating the replication of some strains (Fogeda et al, 2000). Alternatively,
the cell lines used for the study may have been eo-infected with HCV (Ikeda et al, 1997;
Shimizu et al, 1999).
Hepatocytes may not be the primary site of viral replication. Antigenomic GBV-CIHGV
RNA was also detected in the mononuclear cell infiltrates in the portal areas of the liver
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(Kobayashi et aI, 1999;), in lymphoid and megakaryoctoid cell lines and primary vascular
endothelial cells (Handa et aI, 2000) . The detection of replicating virus in hepatic tissue
may reflect virus replication in haematopoietic cells and/or endothelial cells present in the
liver.
In their study of 6 cadaverbiopsies from one GBV-C/HGV positive patient eo-infected
-with lIIV, Mushahwar et al (1998) detected glyceraldehyde-3-phosphate dehydrogenase
(GAP-DH) mRNA and GBV-C/HGV RNA only in the liver which was localised to
individual hepatocytes. In multiple cadaver autopsies of 12 patients (4 with AIDS, 6 lIIV
positive and 2 with end stage liver disease), Laskus et aI, (1998) and Radkowski et al
(1999) consistently demonstrated GBV-CJHGV RNA intermediaries in the bone marrow
and spleen. However, these results are difficult to interpret in irnmunocompromised
patients. In a preliminary study of 23 cadaver biopsies from four GBV-C/HGV positive
patients who were lIIV negative, the spleen and bone marrow biopsies were uniformly
positive for both negative-and positive strand GBV-C/HGV RNA (Tucker et aI, 2000).
The authors concluded that GBV-C/HGV is a lymphotropic virus that replicates primarily
in the spleen and bone marrow (Tucker et aI, 2000) . These findings require confirmation
using in situ hybridisation and irnmunohisochemical staining.
Strand-specific detection of RNA is fraught with problems such as false priming of the
incorrect strands or self-priming related to RNA secondary structure. All of the strand
./
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specific studies used methods to reduce false pruning and self-priming events VIZ.
chemical modification of the 3' ends (Saito et aI, 1997; Madejon et aI, 1997); conducting
cDNA synthesis at high temperature with the thermostable enzyme (rTth) (Laskus et al,
1997, Tucker et al, 2000) ; using in vitro derived templates (Laskus et al, 1997; Mellor et
al,1998; Tucker et al, 2000); using "tagged" primers (Mellor et al,1998; Seipp et al,
1999); in situ hybridisation of liver biopsies (Seipp et aI, 1999; Kobayashi et aI, 1999)
and in vitro infection of human hepatoma cells with GBV-CIHGV mono-infected serum
(Seipp et al, 1999). Only Laskus et -al (1997) and Mellor et al (1998) qualified their
reactions using in vitro derived templates and provided end point titration data. The site
ofGBV-CIHGV replication has been an area of intense interest and remains unresolved.
1.9 Disease association of GBV-CIHGV infection
1.9.1 Liver disease
Despite the accumulated body of knowledge after the discovery of GBV-CIHGV the
clinical significance of GBV-CIHGV and whether it caused significant acute or chronic
liver disease was controversial Most GBV-CIHGV infections appear to be
asymptomatic, transient, and self-limiting, with slight or no elevation of alanine
aminotransferase (ALT) (Alter et al; 1997a,b). Co-infection with GBV-CIHGV -does not
alter the clinical course of community acquired Hepatitis A, B or C (Alter et al; 1997a,b).
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Most of these sub-clinical cases resolve after loss of serum GBV-C/RGV RNA with a
concomitant appearance of anti-E2 antibodies (Dille et aI, 1997; Gutierrez et aI, 1997).
To evaluate the clinical course of GBV-C/RGV infection, patients infected with GBV-
CffiGV only were studied by Wang et al (1996). Among 25 such patients who acquired
their GBV-CffiGV infection by transfusion, twenty (20) patients who were followed up
at 2-4 week intervals over six months maintained normal ALT activities (Wang et aI,
1996); the other five patients showed only moderate elevations in ALT « 124 lUll) over
the first six months, with no further elevations in the subsequent follow-up period of two
years (Wang et aI, 1996). In these five patients, there were no other clinical signs of liver
disease. Jaundice was absent in the 25 patients, whereas it was present in two out of the
seven patients with RCV eo infection (Wang et aI, 1996). GBV-CffiGV is capable of
inducing persistent infection in about 5 -10% of infected individuals. In a retrospective
study, Masuko et al (1996) followed eight haemodialysis patients with GBV-CffiGV
infection for 7-16 years. In two patients, the virus was present at the start of
haemodialysis. One had a history of transfusion, and GBV-CffiGV RNA persisted over a
period of 16 years, the other cleared GBV-CffiGV RNA after 10 years. In five patients,
GBV-CffiGV RNA was first detected 3-20 weeks after blood transfusion and persisted
for up to 13 years. No elevations in serum ALT or signs of active liver disease were
found in these patients. It would appear that in many patients infected with GBV-CIHGV,
virus replication could occur without detectable damage to the liver. GBV-CIHGV
transmission to chimpanzees and tamarins resulted in infection without elevation in ALT
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(Bukh et ai, 1998). On the contrary, GBV-CIHGV infection in macaques (Cheng et ai,
2000) produced mildly elevated ALT levels with mild hepatitis and positive antigenic
expression in hepatocytes, suggesting that GBV-CIHGV may be pathogenic to primates.
A strong association between GBV-CIHGV and fulminant hepatitis has been suggested
(Yoshiba et ai, 1995; Heringlake et ai, 1996a) and may be associated with a specific
strain of GBV-CIHGV (Heringlake et ai, 1996a). However, these studies did not clearly
define whether GBV-CIHGV was transmitted as a result of the transfusions they received
prior to the onset of fulminant hepatitis. Additional studies by Yoshiba et al (1995)
showed that only a few of the fulminant hepatitis patients studied had received blood
transfusion prior to the onset of fulminant hepatitis. In a similar study, GBV-C/HGV
RNA was detected in 3/15 (20%) patients with HBV infection and in 3/25 (12%) patients
without markers of hepatitis A-E infection (Tarneda et al, 1996). Of the six patients with
GBV-CIHGV RNA, only three had a history of transfusion and all of these patients were
eo infected with HBY. According to Tarneda et al (1996) these results support a role of
GBV-CIHGV in inducing fulminant hepatitis either by itself or in concert with other
hepatitis viruses. Using real time detection polymerase chain reaction (RID-PCR), GBV-
elHGV RNA was measured serially in the sera of 3 Japanese patients with non A-E
fulminant hepatitis, none of whom received any therapeutic transfusions before
admission (Inoue et ai, 1999). Serum ALT levels paralleled GBV-C/HGV RNA in all 3
cases and sequence analysis revealed that the same GBV-C/HGV strain infected the
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patients during their entire clinical course, despite plasma exchange therapy. In one
patient hepatocyte destruction continued with persistent viraemia, although ALT levels
decreased. The authors (Inoue et ai, 1999) concluded that their assumption of an
association of GBV-eIHGV with fulminant hepatitis in these 3 patients was further
strengthened by the disappearance or persistence of GBV-CIHGV RNA in serum which
appeared to be linked to the prognosis. However, several other studies have provided no
evidence of an association of GBV':'CIHGV with fulminant hepatitis (Hadziyannis, 1997).
The discrepancies in the association of GBV-C/HGV with fulminant hepatitis may be
influenced by the sensitivity of the detection system and the differences in the GBV-
CIHGV infection rates in the different populations studied. The role of GBV-CIHGV in
the aetiology offulrninant hepatitis remains inconclusive.
Some investigators have reported histological features in liver biopsies of GBV-CIHGV
infected individuals. Among six chronic hepatitis patients with GBV-CIHGV RNA only,
the histology of the liver samples revealed chronic active hepatitis in one patient and
chronic persistent hepatitis in five others (Fiordalisi et ai, 1996). All patients with chronic
hepatitis had elevated ALT levels "between 89 and 478 U/L. In contrast, among the 11
acute hepatitis cases positive for GBV-CIHGV RNA, the ALT levels varied between 615
and 2477 U/L. Colombatto et al (1997) studied GBV-CIHGV in 67 patients with liver
disease without any markers for hepatitis A-E. They reported an association between
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non-specific inflammatory bile duct lesions and elevated cholestatic enzymes (gamma
glutamyl trans peptidase and alkaline phosphatase) in 50% of patients. Ross et al. (1997)
showed that GBV-C/HGV infection might affect the clinical course and outcome after
orthotopic liver transplantation (OLT) by the development of severe cholestasis, which
could result from bile duct damage and bile duct loss. In a preliminary study, an
association between recurrent or de .novo GBV-C/HGV infection and severe post-
transplant cholestasis and ductopenia was also observed in the grafts of GBV-C/HGV.:
positive liver organ transplant patients (Dhillon et ai, 1996). However, in many studies no
correlation between GBV-C/HGV infection and elevation of cholestatic enzymes was
noted. Further investigations are needed to substantiate these findings.
Manolakopoulos et al (1998) found an association between GBV-C/HGV and HCV-
viremia and portal and periportal inflammation. They reported that the duration of
HCVIGBV-C/HGV eo-infection may be an important factor in the progression of liver
disease and that inflammation with necrosis in the portal and periportal tracts was
significantly higher in patients with combined viremia compared to those with HCV
infection alone. The authors suggested that GBV-C/HGV in patients with HCV infection
might accelerate liver injury toward more severe fibrosis in patients with dual infection.
Diamantis et al (1997) reported that mild fibrosis correlated with GBV-C/HGV whilst
Francesconi et al (1997) observed subtleties in histologicalappearance in HCV eo-
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infected patients. However, numerous studies have shown that in HCV eo-infected
individuals, GBV-C/HGV does not affect HCV replication, HCV RNA concentration or
liver disease (Slimane et al, 2000; Enomoto et ai, 1998; Pawlotsky et ai, 1998; Petrik et
ai, 1998; Bra1et et ai, 1997; Tanka et ai, 1996).
During OLT, pre-transp1ant GBV-CIHGV has been reported to be associated with post-
transplant viraemia (Fried et ai, 1997; Feucht et ai, 1997b; Haagsma et ai, 1997). In the
absence of HBV or HCV in liver transplant recipients, the prevalence of GBV-CIHGV
infection has no influence on the graft (Haagsma et ai, 1997). Berg et al (1996b) found a
significantly higher percentage of hepatocellular carcinoma in patients with pre-OLT
GBV-C/HCV eo infection compared with patients with HCV infection alone (5/6 vs.
16/68;P<0.01). Bizollon et al (1998) on the other hand showed that the prevalence of
hepatocellular carcinoma was not different in patients with pre-transplantation GBV-
CIHGV eo infection or with HCV infection. In addition, GBV-CIHGV eo-infection did




In a study in Japan. GBV-CIHGV RNA was detected in 111111(10%) cases of
hepatocellular carcinoma (lICC) (Kanda et ai, 1997). The authors concluded that GBV-
CIHGV was unlikely to be a major aetiological agent of non-B non-C HCC. In a large
series of 503 patients with HCC in Europe, Brechot et al (1998) demonstrated a major
'impact ofHBV (19% positive) and HCV (40%) but not GBV-CffiGV (7%) in HCC. In a
study of 167 Black South Africans with HCC and 167 matched controls, Lightfoot et al
(1997) showed that patients infected with GBV-CIHGV did not have an increased
relative risk of developing HCC. hi addition, eo-infection with GBV-CIHGV did not
further increase the risk ofHCC in patients chronically infected with HBV and HCY. In a
retrospective study ofGBV-CIHGV in formalin-fixed, paraffin embedded (FFPE) tissues
of HCC patients from various geographic areas (Japan, Spain, Korea, United States,
Japanese Americans in Hawaii), GBV-CIHGV was neither detected nor was there any
evidence of any association ofGBV-CIHGV with HCC (Abe et ai, 1998). In this study
HCV genotype ID1 b and HBV were significantly associated with HCC.
In a population based study of non-Asian patients with HCC and community controls in
Los Angeles, California, Yuan et al (1999) concluded that GBV-CffiGV infection may
account for approximately 8% of HCC. GBV-CIHGV RNA was detected in the sera of
12/144 (8.3%) non-Asian patients with HCC and 5/225 (2%) community controls. The
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presence of GBV-CIHGV RNA was associated with a statistically significant 5.4 fold
risk which was independent of the effects of HBV and HCV infections (Yuan et al,
1999). In a hospital based case controlled study in Brescia, Italy the relative risk factor
suggested a fair association between GBV-CIHGV infection and HCC (Tagger et al,
1997). However, GBV-CIHGV did not seem to be a major aetiological agent of HCC
because the population-attributable risk was lower (4%) than those for HBsAg (52%),
HCV RNA (36%) and excessive alcohol intake (52%) (Tagger et al, 1977). Among
subjects with GBV-CIHGV exposure (RNA and anti-E2 positive) a greater proportion of
cases (40%) than controls (14%) had a transfusion history (Tagger et al, 1997).
Hepatocarcinogenicity of GBV-CIHGV is an important question that remains to be
conclusively demonstrated.
1.9.3 Extra hepatic manifestations
Hepatitis associated aplastic anaemia is a rare but well-documented phenomenon unlikely
to be caused by any of the known hepatitis viruses (Brown et al, 1997a; Byrnes et al,
1996). In some cases of hepatitis-associated aplastic anaemia GBV-CIHGV was the only
aetiological agent detected, even if the patients had not received any transfusions before
diagnosis (Zaidi et al, 1996; Kiem et al, 1997a,b; Crepo et al, 1999). Moriyama et ai
(1997) detected GBV-C/HGV RNA in 5/18 (27.7%) patients with aplastic anaemia who
received blood transfusions before diagnosis but not in 8 patients who did not receive
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transfusions. Similarly, Brown et al (1997a,b) detected GBV-C/HGV RNA in 26.3% and
23.1% of patients with aplastic anaemia and multitransfused control patients,
respectively. Kiem et al (1997b) detected GBV-C/HGV RNA in 26.1% of patients with
hepatitis-associated aplastic anaemia and idiopathic aplastic anemia who did not receive
transfusions. The authors concluded that although transfusions are a major source of
GBV-C/HGV infection, the high prevalence in those who did not receive transfusions
suggests an association of GBV-C/HGV with aplastic anaemia, whether associated with
hepatitis or not. Further studies in serial serum samples and meticulous evaluation of the
disorders associated with the infection will be needed to prove or disprove a causal
association of GBV-C/HGV and aplastic anaemia.
It is interesting to note that GBV-C/HGV replication has been consistently shown to
occur in bone marrow and spleen, but not in the lymph nodes and tonsils (Laskus et aI,
1998; Radkowski et aI, 1999; Tucker et aI, 2000) suggesting a haematological cell
tropism Because the genomic organisation, structural and biological characteristics of
GBV-C/HGV are similar to that of HCV, GBV-C/HGV has been investigated as a
possible aetiological agent in the development of haematological disorders. Ongoing
GBV-C/HGV infection was detected in 29 of 60 (48%) multitransfused patients with
hematological malignancies (Skidmore et aI, 1997). GBV-C/HGV prevalence in patients
with B-cell non-Hodgkin's lymphoma was significantly higher than in healthy controls
(1-5%) (Ellenrieder et aI, 1998). All patients were asymptomaticand without clinical or
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sonographic signs of chronic liver disease (Ellenrieder et al, 1998). GBV-CffiGV
prevalence in lymphoma or cryoglobulinemia patients do not support the hypothesis that
this virus also may play a major role in lymphomagenesis or in the production of mixed
cryoglobulinemia (Cacoub et aI, 1997; Nakamura et aI, 1997; Ellenrieder et aI, 1998).
Pavlova et aI (1999) investigated two groups of patients, one with clonal stem cell
disease with long latency period (myelodysplasia, myeloproliferative disease) and one
with malignant haematological diseases (Hodgkin's lymphoma, non-Hodgkin's
lymphoma, acute leukemia, multiple myeloma). The prevalence of GBV-CffiGV RNA in
the group of oncological cases (72%) was significantly higher (P= .02) than in the
patients with clonal stem cell diseases (28%). A correlation could not be confirmed
between GBV-CffiGV and liver enzyme levels, blood transfusions, chemotherapy, or
viral eo infection (Pavlova et aI, 1999). GBV-CffiGV infection in these patients is most
likely to have originated from exposure to blood products, and to persist because of
deficient immune surveillance. However, the clinical significance of these fmdings with
respect to liver dysfunction is not yet clear. The pathogenetic consequences of GBV-
CffiGV infection in lympoproliferative disorders has not been conclusivelyproven.
Viral infections are presumed to trigger autoimmune processes. Although Heringlake et
aI (1996b) reported a higher prevalence of GBV-CffiGV in autoimmune hepatitis (AllI)
type l-Ill (9.8%). It was not statistically significant compared to blood donors (4.7%). In
contrast, Tribl et aI (1999) found a significantly increased prevalence ofGBV-CffiGV in
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patients with AIH (11%) than in healthy controls(2%). However, it remains unclear
whether infection with GBV-CIHGV has an impact on the course of disease in patients
with AIR. Persistent GBV-CIHGV RNA was detected in 7/36 (19.4%) thalassemic
patients but was not associated with significant biochemical evidence of liver damage
(Zemel et al, 1998). Patients with common variable immunodeficiency (CVID) are prone
to unexplained chronic hepatitis whilst patients with X-linked agammaglobulinemia
(XLA) who have a similar primary antibody deficiency are not prone to hepatitis (Morris
et al, 1998). In their study of 78 CVID and 28 XLA patients, Morris et al (1998)
concluded that the high prevalence of GBV-CIHGV viraemia is due to the long-term
exposure to blood products and that GBV-CIHGV does not cause chronic hepatitis in
immuno-compromised XLA patients. In addition, the authors (Morris et al, 1998)
suggested that in the majority of CVID patients GBV-CIHGV is not the cause of chronic
non-B or -C hepatitis. In Japanese leprous patients the prevalence of GBV-CIHGV was
higher (5.2%) than in blood donors (1%) (Egawa et al, 1996). Tucker et al (1998)
suggested an association with glomerulonephritis, hinting that virus replication may
occur in the kidney.
1.10 GBV-CIHGV infection in patients infected with HIV
Based on the detection of GBV-CIHGV RNA and/or ariti-E2, several studies have
reported a high frequency (9-66%) of GBV-CIHGV infectionin HIV-infected risk groups
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(Nubling and Lower, 1996; Feucht et aI, 1996; Jarvis et aI, 1996; Kinoshita et aI, 1997;
Nubling et ai, 1997; Toyoda et ai, 1998; Woolley et al, 1998; Ibanez et aI, 1998; Scallan
et ai, 1998; Nerurkar et ai, 1998; Rey et aI, 1999; Bourlet et aI, 1999), but few studies
have performed a detailed analysis of the clinical significance of GBV-C/HGV in HfV
infected patients. In their study of high risk groups, Rey et aI (1999) reported that the
high prevalence of GBV-C/HGV was not influenced by the clinical status of the patient,
but by the immune (CD4+) status. However, Rey et aI (1999) did not compare their
results to a non-HlV infected cohort. Goubau et aI (1999) observed no significant
difference in the CD4+ lymphocyte counts between RNA and anti-E2 positive patients.
This finding contrasts with the study by Heringlake et aI (1998), who found higher CD4+
lymphocyte counts in GBV-C/HGV RNA positive patients than in E2 antibody carriers.
Wooley et al (1998) on the other hand observed no significant difference in the mean
CD4+ counts between GBV-C/HGV positive and GBV-CIHGV negative patients,
however, the mean CD8+ count in GBV-C/HGV negative group was significantly lower
than the mean CD8+ count in the GBV-CIHGV positive group. The authors (Wooley et
ai, 1998) concluded that this may reflect an expression of CD8 lymphocytes in response
to GBV-CIHGV infection, but this relationship requires further confirmation.
Some researchers have suggested that GBV-C/HGV may be a favourable prognostic
factor in mv infected patients (Toyaoda et aI, 1998; Heringlake et aI; 1998; Lefrere et
aI, 1999; Yeo et aI, 2000). Yeo et aI (2000) and Heriglake et a (1998) reported higher
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CD4 + lymphocyte counts and better AIDS-free survival rate in lllV infected patients eo-
infected with GBV-C/HGV, an association that was independent of age and CCRS
genotype (Yeo et aI, 2000). Toyoda et aI (1998) reported lower lllV viral load and AIDS
incidence with the detection of GBV-C/HGV RNA in serum Conversely, Sabin et aI
(1998) found an increased risk for AIDS and death with detection of GBV-C/HGV RNA
or anti-E2 antibodies. The difference was not statistically significant in either of these
studies. Lefrere et aI (1999) noted significantly lower HfV viral load, higher CD4+
Lymphocyte count, and better AIDS-free survival in patients with GBV-C/HGV RNA
than in those without GBV-C/HGV RNA or anti-E2 antibodies.
Xiang et aI (2000) constructed a full length cDNA from the plasma of a patient with
chronic GBV-C/HGV viraemia. PBMC transfected with these transcripts resulted in viral
replication, primarily in CD4+ T cells (Xiang et aI, 2000). Since GBV-C/HGV
replication has been demonstrated in CD+ T cells in vitro (Xiang et aI, 2000) , it is
tempting to speculate that GBV-CIHGV may cause viral interference with HIV leading to
delayed disease progression (Toyaoda et aI, 1998; Heringlake et aI, 1998; Lefrere et aI,
1999; Yeo et al, 2000) .
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1.11 Interferon (IFN) treatment of and immunity to GBV-C/HGV infection
There are conflicting reports concerning the sensitivity of GBV-CIHGV to interferon
(IFN) therapy. In some studies it seems to be similar to HCV (Tanka et aI, 1996; Berg et
aI, 1996b; Orito et aI, 1997 Jarvis et aI, 1999), in other studies it appears to be
independent (McHutchison et aI, 1997; Umlauft et aI, ,1997; Nagayama et aI, 1997),
however, the response may be different (Saiz et aI, 1997). During IFN-a. therapy, serum
GBV-C IHGV RNA levels decrease in most patients treated, and it may become
undetectable (Nagayama et aI, 1997; Saiz et aI, 1997; Jarvis et al, 1999; Martinot et aI,
1997). In only a small percentage of patients the response is sustained, and in most cases
the GBV-CIHGV RNA concentration returned to pretreatment levels after therapy was
stopped. Predictors for the efficacy of IFN therapy on HCV infection are genotype, viral
load, IFN dose and the amino acid substitutions in the NS5A region, designated 'as the
interferon sensitivity determining region (ISDR) (Shiratori et aI, 1997). However, most
researchers detect no influence of GBV-CIHGV infection in response to IFN-a. in
patients with chronic HCV (Tanaka et aI, 1996; Orito et aI, 1997; Saiz et aI, 1997;
Martinot et aI, 1997; Kato et aI, 1999;). No correlation between the amino acid sequence
in the GBV-CIHGV NS5A region and response to IFN therapy was found, indicating that
the GBV-CIHGV NS5A region does not act as the ISDR (Kato et aI, 1999; Fujisawa et
aI, 2000). A GBV-CIHGV sustained response is predictable in patients with a low
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pretreatment GBV-CIHGV viral load (Saiz et aI, 1997; Nagayama et aI, 1997; Orito et aI,
1997; Enomoto et aI, 1998; Jarvis et aI, 1999).
Little is known about the mechanisms that enable GBV-CIHGV to establish persistent
infection. Although HCV and GBV-CIHGV belong to the same Flaviviridae family, these
viruses have different pathogenicity with the host. Analyses of GBV-CIHGV isolates of
diverse origin have shown a different evolutionary pattern for these viruses (Erker et aI,
1996; Muerhoffetal, 1996; Pickering·etal, 1997; Wang et aI, 1997b; Gimenez-Barcons,
et aI, 1998). Neither a viral hypervariable region, nor putative immune escape variants
have been detected in chronic GBV-CIHGV infection (Erker et aI, 1996; Muerhoff et aI,
1996; Wang et aI, 1997b; Bukh et aI, 1998; Kato et aI, 1998). Recently, Giminez-
Barcons et al (2000) analysing the temporal nucleotide sequence changes in 5' NCR and
NS3 regions of GBV-CIHGV isolates from patients with chronic hepatitis eo-infected
with HCV and who received a single course of IFN therapy, showed to a limited extent
that positive selection may act over the GBV-CIHGV genome during interferon therapy,
and contribute to the persistence of infection with this virus.
Little is known about the intrinsic immunogenecity of the GBV-OHGV envelope E2
protein. Humoral immune response to viral proteins is usually associated with clearance
of GBV-CIHGV RNA (Feucht et aI, 1997a; Tacke et aI, 1997a,b; Dille et al, 1997).
Little or no information concerning the cellular immune responses has been reported.
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Sequence differences between viral strains and genotypes of many viruses can affect
antibody and T cell recognition (Zhang et al, 1997). Immune responses to two
recombinant E2 proteins, representing Genotypes 1 and 2 of GBV-CIHGV were studied
in mice and in individuals with or without chronic or past infection with GBV-CIHGV
(Lazdina et aI, 2000). The authors (Lazdina et al, 2000) observed that immunised mice
developed E2-specific antibodies, recognising linear antigenic regions and IL-2, IL-6 and
y IFN cytokine responses regardless of the viral genotype (Lazdina et aI, 2000). In
addition individuals with past GBV-CIHGV infection had E2 antibody titres that did not
recognise E.coli derived E2 protein or linear antigenic regions. Proliferative E2-'specific
responses were detected in peripheral PBMC from patients with and without GBV-
CIHGV markers (Lazdina et aI, 2000). Whist the study only included 2 of the 4 (Smith et
a12000) current genotypes, immune responses to GBV-CIHGV E2 protein appears to
cross react with different variants of genotypes of GBV-CIHGY. Proliferative responses
appear to be rare and the E2 protein appears to be more immunogenic in immunised mice
than in infected humans. It is generally accepted that the host immune system is a major
cause for the destruction of liver cells and the development of liver disease in most
infection caused by non-cytolytic hepatotropic viruses. Basic studies on the immune
responses to GBV-CIHGV proteins and GBV-CIHGV infections may help to understand
the natural course and pathogenesis, ifany, of this infection.
54
Since 1992 alarm over emerging and re-emerging diseases has resulted in a number of
national and international initiatives to restore and improve surveillance for infectious
diseases in order to detect emerging diseases promptly and to identify new infectious
diseases. At the time of gestation of this dissertation (1996-1997) nothing was known. .
about the prevalence and pathogenic role of GBV-CIHGV in Southern Africa, especially
in Kwa Zulu Natal (KZN), South Africa. In an endemic area where HBV is known to be
associated with chronic liver disease, GBV-CIHGV may be an important cornmensal in
patients with liver disease due to chronic HBV and/or HCV.
South Africa is considered to have the fastest-growing HIV positive population in the
world, and Durban in KZN, is the epicentre of the HIV epidemic. The impact of eo-
infection with HBV or HCV on the outcome of AIDS, although still controversial, is
associated with an impaired survival Most of these patients often die from liver failure
instead of AIDS. Thus one would presume that since GBV-CIHGV is considered to be a
"hepatitis" virus, similar results would be expected in the interaction between GBV-
CIHGVand HIV. To what extent GBV-CIHGV persistence leads to chronic liver disease
is unclear nor is it known whether GBV-CIHGV persistence affects the rate of
progression to AIDS. Long lasting diseases such as chronic viral hepatitis may become
more relevant in these patients, especially in an environment where hepatitis is endemic.
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Initially, systematic analysis of six complete GBV-C/HGV genome sequences revealed
that congruent phylogenetic relationships were obtained for only a minority of fragments,
and that the optimal region was all or part of the 5' NCR At present 33 epidemiologically
unrelated GBV-C/HGV complete virus genome sequences are available in the Genbank
database. A re-analysis of the phylogenetic relationships of GBV-C/HGV complete
genome sequences and the extent to which these can be reproduced by analysis of sub
genomic regions is essential
The routine screening of donated blood will be difficult to implement until the clinical
significance and pathogenicity of GBV-C/HGV are established. Epidemiological studies
based on immune and molecular assays are required to establish whether GBV-C/HGV is
a true pathogen. The prevalence data, pathogenesis and possible genotypes of the virus
may have important implications especially in blood donors which may influence Blood
Bank policies on an already limited resource , blood and blood products.
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Objectives ofthe study:
This dissertation will attempt to define the role of GBV-C/HGV infection in KZN, South
Africa with the following aims in mind:
1. To assess and optimise methods that can be used to diagnose GBV-C/HGV
infection so that the situation of GBV-C/HGV in KZN can be determined.
Nucleic acid amplification by PCR remains the method of choice. A protocol using
published primer sequences will be used to detect GBV-C/HGV in sera. The in-house
assay will be compared with a prototype commercial automated RT-PCR assay. Testing
of GBV-C/HGV by RT-PCR is time consuming and expensive. An alternative to RT-
PCR will be the detection of antibodies to GBV-C/HGY. A prototype serological assay
will be used to detect GBV-C/HGV antibodies and compared to RT-PCR The detection
methods will be used to determine the prevalence and transmission of GBV-C/HGV in
blood donors, patients with liver disease and high-risk groups.
2. To determine an association, ifany, ofGBV-CfHGV to liver disease
The study group will include blood donors (from all four racial groups); patients with
chronic liver disease; patients on maintenance haemodialysis; alcoholic subjects with and
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without liver disease and mv seropositive patients. Detailed demographic, clinical,
hisological and biochemical data will be obtained from all study groups where possible.
3. To establish the molecular epidemiology ofGBV-CIHGV in KZN.
Virus phylogeny will be performed using sub genomic regions of local isolates of GBV-
CIHGY. To determine the phylogenetic relationship of local isolates, sequence data from
various regions of the GBV-CIHGV genome will be compared with sequence data
available in the Genbank database from various geographic regions of the world. A re-
analysis of the phylogenetic relationships of GBV-CIHGV complete genome sequences





DIAGNOSIS AND PREVALENCE OF GBV-C/HGV INECTION IN
KWAZULU NATAL, SOUTH AFRICA
2.1 INTRODUCTION
A sensitive technique for the specific detection of GBV-CIHGV without cross
reactivity to HCV is essential in order to study the epidemiology of GBV-CIHGV
infection. Thus, the identification of viraemic samples has relied on the detection of
viral RNA. Several nucleic acid-based assays have been developed for this
purpose. Although labour-intensive, many of these assays are sensitive and
specific. The second generation RT-PCR assays target highly conserved regions
within the 5' NCR (Schlueter et aI, 1996) that appears to be more sensitive and
more widely used (Kao et aI, 1997a). Kao et al (1997a) compared the sensitivity
and specificity of PCR assays using primers from different regions of the viral
genome viz. 5' NCR, £2 and NS3 . The positive rates by 5' ·NCR, NS3 and £2
primers were 100%, 98% and 84%, respectively, and the sensitivity of the PCR
assays using 5' NCR primers were 10-100 times more likely to detect GBV-
CIHGV RNA than that ofNS3 and E2 primers (Kao et aI, 1997a). These results
were confirmed by other investigators (Bhardwaj et aI, 1997; Cantaloube et aI,
1997). In this dissertation, nested primers from the 5' NCR (Jarvis et aI, 1996) of
the genome will be used to detect GBV-CIHGV RNA.
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Because GBV-CIHGV RNA was detected in blood donors (Table 1.3), the question
arose as to whether blood banks should include the detection of GBV-CIHGV in
their routine screening algorithm. The screening of blood donations is mostly
performed with serological tests. In contrast to what is found for HCV, the
identification of serological markers indicative of ongoing GBV-CIHGV infection
needs to be established. Anti-E2 antibody detection is not associated with active
replication of the virus, and these antibodies are detectable after RNA clearance. It
therefore seems logical to use anti-E2 to study the epidemiology and effectiveness
of treatment (should the virus be found to be associated with clinical disease) of
GBV-CIHGV infection. Third generation RT-PCR assays have been developed
which permit a higher level of through-put in conjunction with ease of use. Very
little is known about the epidemiology of GBV-\CIHGV in African countries and
much less information is available on the prevalence and preferred transmission
routes of GBV-CIHGY
2.2 METHODS
2.2.1 Source of Samples
2.2.1.1 Collection of Sera
Venous blood was collected in a 6ml sterile Vacutainer" SST<!!>GeI and Clot
Activator tubes (Becton Dickenson, UK) . Blood samples were transported in
crushed ice to the laboratory. All blood samples were processed within 2 hours
after bleeding. Vacutainer" Tubes were spun for 5 minutes (min) at 2500 rpm
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(revolutions per minute) at 4°C in a Beckman Model J6B - Centrifuge. Sera were
serially aliquoted and stored at - 85°C. Sera were thawed once only for any given
assay.
2.2.1.2 Patients
Sera were collected from a high-risk group of 70 patients with chronic renal failure
who were undergoing maintenance haemodialysis, 98 consecutive patients with
chronic liver disease and 50 ·patients with biopsy proven alcoholic liver disease
(Table 2.1). Diagnosis of liver disease was based on clinical findings and laboratory
data and confirmed on liver biopsy. Histological examinations were done by the
same pathologist who was not aware ofthe clinical and laboratory findings.
GBV-CIHGV infection was also studied in a "convenience" sample of 75 HfV
positive mothers and their infants who participated in an HfV prospective clinical
investigation on the perinatal transmission ofIllV in KZN (Coutsoudis et aI, 1999)
(Table 2.1). Sera were collected from the mothers at 33-38 weeks ofgestation. The
sera were stored under coded identifier numbers in aliquots at - 85°C. To
investigate mother-to-infant transmission of HfV, babies were followed up for 18
months (Coutsoudis et aI, 1999). To identify mother-to-infant transmission of
GBV-CIHGV, serum samples were only available for 20 mothers and their babies
at 1 week and at 3-monthly intervals for 9 months. Serum samples were not
available for all 20 babies.
2.2.1.3 Control groups
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The control groups included sera obtained from 232 adult volunteer blood donors
from the four racial groups (Africans [n=76], Whites [n=49], "Coloureds" {mixed
origin} [n=54], and Indians [n=52] (Table 2.1). Thirty-five (35) individuals who
did not present to hospitals for signs or symptoms of liver disease were referred to
the local center for alcohol detoxification (Alcoholics Anonymous) were recruited
(Table 2.1). The latter group was studied after at least 2 weeks of alcohol
withdrawal (healthy alcoholic subjects without liver disease).
2.2.2. Extraction of viral RNA and DNA from sera
2.2.2.1 GBV-CIHGV and HCV RNA
GBV-CIHGV and HCV viral RNA were extracted from serum using the Ql.Aamp'"
Viral RNA Kit (Qiagen, Gmbh, Germany). The manufacture's recommended
procedure was modified (Marshall et aI, 1998). Carrier RNA (poly A) (6.7 ug/ml)
was used at a reduced concentration in AVL Buffer. For the 50 prepration QIAamp
Kit(!!,) 1.5ml of buffer AVL was added to the lyophilised carrier RNA tube (825ug)
provided. The RNA was dissolved thoroughly. Three hundred and seventy-five
microlitres (375ul) of the solution was transferred to the Buffer AVL and
thoroughly mixed. For the 250 preparation QIAamp Kit(!!,) 3.0ml of buffer AVL was
added to the lyophilised carrier RNA tube (4200ug) provided. Seven hundred and
62
fifty microliters (750ul) of the solution was transferred to the Buffer AVL and
thoroughly mixed. Buffer AVL/carrier RNA was stored at 4°C in 7.0ml aliquots
(each 7.0ml aliquot was enough for 24 specimens). Ethanol (96-100%) as
recommended by the manufacture was added to the Buffer AW before use.
Aliquots of Iml of 0.1% (v/v) diethylpyrocarbonate (DEPC) treated water was
dispensed into 1.5 ml sterile RNAase free microfuge tubes. Each Iml aliquot
contained enough water to elute approximately 9-0 specimens. The aliquots of
water were equilibrated at 80°C in a water bath. For each serum specimen280ul of
Buffer AVL/carrier RNA was dispensed into a sterile RNAase-free 1.5ml
microfuge tube. The microfuge tubes were transferred to a biosafety hood approved
for working with biohazardous material. Serum specimens were thawed at room
temperature (15-30°C) and stored on wet ice immediately upon thaw. Each
specimen was vortexed for 2-5 seconds (sec) and then centrifuged (Eppendorf
Microcentrifuge Model 5415C) at 14 000 rpm for 5 min at room temperature (15-
30°C) to clear any precipitate which may be present. Twenty-five microlitres
(25ul) of serum was added to 280ul of AVL buffer/carrier RNA. Tube was
vortexed for 2-5 sec and allowed to incubate at room temperature for 10 min to
complete the lysis process. The tubes were pulse centrifuged at 14 000 rpm for 2-5
sec to remove any buffer from the cap of the microfuge tubes. Ethanol (280 ul) was
then added to the mixture which was vortexed for 2-5 sec. The tubes were pulse
centrifuged at 14 000 rpm for 2-5 sec to remove any buffer from the cap of the
microfuge tubes. The entire volume (585 ul) was applied to the QlAamp spin
column without moistening the rim. The cap ofthe microfuge tube was closed and
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the tubes centrifuged at 8 000 rpm for 1 mm. The QIAamp spin column was
transferred to a clean 2ml collection tube and the tube containing the filtrate was
discarded. The QlAamp spin column was carefully opened to prevent aerosol
formation and 500ul ofBuffer AW was added without moistening the rim, the cap
was closed and the tube centrifuged at 8000 rpm for 1 min. The QlAamp spin
column was transferred to a clean 2ml collection tube and the filtrate discarded.
Five hundred micr.oliters (500ul) of Buffer AW was added without moistening the
. rim, the cap closed and the tube centrifuged at 8000rpm for 1 min and at 14 000
rpm for an additional 2 min. The QlAamp spin column was transferred to a sterile
RNase free 1.5 ml microfuge tube and the filtrate discarded. The QIAamp spin
column was carefully opened and 100ul of DEPC-treated water preheated to 80°C
in a water bath was added directly onto the filter matrix, being careful not to run the
water down the side of the column. The tube was centrifuged for 1 min at 8 000
rpm. The column was discarded and the microfuge tube with the purified RNA
stored on ice. Purified RNA was either used immediately within 4 hr or stored at
-70°C. Upon thaw the purified RNA was vortexed for 2-5 sec prior to use and
pulsed centrifuged to remove any residual solution from the cap of the microfuge
tubes. The extracted RNA was used to detect GBV-C/HGV by RT-PCR and by
LCx(!!) system and HCV.
2.2.2.2 HBVDNA
64
HBV viral DNA was extracted from sera using the InstaGene™ Matrix (Bio-Rad .
Laboratories, CA, USA) according to the manufacturer's instructions.
2.2.3 Diagnostic Assays




A table summansmg the tests that were performed on the samples.
Serological (GBV-C/HGV Anti-E2 and HBeAg, HBsAg, anti-HBs, anti-
HBc) and or molecular (PCR, LCx) assays used to diagnose HBV, HCV
and GBV-C/HGV infections in blood donors, patients with liver disease
(ALD and CLD), alcoholics without liver disease and high risk groups
(HAEM, HIV positive)
TEST PERFORMED
Study group No. HBV HCV GBV-CIHGV
eAg sAg sAb cAb PCR PCR E2 IPCR ILCx
HAEM 70 ./ ./ ./
CLD 98 ./ ./ ./ ./ ./ ./
ALD 50 ./ ./ ./ ./ ./ ./ ./ ./




Africans 76 ./ ./
Whites 49 ./ ./
Indians 52 ./ ./
"Coloureds" 54 ./ ./
Alcoholic 35 ./ ./ ./ ./ ./ ./ ./ ./
controls
Total 504
ALD-alcohohc liver disease; CLD-chronic liver disease; HAEM-haemodialysis; GBV-
CIHGV-GB Virus CIHepatitis G Virus ; HCV-hepatitis C virus; HB/HBV-hepatitis B virus;
RIV-human immunodeficiency virus; Ag-antigen; Ab/anti- antibody; c-core; s-surface;






Using a modified method of Brown et al (1992) complementary DNA (cDNA) was
synthesized from 10ul of extracted RNA (GBV-CIHGV and HCV) melted at 70°C
for 10 min and added to 15ul of a mix containing 1.5uM pd/N), random hexamers
(pharmacia Biotech, Uppsala, Sweden), 5 x First Strand Buffer [50rnM Tris-HCI
[pH 8.3]; 40mM KCL; 6IlL.\1 MgCh) [Gibco-BRL, Life Technologies, Paisley,
UK); 250U Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT)
(Gibco-RL, Life Technologies, Paisley, UK), O.5mM (dNTPs) (promega
Corporation, Madison, USA) and 0.1% (v/v) DEPC treated-Hso and incubated at
37°C for 1 hr. The reaction was terminated by incubation at 95°C for 10 min.
2~2.3.1.2 PCRassay
Highly conserved nested pnmers (Oswald DNA Services, Southampton, UK)
designed from published sequences from the 5' NCR of the GBV-C/HGV (Table
2.2) of isolates PNF2161 (044402), RI0291 (U45966) and GBV-C (036380)
[Appendix A] and HCV (Table 2.3) genomes were used to perform the nested PCR.
Table 2.2
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Sequence and location of primers used for amplification of
the 5' NCR of the GBV-CIHGV genome (Jarvis et al, 1996)
Location Region Polarity" Sequence 5' to 3'
108 5'NCR + AGGTGGTGGATGGGTGAT
531 5'NCR TGCCACCCGCCCTCACCCGAA
134 5'NCR + TGGTAGGTCGTAAATCCCGGT
476 5'NCR GGRGCTGGGTGGCCYCATGCW
Orientationof primer sequence (+ sense, - anti-sense)
Table 2.3 Sequence and location of primers used for amplification of 5'NCR
ofthe HCV genome














Orientationof primer sequence (+ sense, - anti-sense)
In the first round of the PCR reaction, 5ul of the cDNA was added to 95ul of a
master mix containing a final concentration of 0.2mM dNTPs (Promega
Corporation, Madison, USA); lOxPCR Buffer (1.5mM MgCh, 20mM [NRthS0 4;
75mM Tris-HCI [pH 9.0]; O.Ol%(w/v) Tween 20) (Advanced
Biotechnologies,Surrey, UK); 0.1% (v/v) DEPC treated - H20, 2.5U Thermoprine
plus DNA Polymerase (Advanced Biotechnologies, Surrey, UK) and 50pmol of each
primer located at positions 108 and 531 (Table 2.1). Two microliters (2ul) of the
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first round PCR product was added to 48 ul of a PCR master mix containing
0.2mM dNTPs; 10 x PCR buffer [1.5mM Mg2CI, 20mM [Nl4hS04; 75mM Tris-
HCI (pH 9.0), 0.01% Tween 20] and 50 pmol of each primer located at positions
134 and 476 (Table 2.2). Amplification was over 25 cycles in a Progene
thermocycler (Progene, Techne, Cambridge, UK) for both first and second rounds
of PCR, using the following temperatures, 96°C for 1 min, 50°C for 1 min, 72°C
for 2.5 min with a final extension at 72°C for 10 min followed by a 4°C soak.
Standard precautions for avoiding contamination for PCR were observed. Known
positive and negative GBV-CffiGV sera together with DEPC-H20 were included in .
each run to ensure specificity.
The amplification of HBV DNA was performed according to the method described
by Wright et al (1992) using the primers targeting the surface antigen (Table 2.4).
Table 2.4 Sequence and location of primers used for the detection
ofHBV DNA (Wright et aI, 1992)
HBV I Polarity* I Sequen.ce
Outer + 5'-GTTAGGGTTTAAATGTATACCC-3'
primers 5.'-CATCTTCTTATTGGTTCTTCTGG-3'
Inner + 5' -CATCTTCTTATTGGTTCTTCTGG-3'
primers 5' -AATGGCACTAGTAAACTGAGCC-3'
Orientationof primer sequence (+ sense, - anti-sense)
2.2.3.1.3 Agarose Gel Electrophoresis
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A 2% agarose gel was poured by melting 2.0g of agarose in IOOmls of Ix TBE
buffer. Five microliters (SuI) of Ethidium bromide (SOug/ml) was added to the gel
before it was poured. Five microlitres (SuI) of each PCR product was added to 5ul
of Bromophenol blue gel loading buffer (SO% glycerol; Ix TAE buffer; 1%
bromophenol blue : 1% Xylene cyanole ff). Two microliters (2ul) of molecular
weight marker (lKb DNA Ladder, (Gibco-RL, Life Technologies, Paisley, UK), .
was diluted in 3 ul of sterile DEPC-H20 and added to SuI of loading buffer. Ten
microliters (IOul) of each reaction along with the molecular weight marker was
loaded into the appropriate wells in the gel. Electrophoresis was performed at a
constant lOOV for approximately 1 hr. The gel was visualised on a DV
transilluminator and photographed.
2.2.3.1.4 Detection of GBV-CIHGV by the Abbott LCx® system
The Abbott LCx<!\) GBV-C Assay uses the nucleic acid amplification method ofRT-
PCR to generate amplified product material from GBV-CIHGV RNA in clinical
specimens and uses the LCx<!\'l Probe System for the qualitative detection of RNA
from the GBV-CIHGV in human serum or plasma in a single tube format. This
material is hybridized to a GBV-CIHGV specific oligonucleotide probe and hybrids
are detected in an LCx® Analyzer. The LCx<!\'l GBV-C Assay includes all of the
necessary components to generate a detectable GBV-CIHGV reaction product in
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the presence of the GBV-CffiGV target. The assay utilizes a primer/probe set that
is specific for the 5' NCR region of the GBV-CffiGV genome (Table 2.5) The first
primer (cDNAlPCR primer) is complementary to the RNA genome and serves as
both the cDNA primer and one of the PCR primers (SI). The second primer (AS2)
is the same sense as the genome and acts as the second PCR primer. A third
oligonucleotide, the probe, is present in the reaction mix and is complementary to
one of the strands of the PCR product (3FS3). In the presence of GBV-CffiGV
amplified product the probe/PCR strand complex serves as the detection product in
the LCx® Analyzer.
Table 2.5 Primer and Probe sequences used in the LCx® GBV-C Assay









The assay was carried out according to the manufacturer's instructions. Briefly,
20ul ofactivation solution (32.5 mM manganese) were added to amplification vials
containing ready to use master mix , and 20ul of extracted RNA were then added to
a "unit dose" tube containing the rest of the reagents (180ul) for RT-PCR, which
included a thermostable combined reverse transcriptase/DNA polymerase. After
vortexing, tubes were transferred to the amplification area and were placed in
LCxlPerkin Elmer Model 480 thermal cycler, where the following cycles were
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performed: a reverse transcription step of 30 min at 60°C, followed by 35 PCR
cycles of 94°C for 40 sec and 63°C for 1 minute. Subsequently the PCR products
were denatured (97°C for 5 min) and rapidly cooled to 15°C for 5 min. After
amplification the vials were allowed to remain at 15°C in the Thermal Cycler for up
to 24 hr prior to detection.
Within four" hours following amplification, tubes were centrifuged and removed to
the detection system (LCx®), which is based on the use of microparticle enzyme
immunoassay (ME lA) technology. A total of 24 samples may be analysed in one
hr, with the presence of GBV-CIHGV indicated by a positive rate of production for
the fluorescent product, 4-Methylumbelliferone. The rate of product generation was
automatically monitored and reported as counts per second per second (c/s/s) . The
cut-off rate for positivity was predetermined by Abbott Laboratories. Any sample
falling within an intermediate zone was re-tested in duplicate. The LCx® GBV-C
Assay reduces the potential of PCR product contamination in a number of ways.
Two high positive, two low positive and two negative controls were included in
each PCR and detection assay. To reduce the risk of amplification product
contamination, at the end of the LCx® GBV-C Assay, amplification product is
automatically inactivated using a two-reagent chemical inactivation system. Both
reagents are delivered into the LCx®Reaction Cells by the LCx® Analyzer after the
amplification product has been detected. The ensuing reaction results in the nearly
complete destruction of any nucleic acid present. This effectively reduces the risk
of contamination of the laboratory by amplification product.
2.2.3.1.5 Purification of the GBV-C/HGV PCR product
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The 344 bp PCR product generated by RT-PCR was purified using the QIA quick
PCR purification kit (Qiagen, GmbH, Germany) according to the manufacturer's
instruction.
2.2.3.1.6 Sequencing reaction
Both strands of the 344 bp PCR product were sequenced by Direct cycle
sequencing using the Big Dye" Terminator Cycle Sequencing Ready Reaction Kit
(perkin Elmer, Biosystems, CA, USA). Briefly, for each reaction 4.0ul of
terminator ready reaction mix, 90ng of the PCR product (DNA), 1.5ul (5pmol) of
either reverse or forward primer in a total volume of20 ul of sterile deinosied water
was added to a 0.2 ml PCR tube. The reagents were mixed, briefly spun and cycle
sequenced in the Perkin Elmer GeneAmp' 2400 thermal cycler (perkin Elmer,
Biosystems, CA, USA) initially at 96°C for 30 sec, followed by 96°C for 10 sec,
50°C for 10 sec, 60°C for 4 min for 25 cycles followed by a 4°C soak. The tubes
were spun briefly. The extension product was purified in microfuge tubes .The
entire contents of each extension reaction was transferred to a sterile 1.5ml
microfuge tube, to which was added 16ul of sterile deionised water and 64ul of
95% ethanol. The contents of the tube were vortexed, allowed to stand for 10-15
minutes in the dark to precipitate the extension products, and the tubes were
centrifuged at 14 000 rpm 15 min. The supematants were carefully aspirated
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without disturbing the "pellet". One hundred microliters (lOOul) of 70% ethanol
was added to the microfuge tube and briefly vortexed to mix. The tubes were spun
for 10 minutes at 14 OOOrpm. The supematant was carefully aspirated without
disturbing the "pellet". The samples were dried on a heating block for 2 min at
90°C. Twenty microliters (20ul) of template suppression reagent was added to the
tube and mixed well. The tubes were heated for 2 min at 100°C and thereafter held
on ice for 1 min. The product was transferred to a sequencing tube and kept in the
dark at 4°C.
2.2.3.1.7 Sequence analysis
The sequences were determined usmg an Applied Biosynthesis Prism 310
Automated Genetic Analyser (perkin Elmer, Biosystems, CA, USA). The
sequences were assemble and analysed using the Staden Package (http://www.mrc-
lmb.cam.ac.uk/pubseq/), Alignment of sequences was done using Clustal W with
minor manual adjustments.
2.2.3.1.8 Phylogenetic analysis
Phylogenetic analysis of GBV-CIHGV sequences was carried out on a 310 base
pair fragment in the 5' NCR region (positions 160-470) in HGV type2a clone,
PNF2161 (Muerhoffet ai, 1996). Sequences were compared using a distance-based
method (p-distance at all sites followed by neighbor joining) as implemented in
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Phylip package (Joseph Felsenstein 1980, http:// evolution. genetics Washington.
edu/phylip.html) Robustness of grouping was assessed by bootstrap re-sampling;
numbers on branches indicate the percentage of 500 bootstrap replicates that
supported the observed phylogeny.
Sequences compared include those of designated genotype for which complete
genomic sequences are available. These include sequences from Group 1-4




Detection of GBV-CIHGV Anti-E2 antibodies
Anti-E2 of GBV-C/HGV were determined by ELISA "J.! Plate Anti-HGenv"
(Boehringher Mannheim, Germany) according to the manufacturer's instructions.
Briefly, viral E2 protein used in this assay was expressed within Chinese ovary
hamster cells and was bound to a streptavidin-coated microtitre plate via a
monoclonal mouse GBV-C/HGV E2 antibody (Tacke et aI, 1997a). Calculation of
the cut-off value was performed according to manufacturer's recommendations (A
cut-off = 0.2 x A positive control + Anegative control ; A:absorbance). Samples with a
borderline absorbance of the cut-off value were subjected to a second run, where
the E2 antigen was omitted to exclude unspecific binding. A specimenwas
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considered negative for Anti-E2 whenever A sample with E2 antigerJAsample without E2 antigen
was < 1.5.
2.2.3.2.2 Detection of HBV and HIV
. Sera were tested for serological markers for HBV and HIV by commercial
microparticle enzyme immunoassays (MEIA) (IMx AUSAB assay, Abbott
Laboratories, North Chicago, IL) and (AxSYM® mv 1I2g0; Abbott Laboratories,
Chicago, IL, USA), respectively. The assays were performed by routine
multianalysis systems in the central laboratory at King Edward VIII Hospital,
Durban.
2.2.3.2.3 Carbohydrate Deficient Transferrin (CDTect®)
Regular high consumption of alcohol results in the appearance of serum transferrin
deficient in carbohydrate (CDT) (Allen et ai, 1994). Analysis of the CDT value,
provides a valuable tool to diagnose and manage -alcohol-related diseases (Allen et
al, 1994). CDT was measured in sera of alcoholics with and without liver disease
by a commercially available CDTect® competitive enzyme immunoassay (EIA) kit
(CDTect®, Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden). The assay
was performed according to the manufacturer's instructions.
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2.3 STATISTICAL ANALYSIS.
The data of blood donors, haemodialysis patients (HAEM), patients with chronic
liver disease (CLD) and patients with alcoholic liver disease (ALD) were analysed
separately. Chi-squared test was used to compare groups (GBV-CIHGV positive
versus GBV-CIHGV negative) with respect to categorical data, while Student's t-
test was applied to continuous data . Analysis of covariance was used to compare
GBV-CIHGV positive and GBV-CIHGV negative patients with respect to liver.
function test, adjusting for age, sex and disease group. Multiple logistic regression
was used to determine any confounding influence of age, sex and disease group on
GBV-CIHGV. Blood donors were compared to CLD and HAEM and ALD patients
with regard to demographic parameters using Student 's t-test or Chi-squared test .
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2.4 RESULTS
2.4.1 Comparison of the GBV-C LCx, the "in-house" RT-PCR and Anti-E2
GBV-C/HGV RNA was extracted from a known GBV-C/HGV positive sample and diluted
serially four-fold. A commercial (GBV-C LCx, Abbott Laboratories) and an "in-house"
RT-PCR assays were used for the detection of GBV-C/HGV RNA in 98 patients with
chronic liver disease. The RT-PCR assays were compared to serology (anti-E2). Fig. 2.1
shows a typical agarose gel stained with ethidium bromide and photographed whilst
Fig.2.2 shows the results of the GBV-C/HGV dilutions.
. Fig. 2.1 Agarose gel demonstrating the results ofRT-PCR for GBV-C/HGV.
Lanes 1 to 8 are extracted sera. Lane 9 is the DEPC H20 blank. Lane
10 is a known GBV-C/HGV positive control serum. Lane 11 is a
known GBV-C/HGV negative control serum. Lane 12 shows the
size distribution of the 1 kilobase molecular weight marker. The
approximate size of the PCR product (344 bp) is indicated by the
arrow
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Fig. 2.2. Agarose gel demostrating the results of GBV-CIHGV RNA
dilutions. Lanes 1-6 have the PCR products in serial four fold
dilutions from undiluted to 1:1024. Lane 7 is a negative control
serum. Lanes 8-9 are DEPC-H20 blanks. Lane 10 shows the
molecular size distribution of the 1 kilobase molecular weight
marker. The approximate size of the PCR product (344bp) is
indicated by the arrow.
A comparison of the test results for the detection of GBV-CIHGV using each of the three
assays is shown in Table 2.6.
Table 2.6. Comparative analysis of the detection of GBV-CIHGV in 98 patients with
chronic liver disease by the "in-house" RT-PCR, the Abbott LCx®GBV-C
and the anti-E2 assays
XI-per cent, --posrttve; - negative; Anti- antibody
RT-PCR+(%) LCx+(%) Anti-E2 + (%) RNA & anti-E2 + (%)
12/98(12 .2%) 27/98(27.5%) 32/98(32.7%) 2/27(7.4%)
0 ..
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GBV-C/HGV was detected in 27/98(27 .5%) serum samples by at least one of the
two RT-PCR assays. All twelve (12) of98 (12.2%) patients detected by the "in-
house" RT-PCR were also detected by the LCx assay. Fifteen (15) additional
samples were positive by the LCx assay. These 15 discordant samples were retested
by the "in-house" RT-PCR with identical results . The samples were not retested by
the LCx assay. There was concordance between the "in -house" RT-PCR and Lex
in 83/98 (84.7%) samples . Two of27 (7%) RNA positive (LCx and/t'in-house" RT-
PCR) samples were also positive for anti-E2 GBV-C/HGV antibodies. Anti E2 was
mutually exclusive in 93%(25/27) of RNA positive samples. A summary of the
precision of the LCx assay is presented in Table 2.7. System variability was
determined by percent coefficient ofvariation (%CV=S.D./Mean) x 100).
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Table 2.7 Variability of the LCx rates (counts/sec/sec) of control specimens
supplied in lots ofthe GBV-C LCx kits (Abbott)
Negnegative; POS,pOS1tIve; No , number, SD,standard deviation; %, per cent; CV, coefficient ofvananon
Lot No. I Nego Control I Pos, Control I Calibrator I No. of tests
0019302F9 9.6 402.4 354.0 17
9.1 419.4 76.2
0019302F9 9.9 247 .8 35.3 11
10.2 532.3 380.7
0019302F9 16.5 440.3 177.3 18
9.8 372.1 293.3
0019302F9 9.7 458.0 428 .1 18
9.7 392.0 411.2
0019302F9 9.4 25.7 59.5 18
9.0 9.8 9.1
0019302F9 10.0 10.7 197.4 16
9.5 350.9 210.3
Mean 10.2 305.12 219.37
SD 2.0 187.12 152.69
%CV 19.6 61.32 69~60
. . .. . .
2.4.2 Prevalence of GBV-CIHGV RNA in blood donors
Of the 232 unpaid volunteer blood donors 76 (32.8%) were African, 49 (21.1%)
Whites, 52 (22.4%) Indians and 55 (23.7%) "Coloureds."(mixed race group) All
the blood donors were negative for HCV, HBV and HIV. None ofthe blood donors
had a history or clinical evidence of liver disease. Overall , GBV-CIHGV RNA was
detected in 44 of232 (18.9%) blood donors [29/76 (38.2%) African, 2/52 (3.8%)
Indians , 2/55 (3.6%) "Coloured" and 11/49 (22.4%) White] (Table 2.8). There was
81
no significant difference in the prevalence ofGBV-C/HGV RNA between Indians
and "Coloured" blood donors (p = 0.81) and between African and White blood
donors (p = 0.07). However, there was a significant difference in the prevalence of
GBV-C/HGV RNA between the other racial groups (Indians vs Whites [p < 0.005];
Asians vs Africans [p < 0,00001]; "Coloureds" vs Whites [p < 0.005] and
"Coloureds" vs Africans [p < 0.00001]).
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2.4.3 Prevalence of GBV-CIHGV RNA in high risk groups and patients with liver
disease
2.4.3.1 Haemodialysis group
Among the 70 haemodialysis patients there were 30 (42.9%) Africans, 29 (42.4%) Indians, 3
(4.3%) "Coloureds" and 8 (11.4%) Whites . Seventeen of 70 (24.3%) haemodialysis patients
(5/30) [16.7%] Africans; 8/29 [27.6%] Indians ; 1/3 [33%] "Coloureds" and 3/8 [11.43%]
Whites) were infected with GBV-CIHGV [95% Cl (5.7%; 18.7%)] (Table 2.8). GBV-C/HGV
positive patients tended to have a longer duration of dialysis (not significant) and had more
transfusions (p = 0.03) than non-infected patients. Four of 70 patients (5.7%) were infected
with HCV but only 2/17 (11.76%) GBV-C/HGV positive patients were eo-infected with HCV.
2.4.3.2 Chronic Liver Disease group
The majority of patients with chronic liver disease were Black [88 Africans (90%), 7 Indians
(7%), 2 "Coloureds" [2%] and 1 White (1%)]. The diagnosis of chronic liver disease was
confirmed by histology in 81 patients and by peritoneoscopy alone in 17 patients. The etiology
of chronic liver disease in the majority ofpatients was alcohol abuse, viral or a combination of
the two (Appendix B). In five patients, chronic liver disease was due to autoimmune liver
disease and in seven it was cryptogenic (Appendix B). None of these patients gave a history of
blood transfusions or intra-venous drug abuse. Theprevalence of GBV-C/HGV RNA in
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patients with chronic liver disease was 12.2% (12/98) [95% Cl (5.7%; 18.7%)] (Table 2.8).
Only 2 of 10 patients with HBV were eo-infected with GBV-CIHGY. GBV-CIHGV RNA was
detected more frequently in patients with an alcoholic etiology alone (6/56 [11%]) or in
combination with alcohol and HBV (1/10 [10%]) or alcohol and HCV (114 [25%]). Two of
seven (29%) patients with cryptogenic liver disease were GBV-CIHGV RNA positive.
There was no significant difference in the prevalence of GBV-CffiGV RNA between blood
donors and patients . There was a significant difference in the prevalence of GBV-CIHGV
RNA between patients with chronic liver disease (12/98; 12.2%) and haemodialysis patients
(17/70; 24.2%) [p =0.04].
2.4.3.3 Alcoholic Liver Disease group
All the patients with ALD were Black Africans (31 males and 19 females). The diagnosis of
ALD was assessed by history and laboratory markers. This included a questionnaire on
alcohol consumption, lab-markers (Appendix C) and histological findings. The prevalence of
GBV-CffiGV RNA in alcoholics without liver disease was 14% (5/35) [Table 2.8]. Two ofthe
5 (40%) GBV-CIHGV RNA positive subjects had a past exposure to HBV (HBc). HCV
infection was detected in 1 (2.9%) alcoholic without liver disease. This patient was positive
for Anti-HBc and anti-E2 to HBV and GBV-C/HGV infections, respectively. The prevalence
ofGBV-CIHGVRNA in ALD patients was 28% (14/50) [Table 2.8]. Eleven of33 (33%)
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ALD patients with HBV infection were eo-infected with GBV-CIHGV RNA Of the two
patients (2/50; 4%) with HCV infection, one had past exposure to HBV (Anti-HBc) and GBV-
CIHGV (anti-E2). Although the prevalence ofGBV-C/HGVRNAin ALD patients was twice
(28%; 14/50) that of alcoholics without liver disease (14%; 5/35), this difference was not
significant (p = 0.153). There was no significant difference in the prevalence ofGBV-CIHGV
RNA between African blood donors and ALD patients. There was a significant difference in
GBV-CIHGV RNA prevalence between African blood donors and alcoholics without liver
disease (p = 011).
2.4.4 Prevalence of Anti-E2
There was a higher prevalence of Anti-E2 in African blood donors (21/76; 27.6%) than White
(14/49; 8.2%), "Coloured" (7/55; 12.7%) or Indian (3/52; 5.7%) blood donors [Table 2.9] and
this difference was significant (p < 0.05). There was a significant difference (p < 0.05) in the
prevalence of Anti-E2 in chronic liver disease [32/98 (32.7%)], and haemodialysis patients
[18/70 (25.7%)] compared to blood donors [35/232 (15.1%)] (Table 2.8). There was no
significant difference in Anti-E2 seroprevalence between chronic liver disease and
haemodialysis patients (p = 0.33). There was a higher prevalence of Anti-E2 in alcoholics
without liver disease (54.3%; 19/35) than ALD patients (42%; 21/50), this difference was not
significant (Table 2.8). There wasno significant difference in Anti-E2 seroprevalence between
African blood donors and ALD patients (Table 2.8).
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African blood donors (45/76; 59.2%) had a greater exposure to GBV-CIHGV infection (RNA '
and/or Anti-E2 positive) compared to White (15/49; 30.6%) [p = 0.002], "Coloured" (9/55;
16.4%) [p < 0.00001] and Indian (5/52; 9.6%) [p < 0.00001] blood donors . There was a
significant difference(p < 0.05) in the overall exposure to GBV-CIHGV (RNA and/or Anti-E2
positive) between blood donors [31.9% (74/232)] and patients [43.9%(43/98) vs 47.1%
(33/70), respectively [Table 2.8]. Alcoholics with or without liver disease had greater
exposure (60%) [Table 2.8] to GBV-CIHGV (RNA and/or Anti-E2) infection. The prevalence
was similar to that in African blood donors (59.2%) [Table 2.8]. GBV-CIHGV RNA and Anti-
E2 were mutually exclusive in almo~t all (91-100%) patients and blood donors. GBV-CIHGV
RNA and Anti-E2 was simultaneously positive in only 1/98 (1.1%) patients with chronic liver
disease , 6/50 (12%) ALD patients , 2/70 (2.9%) haemodialysis patients, 5/232 (2.2%) blood
donors and 3/35 (8.6%) alcoholics without liver disease (Table 2.8).
Table 2.8 .GBV-C/HGV RNA and Anti-E2 prevalence among Blood donors, patients on maintenance haemodialysis, chronic
liver disease and alcoholics with and without liver disease
Study population n GBV-CIHGV GBV-CIHGV GBV-C/HGV GBV-C/HGV Exposure
RNA + Anti-E2 + RNA+ & Anti-E2 + RNA+ &/or Anti-E2 +
(%) (0/0) (%) (%)
Blood Donors
African 76 29 (38.2) 21 (27.6) 5 (6.5) 45 (59.2)
White 49 11 (22.4) 4 (8.2) 0(0) 15 (30.6)
Indians 52 2 (3.8) 3 (5.7) 0(0) 5 (9.6)
"Coloured" 55 2 (3.6) 7 (12.7) 0(0) 9 (16.4)
Total 232 44 (18.9) 35 (15.1) 5 (2.1) 74 (31.9)
Chronic liver disease 98 12 (12.2) 32 (32.7) 1 (1.0%) 43 (43.9)
Haemodialysis 70 17 (24.3) 18 (25.7) 1 (2.9) 33 (47.1)
Alcoholic liver disease 50 14 (28) 21 (42) 6 (12) 30 (60)
Alcoholics without liver disease 35 5 (14.2) 19 (54.3) 3 (8.6) 21 (60)




2.4.5 GBV-CIHGV transmission studies
GBV-C/HGV RNA was detected in 27 of 75 (36%) mv positive pregnant African mothers.
Of the 20 mothers studied for the transmission of GBV-CIHGV, 15 (75%) mothers initiated
breast feeding (12 having breast fed their infants for ~ 3 months), 5 mothers did not breast
feed their infants. Sera were available for 15 infants (3 were not breast fed) at 6 weeks after
birth, none had detectable GBV-CIHGV RNA in their sera (Fig 2.2), implying'that there was
no evidence for in utero and/or intrapaturm transmission ofGBV-C/HGY. At 3 months after
birth, sera were available for 18 infants, GBV-C/HGV RNA was detected in 2 infants whose
mothers were GBV-CIHGV RNA negative of whom one infant was never breast fed (Fig.2.2).
Of the 5 GBV-C/HGV RNA positive mothers, GBV-CIHGV RNA was detected in only two
infants (40%) 3 to 9 months after birth. In one such infant (1021), viraemia persisted from 3 to
9 months . In the remaining 3/5 (60%) GBV-CIHGV RNA positive mothers, no viral RNA was
detected in the sera of their infants till 3 months of life. In two of 20 (10%) GBV-C/HGV
RNA negative mothers, GBV-C/HGV RNA was detected in their infants at 3 months after
birth. Of the five GBV-CIHGV RNA positive mothers, the transmission of GBV-CIHGV to
two infants at nine months of age (Fig 2.2) was confirmed by nucleotide sequences The
homologies for the sequenced fragments in the mother-infant pairs were, 97.6% for Mother-
Child 1021 and 100%forMother-Child 1035 (Fig.2.3). One infant (1021) was never breast-
fed and was mv negative whilst the other (1035) was breast fed for at least nine months and
was mvpositive. By 9 months only 3/20 infants tested positive for mv, one defaulted and no
results were available in two. The phylogenetic tree ofthe sequenced fragment is depicted in
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Fig. 2.4. Phylogenetic analysis ofthese isolates showed a close genetic relatedness to Group 5
isolates from KZN as expected (Fig. 2.4) .
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Fig. 2.3 Detection of GBV-C/HGV in mv infected mothers and their infants during
follow-up. The grey bars indicate the duration of the follow-up of infants born
of GBV-C/HGV positive mothers. Plus (+) and minus (-) signs indicate
positive and negative results of GBV-C/HGV RNA l\1B = mother; C = child;
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TGGTAGCCAC TATAGGTGGG TCTTAAGGGG AGGCTACAGT CCCTCTAGTG CCTGTGGAGA
TGGTAGCCAC TATAGGTGGG TCTTAAGGGG AGGCTACAGT CCCTCTAATG CCCGTGGCGA
TGGTAGCCAC TATAGGTGGG TCTTAAGGGG AGGCTACAGT CCCTCTAATG CCCGTGGCGA
TGGTAGCCAC TATAGGTGGG TCTTAAGGGG AGGCTACAGT CCCTCTAGTG CCTGTGGAGA
GAAAGCGCAC GGTCCACAGG TGTTGGCCCT ACCGGTGTGA ATAAGGGCCC GACGTCAGGC
GAAAGCGCAC GGTCCACAGG TGTTGGTCCT ACCGGTGT-A ATAAGGACCC GACGTCAGGC
GAAAGCGCAC GGTCCACAGG TGTTGGTCCT ACCGGTGT-A ATAAGGACCC GACGTCAGGC
GAAAGCGCAC GGTCCACAGG TGTTGGCCCT ACCGGTGTGA ATAAGGGCCC GACGTCAGGC
TCGTCGTTAA ACCGAGCCCG TTAACCCCCT GGGCAAACGA CGCCCACGTA CGGCCCACGT
TCGTCGTTAA ACCGAGCCCA TTATCCCCCT GGGCAAACGA CGCCCATGTA CGGTCTACGT
TCGTCGTTAA ACCGAGCCCA TTATCCCCCT GGGCAAACGA CGCCCATGTA CGGTCTACGT
TCGTCGTTAA ACCGAGCCCG TTAACCCCCT GGGCAAACGA CGCCCACGTA CGGCCCACGT
CGCCCTTCAA TGTCTCTCTT GACCAATAGG CA-ATGCCGG CGAGTTGGCA AGGGCCAGTG
CGCCCTTCAA TGTCTCTCTT GACCAATAGG CATATGCCGG CGAGTTGGCA AAGACCAGTG
CGCCCTTCAA TGTCTCTCTT GACCAATAGG CATATGCCGG CGAGTTGGCA AAGACCAGTG
CGCCCTTCAA TGTCTCTCTT GACCAATAGG CA-ATGCCGG CGAGTTGGCA AGGGCCAGTG
GGGGCCGGGG GCAGGGGGAA GGACCCCCTG TCTCGCCCTT CCCGGGGGTG CGGGAAATGC
GGGGCCGGGG GTGGGGGGAA GGACCCCCCA TCCTGCCCGT TCCGGGGGAG TGGGAAATGC
GGGGCCGGGG GTGGGGGGAA GGACCCCCCA TCCTGCCCGT TCCGGGGGAG TGGGAAATGC





Alignment of nucleotide sequences from the 5' NCR ofGBV-CIHGV isolates
from mother infant pairs (AF398330 and AF398333; 1035 and AF398331 and
AF398332; 1021), respectively. The sequences were determined using an
Applied Biosynthesis Prism 310 Automated Genetic Analyser (perkin Elmer,
Biosystems, CA, USA). The sequences were assemble and analysed using the
Staden Package (http://www.mrc-Imb.cam.ac.uklpubseq/).Alignment of











































































Fig. 2.4. Phylogenetic analysis ofGBV-CIHGV sequences of mother infant pairs (AF398330-AF398333) were
carried out on a 310 base pair fragment in the 5' NCR region (positions 160-470) in HGV type2a
clone, PNF2161 (Muerhoff et al, 1996). Sequences were compared using a distance-based method
followed by neighbor joining. Robustness of groups were assessed by bootstrap re-sampling; numbers
on branches indicate the percentage of 500 bootstrap replicates that supported the observed pylogeny.
Sequences were compared with designated genotypes 1 to 4 (identified by Genbank acession
numbers) for which complete genomic sequences are available.
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2.5 DISCUSSION
The design, optimization and performance of the Lex assay for the Abbott LCx system has
been described by Marshall et al (1997). The authors reported a sensitivity of 96.04% and a
specificity of 99.76% (Marshall et al, 1997). Although both LCx and the "in-house" PCR
assays are based on RT-PCR technology, there are several differences in the design of the
assays that may contribute to the different detection sensitivities observed. When identical
RNA isolation procedures were used upon the 98 serum samples, the LCx and the "in-house"
PCR assays detected 12 and 27 GBV-CIHGV positive samples, respectively. In the LCx assay,
the input of serum was reduced (25ul) and the volume ofRNA eluate was increased (1OOul) in
contrast to the standard Qiagen virus RNA isolation protocol, input of140ul serum and elution
of RNA in SOul of water. The format of the LCx assay with the use of a combined reverse
transcriptase and DNA polymerase enzyme allows input of large volumes of RNA (20ul)
giving a very sensitive assay. In comparison, the input ofRNA in the "in-house" RT-PCR was
smaller (10ul) and only 1/20 of the RT reaction products were inputs in the first round of
amplifications. Thus in the "in-house" RT-PCR only 0.52 ul RNA solution was analysed. Thus
the higher detection sensitivity in the Lex assay most probably is due to the larger RNA input
GBV-CIHGV is present in sera in very low titers and most assays rely on the RT-PCR to
demonstrate viraemia or active infection. The detection limit of the RT-PCR has been
projected to be as low as 500 genome eqivalents per ml (Fanson et al, 2000).
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Fanson et al (2000) using a similar extraction method and RT-PCR assay also demonstrated .
that GBV-CffiGV RNA was detected at a dilution of 1:16. Fanson et al (2000) showed that
using the phenol-chloroform extraction method increased the sensitivity ofthe RT-PCRassay
16 fold compared to the QIAamp extraction method. However, the latter method is harzardous
(phenol), complicated, time consuming and labour intensive and not amenable to large sample
throughputs: Whilst it is important to determine HCV RNA titers in order to determine
chronicity of infection and to monitor treatment, GBV-CffiGV is not associated with any liver
disease (as discussed in Chapter 3). Perhaps determining GBVC-CIHGV RNA titers may be
important when studying the potentially protective role of GBVC-C-HGV in IDV infection.
Under such circumstances the use of newer technologies such as branched chain DNA assay
and real time PCR will be important (This is discussed in Chapter 5). However, no difference
in the amplification signal on agarose gel electrophoresis was observed when either the
modified (Marshall et ai, 1998) or the manufacturer's method ofRNA extraction was used in
the "in-house" RT-PCR To allow for conservation of the sample and reagents, the modified
method of extraction (Marshall et ai, 1998) was used in all RT-PCR
A 311 base pair fragment in the 5' NCR region (positions 160-470) in the prototype isolates
GBV-C (U36380) and HGV (U44420) was compared with the sequences of the 12 GBV-
CIHGV isolates from CLD patients (AP 172501-AF172512) detected by the "in-house" RT-
PCR Sequencing ofthese 12 GBV-CffiGV isolates confirmed that the PCR products were
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GBV-CIHGV Phylogenetic analysis of these isolates is discussed in detail in Chapter 4.
Sequence analysis of the 15 additional GBV-CIHGV isolates was not possible as the final
product in the LCx assay is "inactivated." The 15 discordant samples were retested by the "in-
house" RT-PCR with identical results. The samples were not retested by the LCx assay.
Discrepancies in the LCx rates between positive and negative controls and the LCx calibration
controls were observed (Table 2.7.). In addition, 2 runs performed by the LCx had to be
invalidated because controls were out ofrange (Table 2.7), meaning that 34 samples would have
had to be retested at an additional cost. However, these samples were not retested by the LCx.
The use ofinternal controls in the "in-house" RT-PCR to expose potential false negative results
contributed to the quality assurance ofthe outer amplification and detection step. Laboratories
performing PCR should participate in repeated quality control studies that include a common
. panel ofGBV-CIHGV RNA-positive and -negative samples (Kunkel et al, 1998; Lefrere et al,
2000a). The inclusion of internal control/s in the LCx assay might be of great value for
identification of false positive results .
The performance of each ofthe primers is decisive for the PCR reaction. Although the primers
used in both assays were from the 5' NCR region of the GBV-CIHGV genome there were
differences in the amplification targets and conditions. The reverse transcriptase and
amplification enzymes used may have also contributed to differences in sensitivities. The
primers chosen for the "in-house" RT-PCR did not participate in primer-dimer foimation. The
LCx assay involves the use of primers labelled with haptens allowing detection of the
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amplified products in an LCx analyser based on MEIA technology; while the "in-house" PCR
products were visualised by the ethidium bromide staining in agarose gels. "Carry-over"
contamination is a substantial concern in nested PCR which includes several manual transfers
of PCR product and gel electrophoresis that might occasionally be performed erroneously.
Guidelines to avoid contamination (Kwok and Higuchi 1989) were strictly followed, which
included separate areas for RNA extraction, reagent preparation, PCR and detection; positive
and negative controls were included in every PCR reaction. The LCx assay is aone tube RT-
PCR assay. The use of "unit doses" in the LCx assay reduces the risk of operational or
technical errors in the testing and reduces the risk of contamination causing false positive
results. The LCx workflow is higher than the "in-house" RT-PCR, although the same
extraction protocol was used, cDNA synthesis, amplification and detection are more time
consuming in the case of the "in-house" RT-PCR The LCx is easier to perform and suits
better the requirements ofa clinical microbiology diagnostic laboratory. .
The overall prevalence of GBV-C/HGV RNA in blood donors in the province of KZN
(18.9%) is higher than that of blood donors in Gauteng (11.1%) (Castelling et aI, 1998) with
the prevalence being higher in African (38%) and White (22%) blood donors in KZN
compared to African (29%) and White (8,5%) blood donors in Gauteng (Castelling et aI,
1998). Tucker et al. (1997) reported a GBV-C/HGV RNA prevalence of 6.3% in a
predominantly "Coloured" rural community in the Eastern Cape which is higher than the 4%
of"Coloured" blood donors infected with GBV-CffiGV in KZN. However, volunteer blood
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donors probably represent a healthier population than rural communities. The prevalence of
anti-E2 in healthy blood donors ranges from 2.7% to 20.3% in different parts of the world
(Dille et ai, 1997; Ross et ai, 1998; Tacke et ai, 1997b). The overall anti-E2 prevalence in our
blood donor population (14.9%) was lower than the 20.3% reported by Ross et al. (1998) for
South African blood donors. However, Ross et al. (1998) did not define the racial breakdown
of the blood donor population, and our results indicate a racial difference in anti-E2
prevalence. The lower viraemia (3.8%) and anti-E2 response (5.7%) in the Indian blood
.donors compared to other racial groups is in agreement with the low prevalence of Anti-E2
(2.7%-6.3%) in Asian countries (Ross et ai, 1998) and reflects the infrequent exposure to
GBV-C/HGV in this community. Anti-E2 prevalence in potential risk groups (haemodialysis
vs chronic liver disease) was higher (25.7% vs 32.7%) than in blood donors (15.1%) [p <
0,05]. Concurrent detection of viraemia and seropositivity was seen in 1-12% of our study
population. This probably indicates an overlap between E2 sero conversion and presence of
viraemia (Tacke et al, 1997b; Dille et al, 1997). It may be possible that at the time of testing
these patients were still viraemic and in the process of seroconverting. Viraemia and sero
reactivity was almost mutually exclusive. The combined overall exposure of GBV-CffiGV
infection in African blood donors (59.2%) was higher compared to that reported in a West
African population (46.7% (pCR + Anti-E2) [Dille et al, 1997]. GBV-CIHGV infection
appears to be a common infection in Kwa Zulu Natal, South Africa.
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There is a higher prevalence of GBV-CIHGV infection in apparently healthy individuals in
African countries (10-40%) (Dawson et ai, 1996; Dille et ai, 1997; Tucker et ai, 1997;
Castelling et ai, 1998; Mphahlele et ai, 1999;) with infection occurring more commonly
during childhood (Mphahlele et al, 1999). compared to blood donor groups in non-African
countries (1-4%) [Linnen et ai, 1996a; Masuko et ai, 1996; Moaven et ai, 1996; Alter et ai,
1997b; Wang et al, 1997a; Roth et ai, 1997). The reason for the high prevalence of GBV-
CIHGV in blood donors worldwide and the basis for the racial differences in GBV-CIHGV
infection in the South African blood donor populations is not known. Racial differences in the
prevalence ofHAV (Sathar et ai, 1994), HBV (Dusheiko et ai, 1989) and HCV (Soni et ai,
1993) infections due to differences in socio-economic factors in South Africa is well
documented, whether this is true for GBV-CIHGV is not known, although a relationship was
noted between GBV-CIHGV infection and the lack of water borne sewage (Tucker et ai,
1997).
Generally, infection with GBV-CIHGV is significantly associated with a history of IVDA,
exposure to blood transfusions, dialysis and with HCV and HBV infections (Tables 1.3-1.5).
The high prevalence in commercial blood donors (5-26%) is probably due to the increased risk
of parenteral acquisition in this group (pilot-Matias et ai, 1996b; Roth et al, 1997; Dille et ai,
1997; Gutierrez et ai, 1997). Prior to this no studies have dealt with GBV-CIHGVpositivity in
alcoholic patients with liver disease in South Africa. In limited studies in non-African
countries, GBV-e/HGV RNA positivity rates of2 -14% have been reported (Linnen et ai,
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1996a; Lampe et ai, 1997; Guilera et ai, 1998; Tran et ai, 1998; Sobue et ai, 1998 ; Shimanaka
et al, 1999). In African ALD patients 14% were GBV-CIRNA positive with 60% of patients
having had some experience with GBV-CffIGV (Table 2.8). Tran et al (1998) reported that
38.8% (9.3% GBV-CffIGV RNA and 29.5% Anti E2) of ALD patients had past or present
infection with GBV-C/HGV Most of the patients were heavy drinkers . The present study
showed that the prevalence ofGBV-CffIGV RNA was twice as high as that in alcoholics with
liver disease than in alcoholics who we~e abstaining. The overall exposure in both groups was
higher though not significant. Reasons for the higher prevalence of GBV-CffIGV may be
similar to that for HCV, viz . that excessive alcohol consumption diminishes the immune
function and that cellular immunity is impaired, but the precise mechanism remains obscure,
even in the case ofHCV.
The prevalence ofGBV-CffIGV infection in patients with mvinfection has been assessed in
non-African countries. Based on the detection of GBV-C/HGV RNA and/or anti-E2, several
studies have reported frequencies as low as 9% and as high as 66% in mv-infected risk
groups (Feucht et al, 1996; Jarvis et ai, 1996; Nubling and Lower, 1996; Kinoshita et al, 1997;
Nubling et ai, 1997; Ibanez et ai, 1998; Scallan et ai, 1998; Nerurkar et al, 1998; Toyoda et
. ai, 1998; Woolley et al, 1998 ; Rey et ai, 1999; Bourlet et ai, 1999). The primary difference
between these studies was the number ofindividuals in each study who were in primarily high
risk groups. Although the current study is biased by a small study group of mv positive
African females, the prevalence of GBV-C/HGV (36%) was similar to that of African blood
donors (38.2%) [Sathar et ai, 1999a] and HIV positive females (39.8%) [Xiang et aI, 2001].
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Since the discovery ofGBV-CIHGV, attempts have been made to clarify its principle mode of
transmission. In non - African countries transmission ofGBV-CIHGV occurs parenterally and
is considered to be similar to HCV (Linnen et al, 1996b). In this study GBV-CIHGV infected
dialysis patients tended to have had more transfusions and a longer duration of dialysis than
non infected patients. The majority of patients on maintenance haemodialysis appear to
acquire their GBV-CIHGV infection through the transfusions they receive (De Lamballerie et
al, 1996; Linnen et al, 1996b; Masuko et al, 1996; Tsuda et al, 1996; Wang et al, 1997a;
Lampe et al, 1997; Shrestha et al, 1997; Castelling et al, 1998; Murthy et al, 1998). The
absence ofa history of blood transfusion and intravenous drug abuse in patients with chronic
liver disease, in addition to the high prevalence ofGBV-C/HGV in blood donors and in rural
communities, especially in African children (Mphahlele et al, 1999), tends to suggest that
GBV-C/HGV is being transmitted by as yet undefined non-parenteral routes in our
environment. It has been suggested that perinatal transmission may be an important source of
infection in blood donors lacking parenteral risk factors (Lefrere et al, 2000b).
In non-African countries the transmission of GBV-C/HGV from mother-to-infant varies from
30%-89% (Feucht et al, 1996; Viazov et al, 1997b; Zanetti et al, 1997; Hino et al, 1998;
Wejstal et al, 1999; Lefrere et al, 2000b). Based on their prevalence study, Mphahlele et al
(1999) reported a GBV-CIHGV prevalence of2.9% in Black South African neonates less than
4 months old. In the absence ofa serial follow-up study, the authors concluded (Mphahlele et
al, 1999) that vertical transmission ofGBV-CIHGV is not common in South Africa.
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Mother-to-infant transmission rates of 10%-60% have been reported in newboms (1-5 days
old) (Viazov et al, 1997b; Wejstal et al, 1999; Lefrere et al, 2000b). The mother-to-infant .
transmission rate ofGBV-CIHGV in Black South Africans in KZN is 40% (2/5). This is close
to the 38.2% prevalence of GBV-CIHGV reported in African blood donors in KZN (Sathar et
al, 1999a). In this study GBV-C/HGV RNA was not detected in infants 1-6 weeks old. The
lower rate in infants perhaps may be due to the lower viral load which may be below the
detection level ofthe "in-house" PCR assay.
Although the current study may be biased by a small select study group (HIV positive
pregnant mothers), the data suggests that some infants (40%; 2/5) acquire their infection
between 3-9 months after birth from their infected mothers, as confirmed by the sequence
data, whilst other infants acquire their infections by routes independent of mother-to-infant
transmission. Similar observations have been reported by others (Zanetti et al, 1997; Viazov et
al, I997b; Wejstal et ai, 1999; Lefrere et al, 2000b). There is a higher risk ofmother-to-infant
transmission in high risk groups (Feucht et al, 1996; Zanetti et aI, 1997; Fischler et al, 1997;
Viazov et aI, 1997b; Wejstal et aI, 1999). However, it is not clear whether eo-infection with
HCV, HIV-1 or both or IVDU are the underlying cause for transmission ofGBV-CIHGV from
mother to infant. GBV-CIHGV has not been detected in breast milk to-date (Schroter et al,
2000) and it is not clear as to whether transmission of GBV-CIHGV is influenced by breast
feeding or by the mode of delivery (Viazov et aI, 1997b; Zanetti et al, 1997; Wejstal et al,
1999). It is therefore possible to formallyconclude that there is some mother-to-infant
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transmission ofGBV-CIHGV in KZN, though it is very probable that infants, or at least some
ofthem could be infected by as yet undefined non-parenteral routes.
HBV infection is endemic amongst the African population of South Africa and the risk of
horizontal transmission of HBV is well recognised (Dusheiko et ai, 1989). Whether the
association of GBV-CffiGV with HBV implies that GBV-CffiGV might spread by sexual
routes can not be determined bythis study. Various studies have pointed to the important role
of sexual exposure as a likely route of transmission of GBV-CIHGV, in both non-HIV
infected subjects without the risk for parenteral transmission (IVDU and multitransfused
. individuals including haemophiliacs) [Kao et ai, 1997b,c; Scallan et ai, 1998; Sawayamaet ai,
1999) and HIV infected individuals with the risk for parenteral and sexual transmission
(homosexuals, heterosexual and prostitutes) [Nubling et ai, 1997; Nerurkar et ai, 1998; Ibanez
. et ai, 1998; Bourlet et al, 1999]. Infection with GBV-CffiGV appears to be more frequent in
patients with a sexual risk than those with parenteral exposure (Thanez et ai, 1998; Bourlet et
ai, 1999). The role of semen in the transmission ofGBV-CIHGV is controversial (Chen et ai,
1997; Seemyer et ai, 1998; Eugenia et al, 2001). Recent reports have suggested that human
saliva may contribute to the spread of GBV-CIHGV RNA (Chen et ai, 1997; Seemyer et ai,
1998; Eugenia et ai, 2001). Tucker et al (2000) did not detect GBV-C/HGV replicative
intermediaries in the cadaver biopsies of salivary glands and the gonads of GBV-C/HGV
positive patients. The results imply that the virus may be present in the saliva and semen of
infected individuals, but not be transmitted via these routes. Despite the evidencefor increased
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frequencies of GBV-C/HGV infection in association with sexual exposure, the mechanism of
transmission remains unclear.
The frequency of positivity for RNA or Anti-E2 varies among groups, depending on the
subjects' origins and the methods used to detect GBV-C/HGV markers. The differences in the
prevalence ofdetecting GBV-C/HGV infection may be due to the differences in the sensitivity
of the various PCR protocols and primers (derived from various regions of the genome) used
by various investigators. The nested PCR used in this study is likely to contribute to an
increase in the sensitivity of the assay as compared to the one step PCR procedures. In
addition the testing of Anti-E2 greatly extends the ability of RT-PCR to define the
epidemiology of GBV-C/HGV. Although the study population may not be representative of
the overall prevalence of GBV-C/HGV in KZN, the results indicate that (1) RT-PCR using
nested primers from the 5 'NCR of the GBV-C/HGV genome is sensitive and specific, (2)
there is a high prevalence ofGBV-C/HGV infection in KZN, South Africa, (3) there are racial
differences in the prevalence ofGBV-C/HGV infection, and (4) that there is some mother-to-
infant transmission of GBV-CffiGV in KZN, though it is very probable that transmission does
occur by as yet undefmed non-parenteral routes. In an environment where HBV is endemic
and mv is considered to be pandemic, the disease potential, ifany, ofGBV-CffiGV infection




CLlNICAL SIGNIFICANCE OF GBV-CIHGV INFECTION IN KWAZULU
NATAL, SOUTH AFRICA
3.1 INTRODUCTION
In South Africa, the prevalence of hepatitis viruses ranges from 8 -15%, depending on
whether the patient originates from an urban or rural environment (Kew, 1996). In
addition, there is a high prevalence of GBV-C/HGV infection in blood donors, high risk
groups and patients with liver disease in KZN, South Africa (Sathar et al, 1999a). Whilst in
non-African countries the clinical association of GBV-C/HGV with liver damage is still
debatable (Mushahwar and Zuckerman, 1998), its association with liver disease in Africa
has not been defined . Alcohol-related medical diseases, including chronic liver disease, are
common in the local hospital population. It has always been questionable whether alcohol
alone is a common cause ofcirrhosis in African patients . Lelbach et al (1975) have shown
that a history of alcohol consumption of more than 80 grams per day to is the minimum
amount necessary to cause alcoholic liver disease. It is doubtful whether many of the
Afiican patients labeled as having,alcohol-related liver disease are able to afford the large
quantity of alcohol required to produce hepatic cirrhosis (160 gm alcohol per day for 5
years in males) (Wands and Blum, 1991). Therefore, one wonders whether alcohol alone
. is able to produce the amount of hepatic injury that is attributed to it, or whether viral
infections serve as a cofactor for the hepatic injury (Brechot et al, 1996), especially in an
area where both contributions are endemic .
103
South Africa has the fastest-growing mv AIDS population in the world. Official
Department of Health figures compiled from antenatal clinics across the country show a
significant increase in the infection rate among pregnant women in most provinces, the
highest figures (35%) being reported for the province ofKZN, which is considered to be
the epicentre of the mv pandemic in South Africa. To what extend GBV-CIHGV
persistence affects the rate of progression to AIDS in African countries is not known.
Whether GBV-CIHGV infection is associated with any abnormality in mv infected
patients in KZN is not known . GBV-CIHGV is a flavivirus with some homology to HCV,
and often co-existing with GBV-C/HGY. mv infection like HBV is a serious health
problem in KZN. AIDS patients infected with HBV or HCV often die from liver failure
instead of AIDS (Ockenga et aI, 1997) With the high prevalence ofGBV-CIHGV in KZN
(Sathar et a11999a) one assumes that GBV-C/HGV (ifit does cause hepatitis) would have
similar interactions in mv infected patients .
This chapter will attempt to determine the clinical association, if any, that GBV-CIHGV
has with liver disease and mv in KZN, South Africa.
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3.2 METHODS
3.2.1. Source of Samples
3.2.1.1 Collection of Sera
Venous blood was collected and stored as described in 2.2.1.1
3.2.1.2 Patients
The study population comprised the same patients studied in Chapter 2.2.1.2 viz.70
patients with chronic renal failure who were undergoing maintenance haemodialysis
(HAEM), 98 consecutive patients with chronic liver disease (CLD) and 50 patients with
biopsy proven alcoholic liver disease (ALD). In addition, sera were collected from 56 HIV
positive mothers, recruited at 33-38 weeks gestation from arandomized placebo-controlled
clinical trial on Vitamin A supplementation (Coutsoudis et al, 1999) and stored at - 85°C
under coded identifier numbers . Serum samples were obtained at baseline for




The control groups included those studied in Chapter 2.2.1 3 viz. 232 adult volunteer blood .
donors from the four racial groups and 35 individuals who did not present to hospitals for
signs or symptoms of liver disease and attended local center for alcohol detoxification
(Alcoholic Anonymous).
3.2.2 Diagnostic assays
3.2.2.1 Detection of GBV-CIHGV RNA
The RT-PCR assay has been described in detail in Chapters 2.2.3.1.1 - 2.2.3 .1.3
3.2.2.2 Detection of GBV-CIHGV Anti-E2 antibodies
The assay has been described in Chapters 2.2.3 .2.1
3.2.2.3 Carbohydrate Deficient Transferrin (CDTect®)
The assay has been described in Chapter 2.2.3.2.2.
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3.2.3 Liver function tests
Raised liver enzymes (alanine aminotransferase [ALT]; aspartate aminotransferase (AST);
alkaline phosphatase [ALP]; gamma-glutamyltransferase [GGT] and bilirubin) are
suggestive of acute or chronic liver disease (Craxi and Almasio, 1996) . The most frequent
cause of high ALT levels (~ 10 times upper normal limits) [Table 3.1], with or without
symptoms, is an acute hepatitis of viral etiology. Liver enzymes and/or liver function tests
were performed by routine multianalysis systems in the central laboratory at King Edward
vmHospital, Durban, KZN.
Table 3.1 Tests used to determine liver function and normal ranges ofliver enzymes



















Immunophenotyping oflymphocytes was performed using specific monoclonal antibodies
on the Becton Dickinson Facs Vantage flowcytometer (Becton Dickinson
Immunocytometry Systems, San Jose, Cal, USA) using a CellQuest software programme.
Briefly lOOul of whole blood sample was added to each Falcon tube . lOul of each
monoclonal antibody was added to each respective tube according to the panel set-up. Each
tube was agitated at medium speed on a vortex and the cells were allowed to incubate for
~O minutes . The peripheral blood samples were lysed with a Coulter Q-Prep.
The samples were read using CellQuest program on the Facs Vantage flowcytometer. To
acquire data on the Facs Vantage flowcytometer, the amplifiers, PMT voltage,
compensation and threshold were adjusted for each sample type and fluorochrome that was
used. Those adjustments positioned the cells ofinterest within the scatter and fluorescence
channels . Collectively this process was known as sample optimisation. The Facs Vantage
instrument settings were optimised using the Cellquest software. Cellquest software was a
general program for acquiring and analysing data from a flowcytometer. It was also used
for adjusting electronics and setting up conditions for data acquisition.
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3.3 STATISTICAL ANALYSIS
The data ofblood donors, HAEM, CLD and alcoholics with and without liver disease were
analysed separately. Chi-squared analysis was used to compare groups (GBV-CIHGV)
positive versus GBV-CIHGV negative) with respect to categorical data, while Student's t-
test was applied to continuous data. Analysis of covariance was used to compare GBV-
CIHGV positive and GBV-CIHGV negative patients with respect to liver function test,
adjusting for age, sex and disease group. Multiple logistic regression was used to
determine any confounding influence of age, sex and disease group on GBV-CIHGV.
Blood donors were compared to CLD and lID patients with regard to demographic
parameters using Student's t-test or Chi-squared test.
Descriptive statistics were calculated by group: means and standard deviations for
continuous and frequencies and percentages for categorical data. ALD patients were
compared with alcoholic controls using Student's t-test for continuous data. Two-way
analysis of variance was used for comparison ofALD and controls, and for GBV-CIHGV
positive and GBV-CIHGV negative patients, and to assess the interactions between these
groups of patients . Chi-squared tests were used to compare groups with relation to
categorical data.
IllV positive patients' data were calculated using descriptive statistics (means and standard
deviation). In IllV positive patients GBV-CIHGV positive and negative patients were
compared with relation to all parameters using non-parametric Wilcoxon 2-sample tests.
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3.4 RESULTS
3.4.1 Alcoholic liver disease
Of the 50 ALD patients 27 of 39 (69.2%) were anti-HBc positive (Table 3.2), 14/27
(52.1%) were anti-HBs positive. Seven of 50 (14%) ALD patients were positive for
HBsAg (Table 3.2). These seven ALD patients were tested for additional HBV viral
markers to assess whether viral replication persisted (Table 3.3). HBV DNA was detected
in 2/7 (28.6%) ALD patients (Table 3.3). Anti HBs and anti-HBc were detected in
217(28.6%) (patient nos. 41 & 131) and HBeAg detected only in one (patient no.!31)
(Table 3.3). Both these patients (41 & 131) were eo-infected with GBV-C/HGV HBsAg
was detected in one alcoholic without liver disease [1/35 (2.9%)], this subject had no other
viral markers for HBV infection. Thirty - three of 50 (66%) ALD patients had one or more
viral markers for HBV infection. There was a higher prevalence of HBV and HCV in
ALD patients than in alcoholics without liver disease, this difference was not significant
(Table 3.2). Twenty of35 (57.1%) alcoholics without liver disease were anti-HBc positive,
suggestive of ongoing or previous infection (Table 3.4). Although not significant, there




Markers for HBV and HCV infection in alcoholics with alcoholic
liver disease and alcoholics without liver disease
PARAMETER ALCOHOLIC ALCOHOLICS WITHOUT p-value
LIVER DISEASE LIVER DISEASE
n(%) n(%)
HBV
Sag 7/50 (14) 1/35 (2.9) os
Cab 27/39 (69.2) 20/35 (57.1) os
DNA 3/50 (6) 1/35 (2.9) ns
HCVRNA 2/50 (4) 1/35 (2.9) os
HEV-Hepatitis B Virus; HCV-Hepatitis C Virus; sAg-surface antigen; cAb-eore antibody; DNA-
deoxiribonucleic acid,RNA-ribonucleic acid;no-number; %-percent; ns-notstatistically significant
Table 3.3 HBV and GBV-C/HGV markers in alcoholic patients with liver disease
(ALD) who were HBsAg positive
Patient Anti- BBeAg Anti- DNA GBV-CIHGV
LD.No. HBs BBc RNA anti-E2
8 +
28 +
41 + + +




HE-hepatitis B virus; sAg-SUIface antigen; eAg-envelope antigen; anti-HEs or Hlsc-antibody
surface or coreantigen;E2- enevelope; nd-notdone; DNA-deoxinbonuleic acid
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3.4.2 Liver biochemistry in patients and control groups
Raised ALT levels were observed in 6 of232 (2.6%) blood donors (Table 3.4). Only 1/44
(2.3%) GBV-C/HGV positive donors had a raised ALT level (69 UIL) (Table 3.4). Raised
ALT levels were observed in 2/70 (2.85%) dialysis patients (Table 3.5); 17/35 (48.6%)
alcoholics without liver disease and 4/50 (8%) ALD patients (Table 3.6). In 3 ALD
patients ALT levels were greater than 10 times the normal range (Table 3.4), [472 UIL;
756 UIL and 1476 UILl All three patients were infected with HBV; one (1476u/l) was co-
infected with HCV (HCV RNA positive) and the other (472UIL) was eo-infected with
GBV-C/HGV RNA. Although ALT and GGT levels were higher in ALD patients
compared to the control group, this difference was not significant (Table 3.6). The ALP
levels in ALD patients were significantly higher than the control groups (p = 0.0001)
(Table 3.6). In contrast, CDTect levels were significantly higher in the control group
compared to ALD patients (p = 0.0005) (Table 3.6).
Using multivariate analysis and controlling for the influence of confounding factors (age,
sex and disease groups) no significant differences were observed between GBV-C/HGV
infected and non-infected blood donors in each of the four racial groups (Table 3.4). No
significant differences in liver biochemistry were observed in CLD patients, HAEM
patients (Table 3.5) and alcoholic subjects with and without liver disease patients (Table
3.6).
Table 3.4 Demographic and Biochemical features ofBlood donors (n = 232)




Meao ± SD (Raoge)
GBV-CIHGV-
Meao ± SD (Raoge) p-value
Africaos (0 = 76) (0=29) (0=47) Ns
ALT(U/L) 17.24 ± 11.40 (9-69) 15.68 ± 6.6 (5-45) Ns
Age (yrs) 32.10 ± 10.06 (19-48) 28.38 ± 10.53 (18-59) Ns
Sex (M:F) 8.6:1 4.2 :1 ns
Indiaos (0 = 52) (0=2) (0=50) ns
ALT(U/L) 16.5 ±l.12 (15-18) 23.48 ± 16.82 (7-92) ns
Age (yrs) 47.0±7.07 (42-52) 30.68± 12.09 (17-67) ns
Sex (M:F) 1':1 11.5:1 ns
Whites (0 = 49) (0=11) (0=38) ns
ALT(U/L) 24.45 ±11.64 (11-54) 23.76± 13 83 (8-63) ns
Age (yTs) 40.27± 9.71 (19-53) 39.32 ±15.19 (17-67) ns
Sex(M:F) 2:0 2.25 :1 ns
Coloureds (0 = 55) (0=2) (0=53) ns
ALT(U/L) 12.5 ±l.12 (11-14) 19.06± 12.51 (5-73) ns
Age (yrs) 19.0 ±1.41 (18-20) 31.23 ±12.46 (17-68) ns
Sex(M:F) 2.67 :1 1.9:1 ns
SD-stmdard deviation; n-number; M-male; F-female; ALT-alanine aminotransferase; ns-not statistically
significant; U/L-units per litre; + positive ; - negative
Table 3.5
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Demographic and Biochemical features ofpatients with chronic liver disease













45.7 ± 15.9 (18-75)
1.4:1
68.6 ±73.4 (7-235)
197.0 ± 163.29 (18-576)





44.8 ± 16.8 (2-81)
1.2:1
63.3 ± 83.3 (7-506)
173.8 ± 143.41 (3-838)








Age (yrs) 38.17± 12.06 (17-65) 39.57± 12.76 (15-67) ns
Sex(M:F) 1:0.8 1: 0.8 ns
Dialysis(mths) 76.23 ± 50.90 (12-180) 59.60 ± 54.82 (3-216) ns
TRANSF(no.) 12.58 ± 7.79 (5-31) 8.07 ± 7.17 (2-30) 0.03
AST (UIL) 14.88 ± 5.33 (6-28) 18.60 ± 13.22 (6-90) ns
ALT (UIL) 12.58 ± 6.97 (5-32) 17.92 ± 18.24 (4-101) ns
ALP (UIL) 132.58 ± 146.39 (36-667) 107.11 ± 131.50 (5-920) ns
T-BIL (umollL) 11.94 ± 2.22 (8-17) 11.32 ± 2.25 (5-17) ns
T-BiI-Total bilirubin; ALT-alanine aminotransferase;GGT-gamma-giutamyltransfernse; ALP-alkaline
phosphatase; TRANS-transfusion; umollL-micromoles per litre; UIL-units per litre; no-number; mths-
months; M-male; F-female;-yrs-years; SD-standard deviation; + positive; - negative.
Table 3.6 Biochemical features ofalcoholic patients with and without liver




Alcoholics with (0=14) (0=36)
liver disease
ALE(gIL) 20.71 ±6.88 24.80± 7.08 ns
GLOB (gIL) 57.00± 17.21 51.80 ± 12.66 ns
T-Bil (umollL) 67.14 ±54.53 58.94 ± 97.13 ns
ALT (UIL) 14.65 ± 117.95 100.00 ± 271 .05 ns
GGT (UIL) 241.57 ± 188.91 222.44 ± 222 .76 ns
ALP (UIL) 283 43 ± 229.45 213 .39 ± 160.35 ns
CDTect (UIL) 22.01 ± 9.721 30.70±21.57 ns
Alcoholics without (0=5) (0=30)
liver disease
ALB (gIL) 40.40 ± 8.67 41.14 ± 6.64 ns
GLOB (gIL) 41.80 ± 10.66 42.51 ±8.17 ns
T-Bil (umollL) 9.00± 1.87 13.51 ±6.33 ns
ALT (UIL) 85.40 ± 22.09 54.51 ± 35.14 ns
GGT (UIL) 104.00 ± 101.07 163.4] ±229.89 ns
ALP (UIL) 51.00 ± 19.46 77.37 ± 46.53 ns
CDTect (UIL) 89.09 ± 34.51 50.99 ± 37.20 ns
ALB-albu.min; T-Bil-Total bilirubin, ALT-alanine aminotransferase; GGT-gamma-glutamyltransferase;
ALP-alkalinephosphatase, CDTect-carbohydratetransferin test; n- number; umollL-micromoles per litre;
UIL-units per litre; SD-standard deviation; +-positive; - - negative.
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3.4.3 HIV infected patients
In 55 HIV positive mothers the mean haematologicallaboratory values in patients with and
without GBV-CIHGV infection were not significantly different (Table 3.7). With the
exception of relative rather than absolute differences in CD3, CD30 and gammadelta T cells
(y8T) [TGD], immune parameters were not significantly different in both groups. There was
no significant differences in CD4 (461.12 ± 163.28 vs 478.42 ± 181.22) and CD8 (680 .83 ±
320 .36 vs 862.52 ± 354.48) absolute cell counts between HIV positive mothers eo-infected
with GBV-CIHGV and those not infected with GBV-CIHGV, respectively (Table 3.8).
However, significantly higher CD3 % [80.0 ± 4.17 vs 70.99 ± 19.79] (p = 0.015), gammadelta
T cells (y8T %) [3.22± 1.30 vs 2.15 ± 29.12] (p=0.052) and lower CD 30 % [35.45 ± 17.86 vs
50.59 ± 9.20] (P= 0.041) status were observed in GBV-C/HGV positive compared to GBV-
CIHGV-negative mv infected patients, respectively (Table 3.8).
Table 3.7 Comparison ofmean haematological indices in mv infected patients with
and without GBV-CfHGV infection
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Haemotological GBV-CIHGV+ GBV-CIHGV- p-value
Indices Mean±SD Mean±SD
[n=22] [n=33]
Haemoglobin (gldl) 10.57 ± 1.32 10.65 ±2.24 ns
Haematocrit (%) 30.59 ± 3.47 31.81 ± 3.26 (%)* os
Mean cell volume (ft) 86.25 ±8.41 88.02 ± 5.82 (fl)* ns
RDW(%) 13.58 ±2.07 13.58 ± 2.48 (%)* ns
Reticulocytes (%) 2.2 ± 1.26 2.49 ± 1.10 ns
RETCORR(%) 1.52 ±0.89 1.77 ± 1.04 ns
RETABS (%) 81.01 ±50.90 87.31 ±43.32 ns
Platelets (xlO' 11) 268.59 ± 81.13 250.16 ± 69.12 (x 10911)* ns
White cell count (xlO' 11) 7.7 ±2.2 7.44 ± 2.09 ns
Neutrophils (x10'11) 5.03 ± 1.99 4.83 ± 1.65 ns
Lymphocytes (x10'11) 1.74 ±0.44 1.73 ± 0.63 ns
Monocytes(xlO'/1) 0.62±0.19 0.66 ±0,63 ns
Eosinophils (xlO'11) 0.29±0.21 0.29 ± 0.27 (x 10911)* ns




Comparison of mean lymphocyte subset indices in HIV infected patients with
and without GBV-C/HGV Infection
GBV-CIHGV+ GBV-CIHGV -
Lympbocyte subsets Mean±SD Mean±SD p-value
[n=22] [n=33]
CD4(%) 26.70 ± 8.30 26.64 ±8.67 ns
CD4(cells/ul) 461.12 ± 163.28 478.42 ± 181.22 ns
CD8 (%) 48.47 ± 10.08 48.70 ± 10.78 ns
CD8(cells/ul) 680.83 ± 320.36 862.52 ± 354.48 ns
CD4/CD8 Ratio 0.58 ±0.25 0.59 ±0.28 ns
CD3(%) 80.0 ±4.l7 70.99 ± 19.76 0.015
CD3(cells/ul) 1395.45 ± 366.79 1451.29 ± 571.37 ns
CD30% 35.45 ± 17.86 50.59 ± 9.20 0.041
CD30(cellslul) 577 .75 ± 307.64 823.88 ± 392.00 ns
y~T(%) 3.22 ± 1.30 2.15±1.08 0.052
-sr 53 .11 ± 18.35 39.15 ± 29.12 ns
CD-cluster ofdifferentiation; yoT- gamma delta T cells; n- number, SD- standard deviation, ns-not statistically
significant; + positive; - negative
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3.5 DISCUSSION
The majority of haemodialysis patients and blood donors, including those with GBV-C/HGV
infection, had normal liver enzymes (Tables 3.4 - 3.6). The high prevalence ofGBV-C/HGV
in blood donors and in haemodialysis patients (Sathar et aI, 1999a) without biochemical
evidence of liver damage suggests that many patients are viraemic in the absence of liver
disease. In positive cases ofGBV-C/HGV RNA persistence where transient elevated levels of
ALT have been observed, these levels subsequently returned to normal (Wang et aI, 1996;
Masuko et aI, 1996; Linnen et aI, 1996a,b; Alter et aI, 1997a,b). Although persistent GBV-
CIHGV infection may not cause liver damage or dysfunction to a greater extent than HCV
infection, there are a few reports on histology in GBV-CIHGV infection (Dhillon et aI, 1996;
Fiordalis et aI, 1996; Colombatto et aI, 1997; Ross etaI, 1997). However, normal ALT levels
do not definitely prove normal histology as shown for HCV infection (Alberti et al,1991).
Numerous studies have shown that in HCV eo-infection, GBV-C/HGV does not influence the
liver histology (Tanaka et aI, 1996; Bralet et aI, 1997; Enomoto et aI, 1998; Pawlotsky et aI,
1998). On the other hand, some investigators have suggested that GBV-C/HGV in Hev
infected patients might accelerate liver injury (Diamantis et aI, 1997; Francesconi et aI, 1997;
Manolakopoulos et aI, 1998). However, in the absence of liver histology to detect GBV-
CIHGV no significant differences were observed in the liver biochemistry of patients with
liver disease and control groups who were infected with GBV-CIHGVas compared to those
not infected with GBV-C/HGY.
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Obtaining an accurate history of the amount of alcohol ingested by a patient is often difficult
because of the unreliability of the patient report (Orrego et aI, 1979). The CDTect™
considered to be the most accurate biochemical marker of alcohol consumption currently
available (Salapro et aI, 1999), was used to assess if there was a discrepancy in the history of
alcohol consumption: Most ofthe patients in the study did not attempt to conceal their alcohol
consumption. The greater spread of CDTect™ values (6.08-166 .7UIL) in the former group
suggests that bloods were taken from these alcoholics at different times/points ofentry into the
local center for alcohol detoxification (Alcoholic Anonymous). In addition, it also reflects the
degree of abstinence. The shorter spread of CDTect™ values of ALD patients (9.52-49.22
UIL) except one (143.22u/l) suggeststhat because these patients are very sick when admitted
into hospital. They were already abstaining and during their period of hospitalisation do not
have access to alcohol. Despite favourable reports concerning the CDTect™, a variety of
important issues on the value and applicability of the test in clinical and research situations
remain inadequately explored. There are still some uncertainties, regarding the sensitivity and
specificity ofthe tests, which probably depends on the cut-offpoint for CDTect™, ethnicity of
the population studied, control groups and time of blood taking in relation to abstinence
(Salapuro et aI, 1999). CDTect™ is a good marker of alcoholism similar to the commonly
used markers. It may be useful in the control of alc?hol consumption in patients with liver
disease. The results also suggest that the CDTect TMwas a significantly better marker in
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detecting high levels of alcohol consumption than the GGT. Similar observations were
reported by Salaspuro etal (1999) in his review ofthe CDTect™
Several factors, in addition to alcohol intake, have been implicated to explain different
evolutions of liver damage observed in alcoholic patients (Nei et al, 1983; Sorenson et aI,
1984; Diehl, 1989; Zetterman,1990;). Among these, HBV infection has received special
consideration (Mills et aI, 1979; Nalpas et aI, 1985; Esteban et aI, 1989). HBV infection may
be present despite the absence of serological markers of persistent viral infection (Brechot et
aI, 1982; 1985; Nalpas et aI, 1985). It is now known that HBV can exist in serum and liver at
very low levels, even when serological markers such as HBsAg and HBV DNA are not
identifiable with the usual methods (Theirs et aI, 1988; Feray et aI, 1990). Antibodies against
HCV antigens (anti-HCY) have been found in several series with alcoholic liver disease,
suggesting a high prevalence ofHCV infection, especially in patients with severe liver injury.
This has been confirmed by identification ofHCV RNA, leading to the hypothesis that chronic
liver disease in alcoholic patients may only have a viral pathogenesis (Brillanti et aI, 1989;
Esteban et aI, 1989; Pares et aI, 1990).
The role of viral infections in alcoholic liver disease varies with the stage of liver disease and
with the race and country of origin of the patients (Brechot et aI, 1996). Several studies have
reported an association ofalcoholism with HBV and HCV, suggesting that alcohol accelerates
liver damage in subjects with HBV and HCV infection (Mills et aI, 1979; Brech~t et aI, 1982;
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1985; Nalpas et al, 1985; Esteban et al, 1989; Brillanti et al, 1989; Pares et al, 1990). A large
proportion of these patients have serological evidence of past exposure to HBV (anti-HBc
positive), and are thus not considered to harbour the virus in liver or serum (Brechot et al,
1996). Approximately, 60% of alcoholics in the current study with and without liver disease
had serological markers indicating previous HBV infection. In contrast HBV PCR showed
HBV replication in only 3-6% of alcoholic patients. This would tend to suggest that inapparent
active HBV infection plays a marginal role in the pathogenesis ofliver disease in the group of
alcoholic patients studied. HBV DNA was detected in 2.9% (1/34) and 9.3% (4/43) ofHBsAg
- negative alcoholics without and with liver disease, respectively. In several series ofHBsAg-
negative alcoholic patients, the prevalence ofHBV DNA approached 10% (Nalpas et al, 1985;
Zignego et al, 1994) . These results demonstrate that HBV serology alone does not accurately
reflect the frequency of infection among alcoholics . The detection ofHBV DNA in the sera of
HBsAg negative alcoholic patients may be related to the production' of low amounts of
HBsAg. Alternatively it may reflect the production of variants not detected by currently
available serological tests. When the results of classic markers are combined with those of
HBVDNA, the overall prevalence ofHBV in alcoholics is > 60%.
Cirrhosis due to both alcohol and the hepatitis viruses is a common occurrence (21% HBsAg+
and 23%anti-HCV +) in KZN (Soni et al, 1996). Whilst the prevalence ofanti-HCV is much
lower in our local population (0.75% in African blood donors in Natal), this virus has a greater
propensity to cause chronic hepatitis and cirrhosis as it is not efficiently cleared by the
immune system (Soni et al, 1993). In KZN, HCV is prevalent in almost one quarter ofpatients
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with cirrhosis (Soni et aI, 1993). Using HCV PCR the prevalence ofHCV in haemodialysis
patients (4/70; 5.7%); in patients with chronic liver disease (6/98 ; 6.1%) and in alcoholic
patients with (2/50; 4%) and without (1/35; 2.9%) liver disease is similar to that reported
previously (4.8%) and confirms the low prevalence ofHCV in KZN (Soni et aI, 1993). Of the
three ALD patients with abnormal ALT levels one was positive for HCV RNA, another was
HBsAg-positive and GBV-CIHGV viraemic and the third had no other viral markers except
anti-HBc.
Although an association between excessive alcohol intake and GBV-C/HGV infection has
been reported in South Africa (Tucker et aI, 1997), no studies have dealt with GBV-C/HGV
positivity in alcoholic patients with liver disease in African countries. In limited studies GBV-
CIHGV RNA positivity rates of2 - 14% have been reported (Linnen et aI, 1996a; Lampe et aI,
1997; Sobue et al, 1998; Tran et aI, 1998; Guilera et aI, 1998; Shimanaka et aI, 1999) in non-
African countries. Tran etal (1998) reported that 38.8% (9.3% GBV-C/HGV RNA and 29.5%
anti E2) of ALD patients had past or present infection with GBV-C/HGY. Most ofthe patients
were heavy drinkers. In the present study the prevalence of GBV-CIHGV RNA was twice that
in alcoholics with liver disease than in alcoholics who were abstaining (28% vs 14%,
respectively) The reasons proposed for the higher prevalence of GBV-CIHGV may be similar
to that for HCV, viz. that excessive alcohol consumption diminishes the immune function and
that cellular immunity is impaired, but the precise mechanism remains obscure, even in the
case ofHCY.
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In South African Blacks HBV has the greater propensity for establishing liver disease, because
of its endemic nature . Although the prevalence of HCV infection is low, it is now accepted
that both HBV and HCV are carcinogenic in humans. In South African Blacks with HBsAg
the relative risk for HCC is 23.3% (Kew et aI, 1997; 2001). The two viruses almost certainly
interact in HCC, and each probably interacts with alcohol in inducing chronic hepatic
parenchymal disease that in turn is complicated by malignant transformation (Kew et ai, 1997;
2001) . However,no association was reported between GBV-CIHGV and hepatocellular
carcinoma in South Africans Blacks (Lightfoot et aI, 1997).
Some studies have suggested that GBV-CIHGV infection did not affect the clinical
characteristics and histological severity of liver injury (Tran et aI, 1998; Sobue et aI, 1998;
Shimanaka et al, 1999) . In the current study no significant association was observed between
GBV-CIHGVand ALD.
Only a few studies have investigated the clinical consequences ofGBV-CIHGV eo - infection
in HfV positive patients, and they confirm the absence ofliyer disease (Stark et aI, 1999; Lau
et al, 1999; Tillman et aI, 2001) . Like Woolley et al (1998) no association was observed
between GBV-CIHGV infection and haematological abnormalities in the current study.
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Recently, researchers have suggested that GBV-CIHGV may be a favourable prognostic factor
in HfV patients, delaying the progression ofAIDS, resulting in prolonged survival (Heringlake
et al, 1998; Toyoda et aI, 1998; Lefrere et aI, 1999; Yeo et aI, 2000; Tillman et al, 2001 ;
Xiang et al, 2001). Tillman et aI, (20001), Yeo et al (2000) and Heriglake et al (1998)
reported higher CD4 + lymphocyte counts and better AIDS-free survival rate in IllV patients
infected with GBV-CIHGV Toyoda et al (1998) reported lower mv viral load and AIDS
incidence with the detection of GBV-CffiGV RNA in serum. Conversely, Sabin et al (1998)
found an increased risk for AIDS and death with detection ofGBV-C/HGV RNA or anti-E2
antibodies. The differences were not statistically significant in either of these studies. Lefrere
et al (1999) noted significantly lower mv viral load, higherCD4+ Lymphocyte count, and
better AIDS-free survival in patients with GBV-CIHGV RNA than in those without GBV- .
CIHGV RNA or anti-E2 antibodies. In this dissertation no association was observed between
GBV-C/HGV infection and "immune abnormalities" specifically, CD4 and CD8 counts, when
the means ofGBV-CIHGV positive and negative groups were compared. Wooley et aI, (1998)
and Goubau et aI, (1999) showed similar results. In addition, Woolley et al (1998) reported a
mild CD8 lymphocytosis associated with GBV-CIHGV infection. Some studies selected their
patients based on CD4 counts (Lau et aI, 1999; Yeo et aI, 2000); like Goubau et al,(1999)
there were no specific inclusion criteria for the study population in this dissertation apart from
being mv positive.
Reported for the first time, significantly higher CD3 and T cell receptor gamma/delta
expression (y8 TCR) and lower CD 30 status were observed in GBV-C/HGV positive
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compared to GBV-C/HGV negative IllV positive patients. T lymphocytes recognise antigen
via CD3/TCR complex (T cell receptor complex) which is expressed on mature T cells in the
periphery. Less than 10% of human peripheral T cells express the y8 TCR complex. y8 T cells
are often found in increasing numbers during the course of several viral infections in humans
and they seem to provide natural immunity at the early stages of the second virus infection by
having a significant impact on virus replication (Sciammas and Bluestone, 1999; Kabelitz and
Wesch, 2001) . GBV-C/HGV viraemia occurs in 35-40% of human IllV-infected individuals
(Nerurkar et al, 1998) . It is well established that GBV-C/HGV maintains a persistent viraemia
for many years (Masuko et aI, 1996), which suggests effective replication of GBV-C/HGY.
Replication of GBV-C/HGV has been demonstrated in CD4 cells and the inhibitory effect of
GBV-C/HGV infection on IllV replication leading to delayed disease progression was
demonstrated in vitro recently (Xiang et aI, 2001). Significant alterations in the peripheral
blood y8 TCR repertoire occur in IllV infected individuals which is thought to be due to
"superantigens I phosphoantigens" derived from pathogenic bacteria, parasites or viruses
(Kabelitz and Wesch, 2001) . Human y8 T cells possess potent cytotoxic activity and are
capable of producing a large array f3-chemokines and pro-inflammatory cytokines which are
known to interfere with mv replication (Kabelitz and Wesch, 2001). The relatively higher
CD3 (due to an increase in T cell status) and an increase in y8T expression, together with a
decrease in CD 30 (reflects a decrease in activation status and an increase in T helper Type 1
response) would tend to suggest an association with protection and or delayed progression of
IDV disease in GBV-C/HGV infected patients. It is tempting to speculate that GBV-C/HGV
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could indirectly affect AIDS risk through the expression of yoT cells; induction of various
chemokines and other soluble factors; and altered expression ofchemokine receptors essential .
for HIV co-receptors (Woitas et aI, 2001). CD30 marker is expressed on all T-celllineages;
CD3+ T cells can be separated into two lymphocyte subsets bearing hetero-dimeric TCR
composed ofeither alphabeta (a.P) or gammadelta (yo) chains . While the role ofTCR a.p cells
is well understood, that ofyo is recently being unraveled . In part they function by modulating
CD4+a.p TCR responses (especially in the gut and lung, and in response to viral infection).
CD30 is a member of the TNF receptor family, (includingTNF-R1, TNF-R2, Fas-R, CD40,
CD27, and TRAIL-R) [Bengtsson, 2001]. Members have pleiotropic effects depending on the
context of activation, causing proliferation of activated T cells and T-cell-like Hodgkin cell
lines but growth inhibition in Ki-1 lymphoma cell lines [Bengtsson, 2001]. There is evidence
that CD30 is involved in negative selection of thymocytes as well as antigen withdrawal-
induced apoptosis [Bengtsson, 2001]. CD30 expression in normal tissue is limited to activated
T cells, activated B cells, and some vascular beds. It is highly expressed in Hodgkin disease,
and some cutaneous lymphomas [Bengtsson, 2001]. There are some anti-CD30 antibody-
based therapies for carcinoma. In terms oflimiting a viral response, CD30 seems to act as an
'immune-brake', as knock-out animals do not clear autoreactive thymocytes [Bengtsson,
2001]." GBV-C/HGV is a Flavivirus with some homology (25%) to HCV, and often the two
viruses co-exist AIDS patients infected with HBV or HCV often die from liver failure instead
ofAIDS (Ockenga et aI, 1998).
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It has been suggested that HCV may reduce HBV replication (Zarski et ai, 1998). If GBV-
CIHGV has a core protein like HCV, as has been suggested (Xiang et ai, 1998), it may
interfere with IllV replication, leading to a favorable prognosis in IllV infected patients. Co-
infection with HCV has been associated with faster progression to AIDS and higher mortality
rates (Mohsen et ai, 2002). In eo-infected mothers, there is evidence to suggest that mother to
child transmission ofHCV is facilitated by IllV infection (Moshen et ai, 2002), which may be
associated with higher HCV viral load, mode of delivery and perhapsbreastfeeding (Moshen
et ai, 2002) . However, few studies have addressed the impact ofHCV on IDV transmission in
eo-infected mothers. The host immune response and the repertoire of lymphocytes expressed
to HCV antigen is thought to determine whether viral clearance or chronicity occurs . Recent
studies have high lighted the essential roles ofCD 30, NK cells, roT cells and NKR+T cells in
. immunity in hepatotropic viruses in immunopathology (Fattovich et ai, 1996; Woitas et ai,
1997; Kakimi et ai, 2000 ; Liu et ai, 2000 ; Tseng et ai, 2002) . Whether, the above phenomenon
is characteristic ofGBV-CIHGV is unknown at this stage.
Recently, Mosier and Chisari (2002) suggested that the cytotoxic T lymphocyte response to
GBV-C IHGV eo-infection may be responsible for the delayed progression of IDV. In
addition, Nunnari et al (2002) reported that T-helper-1 (Th1) cytokine (a-2 and ll.,-12) levels
were significantly higher in mv positive patients eo-infected with GBV-CIHGV, while a
predominant T-helper-2 (Th2) pattern was found in the GBV-CIHGV negative group .
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Nunnari et al (2002) has suggested that GBV-CIHGV could immunologically interfere with
Hlv progression to AIDS by maintaining an intact T-helper 1 cytokine profile. Although
cytokine profiles were not measured in the current study, the data supports the findings of
Mosier and Chisari (2002).
In the absence of histochemical studies of liver biopsies to detect GBV-CIHGV, the higher
prevalence ofGBV-CIHGV (in blood donors,:mY positive patients and patients with chronic
liver disease), the lack of elevated liver enzyme values as well as clinical hepatitis in blood
donors and haemodialysis patients would tend to suggest that GBV-CIHGV is not associated
with liver disease. It is obscure whether alcohol intake plays a role in the development ofliver
injury in patients with GBV-CIHGV infection. In .KZN HBV and not HCV or GBV-CIHGV is
associated with alcoholic liver disease. This has important public health implications that
could influence national policies on vaccination against HBV in this endemic area. Even
though GBV-CIHGV infection is common in :mY patients in KZN, it is not associated with an
identifiable clinical syndrome. There is evidence for a beneficial influence of GBV-CIHGV
infection in Hlv positive patients. To further understand and determine the impact of GBV-
CIHGV infection on the natural course ofHlv infection in KZN, South Africa, the observed
phenomena will require more detailed in vivo and in vitro longitudinal studies Until then,




PHYLOGENETIC ANALYSIS OF GBV-CIHGV ISOLATES FROM
KWAZULU NATAL, SOUTH AFRICA
4.1 INTRODUCTION
A high prevalence of GBV-C/HGV has been documented in KZN (Sathar et al, 1999a),
however, very little is known about the strains of GBV-C/HGV that are infecting or
circulating in the local population. The best approach is to analyse the genetics ofeach strain.
Sequence and phylogenetic analysis of complete genome is expensive and labour intensive.
HCV genotypes can be distinguished by phylogenetic analysis of a variety of subgenomic
regions as small as 200 nucleotide (nt) that reproduce the phylogenetic relationships of
complete genomes (Simmonds et aI, 1994). It was anticipated that studies ofGBV-CIHGV
from different geographical regions of the world might reveal the existence of phylogenetic
groups (i.e. genotypes) and that different groups/genotypes may display specific biological
properties and clinical manifestations similar to that found with distinct HCV genotypes.
Attempts to genotype GBV-CIHGV based on sequence analysisofthe NS3 (Kao et aI, 1996;
Pickering et aI, 1997) and NSSA (Viazov et aI, 1997a) genomic regions have been
unsuccessful. Systematic analysis of six complete GBV-C/HGV genome sequences revealed
that congruent phylogenetic relationships were obtained for only a minority of300, 600 and
1200 nucleotide (nt) fragments, and that the optimal region was all or part ofthe of 5'non-
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coding region (5 ' NCR) (Muerhoff et al, 1997; Smith et al, 1997a). Sequence analysis ofthe
5' NCR provided some evidence that GBV-CIHGV can be separated into three major groups
that correlate with the geographic origin ofthe isolates (Muerhoffet al, 1996; 1997; Smith et
al, 1997a). In addition, sequence and phylogenetic analysis of the 5' NCR was considered to
be predictive of the sequence analysis of the complete genome (Muerhoff et al, 1996; 1997;
Smith et al, 1997a) .
At present 33 epidemiologically unrelated GBV-CIHGV complete virus genome sequences
are available in the Genbank database. The recent discovery of closely related chimpanzee
viruses (Adams et al, 1998) and the availability of a complete genome sequence (GBV-Cm)
(Birkenmeyer et al, 1998) allows phylogenetic trees to be constructed using a more
appropriate outgroup. Based on the assumption that sequence and phylogenetic analysis of
the 5' NCR was predictive of the sequence analysis ofthe complete genome (Muerhoffet al,
1996; 1997; Smith et al, 1997a), the phylogenetic relationship and the nucleotide sequences
of the 5' NCR ofGBV-CIHGV isolates from KZN were compared with published sequences
of GBV-CIHGV isolates from other geographical regions of the world . In addition, a re-
analysis of the phylogenetic relationships ofGBV-CIHGV complete genome sequences was




4.2.1. Source of samples
Sera from individuals who were previously shown to be infected with GBV-CIHGV were
used as a source ofviral RNA [Chapters 2.2.1 and 3.2.1] (Sathar et aI, 1999a). They included
17170 (23%) patients with chronic renal failure who were undergoing maintenance
haemodialysis, 12/98 (12.2%) consecutive patients with chronic liver disease, 44/232
(18.9%) adult blood donors from the four racial groups (Africans, Indians, Whites and
"Coloureds" [individuals of mixed origin] and 22/40 (55%) African female patients
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Fig 4.1 Map ofKwaZulu Natal (KZN) relative to South Africa (insert) showing the
location ofthe eight health regions (A-H)
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4.2.2 Purification of the peR product
The RT-PCR used to detect GBV-C/HGV RNA has been described in detail in Chapter
2.2.2-2.2.3. The 344 bp PCR product generated by RT-PCR was purified using the High
Pure PCR Product Purification Kit (Boehringer Mannheim, RSA) according to the
manufacturer's instruction with slight modifications. Precautions were taken at every step
to prevent contamination. Two hundred microliters (200ul) of binding buffer (3M
guanidine-thiocynate, 10mM Tris-HCI, 5% ethanol (v/v), pH 6.6) was added to 40 ul of the
PCR product and vortexed to mix. The total volume (240ul) was pipetted into the High
Pure filter tube without touching the rim. The tube was centrifuged for 30 seconds (sec) at
14 000 rpm in a micro-centrifuge (Eppendorf Microcentrifuge Model 5415C, Merck,
RSA). The flow through was discarded and the filtered tube transferred to the collection
tube: Three hundred (300ul) microliters of wash buffer (20mM NaCI and 2mM Tris-HCI
pH 7.5) was pipetted into the upper reservoir and centrifuged for 30sec at 14 000 rpm. The
wash buffer flow through was discarded and the filter tube transferred to the collection
tube. The previous step was repeated with 200ul of wash buffer. The collection with the
filtrate was discarded and the filter tube transferred to a sterile 1.5mlmicrocentrifuge tube.
Forty microliters (40ul) of elution buffer (10mM Tris-HCI and 1Mm EDTA, pH 8.5) was
added directly over the membrane and the tube centrifuged for 30 sec at 14 000 rpm. The





Both strands of the 344 bp peR product were sequenced by Direct cycle sequencing using
the Perkin Elmer dRhodamine Terminator Cycle Sequencing Kit (perkin Elmer,
Biosystems, RSA). Briefly, for each reaction, 8.0ul ofte~ator ready reaction mix, 90 ng
of PCR product (DNA), l.3ul (3.2 pmol) of either reverse or forward primer in a total
volume of 20 ul of sterile deionised water was added to a 0.2 m1 PCR tube. The reagents
were mixed, briefly spun, and cycle sequenced in the Perkin Elmer GeneAmp 2400
thermal cycler (perkin Elmer, Biosystems, and RSA) at 96°C for 10 sec, 50°C for 5 sec,
60°C for 4 minutes (min) for 25 cycles followed by a 4°C soak. The tubes were spun
briefly. The extension product was purified from incorporated nucleotides by precipitation.
The entire contents of each extension reaction was transferred to a sterile 1.5m1 microfuge
tube. To which was added 16ul of sterile deionised water and 64ul of 95% ethanol. The
contents of the tube were briefly vortexed . The tubes were allowed to stand for 10-15 min
to precipitate the extension products and microfuged for 15 min. The supematants were
carefully aspirated off without disturbing the "pellet." The "pellets" were then washed with
70% ethanol (100ul) and microfuged for 10 min. The supematant was carefully aspirated
off without disturbing the "pellet." The samples were dried under vacuum for 10-15 min.
Twenty-five microliters (25ul) of template suppression reagent was added to the tube and
mixed well. The tubes were heated for 3 min at 95°C and thereafter held on ice.
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4.2.3.2 Amersham sequencing
The amplification of the £2 gene of KZN GBV-CffiGV isolates and its subsequent
sequencing were performed by Dr Smith and his colleagues (Smith et aI, 2000) and are not
described in any detail in the dissertation. The E2 gene was sequenced using the




Sequence analysis of 5' NCR
GBV-CIHGV isolates from blood donors and patients
The sequences of GBV-CffiGV isolates from Blood Donors and patients (chronic liver
disease and haemodialysis) were determined using an Applied Biosystems Prism 310
Automated Genetic Analyser (perkin Elmer, Biosystems, RSA). The sequences were
analysed using the Sequence Navigator Software (V.1.0.1). (perkin Elmer, Biosystems,
RSA). Nucleotide sequences were aligned manually using the Simmonic - 2000 sequence
editor package supplied by Dr Simmonds of the University of Edinburgh (p. Simmonds,
unpublished).
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4.2.4.2 GBV-CIHGV isolates from the eight geographical health regions of KZN
Nucleotide sequences of GBV-C/HGV isolates from the eight geographical health regions
of KZN were assembled and analyzed usmg the Staden Package
(http://www.mrc.Imb.ac.uk/pubseq/). Sequences were aligned with 28 unrelated sequences
from each of the four major groups (Smith et al, 2000) using Genetic Data Environment
Software (GDE) and Clustal W programmes (Higgins et al, 1992) with minor visual
adjustments.
4.2.5. Sequence analysis of complete genome sequences of GBV-CIHGV isolates
Nucleotide sequences of 33 epidemiologically unrelated complete genome sequences were
obtained from Genbank and manipulated and aligned using Simmonic-2000 software (p.
Simmonds, unpublished) by Dr Smith and his colleagues (Smith et al, 2000). Nucleotide
positions of aligned sequences were numbered relative to the AUG codon at the beginning
of the El gene of the prototype isolate GBV-C (U36380). The 33 epidemiologically
unrelated complete genome sequences were AB003488-93, ABO13500, AF104403,
AB013501, AF031829, D87255, D90600-1, U44402, U45966, U63715, AB008342,
AF006500, D87263, D87708-15, U75356, U94695, AB018667 and AB021287 together
with the outgroup AF070476. The partial sequence (positions -396 to 6118) of an
additional isolate from Thailand (K-1O) was made available by Sirirrug Songsivilai to Dr
Smith (Smith et al, 2000).
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4.2.6 Phylogenetic analysis of 5' NCR
4.2.6.1 GBV-CIHGV isolates from blood donors and patients
Phylogenetic analysis of GBV-CffiGV sequences from Blood donors, haemodialysis and
patients with chronic liver disease were carried out on a 311 base pair fragment in the 5'
NCR region (positions 160-470 in the HGV type 2a clone, PNF2161 (Muerhoff et al,
1997). Sequences were compared using a distance based method (p-distance at all sites.
followed by neighbor joining) as implemented on the Molecular Evolutionary Genetic
Analysis (MEGA) package (Kumar et al, 1993). Robustness of grouping was assessed by
bootstrap re-sampling; numbers on branches indicate the percentage of 500 bootstrap
replicates that supported the observed pylogeny (restricted to values of75% or greater). P - .
distances are indicated on the scale bar. Sequences compared included those of designated
genotype for which complete genomic sequences were available at the time
(GenbanklEMBL accession numbers in parentheses). These include the Group1 sequences,
GBV-C (U36380) and CG12LC (AB003291) which corresponds to variants recently found
in Central African Pygmy populations, which are characterised by an insertion in the NS5
region (Tanaka et al, 1998); Group 2a sequences, PNF2161 (U44402) and R10291
(U45966); Group 2b sequence GBV-C (EA) (U63715); Group 3 sequences GT230
(D90601) and GSI85 (D87262). The following sequences of unclassified genotypes were
also included: HGVC-964 (U75356) from China and G05BD (AB003292) from Japan.
4.2.6.2
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GBV-CfHGV isolates from the eight geographical health regions ofKZN
Phylogenetic analysis of GBV-C/HGV sequences of isolates from the eight geographical
health regions of KZN was carried out on a 311 base pair fragment in the 5' NCR region
(positions 143 - 442) in the GBV-C prototype isolate (U36380). The reliability ofgrouping
was assessed by bootstrap analysis using 500 repeats. Phylogenetic analysis was performed
using the Maximum likelihood method contained in the Phylogeny Inference Package
(pHYLIP) version 3.5c (Felsentein, 1993) and the F-84 model of substitution (Tamura and
Nei, 1993) in the Puzzle program (Strimmer and von Haeseler, 1999).The final
phylogenetic trees were visualized using the TREEVIEW program VERSION 1,5 (IBLS,
University of Glasgow). Sequences of the 5' NCR of KZN isolates were compared with
sequences of 28 geographically distinct isolates whose full genomic sequences are
available at the time in the Genbank. The 28 unrelated sequences were (GenbanklEMBL
accession numbers in parentheses): U36380, AB003291, AB013500 (Group 1); AFI04403 ,
AF031829, AB003289, D87255, D90600, U44402, U45966 and U63715 (Group 2);
AB003288, AB003293, AB008342, AF006500, D87708 -15, D90601 and U94695 (Group
3); AB003292, AB018667 and AB021287 (Group 4); and the outgroup GBV-Ctro
(AF070476). Included in the analysis were 13 sequences ofGBV-CIHGV isolates from the
western and eastern Cape provinces, South Africa (AF13111 - AF13123) (Tucker et aI,
1999).
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4.2.7 Phylogenetic analysis of the complete genome sequences of GBV-CIHGV
isolates
Complete coding region sequences of the 33 complete genome sequences were analysedby




4.3.1 Sequence analysis of 5' NCR of GBV-CIHGV isolates from KZN
Fifty-four (54) of 73 (74%) GBV-CIHGV isolates from blood donors and patients and 18
of 22 (82%) isolates from the eight geographical health regions of KZN were considered
suitable for sequence analysis of the 5' NCR of the viral genome (Appendices D and E).
The remainder giving rise to either faint bands or poor nucleotide sequences. The 5' NCR
sequences of the 54 GBV-CIHGV isolates from blood donors (Fig 4.2 a-c) and 18 isolates
from the eight geographical health regions (Appendix F) of KZN were aligned for
phylogenetic analysiswith representative isolates from each group .
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1 0 9
GSV-C TGGrAGCCAC TATAGGTGGG TcrTAAGGGG AGGCTACGGT CCCTCTI'GCG CATATGGAGG AAAAGCGCAC GGTCCACAGG 'fGT':'GG'l'CCT ACCGGTGT-l\ ATAAGGl\CCC
CG12 LC .. .. .. .. .. . 10.. .. ... .. . •T . .c;x G• • ... .. .. .. .c. .. ...... - . G• ..
KZN-c2 .. . cr . ':'A .T . . •T . . .C . A G• • .. .. .. .. .. . .- .
KZN-C 6 . 10. • . A.A . . . 10. . G. - ....
KZN- 07 ... .. .... " .. . 10.. ........ .. .. . c . . T . • C. . • •10. G•• .. .. .. .. .. ...... c . . .. .. - . G• • •
KZN- 09 .. ..... .. .. .... ... . 10.. .. . . . . ...., . c . . . T • .. .. • • A G• • .. . . .. . .... .. .. .. .. . c .. .. .... - • • • • • •G• • •
KZN- DIO .. .. .. . TA. T. .c . •T . .. .10.• G• • .. .. .. .. .. .. .-. .. ....
KZN-Bl . ceR. .. • CT . TA .T . . T . . c.x G• • .. .. .-. .. ..
KZN-S1 0 .. .. .C . •T . • C • ..10. G• • . c .. - .. .G •
KZN-B14 . CT . TA. T. •T . . .10. G• .. -
KZN- B20 oo . C. • T . • C• . 10. G• • C. - .. . G•
KZN- B23 .. . oo .. .. .. . . . . .. .. .. .. .. . .. .. • C. • T • .c . . ..A G.. .. .. . .. . .. .. ... .c . .. .. - . . .. . .G • • •
KZN- Ll . 10. . .. .. oo .. .. oo .. . • TA . . •• .. • C. ..... .. oo G.. .. . .. oo .. . oo ... -. .. . . . . . . - ..... oo ..
PNE'21 61 .. .. .. . A.A •T • . A .A . T • • T . . e.GC . . C.A G. ce . . .. .. . C• • eG • .. . G•
RI029 1 . A.A • • T . . A .A . T • • T • .e.GC. . C . A G.ce . .. .. .. • C• •eG • .. . G•
HGVC9 6 4 .. .. .. .. . .. .. .. .. oo • C. T T • • Te .A .A . .. . T . . T . GC. . C . P. G oo .. .. . .. c . . .. oo •eG • .. . .. . G•
KZX-Dl .. .. oo . - . -.. .. .. .... . A .A . T . . A . A . T.. .. .. . T . . e . GC. • C.A G.ce .. . _. _ .. . .. .. . _. . c .. oo .. . . G. .. . _• • G• •
KZN-D3 .. oo .. oo •A .A. . T . . A . A. T • •T • .e.GC . •C oP. G. ce . .. oo .. .. • C• • G • . . .. . G• ..
KZN-B3 0 .. .. . A . A • T • . A.A . T • •T • .e.GC . • C.A G.ce. .. • C• • G • . G•
KZN-B 31 . T . .. . A .A • T • . A. A . T • . T • . e.Gc. . C .P. G.ce. . • C. • G • .. .G •
KZN- L12 . 10. . . A .A . T • . A.A . T . . T • .e.GC . . C.l'. G.CC. _ • C. .. • G • . . . G •
GBV-C(EA) .. oo .. . .. .. .. .. .. _A .• T• •A .A . T . . . . T. • e .G . . • C. l'. G. C. . . . oo • .. .. oo .• C. . . . . • eG • -.. .. . G• •.
KZN-05 .. ... .. .. .. .. •10. • • T • •A . . . T • .. .. •T • . e. G. .c . ..... G.C . • . oo .. .. . .. .. oo . . . . . . c . . oo .. . . . GG. ..-.. . G• ..
GSI 85 .. .. oo .T T. .10. oo .. • G. . T .G . • C.A G • .. . .. • C • - .. . G•
GT230 oo .. • T T . •T • •10.• • G• . T. G. . C. A G• .. • C • • G • ... . G• ..
GOSSO .. . .. .. .. . . . . . . .. . .. . A . '1' G. • ':'. •A . oo • . . ... .. • C.GC • . C. . G• .c . . . • oo .. oo ... .. , • C • .. .. . . . . • G • oo .. . . G.. .
KZN- B2 . A • • . A . T . • e . G. .10. G• .. .. . G. ..
KZN-B 3 • • RCCA.. .. oo .. •10. . . AAT. . CCG. . C. >" G• .-.
KZN- B4 • GCil.. •10. • . A . T . . C. G. •10. G• . G• ..
KZN-SS oo •AAT. • e CG. . C.A G• •C• 00 .-. ..
KZN-B6 .. .. oo .... .. . . A . . .. .. . M T. .C CG. • . C. A G.. oo . .. . .. .. .. .. oo oo ... . - ..... oo oo
KZN-s 7 oo .. oo ..... .. . cr . 00 .. . 00 • • . A . . .. . . . A .T• • e . G. •. • . A G • .. . .. . .. .. .. .. oo .. .. . . • • • G. . . . . . . oo ..
KZN- BS oo · .. .. • oo .. .. . A. . .. . MT . . CCG• . . C.A G • .. .. . .. .. .... oo .-. ..
KZN-B 9 •10. . •AAT• . e CG. . C.A G • .. .. oo .. -
KZN-Bll .. •>.. .. •AA. • • CCG. .. C.A G. C. .. oo •10.• .. .-. . T •
KZN- B12 .. .. .. .. .. .... '" .. .. ..A . . oo . A . ':'. • C. G. . 10. G • oo .. oo oo . .. .. .. . G. . . . .. . . . . .
KZN-B13 .. . .. . .. .... oo .. . .. .. . ... . • •A • • .. . •ATT • . e CG. .. c . . G• .c . .. oo .. . . . . '" . . • C• • .. • •• • • G• .. .. . G• ..
KZN- B15 .. oo oo .. oo oo .. .. .. •• A . .. . ATT • .eCG . • • C • G• • C • .. .. .... • C• oo . G. . . G.
KZN-B1 6 oo •10. . .. .A .T . .c.c, ..A G• .. .. . G• ..
KZN- B17 .. .. .. •10.. .AAT . . e CG. . c.x G • .. .. .. oo .-.
KZN-B18 oo •10.. •AAT . . CCG. • C . ..... G • .. .. -
KZN- s 19 .. oo oo •10. . . A .T . . e .G. .10. G • oo . .. . G•
KZN-a21 oo .. ... .. .. • oo . . • •A • . ... . A . T . . e CG. . C. A G• . .. .. .. .. .. .. oo • . . .. . .. . • • • • GA.• . . ... . ..
KZN- s22 .. . oo .. . .. . . .. . . C. '" . • • • • • •1\ . • . . . . . A . T . • C.G . •. •.A G• ... . . .. .. .. . .. oo · .. . . . . .. .. • • • G• .. . .. . . oo
KZN-B24 .. oo .. oo . oo oo C . .. .. .. • . A . .. . A.T. • e .G . ..A G• .... .. 00 . .. .. . . G• ..
KZN'- B2 5 .. .. oo •10. . .. oo .A .T . . C. G. . A .•A G • oo .. .. . G•
KZN- B26 .. oo .. .. •10. . • AP:! . . ecG. • C. >.. G • .. .. .. .. . oo .. 00 .-.
KZN-B2 7 .. .. . . . . .... .. .. . .. • •A • • ... . A .':' . • e .G . .. ..A G• .. . .. oo oo .. . . c . . .. .. . . G• . . . . · oo
KZN-B28 oo ..... .. . oo .. .. . . . . .. . . .. . .• . A• . • •• • . A . T . • e . G. . • . A G• .. .. .. .. . . . . oo • .. .. .... . • . • G• " oo • ...KZN- B29 .. . . . . . .. .. oo .. .. . . A.. ... . A.T . •e . G. • . 0010. G• 00 .. .. .. .. . G•
KZN- 04 oo oo C. .. . . A . . .A .T. . e . G. ..A G • .. .. oo oo .. . G•
KZN-08 oo . 10.. .A. T . . C. G. ..A G. oo .. .. .... . .. . G•
KZN- Oll .. . 10. . . A . T. .c.c. ..A G. .. .. .G •
KZN-L2 .10.. Coo .. .10.. . A . T . . e.G. • • 10. G. ... .. . G •
KZN- L3 .10. .. .. oo . -.. oo .. • .•A. oo • •AAT • . e CG. • . C. A G.. .. .. .. .. . ... .. . . . . . . .. . . . . - .. .. .. . oo
KZN-L4 .10. ... .. .. . . . . 00 • .. .. . . • .• . •A. oo . A. T. . CCG• . • C. A G . C .... . . . . . .. .. . . . . oo . . . . . . . G• ... oo • ..
KZN-I.5 . K. .. .. oo .. .. . . . .. .. oo oo •>.. . A.T . . ecG.. . V. A G.C . .. .. .. .. .. . G• ooKZN-I.6 .10. .. .. •10. . . M T . . e CG. . e.A G.. .. .. '" .-. .. ..KZ.~-L7 . 10. . .. .. .. .. . A.T . .c . c. .10. G.. oo .. oo .. .-. .. ooKZN-Le . 10. . .. .. .. ... .. . .... .. oo .• .A . •AA:! • . CCG. . C. A G.. .. .. . ... ... oo .. .. _. .. . - . '" ...KZN- L9 .A • . oo .. oo . . . . . . . . oo oo .. . .. . . • •A . .. G. . A . T . . e CG. . . C. A G. C. • . .. .. . . . . .. . . . . . . . .... - . .. . . . . .KZN- LIO •A • . oo ... .. .. .. ... oo oo .. . . •A. •AA.•• . CCG. . C. A G.C . . . .A . .. .. .-. .. .T .KZN-Lll . 10. . .. cr . .10. . A.T . .c.c. .10. G• .. . G .
Fig.4.2a Alignment of 54 nucleotide sequences from the 5' NCR of GBV-C/HGV
isolates blood donors (B), haemodialysis (D) and patients with chronic liver
disease (L) from the province of KZN (KwaZulu Natal), South Africa.
Sequences were compared with GBV-C/HGV or representative variants of
GBV-C/HGV (sources listed in Chapter 4.1.5). Symbols: ' .', similar nucleotide
to GBV-C; ", nucleotide not determined; and ' -', gap introduced to preserve





GBV-C GGCGCTAGGC ACGCCGTTAA AC CGAGCCC G TT ACTCCCC- TGGGCAAA.CG ACGCCD.CGT ACGGTCCACG TCGCCCTTCP. AT GTCTCTCT T GACCAA.TAG GCGTAG- -CC
• C• • G• • . ~ . C . -G • •CG12LC .. .. .. .. . .. . .. . ........ • C.Te •• • - . .. .. . Oo • ...... . ..... -.... .. ...
- . CT • • • • ....... .. . .. .. .. ... .. .. . T • • --KZN-D2 .. .... .. . ..... .. .. .. .. .. . TC • • .. .. .. • •• 0 • .. Oo
. • T .- •T • .. .. . .. .. .. .. . .. .. . .. .. .. . 1' • • .--...KZN- D6 .. ... .. .. .. .. . ..
KZN-D7 •A. .. • 'rC • - . . •T • . C . T . . TATTAG •
KZN- 0 9 •A. • TC • - C• •G. • C .T • . . .. .T G'I'TAG•..
• TAC • .T . . T . . TC • --KZN-D I O .. •A. .- ..
KZN-Bl .. .rc . - .. .CT . .. . T . 0 ' - -'
KZN-BI O •A. C.TTC • • C • C• .. .. . AAT .-- •
KZN-B14 .. .. •TC. - •G• .. .CT • .. .. . T . --
KZN- B20 Oo • • .h o ._ c.ne. . •C .. Oo .. .. . . . c. .... .. ... .. Oo. .... .. .. .AAT- - G•. . .... ...
C.TTe . . C .C. .... . .... .. .. ... .. . AAT . - - ••KZN-B23 .. . .. .. ... .. ••A • • • . . .... .. .. .. .. ..
•TC . T • • - ..1' • .. .. . .. . .. .. .. . .. . 1' . T. - - . ..KZN-Ll .. ...... ... . .. . .. ..... ...... .. ..
PNF2161 . A . . TC. T . .T . . C . A . - .. .. --..
RI 0291 .A. . TC . T • •T . •A . •C .G • - .. • G. .T • .--.
P.GVC964 . A . . rc, T • •T . .. .. •A . . C . G• - .. .. .. .. .. ... .. .. .. • G• • .. ..T • --..
•TA • . T- - ..KZN-Dl . TC • • T. .. .... .. .. •A• • C.A. - • • • • T • .. . .. .. .. ...... .. . .. . . .. • C• .. .. ..G.. .. .... .. .
.~ ..A-- ._KZN- D3 . A •• TC • • .. T . .T. Oo ' .. .. .. .. . . C'l' . C . G . - ........ .. . ..... .. '" ... ...Oo • .. .. Oo ' ... ..
KZN- B30 . A. ATC. TT .T . .. .. .. .. •C.Te .G . - ... . T • .. .. .. .. .. Oo. .. . ..... .. . TT..T- - •
KZN-B31 . A. . TC. T • . T . • C . A. .- .. • C• .. • G• •TT • . T- - ..
KZN- Ll2 . A• • TC . T • • T . • C. . C. A • - .. .. . T . 0 ' - - '
GBV-C (EA ) . A. •TC • • T . . T. •A• AC • •C .A • - .. .. .. . '1'. '1'. -- • •
KZN-D5 . A. . TC . T • • T . .... •A. CC• •C . A • - .. .. .. .. . '1'. T . - -.
GSIB5 • A.• • TC . T • • T . .. .... .. • •A • C .A•• - .. .. .. .. ....... .. ..... .. .. Oo Oo .... .. .... C.T . T . -G • •
GT23 0 .A. .r c. . . T • • T• • • .. .. . .. .. ..A CCT.C.A• • - ..... ..A . .. ....... .• C • • • • ........ .. . ... ... .. .. ..T • ..-- ..
GOSSO •A. . TC • T . . T . . T . . •A ••A c .'r.C .A • • - .. .. ... .... . . .. . T. T . - - .
KZN-B2 .A• •TC . T • •T . .. •AC. .. 0 .T • • C• • • ... . C• --
KZN- B3 . A• •TC. T. .. .. •A •TC• ..- .. .. . •T• • • T • .. .... Oo . . A •• T-G • •
KZN-B~ .A • •TC. .. T . .. ... .. ...... .. •• •AC. ..- ... ... .... .. . .. .. • C• • • • • .. ... Oo .. .. .. .. .. .... .. . AAT . - - •
KZN- B5 •A . . TC• • .. T . . '1'. .. ... ..... •A • • •TC • • ..- ......... Oo • .. .. .. •• T• ... . .. .. .. .... .. oo .. · .AAT.-- . .
KZN- B6 . A•• TC • • .. T • •T . .. .. .. •A .rc. - .. .... ...•T.. • •T • • • .. . .. .. .. Oo .... · .AG.r-G. .
KZN- B7 .A. . TC.. T • •T . •AC. - .. • C• .. .. .. .. .. . AAC. - - •
KZN- s9 . A • • TC . T. . T . •A . TC • - • C. . T • --
KZN-s9 . A. .TC . T • . T. •A . rc . - •T . •T • .. . T- G•
KZN-Bll .A. •TC . T • •T • .. •A C• •AC • - .. •T . .A . CA-G •
KZN-S12 .A • •TC . T • •T . .. •AC. - .. . c . . . ... . . AAT. - - .
KZN- s13 . A• •TC. .. T • •T . .Y . .. •TC. - .. .. . CT • • • .. .. Oo ' .. --
KZN- B1S •A. .Te•. .. T. •T • • • ..Y• .... . .. •TC. .. - ....... .. .. Oo ...Oo . .CT•• • • .. .. .. .. .. . ' . ' . .. oo .... oo --..
KZN- B16 . A • •Te • • T • •T . oo .. .. ...... .. •AC. .. - ....... .. .. .... • • • C.T.. . . . . . ...... .. .. .. ... ... .. . . . . AAT . - - • •
KZN- Bl1 . 1\ • • TC • • T • • T . .. oo .. ... .. •A .. .rc . .. - .. .. oo . . .. .. Oo .. ..... .. .. .. Oo ... ... ... .. .. . . V• •T- G•
KZY- B1B . A• .rc . . T. .T . ..... •A •TC• ..- .. .. .. . T • .. Oo .. Oo .. . C . T-G•
KZN- B19 .A • •TC. T . • T. .. .. .. •AC. - .. .. . C.T • .. .. . AAT.- - •
KZN-B21 . A• . TC . T . •A •TC • 0 • T• •T • .. . T-G•
KZN- B22 •A• •TC • • T •• T • • • • • • oo .. •AC. - .. .. .. .. .. .. . c. . . .. .. .. .. .. ... .. • . AA.T .-- •
KZN-B2~ .A • •TC • • • • ':' • •T •. • • • • ...... . . • •AC• • ..- . . ...... .. .. .. .. . .. .c .. . .. .. .. ... .. ..... . . . . Oo . AAT .-- • •
KZN- B2S . A• • TC ••• ':' •• T • • • • • • . .. . .. .. .. • AC . - .. .... ... .... .. .. . AC•• • .. ... ... .... .. ... oo .. .. ...--..
KZN-s26 . A• •TC . .. T • • T • • .. ... ..A .. •TC• - .. . .. ... .. • T • • . . ••T • • .. . . .. .. .. . . AG. T-G• .
KZN-B27 •A• •TC . T • . T . .. •AC . - • •T • . c. . . C •• --
KZN- B2 B •A• •TC . T • . T . •AC • • - • G• .... .c. . . . AAT . -- •
KZN-B 29 .A. •TC. T. . T • •T . •AC • - .. •T • • C• .. . c. . .--.
KZN- 04 •A. . TC • • T . •T . Oo •AC . - • C• . AAT . - - •
KZN- ca . A• .r c . T • • T. .. .. •AC. 0 .. • G •• •C .T • .. .. . AAT . - - •
KZN- Dll . A. . TC •• T • •T . .. .. .. •AC. - .. • C • • .. ' Oo .. oo . '" ..AA.• --KZN- L2 •A. .rc • • • T••T . .. .. ..... .. •AC. 0 ....... .. . . .. .... • C • • •• • .. .. Oo • ... .. . ... .. .. • . AA.T . - - •
KZN-L3 . A• •TC• •• T • • T . .. .. • ••• • • • ••A .. •TC• 0 ........ ... • • C•• .. . .... .. ........ .. .... .. ..T .. . - G•
KZN- L4 .A• •TC . oo T •• T. oo oo .... .. •A . TC. .. - .. . .. Oo .. .. .. .... • • C • • ... .. .. . ... c. . .. . G• oo Oo .. • '!"l" . ':'l' --
KZN- LS . A • •TC . oo T • • ':' . .. •A • 'rc • ..- .. oo • C• .. • C• .. • G• .. . ':'l' . TA- - .
KZN-I.6 . A • •TC . T. . '1'. .. .A •'r C. .- .. .c. , •T . .. .. . A• .A- G•
KZN- I, 7 •A. . TC. T. .T . Oo .. •AC. - .. .. .c .. .. .. · .AAT.-- ..
KZN-Le . A • •TC. '1'•• '1'. .. .. .. ..A .ec. ..- .. . c . . .. .. Oo .. ' .." .. . . • . ': •• • - G• •
K%N- L9 •A• • r c • • • '1'• • '1'• .. ... ....... ..A . TC. .. .- .. •G.. . . ... .. .... ... ... .. . '" .. .. .... ... ........ . ..CAC .':"G• •KZN- L1O •A • • Te •• '1'• • '1'• .. .. .. .... •A C• . AC. .. .- .. . .. . .. . .. .. .... . . . .. ... . . ... . . .. . .. .. ... . .. oo • .. . A. CA- G.
KZN-Lll . A• •TC. T •• T . .. .. . .. .. .. .. •AC. ..- ... .. .. ..... .. . c . . .. .. . oo ... .. .. .. • . AAT . - - .
Fig.4.2b Alignment of 54 nucleotide sequences from the 5' NCR of GBV-C/HGV
isolates from blood donors (B), haemodialysis (D) and patients with chronic
liver disease (L) from the province of KZN (KwaZulu Natal), South Africa.
Sequences were compared with GBV-e/HGV or representative variants of
GBV-C/HGV (sources listed in Chapter 4.1.5). Symbols: ".', similar nucleotide
to GBV-C; ", nucleotide not determined; and ' -', gap introduced to preserve




GBV-C GGC~GA CAAGGACCAG T GGGGGCCGG GCGGGAGGGG GAAGGACCCC -CACCGCI' GC CCT'I'CCCGGG GAGGC-GGGA. AATGCATGGG GCCACCC
CG12 LC .... • • G . . .. .. . T . T.- . .. •T . -. CA. A . . .. ...... . GAR. - • .. .. • • __ 0 •
KZK-D2 .... .. .. .. . •AG. . . . ., ..... .. . . . ACT- . .. .. . T CAGTG-o", .. • • • 0 • • • GA. - . T • . . . . . . A• .....
- . A.KZN-D6 .. .. .. ..... .. ., . . . . .. .. - .. .. " ...... .. ..
KZN- D7 . G. .. • C- . - .G . •GA. - . A•
KZN-D9 .G . . C-. - .G T • •ACT. • GA• - . A•
KZN-DI O ..M .-A. •T • -TeTT . . T • • G. A . -. .A •
KZN- Bl . . AG. .C'r- .A. •T CAG'I'G- • .. . GA. - . T . . A. .A
KZN-B I O .. ..•G • • 00 . ..... .. . T • . T- . .. •• T - •A• " ... . G• • .- . ... • •.heM..
• GA• - • • •A•KZN-B14 ..... .. • ••AG. ., .. .. .. .cr - ;c. .. •• G - •G• .. . . .. . . .. .. . . . . .
KZN- BZO • • . G • G. .. .... . T- . . •T - •A • .. .. •G• • GC• .. . . A. ..
KZN-B 23 . G . G. .. .. •T . . T- • •T - •A • .. •G• • GC • . A•
KZN-Ll .. .. . A- . •T - .n. .... . GA. - . A. . A
P:iF2161 ... ... .. .. .. .. . . .. .. • G.C'T- T •• A . G. . • T.. AAGT.- . C. . _ . . . • •T . G. C. - . .. .. ... .. ..
RI0291 .. .... .. •GT'M'. T • • .. AA• " - .. . - . - •C . GAC. - . ..
HGVC964 . GT'I'TTT . AA• - ... •C . GAC. - . ..
KZN-Dl .. .. . G.TT.T . -A.A .C . .. • T • GA• - . A•
KZN-D3 . G.TC .!. - AGA. C. • C . G. C. - . ..A .
KZN- B30 . G.TT .T . . - A. A. C . • • C . GAC.- . • •A• .. . .
KZN-B 31 .... .. .. , .... .. .. .. . G. TC- T . . A. . G• . . T . • AAG• - .. • • • . • .. T . G. C.- • . .. . •A • ...
AAGT.- . . • • • . • • • T •G.C . - . . .. .. . A• ... . . MGKZN-L12 .......... . . . - ... . 0. - .. .. . G. CT-T . . ... .. ..
GBV-C (EA,) .. .... .. .. .. . G. T. -. A. ". T CTCA.e . • Y •T . G. A .- . . . ..
KZN- OS .. .. • GA.C . - . e .G • - . . •T • G. A .- . .. .A •
GSIBS .. .. ... . . . . . .. . . . . . ..... . ':'.CC-A.. .. .. . . . . - TG'l'.A . • • . .. •• •• • •'1' . G.. T .... . . . . . .. .. .
GT230 .. .• G. .. .. .. • '1'• • . C-A. .. -TGT . .. .... .. T .bA. T- . . A. .. .. ..
GOSBD .. .. .. . AC .T .A. . G• •T -.CG'!'. •T . GT. T . T • .... ..
KZN-B2 . G .G . . G. CA- . CTGT.- . . GT . - .R• . AC. H
KZN-B 3 . . . .... •G .. . .. .. .. . . . G.T. - .. .. ... c . •T . - • .. . .. . . . . .. • GA. T- . .. .• . A . .. . ..
KZN- B4 .. .. ... . G . . . . . G. .. . .. ..... . G.Ci\- . . .. .. . CT.G'l'. - . ... .. . .. . .. . • (;T . - .. ... . A• .....
KZN- BS .. .. . A . . .. .. .. . G. C.- •. A . .. ... C.G'l' . - . .. .. . .. l GA.T- . .. .. • •A. .ACl!
KZN-B 6 .. • G •A • .. . G. ':'A- . • G• CT.T . - • .. .. . GA. T- . ..R . . AOl
KZN-B7 • G . G• . G. CA-. CTGT. - .C • .. • (;T. - • • R• .AOl
KZN- B6 . . ... • G .. .. •G• .. .. .. . G. t' . - . .. .. .. C• • '1' . - . .. . .. .. .. •GA.':'- . .. .A • .. ...
KZN- B9 .. ..G ...... .. ... .... .. . G. T . - . .. ... . . .. C•• ':'. - . .. .. .. .. . . . GA. T- . ..... . • R• . >J'A
KZN- Bll .. .. •A. .. . G. CA- . .. .. . . .. CTG.T- . . .. .... .. . GT.'!- . ..... . A•
KZN- B12 . G • G. .. .. • G. CA- . CTGT. -.C . .. .. . GT. .-. . R • .AC
KZN-B13 .AG. .. .. . G. T . .. •T • C • - .. . GA. - . ACMGM
KZN-B15 .. .• AG. .. . G. T. •T • c . - .. • GA. - .. .A •
KZN-B 16 . G . G. . G.CA - . CTGT.- . .. .. .. • (;T . - . G . . .A•
KZN-B17 . . .. .. G .. .. .. .. . . . G. T. - . . . .... .. C• . T . - . . . . ... .. . . . GA. T- . ... .A . . .
KZN-B I B .. .. G .. .A• • .. . . . . ... . GCT. - . .. .. . . .. . .. - .CATC. •. .. . .. . . . .. . GA.T - . . . . . . ...A• .. ...
KZN-B I 9 .. • • •. G •G• .. .. .. .. . G.CA- . .. .. .. C'l'G"I' . - . .. .. .. .. .. .GT. - • G .. ..... . A•
KZN-B 2 1 •G . A• .. .. . G. T. - . .. CTT.G - . .. .. • GA. - .. .. . A•
KZN-B22 • G .. . G• . G. CA-. .. CTGT. -. . . .. . (;T • - .A . ..
I !aN-B24 • •• G . . • • • G• .. .. .. .. . G. TA- . . .. .. .. ..... CTG• .- .c . . ... . . .. . (;T . - .. .. .. ..... . A. .. .A
KZN- 825 .. .• . A. .. G .. • G• • .. .. .... ... . G. CA- • .. . . .. .. CT(;T. - • • • ..... . . .. . (;T • .. .. ... .. . A. ..
K.ZN-B26 .. .. •G .A • .. .. .. . G.TA- . .. CT.T .- . . . . .. . . . . GA.T -. .. . A•
KZN- B27 . G •G. . G. CI\- . CTGT.- . .. • (;T. - .A •
KZN-B2 8 •G .. . G. .. • G.CA- . .. CTGT.- . C. .. .. • GT. - .A •
KZN-B29 •G . G. . G .CA- . CTGT.- . . GT . - . A.
KZN- D4 • G . G. .. AG• .. C .CG .-. .. .. . GT. - . A• ..
KZN- DS .. .... .. . A. G. .... .. .. AG. CA- • .. • • . '1'. CTGT. - TC . .. .. . .. . . (;T . - .. ... . .A • . .
KZN-Dll .. . •. . G .. .. • G• • .. .. .. . G. CA- . ..A .. ... CTG'!' . - . . .. ... ... . GT. . - . . ... .. . . .A. ..
KZN-L2 .. .. G .. . G. . .... AG.a- . .. .. CTGT. ~AC .. .. .. .. . (;T. - .. . A. .A
KZN-L3 .. G • G• . G. T . G. . A• - . A .C . .. . GA. T- . .. .A
KZN- L4 .. G .. • G• CG.CA- . .. C'I"G'I'.-G. .. .. . GA. T- .. .A
KZN-L5 .. G .. . G• .. .. CG. CA- • . . ... ... CTG'I".-G. .. . ... •GA.T - . ... . . .. .A • .ACX
KZN-L6 .. .. •• . . G .. . A . . .. .... .. . G. T . •. .. ...... - . CA. C• • . • .. •T • .. . • GA. 'l'- . • .... .A• . . ..A
KZN-L7 .. .. G .. . G• .. . . .. .... . G. CA-. .. ... CTG1'. - . .. .. . . . . • G1'• • - • • . A• .A
KZN-L 8 •G . G. .. .. . G. T .G . A. -.•A . C. . G• .. .GAAT- . .A
KZN-L9 .. . G.T . - . •A. . T • T.CA..C . .. . GA. T- . .A . .A
KZN- LI O .'. . A• .. . G.CA . CTG.T- . .. •T • . GA. T- . .A. . A
KZN- Lll • G . G• .. AG.CA - . . • T . .. CTGT.-TC . .. .. . GT . - .. .. . . . A
Fig.4.2c Alignment of 54 nucleotide sequences from the 5' NCR of GBV-CffiGV
isolates from blood donors (B), haemodialysis (D) and patients with chronic
liver disease (L) from the province of KZN Kwa Zulu Natal), South Africa.
Sequences were compared with GBV-CffiGV or representative variants of
GBV-CffiGV (sources listed in Chapter 4.1.5). Symbols: '.', similar nucleotide
to GBV-C; ", nucleotide not determined; and '-' , gap introduced to preserve
alignment (Sathar et al, 1999b)
4.3.2.
4.3.2.1
Phylogenetic analysis of 5' NCR
GBV-CIHGV isolates from blood donors and patients
144
The phylogenetic tree comparing sequences from the 5' NCR of the 54 isolates (31 blood
donors [KZN BI-31]; 11 haemodialysis patients [KZN Dl-11] and 12 patients with chronic
liver disease [KZN 1-12]) with isolates from other geographic regions is shown in Fig.4. 3.
Using either the full sequence, or a portion excluding regions that are variable but do not
correlate with the geographical origin of the isolates (Smith et aI, 1997a). GBV-C/HGV
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Sca l e: equa ls a di s tance of of 0 . 0131
Fig. 4.3 Phylogenetic tree of GBV-C/HGV 5' NCR sequences from blood donors and patients. A neighbour joining tree
was constructed from p-distances between representative published nucleotide sequences (GenBanklEMBL;
accession numbers in parentheses) and from KZN isolates (KZN-KwaZulu Natal, South Africa; KZN Dl-DlI
for haemodialysis patients, KZN 11-112 for CLD patients, KZN BI-B31 for blood donors). Bootstrap values
greater than 75% are indicated (500 replicates) (Sathar et al.'I999b).
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The majority (37/54) of GBV-C/HGV sequences formed a cluster which was distinct from all
other known GBV-C/HGV sequences, supported by 88% of bootstrap replicates (Fig 4.3)• .
Eleven (11) isolates clustered as group 1, with a bootstrap support of 90% (Fig 4.3). Six
additional isolates clustered as group 2 variants, 5 of which grouped with 2a (bootstrap
support of 91%) and one (KZN D5) with 2b (bootstrap support of 87%) (Fig 4.3). Although
this analysis did not strongly support the groupings of group 2a and 2b sequences (58% of
replicates), this analysis included the ·group 3 isolate HGVC 964 (Fig.4.3) which has
previously been shown to cluster with group 2 isolates upon phylogenetic analysis of the 5'
NCR (Muerhoff et aI, 1996; Smith et al, 1996). Analysis of nucleotides 1-201 in this
alignment but excluding HGVC 964 produced very similar results except that the bootstrap
support for group 2 isolates was increased to 75% (Fig.4.4). Sequences in groups 2 and 3
together with that of isolate G05BD grouped separately from sequences of group 1 and the
new KZN sequences (bootstrap support 90%) (Fig.4.4). None of the KZN isolates clustered
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Fig. 4.4 Phylogenetic tree of GBV-CIHGV 5' NCR sequences from blood donors and patients (shortened
region [J-C 100 replicates]) excluding HGVC964. A neighbour joining tree was constructed from p-
distances between representative published nucleotide sequences (GenBank/EMBL; accession
numbers in parentheses) and from KZN isolates (KZN-KwaZulu Natal, South Africa; KZN Dl-OIl
for haemodialysis patients, KZN Ll-Ll2 for CLD patients, KZN B1-B31 for blood donors).
Bootstrap values greater than 75% are indicated .
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There was a high degree of overlap in the ranges of distances between and within groups
(Table 4.1). GBV-C/HGV infects all racial groups in the provirice of KZN, South Africa
(Table 4.2). The new variant of GBV-C/HGV seems to be more prevalent amongst Africans
than amongst Indians, Whites or 'Coloureds' (Table 4.2).
Table 4.1 The pairwise distances for the full length of the sequences of GBV-/HGV
Groups 1-4 and the new group (mean [rangej)
1 2 3 4 New Group 0
1 0.082 (0-0 .119)
2 0.138 (0.112-0.167) 0.059 (0.029-0.088)
3 0.12 (0.106-0.138) 0.099 (0.073-0.122) 0.045·
4 0.14 (0.132-0.158) 0.114 (0.089-0.135) 0.092· (=G05BD)#
5 0.116 (0.084-0.162) 0.122 (0.092-0.151) 0.109 (0.09-0.132) 0.139 (0.122-0.154) 0.059[0-0.113]
* (only 1 comparison); • only 2 comparisons); ) # only 1 sequence; @ KZN, South African
Table 4.2 GBV-C/HGV infection according to phylogenetic and race groups
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Race GBV-CIHGV Groups
1 2a 2b 3 New Total no.
Africans 7 2 32 41
Indians 2 2 1 5
Whites 1 5 6
"Coloureds" 1 1 2
"Coloureds": persons of mixed origin
4.3.2.2 GBv-ciHGVisolates from the eight geographical regions ofKZN
Phylogenetic analysis of the 5' NCR sequences of 18 GBV-C/HGV isolates from the 8 health
regions of KZN together with the 5'NCR sequences of 28 GBV-C/HGV isolates whose
complete genomic sequences were available in Genbank database yielded evidence of five
groups (FigA.5). Group 1 (bootstrap support 86%), Group 2 (bootstrap support 98%), Group 3
(bootstrap support 83%), Group 4 (71%) and a fifth group (Group 5) (94%) (FigA.5). The
classification of Groups 3 and 4 as separate groups is based on the analysis of complete
genomic sequences (Smith et al, 2000). The majority 17/18 (94%) ofGBV-C/HGV sequences
from the province of KZN clustered as a fifth group (Group 5) which was distinct from all
other known GBV-C/HGV isolates (FigA.5). Only one isolate (KZN-Ell) from Zone E
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clustered with group 1 African variants (bootstrap support, 84%) (Fig.4.6). Excluding the
Cape isolates with major deletions from the current phylogenetic analysis, improved not only
the bootstrap values of the tree but clustered the majority of the GBV-C/HGV isolates from
the Cape provinces with the KZN isolates as the fifth group (Fig.4.5). None of the South























Fig. 4.5 Consensus phylogenetic tree of 5' NCR sequences of GBV-CIHGV isolates
from 8 geographical regions of KZN, South Africa and representative
published sequences from GenbanklEMBL. Phylogenetic analysis was carried
out on a 311bp fragment, positions 143-442 in the GBV-C prototype isolate
(U36380). Maximum likelihood distances between sequences were calculated
using Phylip DNADIST ( ts:tv = 3, assuming no rate variation between sites),
and used to produce a neighbour joining tree using Phylip NEIGHBOR.
Bootstrap values (100 replicates) were obtained with the SEQBOOT and
CONSENSE options of Phylip. The tree was produced using Treeview version
1.5. (KZN = KwaZulu Natal; A-H = 8 geographical health regions of KwaZulu
Natal) [Sathar and York, 20011
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4.3.3 Phylogenetic analysis of the complete genome sequences of GBV-C/HGV isolates
Phylogenetic analysis of the coding region of the 33 epidemiologically unrelated complete
GBV-CIHGV genome sequences yielded evidence for four distinct phylogenetic groupings
each of which was supported by high levels of bootstrap support [74-100%] (Fig. 4.6). Three
group 3 isolates from China (U75356, U94695 and AF006500) grouped together with high
bootstrap support, while the isolates AB013501 and U63715 grouped separately from the
other group 2 isolates (group 2a) and isolate AB003292 from Japan was relatively divergent

















Fig. 4.6 Phylogenetic tree of GBV-C/HGV complete coding sequences.
Maximum likelihood distances between sequences were calculated
with Phylip DNADIST(ts:tv = 2, assuming no rate variation
between sites), and used to produce a neighbour joining tree with
Phylip NEIGHBOUR. Bootstrap Values (lOO replicates) were
obtained with the SEQBOOT and CONSENSE options of Phylip.
The tree was produced using Treeview version (1.5) [Smith et al,
2000].
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4.3.4 Phylogenetic analysis of the E2 gene ofGBV-CIHGVisolates
Analysis of individual viral genes failed to produce congruent phylogenetic trees with the sole
exception of the E2 gene (Fig. 4.7). Similar analysis of subgenomic fragments of 2000, 1000
or 500 nt produced congruent trees only for fragments including the COOH-tenninal region of
the E2 gene (Fig.4.7). Analysis of the entire 3'-tenninal half of the virus genome or any of its




NSSASS3S-NCR E l E1 NS~
-400 AUG 612 1773 2682
~~~----...,...-~---~-==-=~~~
Level of Bootstrap support for group
< 70% 70 -79%
Fig. 4.7 Congruence between phylogenetic analysis of complete genomes and subgenomic fragments.
The ~evel of ~ootstrap support for the phylogenetic groupings 1-4 is indicated by the degree of
shadmg for different genes and sugenomic fragments (Smith et al, 2000)
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Congruent phylogenetic trees (boostrap support> 75%) were produced using a region as small
as 200 nt (positions 1344 - 1543) [Fig.4.8] within the E2 gene. The shortest region that gave a
congruent tree with more than 98% bootstrap support for each group was the 600 nt region
from positions 994 - 1594 [Fig. 4.8]. This region also produced a congruent tree when
analysed at synonymous sites (>85% support) but not at nonsynonymous sites
1::2





1 Group correct 2 Groups correct 3 Groups correct All groups correct
Fig.4.8 Congruence of phylogenetic relationships produced using fragments of the E2
gene. The extent to which phylogenetic groupings observed from analysis of
complete genome sequences are supported by comparisons of the fragments of
the E2 gene is indicated by the level of shading. The number of groups
supported by more than 70% of bootstrap replicates is indicated (Smith et at
2000) ,
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E2 sequences for the 350 nt region (positions 1146 to 1495) of five GBV-C/HGV variants
from KZN with unusual 5'-NCR sequences (L6 [AFI72506]; L7 [AFI72507]; B16
[IFI72528]; B18 [AFI72530]; D4 AFI722530]) were aligned and compared with published
sequences of the same E2 region of 33 geographically distinct isolates whose complete
genomic sequences are currently available in the Genbank database.' The 4 major groups
identified by analysis of the complete sequences were reproduced by the analysis of the E2
gene with good bootstrap support for each group (Fig. 4.9). Only the KZN isolates with
























































Fig.4.9 Phylogenetic tree E2 sequences of GBV-CIHGV isolates from KZN, South
Africa. South African isolates form an additional E2 phylogenetic grouping
(Group 5) [Smith et al, 2000) [KZN-KwaZulu Natal; B-blood donors; D-
haemodialysis patient; L-chronic liver disease patient]
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4.3.5 Genbank accession of GBV-CIHGV isolates from KZN, South Africa
Sequences of GBV-CIHGV isolates from KZN have been deposited m Genbank. The
Genbank accession numbers are as follows:
AF172501 - AF172554 from Blood donors; haemodialysis patients and patients with chronic
liver disease (Fig. 4.3)
AY032956 ~ AY32973 from the eight geographical health regions of KZN, South Africa
(FigA.5)
AF181977 - AF181981 are isolates used to analyse the E2 gene (Fig. 4.9)
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4.4. DISCUSSION
Several groups have examined the genetic variation in GBV-CIHGV by comparing sequences
from different segments of the GBV-CIHGV genome. Initial analysis of complete genome
sequences suggested that GBV-CIHGV could be classified into three groups based on pairwise
distances greater than 0.12 over the entire genome (Okamoto et al, 1997) or into four or five
groups based upon the phylogenetic analysis of complete genome sequences (Takahahsi et al,
1997). However, studies with NS3, NS5A and envelope regions have been unsuccessful or
contradictory in defining groups of GBV-CIHGV isolates (Kao et al, 1996; Kim et al, 1997;
Muerhoff et al, 1997; Pickering et al, 1997; Viazov et al, 1997a). In contrast, analysis of
regions within the 5 ' NCR allowed the discrimination of three major groupings that correlated
with the geographic origin of the isolates and with the analysis of complete genome sequences
(Muerhoff et al, 1997; Smith et al, 1997). Based on this assumption, phylogenetic analysis of
the 5' NCR of isolates from blood donors and patients identified three variants of GBV-
CIHGV in KZN (FigA.3) viz. Group 1, found predominantly in West and Central Africa;
Group 2 found in Europe and North America but also including isolates from Pakistan, Japan
and East Africa, and a new group of variants whose sequences are different from all other
known GBV-CffiGV sequences (FigA.3). (Sathar et al, 1999b). This new grouping is
supported by bootstrap analysis (88% of replicates) and although they cluster with group 1
sequences (bootstrap support of 90%) they are distinct from any previously described African
group 1 isolates sequences (Muerhoff et al, 1997; Smith et al, 1997a).
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Sequence analysis of the 5' NCR of GBV-ORGV isolates from eight health regions within
the province of KZN depicts this new variant of GBV-C/HGV as a distinct group (bootstrap
support of 94%) [Fig. 4.5] (Sathar and York, 2001). Seventeen of these 18 (94%) isolates
clustered as an additional group while one isolate (KZN-Ell) grouped with Group 1 variants
(bootstrap value of 86%), confirming that this new variant of GBV-C/HGV is the predominant
"genotype" in KZN. Included into the phylogenetic analysis were sequences of 5' NCR of
GBV-C/HGV isolates from the western and eastern Cape provinces of South Africa (Tucker et
aI, 1999) Based on their analysis, Tucker et aI (1999) suggested the presence of a novel
"fourth genotype." Five of their 13 isolates were characterised by major deletions in the 5'
NCR (Tucker et aI, 1999). Unlike Tucker et aI (1999) neither major deletions nor additional
bands to the predicted 344bp PCR fragment were observed in any of the isolates from KZN
(Sathar et aI, 1999b). In their proposal that South African GBV-CIHGV isolates be classified
as "Genotype 5", Tucker and Smuts (2000) did not make reference to the findings of Smith et
aI (2000) nor did they include in their analysis GBV-C/HGV isolates from the province of
KZN (Sathar et aI, 1999b). Phylogenetic analysis of 5' NCR sequences of the "novel" South
African GBV-C/HGV isolates from the provinces of the Western, and Eastern Cape
(excluding the deletants) (Tucker et aI, 1999) and from KZN (Sathar et aI, 1999b), grouped
South African isolates as an additional fifth group (Fig.4.5) (Sathar and York, 2001). In the
proposal made by Tucker and Smuts (2000) that South African isolates be classified as
Genotype 5, the inclusion of GBV-C/HGV isolates from KZN would have been more
representative ofGBV-C/HGV isolates from South Africa. South African GBV-CIHGV
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isolates cluster as a phylogenetically distinct group and constitute an additional new group, i e.
Group 5 (Sathar and York, 2001) .
The extreme 5'-terminal sequence is available for only a single Group 1 and none of the
Group 4 isolates, so an adequate analysis could only be carried out from positions -388 to -1
(Smith et aI, 2000) . Analysis of this region and of various subfragments failed to produce
congruent phylogenetic trees, with two sequences responsible for the majority of aberrant
groupings; AB013500, an extreme Group 2 isolate from Bolivia, groups with Group 3 isolates
for the 5'-NCR and some subgenomic fragments in the 3' half of the genome, although the 5'-
NCR is atypical (Smith et aI, 2000). Similarly, U75356, an unpublished Group 3 isolate from
China, has a 5'-NCR sequence similar to but distinct from those of Group 2 isolates (Smith et
aI, 2000) . This sequence also has a frameshift within NS5A and an unusual sequence at the 3'
terminus (Smith et aI, 2000). Hence, it- is uncertain whether these isolates represent
recombinants (An et aI, 1997) or divergent variants with unique 5'-NCR sequences. When
these two sequences were excluded from the data, a congruent tree is obtained when the region
-388 to -1 was analysed (Smith et aI, 2000). However, subfragments of this region, including
those previously identified as reproducing the phylogenetic relationships of Group 1 and 2
isolates (Smith et aI, 1997a) provide < 70% bootstrap support for either Groups 3 or 4 (Smith
et aI, 2000) . The large number of sequences available within this region (1409 Accessions)
and the inconsistent phylogenetic relationships of all but the largest fragments complicate
similar analysis of 5' -NCR sequences (Smith et aI, 2000). Visual examination for ~otifs
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distinct from those typical of Groups 1, 2, 3 and 4 revealed a small number of unusual
sequences, but of these only the variants from KZN (Sathar et aI, 1999b) and isolates from
Spain (Smith et aI, 2000) grouped separately from the 5' NCR sequences of complete genome
sequences for the region -388 to -1) (Smith et aI, 2000).
HGVC 964 is a group 3 isolate based on the analysis of the complete genome sequence
(Takahahsi et aI, 1997) but groups with group 2a isolates when analysis is confined to the 5'
~CR (An et aI, 1997; Muerhoff et aI, 1997; Smith et aI, 1997) [Fig. 4.4]. Similarly, the isolate
G05BD appears to represent a distinct phylogenetic group by analysis of the complete genome
sequence (Takahahsi et aI, 1997) but groups with Group 2 and Group 3 sequences upon
analysis of the 5' NCR sequence (Fig 4.3) . In addition, Groups 3 (bootstrap support, 83%) and
Group 4 (bootstrap support, 71%) isolates are not clearly differentiated by phylogenetic
analysis of 5' NCR sequences (Fig.4.5). The high degree of overlap in the ranges of sequence
distances between and within groups does not permit the establishment of "cut-off distances
that define different groups or subgroups (Table 4.1). Therefore, analysis of the 5' NCR
sequences may not always provide an accurate guide to the relationship of complete genome
sequences.
Phylogenetic analysis of the coding region of 33 published complete or near complete
genomic sequences of GBV-C/HGV provided consistent evidence for four phylogenetic
groups each supported by high bootstrap values (Fig.4.6). These groupings correspond to the
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three groupmgs previously identified from the analysis of complete genome sequences
(Okamoto et al, 1997) together with an additional group consisting ofan unclassifiedJapanese
sequence (Takahahsi et al, 1997) and three sequences one each from Thailand (K-1O, Sirirurg
Songsivilai, unpublished results), Vietnam (ABOI8667) and Myanmur (AB021287). Group I
includes isolates from Ghana, West Africa and a single Japanese isolate; Group 2 includes
isolates from Europe, North and South America and Japan; Group 3 includes isolates from
Japan and China and the fourth group consists of isolates from south - east Asia (Fig.4.6).
Although subgroupings of Groups 1, 2 and 3 have been distinguished by phylogenetic analysis
of subgenomic regions (Muerhoff et al, 1996; 1997) there was only limited evidence from the
analysis of complete genome sequences for subgroupings (Fig.4.6). The existence of the
fourth group had been suggested from the analysis of 5' NCR sequences of south East Asian
isolates._A previous phylogenetic analysis of complete genome sequences also proposed four
groups in which Groups 1 and 4 were combined and Group 3 was split into two (Charrel et al,
1999; Naito et al, 1999), but the bootstrap analysis did not support these groupings. Similarly,
an analysis based upon genetic distances identified five groups with Group I split into two
(Takahahsi et al, 1997).
An unexpected finding was that short COOH-terminal fragments of the E2 gene (Fig.4.8)
could reproduce the phylogenetic relationships of complete GBV-CffiGV sequences (but not
subgroupings). Previous studies of smaller numbers of sequences have shown that
phylogenetic relationships are inconsistent when comparisons are made for individual genes
(Takahahsi et al, 1997) or subgenomic fragments (Smith et al, 1997). Although three
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(Cong et aI, 1999) or four (Kim et aI, 1997) phylogenetic groupings are observed when
fragments larger than 1500 nucleotides including the E2 gene are compared, interpretation of
these studies is complicated by idiosyncratic labelling, the absence of Group 4 isolates and the
failure to assess the robustness ofgroupings. The analysisofa 200 nt fragment from the center
of the E2 gene (positions 1344 - 1543) provides> 70% bootstrap support for all four
phylogenetic groupings, while a 600 nt region (positions 994 - 1594) provided> 98% support
(Fig. 4.8) [Smith et aI, 2000]. This is in stark contrast to other coding regions: all subgenomic
fragments of 2000 nt or less that did not contain this region ofE2 failed to produce congruent
trees with the sole exception of a 2,000 nt fragment encompassing the remainder of the E2
gene, NS2 and the NH2-terminal half ofNS3 (Fig. 4.7) [Smith et aI, 2000]. Smith et aI, (2000)
provides several potential explanations for the observation that analysis of the E2 gene or
specific subfragments produces phylogenetic trees congruent with those observed for complete
genome sequences.
The analysis helps to clarify previous conflicting studies on the extent to which subgenomic
regions can be used to identify GBV-CIHGV phylogenetic.groupings. Most early studies of
virus diversity concentrated on a 118 - 135 nt fragment within NS3 that was the first part of
the genome to be sequenced (Simons et aI, 1995a,b; Berg et aI, 1996b; Heringlake et aI,
1996a; Kao et aI, 1996; Masuko et aI, 1996; Schmidt et aI, 1996; Schreier et aI, 1996; Tsuda
et aI, 1996; Muerhoff et aI, 1997; Pickering et aI, 1997; Ibanez et aI, 1998). However, the
phylogenetic conclusions of these studies appear to be unreliable since analysis of even the
entire NS3 gene fails to produce congruent groupings. Inconsistent phylogenetic groupings
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have also been observed for the NH2-terminus of E2 (Kim et aI, 1997), 354 nt of NS5A /
NS5B (Viazov et aI, 1997a) or 279 nt ofNS5B (Muerhoffet aI, 1997).
Phylogenetic analysis of the 5' NCR and E2 sequences of KZN isolates suggests that at least
three groups (Groups 1, 2 and a new variant) of GBV-C/HGV are present in KZN. GBV-
CIHGV in KZN infects all racial groups. In the study of blood donors and patients, Groups 1
(Central and West Africa), 2 (Europe, North and South America) and 5 (South Africa) isolates.
were detected in a heterogeneous population which included subjects from all four racial
groups in KZN, viz. Africans, Whites, Indians and "Coloureds" (individuals of mixed origin).
"Genotypes" 1, 2 and 4 were detected in a predominantly Black community in the Eastern and
Western Cape provinces (Tucker et aI, 1999). The absence of Group 2 variants in the study of .
GBV-CIHGV isolates from the 8 geographical health regions of KZN, is perhaps a reflection
of a more homogenous study population (Black Africans). To-date both Groups 3 (China and
Japan) and 4 variants (Southeast Asia) have not been detected in Southern Africa.
The diversity amongst Group 1 African isolates (Muerhoff et ai, 1997~ Smith et ai, 1997a~
Tanaka et aI, 1998~ Sathar et aI, 1999a~ Tucker et aI, 1999) and the confirmation of a fifth
group in South Africa reflects the extensive human population diversity in Southern Africa.,
consistent with the possibility that this virus may have emerged in Africa (Tanaka et al, 1998).
The spread of geographically distinct GBV-CIHGV groups has been associated with human
migration (Gonzales-Prez et aI, 1997; Tanaka et aI, 1998; Gallian et aI, 1998; Wong et aI,
1999) and is consistent with their eo-evolution with humans during pre-historic migrations.
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Group 1 and 5 isolates are African and have relatively diverse 5 ' NCR sequences (Muerhoff
et aI, 1997; Smith et aI, 1997a, Naito et aI, 1999) while the remaining groups correspond to
the three main waves of human migration from Africa to Europe (Group 2), Northern Asia
(Group 3) and Southern Asia (Group 4). In addition, the presence of group 3 variants amongst
native populations in South America (Pujol et aI, 1997;Gonzales-Prez et aI, 1997) is consistent
with the first colonisation. of this continent from Northern Asia via the Behring Strait.
Although Japanese isolates have been found belonging to Groups 1-4 (Okamoto et aI, 1997),
most are Group 3 suggesting that the presence of other groups represents recent introductions.
Since a virus related to GBV-C/HGV is present in chimpanzees (Adams et aI, 1998;
Birkenmeyer et aI, 1998), while New World monkeys harbour more distantly related but
species-specific variants (Leary et aI, 1996a; Bukh and Apgar, 1997) it is possible that GBV-
CIHGV has been continuously present in human populations since speciation
Further sequence analysis of the E2 region from GBV-C/HGV variants isolated from different
geographical regions may help clarify the origins of this unusual virus. It would certainly be
interesting to obtain the E2 sequences of additional South African isolates. However, the
complete sequence of one or more of the novel South African isolates would indeed settle the
question of whether or not tills is in fact a new phylogenetic variant. Although DNA
sequencing is expensive and impractical for large scale epidemiological studies, GBV-CfHGV
genotyping by phylogenetic analysis based on nucleotide sequences provides the most reliable
genotyping results to-date and remains the gold standard by which other typing assays are
compared. The current study confirm that the majority of the GBV-CIHGV isolates infecting
167
the local population in KZN are members of GBV-CIHGV Group 5. Whilst genotyping
systems for GBV-CIHGV using restriction fragment length polymorphism (RFLP)[Mukaide et .
ai, 1997; Fan et ai, 2002], single strand polymorphism (SSCP)[White et ai, 1999; Kato et ai,
1998], heteroduplex mobility analysis (HMA)[White et ai, 1999; Viazov et ai, 1997a] and
genotyping system based on PCR using type specific primer (Naito and Abe, 2001) methods
have been reported, these methods have limitations as they are not sensitive enough in
determining the degree of diversity among Groups 1-5 genomes. Group 1 and 5 GBV-CIHGV
are African isolates that are closely related, however they have relatively diverse 5'NCR
sequences. The complete sequence of Group 5 variants would establish whether this is a new
phylogenetic variant or a recornbinant. The complete sequence of Group 5 variants from KZN,
the development of rapid, sensitive and inexpensive "genotyping" assays similar to that used
to genotype HCV is the subject of further investigations. In view of the "potential" protective
role that GBV-CIHGV genotypes may or may not play in HIV infection this could become a






GENERAL DISCUSSION AND CONCLUSIONS
At present there is no antibody profile that can distinguish ongoing GBV-CIHGV replication.
GBV-CIHGV antibody test does not exclude viraemia. Therefore, the detection of GBV-
CIHGV RNA is necessary for the diagnosis of active GBV-C/HGV infection. As with all
target amplification technologies, nucleic acid contamination leading to false positive results is
a: continual problem and rigorous precautions and anti-contamination measures were followed.
A negative control was included in each analysis. Sample handling and storage can affect the
reliability of quantitative analysis especially in samples with .low viral titres. In this study
specimens were processed immediately, dispensed into aliquots for single use and stored
frozen at - 80°C. There are numerous methods that are available to extract viral nucleic acid
from biological samples, each with their own advantage. The best methods combine a
quanidiurn-based extraction process with few steps as possible to prevent physical loss of
RNA (QIAamp extraction kit used in this study). Although, the RT-PCR has its pitfalls it is
the "gold standard" by which GBV-CIHGV RNA is detected. There are numerous formats
using primers from the different regions of the GBV-C/HGV genome, based on single round
or nested PCR, one or two tube reactions and various product detection techniques. It is
perhaps not surprising that standardisation has not taken place . For this reason, results from
different laboratories do not always agree. The introduction of internationally recognised
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quality controls will be of major importance in the comparisons of laboratory procedures and
results. For our study we created our own internal control which was used in each analysis.
The effect of GBV-C/HGV viral load on the disease process is not known. Among the
techniques reported to detect GBV-C/HGV RNA, the majority are based on RT-PCR and
include limiting dilution, competitive and dot plot procedures. All are extremely labour
intensive, require considerable preparation and evaluation in terms of specificity and
reproducibility, and are not appropriate for handling large numbers of samples. Traditional
detection ofamplified DNA relies upon electrophoresis of the nucleic acids in the presence of
ethidium bromide and visual or densitometric analysis of the resulting bands with ultraviolet
light. Southern blot detection ofamplicon using hybridisation with a labeled oligo-nucleotide
probe is also time consuming and requires multiple PCR product handling steps, further
risking contamination. Alternatively, PCR-ELISA may be used to capture amplicon onto a
solid phase using biotin or digoxigenin-labelled primers, oligonuleotide probes (oligoprobes)
or directly after incorporation of the digoxigenen into the amplicon. The amplicon can be
detected using an enzyme-labelled avidin or anti-digoxigenin reporter molecule similar to a
standard ELISA format The LCx assay is based on single tube, single round RT-PCR,
however, the use of internal controls is lacking. The branched chain DNA assay is being
developed, but is not widely used to quantitate GBV-C/HGV RNA The technology is based
on hybridisation followed by signal amplification using novel branched chain oligonucleotides
and the luminescent signal compared with that obtained from external standards. Quantitative
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real-time PCR is a relatively new technology that provides a broad dynamic range for
detecting specific gene sequences. This technology is based on the detection ofa fluorescent
signal produced proportionally during amplification ofa PCR product. DNA and RNA can be
quantified without the laborious post-PCR processing. Whether all genotypes ofGBV-CIHGV
can be quantified equally using these methods are not known. For this reason selective primers
and hybridisation probes is of major importance. Although these assays bring the field of
quantitative virology within the technical reach of most laboratories, they are still very
expensive and are not widely available. Having recently acquired a light eyeler the prospect of
using real-time PCR in studying the potential beneficial role of GBV-CIHGV eo-infection in
mv infection has become a reality for future studies.
Recent advancements in nucleic acid sequencing have overcome many ofthe pitfalls that were
encountered a few years ago. In the past DNA fragments had to be cloned into an Ml3 vector
so that high concentrations of pure single strand transcripts of the insert were produced for
sequencing. The finding that sequenase a T7 DNA polymerase could be used to efficiently
sequence double stranded templates meant that purified plasmid DNA could be used instead of
single stranded templates. The next advancement was the development of mutated Taq DNA
polymerase (Taq-FS). This enzyme enabled PCR products to be sequenced directly. Taq FS is
.a mutant Taq polymerase that has a tyrosine substituted for a phenylalanine at the active site .
Dye labeled di-deoxy chain terminators are incorporated with
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far more efficiency than wild type Taq and sequencing with dye labeled primers resulted in
near uniform peak heights (Appendix B and C). The technology and dyes have been further
improved and it is now possible to easily sequence PCR products and with the use ofcapillary
sequences such as the automated ABI 310 genetic analyzer (which was used for this study)
many of the difficulties associated with sequencing have been overcome. The use of PCR
sequencing meant that the amplicons resulting from the RT-PCR amplification of GBV-:
CIHGV positive samples could be sequenced directly. The PCR primers were used to
sequence the PCR products and by performing two separate PCR sequencing reactions both
strands ofthe amplicons could be sequenced.
Virus populations within individuals can be heterogenous. Virus populations are not
homogenous but consist of variants that may differ at one or more positions in the viral
genome. These variants are described as "quasispecies." (Smith et aI, 1997b). The suggestion
that GBV-CIHGV "quasispecies" exsist has been derived from the sequence analysis of
multiple cloned copies ofvirus genomes derived from one or two infected individual (Viazov
et aI, 1997; Pickering et aI, 1997; Nakao et aI, 1997; Fan et aI, 2002) with 4-8 years of
persistent infection. Recently, Worobey and Holmes (2001) in their phylogenetic analysis of
the 33 full or nearly full genome sequences of GBV-CIHGV isolates provided evidence for
inter-and/or intra-genotype recombinations and suggest that GBV-CIHGV may be a
recombinogenic virus. Although some subpopulations ofGBV-CIHGV, may recombine freely
within themselves, they may have been isolated enough from one another in the past to
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accumulate characteristic differences. Although Group 5 variants from KZN cluster with
Group 1 sequences they are distinct from any previously described African Group 1 isolates
sequences. The sequence data (Appendices B and C) did not suggest the presence of GBV-
CIHGV recombinant infections in any patient.
GBV-C also referred to as HGV are closely related Flaviviruses of human ongm.
Transmission by blood transfusions and from infected mothers to their infants has been
documented. It is very probable that GBV-CIHGVis also transmitted by non-parenteral routes
in KZN. In the absence of histochemical studies of liver biopsies to detect GBV-CIHGV, the
higher prevalence of novel Group 5 GBV-CIHGV isolates in blood donors, HIV positive
patients and patients with liver disease, the lack of elevation in liver enzymes or clinical
hepatitis in blood donors and haemodialysis patients suggests that GBV-CIHGV is not
associated with liver disease in KZN, South Africa. However, some findings suggest that
GBV-CIHGV is involved with some cases of acute and chronic hepatitis , that GBV-CIHGV
may be pathogenic to primates considered to be appropriate non-human hosts for viral
hepatitis studies; and that GBV-CffiGV does indeed replicate in human liver. Whilst there is
no consensus reached about the pathogenecity of GBV-CffiGV, it would be premature to
screen blood donors for GBV-CIHGVand exclude a large proportion ofblood donors from the
donor pool without solid evidence that GBV-C/HGV is indeed pathogenic to humans. Thus
GBV-CffiGV is a virus still searching for a disease.
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There is evidence to suggest that GBV-C/HGV infection may have a beneficial influence in
mv positive patients. Longitudinal studies indicate that GBV-C/HGV infection slows down
the progression to AIDS and eventually death by inhibiting mv replication and enhancing
immune competence.. The definitive mechanism ofhow GBV-C/HGV inhibits the progression
to AIDS is not known. For the first time relatively higher CD3 (due to an increase in T cell
status) and.an increase in y8T expression, together with a decrease in CD 30 (reflects a
decrease in activation status and an increase in T helper Type 1 response) has been
demonstrated in mv positive patients eo-infected with GVBV-C/HGV. These preliminary
findings would tend to suggest an association with protection and/or delayed progression of
mv disease in GBV-C/HGV infected patients. Human y8 T cells possess potent cytotoxic
activity and are capable of producing a large array f3-chemokines -and pro-inflammatory
cytokines which are known to interfere with HIV replication. It is tempting to speculate that
GBV-C/HGV could indirectly affect AIDS risk through the expression ofy8T cells; induction
of various chemokines and other soluble factorsand altered expression ofchemokine receptors
essential for HIV co-receptors . In KZN, the epicenter of the HIV pandemic where mv is
having a devastating effect, a more detailed in vivo and in vitro longitudinal study of the
observed phenomena may impact on new approaches to treat or prevent HIV infection.
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AIDS is the fourth most common cause of death worldwide (Esparaza and Bhamarapravati,
2000). The impact ofAIDS humbles any prior infectious disease threat in our history. In KZN
the IllV epidemic and the consequential development of AIDS poses an enormous threatto
the social, political and economic landscape of the province. With no effective vaccine
available, the majority ofIllV infected individuals living in Sub-Saharan Africa cannot afford
antiretroviral drugs (70%). Despite short course antiretroviral regimens for the prevention of
mother to child transmission (MTCT) of IllV, transmission at antepartum (7%) and through
breastfeeding (4%) remains high. In Africa, 55% ofIDV-l positive adults are woman of child-
bearing age. The cumulative risk ofmother to child transmission ofIllV is between 25%-45%
in Africa (Dabis and Ekpini, 2002). Data from antenatal clinics show that in several parts of
southern Africa, more that 30% of pregnant women are infected with IllV-l (Dabis and
Ekpini, 2002). South Africa is considered to have the fastest-growing IllV positive population
in Africa if not the world. Official Department of Health figures compiled from antenatal
clinics across the country show a significant increase in the infection rate among pregnant
women in most provinces, the highest figures (33%) being reported for KZN (prof A Smith-
Dept ofVirology-personal communication). Therefore, effective IllV vaccines are needed to
combat the pandemic.
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Several candidate AIDS vaccines have been studied in human volunteers. It is currently
believed that AIDS vaccines will need to induce neutralising antibody and cell-mediated
immune responses to be protective (Haynes et aI, 1996). Cell-mediated immune responses
protective against intracellular pathogens typically involve CD4+ T helper cells of the type 1
(IFN-y) phenotype and CD8+ cytotoxic T lymphocyte (CTL) responses (Abbas et aI, 1996).
The most promising AIDS vaccine strategy studied to-date has involved the use of live
poxvirus vectors to express mv antigens (Taylor et ai, 1991). It has been suggested that live
vaccines may be more potent than soluble protein vaccines because they induce
proinflammatory cytokines, which act as adjuncts for the induction ofcell-mediated immunity
(Ramshaw and Ramsay, 2000).
Direct human to human microbial transmission as therapy for infectious diseases may seem
anachronistic. Before the development ofpenicillin, syphilis was treated with the blood borne
pathogen Plasmodium vivax. Plasmodium vivax has been used to treat Lyme disease (Annon,
1991) and to "stimulate" the immune response of mv infected individuals (Heimlich et aI,
1997). Malaria therapy has been recommended as an adjunct cancer treatment (Greentree,
1981). Enemas using stools from apparently healthy individuals were used to treat individual
patients suffering from refractory Clostridium difficile colitis (Schwan et aI, 1984). Recently,
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2. Determine whether GBV-CffiGV could be used as an alternative vector to express mv
antigens or alternatively the insertion ofGBV-CffiGV genes into viral vectors such as pox
viruses (vaccinia or canarypox) or bacteria could induce more potent mv specific
immunity including a cytotoxic T cell response.
3. Determine the impact ofGBV-CffiGV on mv transmission from mother to infant and/or
rise versa.
4. Determine whether GBV-CffiGV eo-infection is an additional favourable prognostic
factor in mv positive adults (mothers) and/or their children (long term slow progressors).
5. Replication ofGBV-CffiGV has been demonstrated in peripheral-blood mononuclear cells
(Xiang et aI, 2001) and CD4 T cells (Xiang et al, 2000) and the inhibitory effect of GBV-
CffiqV infection on mv replication leading to delayed disease progression was
demonstrated in vitro (Xiang et aI, 2001). These In vitro inhibition studies need to
duplicated using African mv Clade C and GBV-CffiGV Group 5 variants from KZN,
South Africa in different PBMC subsets (CD4, CD8 etc.).
Current evidence suggests that other viral agents or other factors may be responsible for a
large majority ofpost-transfusion or community-acquired non-A-E hepatitis. A new pathogen,
namely, Transfusion Transmissible Virus (TTV) has become a new focus of viral hepatitis
research. This DNA non-enveloped virus has numerous similarities to GBV-CffiGY. Several
independent studies have east doubts on the pathogenicity ofTTY. More recently, a novel
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hepatitis virus, SEN-Virus (SEN-V), has been isolated. SEN-V is now considered to be a
likely candidate for previously unexplained hepatitis.
The past 5 years has seen the discovery of GBV-C, HGV and now the enlarging family of
circoviruses that include, TTV, SANBAN, YONBAN and SEN-V. Each time a novel
sequence IS discovered, a search for disease association ensues. The sophistication and
sensitivity of recombinant DNA technology for viral discovery virtually ensures that new
viruses will continue to be discovered. At issue is whether these agents cause non-A to E
hepatitis or some extra-hepatic manifestation and, if so, with what frequency and with what
degree of clinical relevance. These viruses are so diverse that they might have very different
pathogenecity and each phylogenetic grouping may have to be studied independently to assess
its clinical relevance. Although some viruses recovered from blood may cause disease while
others may be "innocent bystanders" or even be beneficial, the surveillance of all new and
novel viral infections must be maintained.
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Appendix A
Published sequencesfrom the 5' NCR ofthe GBV-C/HGV isolates PNF2161 (U44402),
RI0291 (U45966) and GBV-C (U36380) showingtheposition ofthe primers used inRT-PCR
50
u44402 ACGTGGGGGA GTTGATCCCC CCCCCCCGGC ACTGGGTGCA AGCCCCAGAA
u45966 .
u36380 ' CCCCCCCGGC ACTGGGTGCA AGCCCCAGAA
51 100
u44402 ACCGACGCCT ATCTAAGTAG ACGtAATGAC TCGGCGCCGA CTCGGCGACC
u45966 . . . . . . . . . . . . . CAATGAC TCGGCGCCGA CTCGGCGACC
u36380 ACCGACGCCT ACTGAAGTAG ACGTAATGGC CCCGCGCCGA ACCGGCGACC
101 150
u44402 GGCCAA AAGGTGGTGGATGG GTGAT GACAGGGT TGGTAGGTCGTAAATCC
u45966 GGCCAA AAGGTGGTGGATGG GTGAT GACAGGGT TGGTAGGTCGTAAATCC
u36380 GGCCAA AAGGTGGTGGATGG GTGAT GACAGGGT TGGTAGG'TCGTAAATCC
151 200
u44402 CGGTCACCTT GGTAGCCACT ATAGGTGGGT CTTAAGAGAA GGTTAAGATT
u45966 CGGTCACCTT GGTAGCCACT ATAGGTGGGT CTTAAGAGAA GGTTAAGATT
u36380 CGGTCATCCT GGTAGCCACT ATAGGTGGGT CTTAAGGGGA GGCTACGGTC
201 250
u44402 CCTCTTGTGC CTGCGGCGAG ACCGCGCACG GTCCACAGGT GTTGGCCCTA
u45966 CCTCTTGTGC CTGCGGCGAG ACCGCGCACG GTCCACAGGT GTTGG,CCCTA






















u44402CCCAAGAATC C TTCGGGTGAGGGCGGGTGGCA TTTCCTTTTTCTATACCA
u45966CCCAAGAATC C TTCGGGTGAGGGCGGGTGGCA TTTCTCTTCCTTATACCA




The etiology ofchronic liver disease at King Edward VIII Hospital, Durban.
HBV-Hepatltls B VIrUS; HCV-HepatItls C VIruS
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Biochemical tests in alcoholic patients with and without liver disease
ALD, alcohohc hver disease; ALB, albumin; T-Bll, Total bilirubin; ALT, alanine
aminotransferase; GGT, gamma-glutamyltransferase ; ALP, alkaline phosphatase; CDTect,
carbohydrate deficient transferrin; umol/L, micromoles per litre; U/L, units per litre; SD,
standard deviation
Biochemical Tests ALD Alcoholic controls p-value
Mean±SD Mean±SD
ALB (g/L) 23.66 ± 7.19 40.74±6.94 P<O,OOOOl
GLOB (g/L) 53.28 ± 14.12 42.97± 8.91 P=0,0001
Total-Bil (umol/L) 61.24± 86.84 12.74±6.03 P=0.0003
ALT (UIL) 89.78± 236.80 58.31± 34.83 ns
GGT (UIL) 227.80 ± 212.11 152.74± 212.84 ns
ALP (UIL) 233 .0 1± 82.60 74.86± 44.49 P=0.0001









Signal G:2506 A:969 T:684 C:1463
DT POP6{SD Set-Any Primer}
SDdR,POP6
Page 1
Sat, Apr 18, 1998 11:04
Sat, Apr 18, 1998 4:32
Spacing: 9.94 SemiAdaptive
C TAC T T ClClT a ClC oo.C T A T A ClClT Cl ClCl C T T T A ACl G Cl Cl ACl Cl C T A C A Cl T C C C T C T A ClT Cl C C T ClT Cl Cl AG A G A A ACl C ClC A C ClCl T C CAC A G G T ClT T G G T C C T A C C ClG T ClT Cl A A T A A G Cl A C CC ClI
10 20 30 40 50 60 70 00 90 100 110
~ T CA ClG C T C ClT C ClTT A A A C C G AG C C C G T T A A C CC C C T ClClG C A A A C G A C ClC C C AC G T A C Cl ClC CC A C Cl T C GC CC T T C A A T G T C T C T C T T G AC C." A T A Cl Cl C A A T ClCC G G C ClA ClTT Cl GC A A G Cl G C
120 130 140 150 160 170 100 190 20 0 210 220 230
A G TGGGGG C C G G AG ClC A ClClG ClG A TCl G A C C C C C T G T C T C ClC CC T T C C C ClG ClG GT GC GClG A A A TGC A T ClA GGC CAC C AA ClCT C CA N N N N N N N N N N




















































Signal G:1514 A:746 T:555 C:1115
DT POP6{BD Set-Any Primer}
BDdR,POP6
Page 1 011
Sat, Apr 18, 1998 11:07
Sat, Apr 18, 1998 5:28
Spacing: 9.84 SemiAdaptive
a Aa a a A C T a T A a c e T C C C C T T A A A a c C C A C C T AT A G T a a C T A C C A A G A T a A C C a a a A T T TA C a A C C TT A C C A A N N N N N N N N N N
250 26 0 270 280 290 300 31a 320 330
T T CCCGC c ccc c c o o M GG a C GAG ACAG Ga a G T CCAT C CC CC T ac CT CCGaC C CC CIIC T ao c CC T r a c CII AC T c a c CG aC A T T o c CT A T T G c r CA A a A a A a ACA T T a A A G a G C a A c o r a a G C C o r A c o r a a a C
10 20 30 40 50 60 70 80 90 100 110 120 130
10 T e a T T r a C C CA a a a a a T T A A C a a a C T C G G T T T A A C a A C a A a C C T a A c e r c a a a r C C T T A T T C A C A C C Ga T A a a AC C A AC A C C r G T a a AC c o r a C e c T ,. r C T C T C C A C A a a C A C T ~
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---TAGCCAC TATTGGT-GG GT-CTTAAG- GGGTGGTCAA GGT-CCCTCT GGCGCTTGTG
TGGTAACCAC TATAGGT-GG GT-CTTAAG- GGTTGGTCAA GGT-CCCTCT GAACCCTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTGGTCAA GGT-CCCTCT AGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTAGTCAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTGGTCAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTGGGTCAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTGGTTAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTGGTTAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTGGTTAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG~ GGTTGGTTAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGCTGGTCAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTGGTCAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTGGTCAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTGGTCAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTGGTCAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGTTGGTCAA GGT-CCCTCT GGCGCTTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- AGTGGGTTAA GGT-CCCTCT TTCGCCTGCG
---TAGCCAC TATAGGT-GG GT-CTTAAG- GGTGGGTCAA GGC-ACCTCT TACTCCTGCG
---TAGCCAC TATAGGT-GG GT-CTTAAG- GGTGGGTCAA GGC-ACCTCT TACTCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGAAGGTTAA GAT-TCCTCT TGTGCCTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- AGAAGGTCAA GAT-TCCTCT TACGCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- AGAAGGTTAA GAT-TCCTCT TGTGCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- AGAAGGTTAA GAT-TCCTCT TGTGCCTGCG
----ATCCAC TATAGGT-GG GT-CTTAAG- AGAAGGTTAA GAT-TCCTCT TGTGCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- AGAAGGTTAA GAT-TCCTCT TGTGCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- AGAAGGTTAA GAT-TCCTCT TGTGCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- AGAAGGTTAA GAT-TCCTCT TGTGCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- AGAAGGTTAA GAT-TCCTCT TGTGCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- AGAAGGTTAA GAT-TCCTCT TGTGCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- CGTTGGTCAA GAT-CCCTCT TGTGCTTGCG
TGACAGCC-A T-TAGTG-GC G--TTTAAG- -CGAGCT-AC AGT-CCTGT- -ATGCCTG-G
---ATGCCAC TATAGGTTGG GTGCTTAAGG CGGAGGCTAC AGT-CCCTCT AGTGCCTGTG
---CAGCCAC TATAGGTTTG GT-CTTAAG- CGGAGGCTAC AGT-CCCTCT AGTGCCTGTG
--GTAGCC-C TATATGT-GG GC-CTTAAG- GGGAGGCTAC AGT-CCCTCT AGTGCCTGTG
--GCAGCC-C TATAGGT-GG GT-CTTAAG- GGGAGGCTAC AGT-CCCTCT AGTGCCTGTG
--CCAGCC-C TATAGTT-GG GT-CTTAAG- CGGAGGC-TC AGT-CCCTCT GTTACCTGTG
--GAAGCC-C T-ATGGT-GG G--TCTAGC- GGGAGGC-TC AGT-CCCTCT -ATGCCTGTG
---GCGCC-C T-TAG-T-GG G--CTTACG- -GGAG---TC AGC-CCTT-- -ATGCCTG-G
- GGACACC- C T-AAGGT~GG G--CCTAAG- CGGAGGC-TC AGT-CCCTCT AGTGCCTG-G
TGGTAGCCAC TATAGGT-GG GC-CTTAAG- GGGAGGCTAC AGT-CCCTCT AGTGCCTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGGAGGCTAC AGT-CCCTCT AGTGCCTGTG
TGACAGCC-A TATAGGT-GG GC-TTTAAC- GGGAGGCTAC AGT-CCCTCT AGTGCCCGTG
TAACAACC-A TATATTT-GG GT-CTTAAG- CGGAGGCTAC GGT-CCCTCT AATGCCCGTG
TGGCAGCC-A TATAGGT-GG GTGCTTAA-G GGGAGGCTAC GGT-CCCTCT AATGCCCGTG
TGGCAGCC-A TATAGGT-GG GTGCTTAA-G CGGAGGCTAC AGT-CCCTCT AACGCCCGTG
-TGCAGCC-C TATAGGT-GG GT-CTTAA-C CGGAGGCTAC AGT-CCCTCT AATGCCCGTG
-GGTCAGCCC TATAGGT-GG GT-CTTAA-G GGGAGGCTAC AGTACCCTCT AATGCCCGTG
-GGTAGCCAC TATAGGT-GG GT-CTTA--G GGGAGGCTAC AGT-CCCTCT AATGCCCGTG


























































- -GAGACC-C TATATTT-GG GT-CTTAAC- GGGAGGCTAC AGT-CCCGCT AGTGCCCGTG
GGGCCGCC-C TATATTT-TG GT-CTTA--- GGCGGGCT-C AG--CCCGT- -ATGCCCG-G
TGGTAGCCAC TATAGGT-GG GT-CTTAAA- GGGAGGCTAC GGT-CCCTCT TGCGCTTATG
---TAGCCAC TATAGGT -GG GT-CTTAAG- GGGAGGTTAT GGT-CCCTCT CGCGCTTATA
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGGAGGCTAC GGT-CCCTCT CGCGCTTACG
TGGTAGCCAC TATAGGT-GG GT-CTTAAA- GGGAGGCTAC GGT-CCCTCT CGCGCTTACG
TGGCAGCCA- TATAGGT-GG GT-CTTAAA- GGGAGGCTAC GGT-CCCTCT CGCGCTTATG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGGAGGCTAC GGT-CCCTCT TGCGCATATG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GCTAGGTAAT GGT-CCCTCT TGCGCTTATG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- AGAAGGTTAA GAT-TCCTCT TGTGCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAA-G GGGAGGCTAC AGT-CCCTCT AATGCCCGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAA-G GGGAGGCTAC AGT -CCCTCT AATGCCCGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGGAGGCTAC AGT-CCCTCT AGTGCCTGTG
TGGTAGCCAC TATAGGT-GG GC-CTTAAG- GGGAGGCTAC AGT-CCCTCT AGTGCCTGCG
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGGAGGCAAC GGT-CCCTCT CGCGCATATG
TGGTAGCCAC TATAGGT-GG GT-CTTAA-G GGGAGGCTAC AGT-CCCTCT AATGCCCGTG
TGGTAGCCAC TATAGGT -GG GT-CTTAAG- GGGAGGCTAC AGT-CCCTCT AGTGCCTGTG
TGGTAGCACC TATAGGT-GG G---TTGACT GGCGGCGAGA AGTCCCTAAT ACCTCTTGCA
TGGTAGCCAC TATAGGT-GG GT-CTTAAG- GGGAGGCTAC AGT-CCCTCT AGTGCCTGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAA-G GGGAGGCTAC AGT-CCCTCT AATGCCCGTG
TGGTAGCCAC TATAGGT-GG GT-CTTAA-G GGGAGGCTAC AGT-CCCTCT AATGCCCGTG .
TGGTAGCCAC TATAGGT-GG GT-CTTAA-G GGGAGGCTAC AGT -CCCTCT AGTGCCTGTG
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GCGAAAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GGGAATAAGG GCCCGACATC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAA-GC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GT-AATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTTCA CAGGTGATGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGGGAACGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGGGACAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGGGACAGC GCACGGTCCA CAGGTGATGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGACAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GGGAATAAGG GCCCGACGTC
GCGAGACCGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACATC
GCGAGACCGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGACCGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGACCGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
ACGAGACCGC GCACGGTCCG CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGACCGC GCACGGTCCA CAGGTGCTGG CCTTACCGGT GTGAATAAAG GCCCGACGTC
GCGAGACCGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGACCGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GGGAATAAGG GCCCGACGTC
GCGAGACCGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GGGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GGGAATAAGG GCCCGACGTC
-AGAAAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGTo GTGAATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC

























































GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
GCGAGAACGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAACGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GCGAGAACGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GCGAGACA-C GCACGGTCCA CAGGTGTTGA TCCTACCGGT GT-AATAAGG ATCCGACGTC
GCGAGACAGC GCACGGTCCA CAGGTGTTGA TCCTACCGGT GT-AATAAGG ATCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GCGAAAA-GC. GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GCAGACA-GC GC-CGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GT-AATAAGG GCCCGGCGCT
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GT-AATAAGG GCCCGGCGCT
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GT-AATAAGG GCCCGGCGCT
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GT-AATAAGG GCCCGGCGCT
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GT-AATAAGG GCCCGGCGCT
GAGGAAAAGC ' GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGGCGCT
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGGCGCT
GCGAGACCGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAACGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
GAGAGACAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GAGGGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGGCGCT
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GTGAATAAGG ACCCGACGTC
-CGTGAT-GC GCACGGTCCA CAGG-ATTGG TCTCTCCGGT GTGAATGA-G ACCCGACGCC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GCGAGAAAGC GCACGGTCCA CAGGTGTTGG TCCTACCGGT GT-AATAAGG ACCCGACGTC
GAGAGAAAGC GCACGGTCCA CAGGTGTTGG CCCTACCGGT GTGAATAAGG GCCCGACGTC
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AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTACCC ACC-TGGGCA AACAACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACTGAG CCCATTACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTTCCC ACC-TGGGCA AACGACGTCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCACTACCC ACC-TGGGCA AACAACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCACCTCCC ACC-TGGGCA AACAACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTACCC ACC-TGGGCA AACAACGCCC ATGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTACCC ACC-TGGGCA AACAACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTACCC ACC-TGGGCA AACAACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTACCC ACC-TGGGCA AACAACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTACCC ACC-TGGGCA AACAACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACTGAG CCCATTACCC ACC-TGGGCA AACAACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACTGAG ACCACTTCCC ACC-TGGGCA AACGACGCCC ACGTACGGTC


























































AGGCTCGTCG TTAAACCGAG CCCGTTACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG ACCGACACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCATGTCG TTAAACCGAG CCCGTTACCC GCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTTCCCC GCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTCTCCC GCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTTACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTCACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTTACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTCACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTTACCC ACC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTAACCC GCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTAACCC GCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACTGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTGACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ATGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ATGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGT~CGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ACGTACGGCT
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ACGTACGGCT
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCACTAACC CCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCACAAACC CCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATAATCC CCC-TGGGCA AACGACGCCC ATGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCG AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCACGCCG TTAAACCGAG CCCGTCATCC CCC-TGGGCA AACGACGCCC ATGTACGGTC
AGGCACGCCG TTAAACCGAG ACCGTTACCC CCC-TGAGCA AACGACGCCC ACGTACGGCC
AGGCACGCCG TTAAACCGAG ACCGCTTTCC CCCCTGGGCA AACGACGCCC ACGTACGGCC
AGGCACGCCG TTAAACCGAG ACCGTTATCC CCC-TGGGCA AACGACGCCC ATGTACGGCC
AGGCACGCCG TTAAACCGAG ACCGTTATCC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCACGCCG TTAAACCGAG CCCGTTACTC CCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCACGCCG TTAAACCGAG CCCGTTATCC CCC-TGGGCG AACGACGCCCACGTACGGCT
AGGCTCGTCG TTAAACCGAG CCCGTTCCCC GCC-TGGGCG AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ATGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCG AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTACCC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCACGCCG TTAAACCGAG CCCGTTATCT CCC-TGGGCA AACGACGCCC ACGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGTCACGTCG TTAAACAGAG TGCCTTTCCC CAT---CGCA ACGCCGGCCC TCGTACGGGA
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ATGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCATTATCC CCC-TGGGCA AACGACGCCC ATGTACGGTC
AGGCTCGTCG TTAAACCGAG CCCGTTAACC CCC-TGGGCA AACGACGCCC ACGTACGGCC
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CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCGAT G---CCGGCG AATTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG






























































CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTA G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGCCTTT G--GCCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTA G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTA G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTA G-- -CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG
CACGTCGCCC TAC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG
CACGTCGCCC TAC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG
CACGTCGCCC TAC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG
CACGTCGCCC TAC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG
CACGTCGCCC TAC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGGCC AATAGGCTTT G---CCGGCG AGTTGACAAA
CACGTCGCCC TAC-AATGTC TCTCTTGACC AATAGGCTAT G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTT G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGTTTA T---CCGGCG AGTTGGCAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGTTCG T---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGTTTA A---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGCC TCTCTTGGCC AATAGGTTTA T---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGCC TCTCTTGGCC AATAGGTTTA A---CCGGCG AGTTGGCAAG
CACGTCGCCC TTC-AATGCC TCTCTTGGCC AATAGGTTTA T---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTA G-- -CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCGTA G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC GCTCTTGACC AATAGGCTTA G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC GCTCTTGACC AATAGGCTTA G---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-AA --TGTTTGCG AGTTGGCAAA
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-TG --TGTTGGCG AGTTGGCAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-TA --CGCCGGCG AGTTGGCAAA
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-AA --TGCCGGCG AGTTGGCAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-AA --TGCCGGCG AGTTGGCAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-TA --TGCCGGCG AGTTGGCAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-TA - -TGCCGGCG AGTTGGCAAG
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCGAA --TGCCGGCG AGTTGGCAAG
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCGAA --TGCCGGCG AGTTGGCAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-AA --TGCCGGCG AGTTGGCAAG
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-AA --TGCCGGCG AGTTGGCAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCGTA ---GCCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCAA- --TGCCGGCG AGTTGACAAA
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCA-A --TGCCGGCG AGTTGACAAA
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCATC --AGCCGGCG AGTTGACAAA
TACGTCGCCC '£TC-AATGTC TCTCTTGACC AATAGGCACG --AGCCGGCG AGTTGGCAAA
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCATA --TGCCGGCG AGTTGGCAAA
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCGCA --TGCCGGCG AGTTGGCAAA
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCATA --AGCCGGCG AGTTGGCAAA
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCAAT A-TGCCGGCG AGTTGGCAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCGAA T-TGCCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGCC TCTCTTGGCC AATAGGCTTC - GG- CCGGCG AGTTGGCAAG
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCGAT --G-CCGGCG AGTTGACAAA
C.~CGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCAAT --G-CCGGCG AGTTGGCAAG
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTAT TAG-CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCAAT TTG-CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCGTA --G-CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTA --G-CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGTTTA T---CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCATA --AGCCGGCG AGTTGACAAG
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCA-A --TGCCGGCG AGTTGACAAA
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-AA --AGCCGGCG AGTTGACAAA


























































CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTA --G-CCGGCG AGTTGACAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCTTA --GGCCGGCG AGTTGGCAAG
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-AA --TGCCGGCG AGTTGACAAG
-ACGTCGCCC TTTTAATACC ACTCT-GGTC AGTAGCATGT G----CGGCG AGTTGGCAAT
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-AA --TGCCGGCG AGTTGGCAAG
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCATA --TGCCGGCG AGTTGGCAAA
TACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGCATA --TGCCGGCG AGTTGGCAAA
CACGTCGCCC TTC-AATGTC TCTCTTGACC AATAGGC-AA --TGCCGGCG AGTTGGCAAG
.... I .... I .... I ••.. I .... I .... I .... I ...• I ...• I .... I .. •. I • . . • I
250 260 270 280 290 300
GACCAATGGG GGCCGGGCGT C-AGGAAATG GACTCCTGC- CGCTGCCCTT CCCGGGGGAG
GACCAGTGGG GGCTGGGCGT C-GGGGGAAG GACCCCCGG- CGCTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCCGGGCGG C-GGGGGAAG GACCCCCGT- CGCTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCCGGGCGG C-CGGGGAAG GACCCCTGT- CGCTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCCGGACGG C-CGGGGAAG GACCCCGGT- CGTTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCCGGGCAG C-AGGGGAAG GACCCCTGT- TGTCGCCCTT CCCGGTGGGG
GACCAGTGGG GGCCGGGTGC C-AGGGGAAG GACCCCTGT- CACTGCCCTT CCCGGTGGGG
GACCACTGGG GGCCGGGCGG C-AGGGGAAG GACCTCTGT- CTCTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCTGGGCGG T-AGGGGAAG GACCCCTGC- CGCTGCCCTT CCCGGTGGAG
GGCCAGTGGG GGCTGGGCGG C-AGGGGAAG GACCCCTGT- CGCTGCCCTT CCCGGTGGAG
GACCAGTGGG GGTTGGGCGG T-GGGGGAAG GACCCCTTT- CGCTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCTGGGCGG C-GGGGGAAG GACCTCCGT- CGCTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCTGGGCGG C-AGGGGAAG GACCTCTGC- CGCTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCTGGGCGG C-AGGGGAAG GACCTCTGT- CGCTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCTGGGCGG C-AGGGGAAG GACCCCTGT- CGCTGCCCTT TCCCGTGGGG
GACCAGTGGG GGCTGGGCGG C-GGGGGAGG GACCCCCGT- CGCTGCCCAT TCCGGTGGGG
GACCAGTGGG GGCCGGGCAC GTGAGGGAGG GACCCTCCG- TGCTGCCCTT CCCGGTGGTG
GACCAATGGG GGCCGGGCAC A--GGGGGAA GGACCCCTG- TGCTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCCGGGCGT TATGGGGAAA GACCCCCTG- CGCTGCCCTT CCCGGTGGGG
GACCAGTGGG GGCCGGGGGT GGAGGGAAGG ACCCTCTCA- CCCTGNCCTT CCCGGTGGGA
GACCAGTGGG GGCCGGGGGC TATGGGGAAG GACCCCAAG- CCCTGCCCAT CCCGGCGGGC
GACCAGTGGG GGCCGGGGGT CATGGGGAAG GACCCCAGA- CCCTGCCCTT CCCGGCGGGT
GACCAGTGGG GGCCGGGGGT CATGGGGAAG GACCCCAGA- CCCTGCCGTT CCCGGCGGGC
GACCAGTGGG GGCCGGGGGT C-TGGAGAGG GACTCCAAG- CCCTGCCCTT CCCGGTGGGC
GACCAGTGGG GGCCGGGGGC T-TGGAGAGG GACTCCAAG- TCCTGCCCTT CCCGGTGGGC
GACCAGTGGG GGCCGGGGCC T-TGGAGATG GACTCCAAG- TCCTGCCCTT CCCGGTGGGC
GACCAGTGGG GGCCGGGGGC T--GGAGAGG GACTCCAAG- CCCTGCCCTT CCCGGTGGGC
GACCAGTGGG GGCCGGGGGC T-TGGAGAGG GACTCCAAG- TCCCGCCCTT CCCGGTGGGC
GACCAGTGGG GGCCGGGGTT TATGGGGAAG GACCCCAAA- CCCTGCCCTT CCCGGCGGAC
GACCAGTGGG GGCCGGGGTT TTTGGGGAAG GACCCCAAA- CCCTGCCCTT CCCGGCGGAC
GGCCAGTGGG GGCCGGGGGT AGGG-GGAAG GACCCTCTA- CCCTGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGGGGGC AGGG-GGAAG GACCCCCTG- TCCTGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGGGGGC AGGG-GGAGG GACCCCCTG- TCCTGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGGGGGC AGGG-GGAAG GACCCCCTG- TCCCGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGGGGGT AGGG-GGAAG GACCCCCTG- CCCTGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGGGGGT AGGG-GGAAG GACCCCCTG- CCCTGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGAGGGC AGGC-GGAAG GACCCCCTG- TCCCGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGGGGGC GGGG-GGAAG GACCCCCCG- TCTCGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGGGGGC GGGG-GGAAG GACCCCCCG- TCTCGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGGAGGG GGGG-GGAAG GACCCCCCC- GCCTGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGGGGGC AGGG-GGAAG GACCCCCTG- TCCTGCCCTT CCCGGGGGTG
AGCCAGTGGG GGCCGGGGGT GAGGGAGATG GACTCCCCA- CCCTGCCCTT" CCCGGGGGAG
GACCAGTGGG GGCCGGGGGC GGAG-GGAAG GACCCTCCG- TCCTGCCCTT CCCGGGGGAG
GACCAGTGGG GGCCGGGGGT GAGGGGGATG GACCCCCCG- CCCCGCCCTT CCCGGGGGAG
GACCAGTGGG GGCCGGGGGC AGGGGGAA-G GACCCCCTG- CTCTGCCCTT CCCGGGGGAG
GACCAGTGGG GGCCGGGGGT AAGGGGAA-G GACCCCTTG- CCCTGCCCTT CCCGGGGGAG
GACCAGTGGG GGCCGGGGGT A-GGGGGAAG GACCCCCTA- TCCTGTTTTT CCCGGGGGAG

























































GACCAGTGGG GGCCGGGGGT GAGGGGGAAG GACCCCCCA- CCCTGCCCTT TCCGGGGGAG
GGCCAGTGGG GGCCGGGGGT GGGGAGGAAG GACCTCCCCA TCCCGCCCTT CCCGGGGGAG
GGCCAGTGGG GGCCGGGGGT GGGG-GGATG GACCCCCTGA CCCTGCCCTT CCCGGGGGAG
GACCAGTGGG GGCCGGGTGT G-GGGGGAAG GACCTCCCA- CACTGCCCTT CCCGGGGGAN
GGCCAGTGGG GGCCGGGCGG C-AGGGGAAG GACCCCTGT- CGCTGCTCTT CCCGGGGGGG
GGCCAGTGGG GGCCGGGTGG T-GGGGGAAG GACCCTCAC- CACTGCCCTT CCCGGGGGGG
GGCCAGTGGG GGCCGGGCGG C-GGGGGAAG GACCCCCGC- CGCTGCCCTT CCCGGGGGAG
GGCCAGTGGG GGCCGGGCGG T-GGGGGAAG GACCCCCAC- CGCTGCCCTT CCCGGGGGAG
GACCAGTGGG GGCCGGGCGG GAGGGGGAAG GACCCCCAC- CGCTGCCCTT CCCGGGGAGG
AGCCAGTGGG GGCCGGGCGC T-GCGGGAAG GACCCGCAG- CGCTGCCCTT CCCGGGGGAG
GACCAGTGGG GGCCGGGGGT C-TGGGGAAG GACCCCAGA- TCCTGCCCTT CCCGGCGGGT
GACCAGTGGG GGCCGGGGGT G-TGGGGAAG GACCCCGCA- TTCTGCCCTT CCCGGGGGAG
GACCAGTGGG GGCCGGGGGT G-GGGAGAAG GACTCCCCA- TCCTGCCCTT CCCGGGGGAG
GGCCAGTGGG GGCTGGAGGC AGGG-GGAAG GACCCCCTG- TCTCGCCCTT CCCGGGGGTG
GGCCAGTGGG GGCCGGGGGC AGGG-GGAAG GACCCCCTG- TCTCGCCCTT CCCGGGGGTG
GACCAGTGGG GGCCGGGCGA GGGGGGGAAG GACCCCCCC- CGCTGCCCTT CCCGGGAGAG
GGCCAGTGGG GGCCGGGGGT G-GGGGGAAG GATCCCCCA- TCCTGCCCTT CTCGGGGGAG
GGCCAGTGGG GGCCGGAGGT AGGG-GGAAG GACCCCCTG- CCTCGCCCTT CCCGGGGGTG
CCCAGAGGGC GGGCGGGGCG TACACGGTAG GACCGTGCC- GCCTGCGTTG TCGGGGTCTG
GGCCAGTGGG GGCCGGGGGC AGGG-GGAAG GACCCCCTG- TCTCGCCCTT CCCGGGGGTG
GACCAGTGGG GGCCGGGGGT G-GGGGGAAG GACCCCCCA- TCCTGCCCGT TCCGGGGGAG
GACCAGTGGG GGCCGGGGGT G-GGGGGAAG GACCCCCCA- TCCTGCCCGT TCCGGGGGAG
GGCCAGTGGG GGCCGGGGGC AGGG-GGAAG GACCCCCTG- TCTCGCCCTT CCCGGGGGTG
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GB Virus ClHepatitis G Virus Infection in KwaZulu
Natal, South Mrica
Mahomed A. Sathar,"! Paresh N. Soni,1 Sarala Naicker,l Jan Conradie," Fathima Lockhat," and
Eleanor Gouws" .
1Department ofMedicine, Universi ty ofNatal! King Edward VIII Hospital, Natal, South Africa
2Natal Blood Transfusion Services, Durban, South Africa
3Center of Epidemiological Research, Medical Research Council, Durban, South Africa
Sera from 70 patients on maintenance haemodi-
alysis, 98 patients with chronic liver disease, and
232 volunteer blood donors in the province of
KwaZulu Natal , South Africa, were screened for
GB virus/hepatitis G virus (GBV-C/HGV) RNA and
anti-E2 by reverse transcription-polymerase
chain reaction (RT-PCR) and by an enzyme-
linked immunosorbent assay (ELlSA), respec-
tively. GBV-C/HGV RNA was detected in 17nO
(24.3%) haemodialysis patients, 12/98(12.2%)
patients with chronic liver disease , and 44/232
(18.9%) blood donors (Africans [29n6; 38.2%];
Asians [2/52; 3.8%]; Whites [11/49; 22.4%], and
"Coloureds" [persons of mixed origin; 2/55 ;
3.6%]). Overall (anti-E2 and/or RNA) 43.9% (43/
98) of patients w ith chronic liver disease, 47.1%
(33nO) of haemodialysis patients, and 31.9% (741
232) of blood donors (Africans [44n6; 5.9%] ;
Asians [5/52; 9.6%]; Wh ites [15/49; 30.6%], and
Coloureds [9/54; 16.6%]) were exposed to GBV-
C/HGV infection. There was a significant differ-
ence in the prevalence of GBV-C/HGV infection
(RNA and/or anti- E2) between African blood do-
nors and the other racial groups (P < .001), and
between blood donors and haemodialysis pa-
tients (P = .02) and patients with chronic liver
disease (P= .04). Anti-E2 antibodies and GBV-C/
HGV RNA were almost mutually exclusive. GBV-
C/HGV-infected haemodialysis patients received
more transfusions (P = .03) than noninfected pa-
tients. There was no significant difference in
liver biochemistry between GBV-C/HGV-infected
and noninfected patients and between blood do-
nors in each of the four racial groups. The high
prevalence of GBV-C/HGV infection in blood
donors and chronic liver disease patients, and
the lack of elevated liver enzymes and clinical
hepatitis in blood donors and haemodialysis pa-
tients, suggest that GBV-C/HGV may not be as-
sociated with liver disease. J. Med. Virol. 58:38-
44, 1999. © 1999 Wiley-Liss, Inc.
KEY WORDS: GBV-C/HGV; blood donors;
© 1999 WILEY.LISS, INC.
haemodialysis; chronic liver
d isease; racial difference;
South Africa
INTRODUCTION
Liver disease is a major cause of morbidity and mor-
tality among patients with end-stage renal disease due
primarily to hepatitis B virus (HBV), hepatitis C virus
(HCV), alcohol, and hemosiderosis [Rao and Anderson,
1992; Huang, 1997]. However, the etiology of liver dis-
ease remains unknown in about 4-23% of dialysis pa-
tients [Rao and Anderson, 1992; Huang, 1997]. Ap-
proximately 10-20% ofnon-A-E hepatitis cases remain
unidentified, suggesting the existence of additional vi-
ral agents [Linnen et al. , 1996]. The recent identifica-
tion of GB virus C (GBV-C) [Simmons et al. , 1995] fol-
lowed by the identification of hepatitis G virus (HGV)
[Linnen et al ., 1996], are among possible transfusion
transmissible viruses currently being investigated for
human hepatitis of unknown etiology.
Whilst some studies did not show a direct association
between GBV-C/HGVinfection and liver pathology [Al-
ter et al ., 1997a, 1997b], other studies have reported a
spectrum of liver pathology [Mushahwar and Zucker-
man, 1998]. The site ofGBV-C/HGV infection and rep -
lication in the liver, peripheral blood mononuclear
cells, or other tissues have been observed by some in-
vestigators [Madejon et al. , 1997; Saito et al., 1997],
whilst other studies suggest that the actual site of
GBV-C/HGV replication remains to be identified
[Laskus et al ., 1997; Melior et al. , 1998]. There is con-
troversy about the relevance of GBV-C/HGV infection
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GBV-CIHGVInfection in KwaZulu Natal, South Africa
in fulminant hepatic failure [Heringlake et al ., 1996;
Toshiba et al. , 1996; Kanda et al ., 1997].
Only some 12-15% of chronic non-ABC hepatitis pa-
tients are GBV-CIHGV infected [Linnen et al. , 1996].
High prevalence of GBV-CIHGV has been found in sub-
jects with frequent parenteral exposure and in groups
at high risk of exposure to blood and blood products
[Jarvis et al., 1996; Linnen et al., 1996], including in- ,
travenous drug abusers [Aikawa et al. , 1996; Linnen et
al. , 1996], patients on maintenance haemodialysis [Ma-
suko et al. , 1996; Tsuda et al ., 1996; Lampe et al., 1997;
Shrestha et al., 1997; Wang et al., 1997; Murthy et al .,
1998] , multitransfused individuals [Linnen et al ., 1996;
Neilson et al ., 1996], and haemophiliacs [Jarvis et al .,
1996 ; Linnen et al ., 1996; Castelling et al ., 1998]. In
non-African countries, the highest prevalence of GBV-
CIHGV has been documented in patients with acute
and chronic HCV (18%) infection [Linnen et al ., 1996] .
The risk of GBV-CIHGV infection seems to be increased
in those eo-infected with HEV or HCV [Linnen et al .,
1996; Alter et al ., 1997a] . These results indicate that
GBV-CIHGV is transfusion transmissible, therefore
patients receiving 'blood transfusions, haemodialysis,
and organ transplant patients are at risk of infection.
Most GBV-CIHGV infections remain subclinical and re-
solve after the loss of serum GBV-CIHGVRNA with the
concomitant detection of antibodies to the putative en-
velope E2 protein (anti-GBV-CIHGV E2 ) [Dille et al. ,
1997; Tacke et al., 1997]. There is evidence to suggest
that anti-E2 is a neutralising and protective' antibody
[Hassoba et al ., 1998; Tillmann et aI., 1998] .
Very little is known about the epidemiology and
pathogenic role of GBV-CIHGV in Southern Africa
[Lightfoot et al., 1997; Mphahlele et al. , 1997; Tucker et
al., 1997; Castelling et al ., 1998]. Because GBV-CIHGV
is transmitted parenterally, we screened for the pres-
ence GBV-CIHGV RNA and anti-E2 in a high-risk
population of haemodialysis and chronic liver disease
patients and a representative sample of blood donors
(from four racial groups) in the province of KwaZulu
Natal, South Africa. The aim of the study was also to
determine an association, if any, between GBV-CIHGV
infection and liver disease.
METHODS
Patients
The study population included 70 patients with
chronic renal failure who were undergoing mainte-
nance haemodialysis and 98 consecutive patients with
chronic liver disease. As a control group, 232 adult un-
paid volunteer blood donors were studied from the four
racial groups (Africans, Indians, Whites, and "Col-
oureds" [persons of mixed originl ), Patients gave writ-
ten, informed consent, and the study was approved by
the Ethics Committees of the University and the Natal
and Blood Transfusion Services.
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Serological Assays
Sera were tested for serological markers for HBV
(HBsAg, HBeAg) by commercial radioimmunoassay
(RIA; Abbott Laboratories, North Chicago, IL). Anti-
bodies to the putative envelope protein (E2) of GBV-C/
HGV were determined by enzyme-linked immunosor-
bent assay (ELISA) "IJ. Plate Anti-HGenv" (Boehringer
Mannheim, Germany) according to the manufacturer's
instructions. Liver enzymes and liver function tests
were carried out by routine multianalysis systems in
the central laboratory.
RNA Extraction and Reverse Transcription
HCV and GBV-CIHGV viral RNA were extracted and
purified from serum with a QIAmp Viral RNA Kit (Qia-
gen, Gmbh, Germany). Complementary DNA (cDNA)
was synthesized from 10 IJ.I of extracted RNA melted at
70°C for 10 min and added to 15 IJ.I of a mix containing
1.5 IJ.M pd(N)6 random hexamers (Pharmacia Biotech,
Uppsala, Sweden), 5x first strand buffer (50 mM Tris-
HCl [pH 8.3]; 40 mM KCI; 6 mM MgC12; 1 mM DTT)
(GibcoBRL, Technologies, Paisley, UK); 250 U M-MLV
reverse transcriptase (GibcoBRL) , 0.5 mM dNTPs (Pro-
mega, Madison, WI), and diethylpyrocarbonate
treated-Hjf) and incubated at 37°C for 1 hr. The reac-
tion was terminated by incubation at 95°C for 10 min.
HCV RNA Detection
The presence ofHCV RNA in serum was determined
by reverse-transcription nested polymerase chain reac-
tion (RT-PCR) using primers from the 5' NCR region,
as described previously [Brown et al ., 1992] .
GBV-CIHGVRNA Detection
Highly conserved nested primers using published se-
quences from the 5' NCR ofGBV-CIHGV genomes were
used to carry out the nested PCR [Jarvis et al. , 1996].
Briefly.fi IJ.I of the cDNA were added to 95 IJ.I of a first
round PCR mix containing 0.2 mM dNTPs (Promega);
10x PCR buffer (1.5 mM MgC12, 20 mM [NHJ2S04; 75
mM Tris-HCl [pH 9.01; 0.01% Iw/vl Tween) (Advanced
Biotechnologies, Surrey, UK); diethylpyrocarbonate
(DEPC)-H20, 2.5 U Thermoprine plus DNA Polymerase
(Advanced Biotechnologies) and 50 pmol of each primer
located at positions 108 (5'-AGGTGGTGGATGGGT-
GAT-3' ; sense, outer) and 531 (5'-TGCCACCCGCCCT-
CACCCGAA-3'; antisense, outer) (Oswald DNA Ser-
vices , Southampton, UK). Two microliters of the first-
round PCR product were added to 48 IJ.I of PCR mix
containing 0.2 mM dNTPs (Promega); 10x PCR buffer;
DEPC~H20, 2.5 U Thermoprine plus DNA Polymerase,
and 50 pmol/ul of each primer located at positions 134
(5'-TGGTAGGTCGTAAATCCCGGT-3' ; sense, inner)
and 476 (5'-TGRGCTGGGTGGCCYCATGCWT-3 ' ; an-
tisense, inner). Amplification was over 25 cycles for
both first and second rounds for PCR, using the follow-
ing temperatures: 96°C 1 min, 50 aC 1 min, 72°C 2.5
min, with a final extension at 72°C 10 min followed by
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TABLE I. Demographic and Biochemical Features in Blood Donors (n = 232) With and
Without GBV-CIHGVInfection
GBV-CIHGV' GBV-CIHGV-
Blood donors Mean ± SD (Range). Mean ± SD (Ran ge) P
African (n = 76) (n = 29) (n = 47)
ALT (UIL) 17.24 ± 11.40 (9-69) 15.68 ± 6.6 (5-45) NS
Age (years) 32.10 ± 10.06 (19-48) 28.38 ± 10.53 (18-59) NS
Sex (M:F) 8.6:1 4.2:1 NS
Asian (n = 52) (n = 2) (n = 50)
ALT (UIL) 16.5 ± 2.12 (15-i8) 23.48 ± 16.82 (7- 92) NS
Age (years) 47.0 ± 7.07 (42- 52) 30.68 ± 12.09 (17-67) NS
Sex (M:F) 1:1 11.5:1 NS
White (n = 49) (n = 11) (n = 38)
ALT (UIL) 24.45 ± 11.64 (11- 54) 23.76 ± 13.83 (8-63) NS
Age (years) 40.27 ± 9.71 (19-53) 39.32 ± 15.19 (17-67) NS
Sex (M:F) 2:0 2.25:1 NS
Coloured (n = 55) (n = 2) (n = 53)
ALT (UIL) 12.5 ± 2.12 (11- 14) 19.06 ± 12.51 (5-73) NS
Age (years) . 19.0 ± 1.41 (18-20) 31.23 ± 12.46 (17-68) NS
Sex (M:F) 2.67:1 1.9:1 NS
GBV-C, GB virus C; HGV, hepatitis G virus; ALT, alanine aminotransferase; NS, not significant. cei-
oured, persons of mixed origin .
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a 4°C soak. Known positive and negative GBV-CIHGV
sera together with DE PC-H20 were included in each
run. The 344-bp PCR product was detected in 2% aga-
rose gel prepared in Lx TBE buffer stained with ethid-
ium bromide (10 mg/ml),
Statistical Analysis
Blood donor, haemodialysis, and chronic liver dis-
ease patients' data were analysed separately. The chi-
square test was used to compare groups (GBV-CIHGV
positive vs. GBV-CIHGV negative) with respect to cat-
egorical data, and Student's t-test was applied to con-
tinuous data. Analysis of covariance was used to com-
pare GBV-CIHGV-positive and GBV-CIHGV-negative
patients with respect to liver function test, adjusting
for age, sex, and disease group. Multiple logistic regres-
sion was used to determine any confounding influence .
of age, sex, and disease group on GBV-CIHGV. Blood
donors were compared with patients with chronic liver
disease and haemodialysis patients with regard to de-




Of the 2.32 unpaid volunteer blood donors 76 (32.8%)
were African, 49 (21.1%) Whites, 52 (22.4% ) Asians,
and 55 (23.7 %) Coloureds. All the blood donors were
negative for HCV, HBV, and human immunodeficiency
virus (HlV). None of the donors had a history or clinical
evidence of liver disease. Overall, GBV-CIHGV RNA
was detected in 44 of 232 (18.9%) blood donors (29/76
[38.2%] African, 2/52 [3.8%] Asian, 2/55 [3.6%] Col-
oured, and 11/49 [22.4%] White) (Table D. There was
no significant difference in the prevalence of GBV-C/
HGV RNA between Asian and Coloured blood donors
(P = .81) and between African and White blood donors
(P = .07 ). However, there was a significant difference
in the prevalence of GBV-CIHGV RNA between the
other racial groups (Asians vs. Whites [P < .005];
Asians vs . Africans [P < .00001; Coloureds vs. Whites
[P < .005 ) and Coloureds vs. Africans [P < .00001]).
Among the 70 haemodialysis patients, there were 30
(42.9%) Africans, 29 (42.4%) Asians, 3 (4.3%) Col-
oureds, and 8 (11.4%) Whites. Seventeen (17) of 70
(24.3%) haemodialysis patients (5/30 [16.7%] Africans;
8/29 [27.6%] Asians; 1/3 [33%] Coloureds; and 3/8
[11.43%] Whites) were infected with GBV-CIHGV (95%
confidence interval [Cl] = 5.7%; 18.7%). GBV-CIHGV-
positive patients tended to have a longer duration of
dialysis (not significant) and have had more transfu-
sions (P = .03) than noninfected patients (Table m.
Four of 70 patients (5.7%) were infected with HCV but
only 2/17 (11.76%) GBV-CIHGV-positive patients were
eo-infected with HCV.
Most of the patients with chronic liver disease were
Black [88 Africans (90%), 7 Asians (7%), 2 Coloureds
(2%), and 1 White (1%)]. The diagnosis of chronic liver
disease was confirmed by histology in 81 patients and
by peritoneoscopy alone in 17 patients. The etiology of
chronic liver disease in most of the patients was due to
alcohol abuse, viral infection, or a combination of the
two . In 5 patients, chronic liver disease was due to
autoimmune liver disease and in 7 it was cryptogenic.
None of the patients gave a history of blood transfu-
sions or intravenous drug abuse. The prevalence of
GBV-CIHGV RNA in patients with chronic liver dis-
ease was 12.2% (12/98) (95% Cl = 5.7%; 18.7%) (Table
m. Only 2 of 10 patients with HBV were eo-infected
with GBV-CIHGV. GBV-CIHGV RNA was detected
more frequently in patients with an alcoholic etiology
alone (6/56 [11%]) or in combination with alcohol and
HBV (1/10 [10%]) or alcohol and HCV (1/4 [25%]). Two
of seven (29%) patients with cryptogenic liver disease
were GBV-CIHGV RNA positive.
There was no significant difference in the prevalence
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TABLE Il. Demographic and Biochemical Features of ChronicLiver Disease and
Haemodialysis Patients With and Without GBV-CIHGV Infection
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GBV-CIHGV+
Mean ± SD (Range)
GBV-CIHGV-
Mean ± SD (Range) p
Chronic liver disease
(n = 98) tn. = 12) (n = 86)
Age (years) 45.7 ± 15.9 (18-75) 44.8 ± 16.8 (2-81) NS
Sex (M:F) 1.4:1 1.2:1 NS
T-Bil (umol/L) 68.6 ± 73.4 (7- 235) 63.3 ± 83.3 (7- 506) NS
ALP (UIL) 197.0 ± 163.29(18-576) 173.8± 143.41 (3-838) NS
AST (UIL) 92.2 ± 48.4 (23- 173) 154.6 ± 350.6(14-2454) NS
Haemodialysis (n = 70) (n = 17) (n = 53) .
Age (years) 38.17± 12.06 (17-65) 39.57± 12.76(15-67) NS
Sex (M:F) 1:0.8 1:0.8 NS
Dialysis (months) 76.23± 50.90 (12- 180) 59.60 ± 54.82 (3-216) NS
TRANSF (no.) 12.58± 7.79 (5-31) K07 ± 7.17 (2-30) .03
AST (UIL) 14.88± 5.33 (6--28) 18.60 ± 13.22 (6--90) NS
ALT (UIL) 12.58 ± 6.97 (5-32) 17.92 ± 18.24 (4-101) NS
ALP (UIL) 132.58± 146.39(36-667) 107.11 ± 131.50(5-920) NS
T-BIL (umol!L) 11.94± 2.22 (8-17) 11.32 ± 2.25 (5-17) NS
GBV-C, GB virus C; HGV, hepatitis G virus; TRANSF, transfusion; AST, ~paz::ate aminotr~.ferase;
ALT, alanine aminotransferase; ALP, alkaline phosphatase; T-BIL . total bilirubm; NS, not significant,
of GBV-CIHGV RNA between blood donors and pa-
tients. There was a significant difference in the preva-
lence of GBV-CIHGV RNA between with chronic liver
disease (12/98; 12.2%) and haemodialysis patients (17/
70; 24 .2%) (P = .04).
Anti-E2
There was a higher prevalence of anti-E2 in African
blood donors (21/76; 27.6%) than White (14/49; 8.2%),
Coloured (7/55; 12.7%), or Asian (3/52; 5.7%) blood do-
nors (Table lID, and this difference was significant (P <
.05). There was a significant difference (P < .05) in the
prevalence of anti-E2 in chronic liver disease (32/98
[32.7%]), and haemodialysis patients (18170 [25.7%])
compared with blood donors (35/232 [15.1%]) (Table
lID. There was no significant difference in anti-E2 se-
roprevalence between chronic liver disease and haemo-
dialysis patients (P = .33).
African blood donors (45/76; 59.2%) had a greater
exposure to GBV-CIHGV infection (RNA and/or anti-
E2 positive) compared with White (15/49; 30.6%; P =
.002), Coloured (9/55; 16.4%; P < .00001), and Asian
(5/52; 9.6%; P < .00001) blood donors. There was a sig-
nificant difference (P < .05) in the overall exposure to
GBV-CIHGV (RNA and/or anti-E2 positive) between
blood donors (31.9% [74/232]) and patients (43.9% [49/
98] vs . 47.1% [33170]), respectively (Table lID. GBV-C/
HGV RNA and anti-E2 were mutually exclusive in al-
most all (88-100%) patients and blood donors. GBV-C/
HGV RNA and anti-E2 was positive simultaneously in
only 1/98 (1.1%) patients with chronic liver disease,
2/70 (2.9%) haemodialysis patients, and in 5/232 (2.2%)
blood donors.
Liver Biochemistry
Elevated alanine aminotransferase (ALT) levels
were observed in only 2170 (2.85%) dialysis patients.
Mildly elevated ALT levels were observed in 6/232
(2.6%) blood donors. Only 1/44(2.3%) GBV-CIHGV-
positive donors had a mild elevated ALT level (69 VII,).
Using multivariate ·analysis and controlling for the in-
fluence of confounding factors (age, sex, and disease
groups), no significant differences were observed be-
tween GBV-CIHGV infected and noninfected blood do-
nors in each of the four racial groups (Table D, nor were
such differences observed in patients with chronic liver
disease and haemodialysis patients (Table m.
DISCUSSION
Although the study population may not be represen-
tative of the overall prevalence of GBV-CIHGV in Kwa-
Zulu Natal, the results indicate that there is a high
prevalence ofGBV-CIHGV infection in KwaZulu Natal,
South Africa and that there are racial differences in the
prevalence of GBV-CIHGV infection. The overall preva-
lence of GBV-CIHGV RNA in blood donors in the prov-
ince of KwaZulu Natal (18.9%) is higher than that of
blood donors in Gauteng (11.1%) [Castelling et al .,
1998], with the prevalence being higher among African
(38%) and White (22%) blood donors in KwaZulu Natal
compared with African (29%) and White (8,5%) blood
donors in Gauteng [Castelling et al., 1998). Tucker et
al. [1997] reported a GBV-CIHGV RNA prevalence of
6.3% in a predominantly Coloured rural community in
the Eastern Cape that was higher than the 4% of Col-
oured blood donors infected with GBV-CIHGV in Kwa-
Zulu Natal. However, volunteer blood donors represent
a healthier population than rural communities.
The prevalence of anti-E2 in healthy blood donors
ranges from 2.7% to 20.3% in different parts of the
world [Dille et al ., 1997; Tacke et al. , 1997; Ross et al.,
1998]. The overall anti-E2 prevalence in the blood do-
nor population (14.9%) was lower than the 20.3% re-
ported by Ross et al. [1998] for South African blood
donors . However, Ross et al. [1998] did not define the
racial breakdown of the blood donor population, and
our results indicate a racial difference in anti-E2
prevalence. The lower prevalence of viraemia (3.8%)
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TABLE ill. GBV-CIHGV RNA and Anti-E2 Seroprevalence Among Blood Donors and Patients on Maintenance
Haemodialysis or With Chronic Liver Disease
GBV-CIHGV GBV-CIHGV GBV-CIHGV GBV-CIHGVexposure
Study RNA" anti-Ez" RNA and anti-Ez" fu~A and/or anti-Ez"
population No. (%) (%) (%) (%)
Blood donors
African 76 29 (38.2) 21 (27.6) 5 (6.5) 45 (59.2)
White 49 11 (22.4) 4 (8.2) 0 (0) 15 (30.6)
Asian 52 2 (3.8) 3.(5.7) 0 (0) 5 (9.6)
Coloured 55 2 (3.6) 7 (12.7) 0(0) 9 (16.4)
Total 232 44 (18.9) 35 (15.1) 5 (2.1) 74 (31.9)
Chronic liver disease 98 12 (12.2) 32 (32.7) 1 (1.0%) 43 (43.9)
Haemodialysis 70 17 (24.3) 18 (25.7) 1 (2.9) 33 (47.1)
GBV-C, GB virus C; HGV, hepatitis G virus; Coloured, persons of mixed origin.
and anti-E2 response (5.7%) in the Asian blood donors
compared with other racial groups is in agreement with
the low prevalence of anti-E2 (2.7-6.3%)in Asian coun-
tries [Ross et al., 1998] and reflects the infrequent ex-
posure to GBV-CIHGV in this community. Anti-E2
prevalence in potential risk groups was higher (25.7%
vs. 32.7%) than in blood donors (15.1%) (P < .05). Con-
current detection of viraemia and seropositivity was
seen in only 2-3% of our study population. This low
rate probably indicates an overlap between E2 serocon-
version and presence of viraemia [Dille et al., 1997;
Tacke et al., 1997]. It may be possible that at the time
.of testing these patients were still viraemic and in the
process of seroconversion. Viraemia and seroreactivity
was almost mutually exclusive. The combined overall
exposure of GBV-CIHGV infection in African blood do-
nors (59.2%) was higher compared with 46.7% (PCR +
anti-E2) reported in a West African population [Dille et
al., 1997] . GBV-CIHGV infection appears to be a com-
mon infection in our community.
There is a higher prevalence of GBV-CIHGV infec-
tion in apparently healthy individuals in African coun-
tries (10-40%) [Dawson et al., 1996; Dille et al ., 1997;
Mphahlele et al ., 1997; Tucker et al. , 1997; Castelling
et al., 1998], with infection occurring more commonly
during childhood [Mphahlele et al., 1997], compared
with blood donor groups in non-African countries (1-
4%) [Linnen et al., 1996; Masuko et al., 1996; Moaven
et al., 1996; Alter et al ., 1997b; Roth et al. , 1997; Wang
et al. , 1997]. The reason for the high prevalence of
GBV-CIHGV in blood donors worldwide and basis for
the racial differences in GBV-CIHGV infection in the
South African blood donor populations is not known.
Racial differences in the prevalence of HAV [Sathar et
al ., 1994], HBV [Dusheiko et al. , 1989), and HCV [Soni
et al., 1993] infections due to differences in socioeco-
nomic factors in South Africa is well documented.
Whether this difference holds true for GBV-CIHGV is
not known, although a relationship was noted between
GBV-CIHGV infection and the lack of waterborne sew-
age [Tucker et al., 1997]. The differences in the preva-
lence of detecting GBV-CIHGV infection may be due to
the differences in the sensitivity of the various PCR
protocols and primers (derived from various regions of
the genome) used by various investigators. The nested
PCR used in this study is likely to contribute to an
increase in the sensitivity of the assay as compared
with the one step PCR procedures. In addition the test-
ing of anti-E2 greatly extends the ability ofRT-PCR to
define the epidemiology of GBV-CIHGV.
In this study, most haemodialysis patients and blood
donors, including those with GBV-CIHGV infection,
had normal liver enzymes. The high prevalence of
GBV-CIHGV in blood donors and haemodialysis pa-
tients without biochemical evidence of liver damage
suggests that many patients are viraemic in the ab-
sence ofliver disease. However, normal ALT levels do
not prove definitely normal histology, as shown for
HCV infection [Alberti et al ., 1991]. No significant dif-
ference was observed between GBV-CIHGV RNA-
positive and -negative patients. More recently, no as-
sociation was reported between GBV-CIHGV and he-
patocellular carcinoma in Black South Africans
[Lightfoot et al., 1997]. The prevalence ofHCV in hae-
modialysis patients (4/70; 5.7%) and in patients with
chronic liver disease (6/98; 6.1%) in KwaZulu Natal is
similar to that reported previously (4.8%) and confirms
the low prevalence of HCV [Soni et al. , 1993].
In non-African countries, the mode of transmission of
GBV-CIHGV occurs parenterally and is considered to
be similar to HCV [Linnen et al ., 1996]. In this study,
GBV-CIHGV-infected dialysis patients tended to have
had more transfusions and a longer duration of dialysis
than noninfected patients. Therefore, most patients on
maintenance haemodialysis acquired their GBV-C/
HGV infection through the transfusions they received
[De Lamballeric et al. , 1996; Masuko et al. , 1996;
Tsuda et al. , 1996; Lampe et al., 1997; Shrestha et al.,
1997; Wang et al., 1997; Castelling et al., 1998; Murthy
et al. , 1998]. The absence of a history of blood transfu-
sions and intravenous drug abuse in patients with
chronic liver disease, in addition to the high prevalence
ofGBV-CIHGV in blood donors and in rural communi-
ties, especially in African children, tends to suggest
that GBV-CIHGV is being transmitted by as yet unde-
fined nonparenteral routes in South Africa. Both ver-
tical [Feucht et al., 1996] and sexual [Ibanez et al .,
1998; Scallan et al., 1998] transmission ofGBV-C/HGV
has been suggested. HBV infection is endemic amongst
the African population of South Africa and the risk of
horizontal transmission of HBV is well recognised
[Dusheiko et al ., 1989]. Whether the association of
GBV-CIHGV Infection in KwaZulu Natal, South Africa
GBV-CIHGV with HBV implies that GBV-CIHGV
might spread by sexual or prenatal routes cannot be
determined by this study and would require a more
comprehensive epidemiological study to elucidate the
high prevalence of GBV-CIHGV in our population.
Although histochemical and hybridisation studies of
liver biopsies to detect GBV-CIHGV were not under-
taken in this study, the higher prevalence of GBV-C/
HGV in blood donors and patients with chronic liver
disease and the lack of elevation in liver enzymes as
well as clinical hepatitis in blood donors and haemodi-
alysis patients would suggest that GBV-CIHGV may
not be associated with liver disease.
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Abstract
Phylogenetic analysis of the 5' non-coding region (5'NCR) sequences has demonstrated that GB virus Cfhepatitis
G virus (GBV-CjHGV) can be separated into three major groups that correlate with the geographic origin of the
isolate. Sequence analysis of the 5'NCR of 54 GBV-C/HGV isolates from 31 blood donors, 11 haemodialysis patients
and 12 patients with chronic liver disease suggests the presence of a new variant of GBV-CjHGV in the province of
KwaZulu Natal, South Africa. Eleven isolates grouped as group I variants (bootstrap support, 90%) found
predominantly in West and Central Africa, a further six isolates grouped as group 2 variants (bootstrap support,
58%) found in Europe and North America; five of which grouped as 2a (bootstrap support, 91%) and one as 2b
(bootstrap support, 87%), the latter also includes isolates from Japan, East Africa and Pakistan. Although the
remaining 37 GBV-CjHGV isolates were more closely related to group 1 variants (bootstrap support, 90%), they
formed a cluster, which was distinct from all other known GBV-CjHGV sequences. None of the South African
isolates grouped with group 3 variants described from Southeast Asia . Three variants of GBV-CjHGV exist in
KwaZulu Natal: groups 1,2 and a new variant, which is distinct from other African isolates. © 1999 Elsevier Science
B.V. All rights reserved.
Keywords: Hepatitis GBV-CjHGV; Sequence and phylogenetic analysis; 5' Non-eoding region (5'NCR); South Africa
* The Genbank Accession numbers of the sequences re-
ported here are AF 172501-AF 172554.
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Congella, 4013 South Africa. Tel.: + 27-31-2604236; fax: +
27-31-2604420.
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1. Introduction
The clinical significance of human infection
with the recently identified f1.avivirus, GB virus-C
(GBV-C) (Simons et al., 1995) also called hepatitis
0168-1702/99/$ - see front matter © 1999 Elsevier Science RV. All rights reserved.
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G virus (HGV) (Linnen et al., 1996) is currently
unclear (Mushahwar and Zukerman, 1998). Al-
though originally proposed as an agent of hepati-
tis a direct association with liver pathology is still
lacking (Alter et al., 1997a,b), and it is not yet
clear as to whether GBV-CjHGV is indeed a
hepatotropic virus (Laskus et al., 1997; Miyakawa
and Mayumi, 1997; Mellor et al., 1998). Only
some 12-15% of chronic non-A, B, C hepatitis
cases are GBV-CjHGV infected (Alter and Bra-
dley, 1995). High prevalences of GBV-CjHGV
have been found in subjects with frequent par-
enteral exposure and in groups at high risk of
exposure to blood and blood products (Jarvis et
al., 1996; Linnen et al., 1996), including intra-
venous drug abusers (IVDA) (Linnen et al., 1996),
patients on maintenance haemodialysis (Masuko
et al., 1996), multitransfused individuals (Linnen
et aI., 1996) and haemophiliacs (Jarvis et al.,
1996). There is some controversy about the rele-
vance of GBV-CjHGV infection in fulminant hep-
atic failure (Heringlake et aI., 1996; Toshiba et al.,
1996; Kanda et al., 1997).
Attempts to genotype GBV-CjHGV based on
sequence analysis of the NS3 (Kao et al., 1996;
Tsuda et al., 1996; Pickering et al., 1997) and
NS5A (Viazov et al., 1997) genomic regions have
been unsuccessful. However, sequence analysis of
5' non-coding region (5'NCR) has provided evi-
dence that GBV-C/HGV can be separated into
three major groups that correlate with the geo-
graphic origin of the isolates (Muerhoff et al.,
1996, 1997; Smith et aI., 1997). Group 1 is preva-
lent in West and Central Africa, group 2 in Eu-
rope and North America, but also includes
isolates from Japan, Pakistan and East Africa and
group 3 in Southeast Asia. In addition, group 2
can be subdivided into groups 2a and 2b; the
sub-division of group 1 is less certain (Muerhoff
et aI., 1997).
It has been suggested that GBV-CjHGV may
have originated in Africa (Tanaka et al., 1998).
Very little is known about the molecular epidemi-
ology and pathogenic role of GBV-CjHGV in
southern Africa (Castelling et al., 1998; Lightfoot
et aI., 1997; Tucker et al., 1997). Since analysis of
the 5'NCR is considered to be predictive of the
classification of GBV-CjHGV into the three or
more major groups displayed by sequence analysis
of the complete genome (Muerhoff et aI., 1996,
1997; Smith et al., 1997), we determined the nucle-
otide sequences of the 5'NCR region of GBV-Cj
HGV isolates from 31 blood donors (KZN
Bl-B3l), 11 haemodialysis patients (KZN Dl-
D11) and 12 patients with chronic liver disease
(KZN Ll-Ll2) from the province of KwaZulu
Natal (KZN) in South Africa. The sequences were
then compared by phylogenetic analysis with pub-
lished sequences to establish their phylogenetic
relationship with GBV-C/HGV isolates from
other geographic regions of the world.
2. Materials and methods
2.1. Patients
Sera from individuals previously shown to be
infected with GBV-CjHGV were used as a source
of viral RNA (Sathar et al., 1999). Tliey included
17 of 70 (23%) patients with chronic renal failure
who were undergoing maintenance haemodialy-
sis,12 of 98 (12.2%) consecutive patients with
chronic liver disease and 44 of 232 (18.9%) adult
volunteer blood donors from the four racial
groups (Africans, Indians, Whites and 'Coloureds'
[mixed origin]) in the province of KwaZulu Natal,
South Africa. Patients gave written, informed
consent, and the study 'was approved by the
Ethics Committee of the University of Natal.
2.2. Detection of GBV-C /HGV RNA
GBV-CjHGV viral RNA was extracted from
sera with a QIAmp Viral RNA Kit (Qiagen,
Gmbh, Germany) with modifications (Marshall et
aI., 1998). Complementary DNA (cDNA) was
synthesised from 10 Jll of extracted RNA at 37°C
for 1 h using Moloney murine leukaemia virus
reverse transcriptase (M-MLV-RT) (Gibco-Rl.,
Paisley, UK) and 1.5 JlM pd (N) 6 random hex-
amers (pharmacia Biotech, Uppsala, Sweden).
Highly .conserved nested primers using published
sequences (Jarves et aI., 1996) from the 5'NCR of
GBV-CjHGV genomes were used to perform the
nested PCR. Briefly,S ul of the cDNA was added
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to 95 III of a first round PCR mix containing: 0.2
mM dNTPs (Promega, Madison, USA); 10 x
PCR buffer (1.5 mM MgCI1, 20 mM [NH4hS04,
75 mM Tris-HCl [pH 9.0]; 0.01% (wjv) Tween
20) (Advanced Biotechnologies, Surrey, UK); di-
ethylpyrocarbonate treated water (DEPC-H10),
2.5 U Thermopriner'" DNA polymerase (Ad-
vanced Biotechnologies, Surrey, UK) and 50 pmol
of each primer located at positions 108 (5'-AG-
GTGGTGGATGGGTGAT-3'; sense, outer); and
531 (5'-TGCCACCCGCCCTCACCCGAA-3';
antisense, outer) (Oswald DNA Services,
Southampton, UK). Two microlitres of the first
round PCR product was added to 48 III of a PCR
mix containing: 0.2 mM dNTPs ; 10 x PCR
buffer; DEPC-H10; 2.5 U Thermopriner''" DNA
polymerase and 50 pmol/ul of each primer located
at positions 134 (5'-TGGTAGGTCGTAAATCC-
CGGT-3 '; sense, inner) and 476 (5'-TGR-
GCTGGGTGGCCYCATGCWT-3'; antisense,
inner). Amplification was over 25 cycles for both
first and second rounds for PCR, using the fol-
lowing temperatures: 96°C for 1 min, 50°C'for 1
min, 72°C for 2.5 min with a final extension at
noc for 10 min followed by a 4°C soak. Stan-
dard precautions for avoiding contamination for
PCR were observed. Known positive and negative
GBV-C/HGV sera together with DEPC-H10 were
included in each run to ensure specificity. The 344
bp PCR product was detected in 2% agarose gel
prepared in 1 x TBE buffer stained with ethidium
bromide (10 mgjml).
2.3. Sequence analysis
Purification of the amplified products from the
PCR reactions were performed using the High
Pure PCR Product Purification Kit (Boehringer
Mannheim, Germany) according to the manufac-
turer 's instructions. Both strands of the 344 bp
PCR product were sequenced by direct cycle se-
quencing using the Perkin Elmer dRhodamine
Terminator Cycle Sequencing Kit (perkin Elmer,
Biosystems, CA, USA) on the Perkin Elmer Ge-
nearnp PCR system 2400 thermal cycler. The se-
quences were determined using an Applied
Biosynthesis Prism 310 Automated Genetic
Analyser (Perkin Elmer, Biosystems, 'CA, USA).
The sequences were analysed using the Sequence
Navigator Software (V.l.0.1). (Perkin-Elmer,
Biosystems, CA, USA). Nucleotide sequences
were aligned manually using the Sirnmonic 2000-
sequence editor package (P. Simmonds) (Fig. 1).
2.4. Phylogenetic analysis
Phylogenetic analysis of GBV-CjHGV se-
quences was carried out on a 311 base pair frag-
ment in the 5'NCR region (positions 160-470 in
the HGV type 2a clone, PNF2161 (Muerhoff et
aI., 1996». Sequences were compared using a
distance based method (p-distance at all sites fol-
lowed by neighbour joining) as implemented on
the MEGA package (Kumar et al., 1993). Ro-
bustness of grouping was assessed by bootstrap
re-sampling; numbers on branches indicate the
percentage of 500 'bootstrap replicates that sup-
ported the observed phylogeny (restricted to val-
ues of 75% or greater). p-Distances are indicated
on scale bar (Fig. 2). Sequences compared in-
cluded those of designated genotype for which
complete genomic sequences are available (Gen-
BankjEMBL accession numbers in parentheses).
These include the group 1 sequences, GBV-C
(U36380) and CG12LC (AB003291) which corre-
sponds to variants recently found in Central
African Pygmy populations, which are character-
ised by an insertion in the NS5 region (Tanaka et
al., 1998); group 2a sequences, PNF2161
(U44402) and R10291 (U45966); group 2b se-
quence GBV-C (EA) (U63715); group 3 sequences
GT230 (D90601) and GSI85 (D87262). The fol-
lowing sequences of unclassified genotypes were
also included: HGVC-964 (U75356) from China
and G05BD (AB003292) from Japan.
3. Results
Fifty-four of 73 (74%) GBV-C/HGV isolates
were sequenced, the remainder giving rise to faint
or poor nucleotide sequences. The 5'NCR se-
quences from 54 GBV-CjHGV isolates were
aligned for phylogenetic analysis with representa-
tive isolates from each group and are presented in
Fig. 1. The phylogenetic tree comparing sequences
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from the 5'NCR of our 54 isolates (31 blood
donors [KZN BI-31]; 11 haemodialysis patients
[KZN Dl-11] and 12 patients with chronic liver
disease KZN 1-12]) with isolates from other geo-
graphic regions is shown in Fig. 2. Using either
the full sequence, or only the first 200 nucleotides
in order to exclude regions that are variable but
do not correlate with the geographic origin of the
isolates (Smith et al., 1997), our isolates segre-
gated into three distinct phylogenetic groups
(groups 1, 2 and a new group) (Fig. 2).
The majority (37/54) of GBV·C/HGV se-
quences formed a cluster, which was distinct from
all other known GBV-C/HGV sequences, sup-
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GBV-C T=AGCCAC TATAGGTGGG =xAAGGGG AGGCTACGGT C=ITGCG CATATGGAGG AAAAGCGCAC GGTCCACAGG TG'l'TGG'l'CeT ==GT-A ATAAGGACCC
CG12LC •A. . 1' . •C.A G• .c . - .G .
KZN-02 •eT . TA.T. .1' . .C. A G• -
KZN-06 .A. .A.A. . A. G. -
KZN-07 . A. .c. ....c . •A G• .c . .. - . G•
KZN- 0 9 •A. . C. d . . A G. .C . - .G .
KZN-010 •TA. T. . C• •1'. . A. G• -
KZN-Bl •e CR. . CT . TA. T. . T. . C. A G. .-.
KZN-B1O .C . •1' • •C . . A G. . C . .-. .G •
KZN-B14 •eT .TA .T. . 1'• .A G• -
KZN-B20 . C . .1' . •C • •A G• .C. - . G.
KZN-B23 •C. • 1'• . C • •A G• . C . - .G .
KZN-Ll •A. . TA. .C • . 1'. G. -
~NF21 61 •A.A . 1'. . A. A• 1'. . 1'. . C. GC• •C.A c.cc. •C. . GG• .G .
Rl0291 •A.A .1' • •A.A• T. . 1' . .e . GC• •C. A G. CC. •C. oo . . GG• .G.
HGVC964 •C.T T • . TC.A . A. •1'. •T.GC • . C. A G• .. •C. .GG • . G•
KZN-Ol . A. A .. . . A. A. , . .. 1'. . C.GC • •C .A c.cc , •C . .G • .G •
KZN-03 •A.A . 1'• . A. A. T. . I. . C. GC• •C .A s.cc. •C. .G • .G .
KZN-B30 . A. A ....A .A. 1'. .1' . . C .GC • •C.A c. cc. •C . . G• . G•
KZN-B31 . 1'. . A. A . 1'• •A.A. T. .1' • . C.GC . .C . A s .cc. . C. . G. . G.
KZN-L12 •A. . A. A .1' • .A.A. T. .1' . •C.GC. . C. A G. CC• . C•• . G. .G .
GBV·C(EA ) •A .1' . .A.A• T. . 1'. . C. G• . C. A G.C . : •C. .GG • . G.
KZN- 05 .A . 1'• • A. T. . 1'. .C .G • •C .A G.C • •C. .GG• .G .
GSI85 . 1' 1'• . 1'• • A. . G. . T. G• •C.A G. ' CoO .-. .G •
G'l'230 . 1' T• .1' • •A. •G. . T. G• •C.A G• . C. . G. .G .
G05BO . A. I G• • I • •A. . 1'. . C. GC. .C • G• •C • .C . .G. .G.
KZN- B2 •A. •A.T • . C . G. . A G• .G .
KZN-B3 • RCCA . •A. . AAT • .ccc , . C. A G• .. .-.
KZN- B4 • OCR. .A. •A.T. . C. G• •A G• . G.
KZN-B5 .AAT. .CCG. . C. A G• •C . -
KZN- B6 •A. •AA! • . ecG • . C..~ G. . . .. .-.
KZN-B7 cr. •A. . A. T • •C .G • . A G. . G.
KZN-B8 •A. . AAT • .ccs . . C . A G. .- . ..
KZN-B9 •A. . AAT • .ccs, . C. A G. -
KZN- Bll •A. .AA• . CCG• •C. A G. C. . A. - ., . 1'.
KZN-B12 .. •A. . A. T• . C. G. .A G. .G •
KZN-B13 •A. •AIT • •ecG• . C• G. . C . . C. . G. . G.
KZN-B15 .. •A. .AIT• •ecG. . C. G• .C . •C. . G. .G •
KZN-B16 •A. . A. T • •C . G. . A G• : .G .
KZN- B17 •A. •AAT • . CCG• . C. A G. -
KZN- B18 •A. . AAT • .ecG• •C.A G. -
KZN- B19 .. •A. . A. T• .c.c. .A G. . . .G •
KZN-B21 .. . A. •A.T. .ecG• .c.x G. . GA•
KZN- B22 C. •A. . A. T• •C.G • .A G. .G.
KZN-B24 C. •A. .A . T• •C .G . .A G• . G.
KZN-B25 •A. . A. T • . e. G• •A. •A G• .G .
KZN-B26 . A. •AAT. . ecG• •C.A G• -
KZN- B27 •A. . A. T• .c .s. •A G• . C. .G .
KZN-B 28 . A. •A. T. . C. G. .A G• . G.
KZN-B29 • A. . A.T • . C .G. .A G. . G.
KZN-04 C. .. . A. . A. T• •C.G. •A G• . G•
KZN-08 ., oO .A . •A.T . .C .G • .." G. . G•KZN-Oll •A. .A.T • .c. s. . A G. .G .
KZN-L2 .A . C. . A. •A.T . . C. G• . A G. .. .. . G•
KZN-L3 . A. •A. . AAT • .ccc, .c. x G. -KZN-L4 . A. .A. . A. T. .ecG• •C.A G.C . .G.
KZN-L5 .K . : .A . •A.T . .ecG• . V. A G.C. . G.
KZN-!.6 .A. . A. •AAT . . CCG• . C. A G.
KZN-L7 .A . .A .T • •C.G .
.-.
.A G. .-.
KZN-L8 •A. .A . . AAT.
..
.ccs. •.•C.A G. -KZN-L9 . A. •A. . G• •A.I • . ecG• •C. A G.C . -KZN-L10 . A. •A. .AA• . ecG• •C.A G. C . .. .A . . 1'•.-.KZN-Lll . A. CT . •A. . A. T • .c .c, .A G. . G.
Fig . 1. Alignment of nucleotide sequences from the 5'NCR of GBV-C/HGV isolates from blood donors (B), haemodialysis (D) and
pa tients with chronic liver disease (L) from the province of KwaZulu Natal (KZN), South Africa. Sequences were compared with
GB V-e/HGV or representative variants of GBV·C/HGV (sources listed in Section 2). Symbols: ' .' , similar nucleotide to GBV-C; " ,
nucleotide not determined; and '-', gap introduced to preserve alignment.
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GBV- C GGCGCTAGGC lICGCCGTTAA 1\CCGl\=G = -TGGGCAAlICG ACGCCCi\CC>Z ACGGTCClICG rcccecrrcx AT= TG1\CCAATAG GCGTAG--CCCG12LC •C.:rc . .- • T • •C • . G. .T .C .-G•
KZN-D2 .rc . .- •CT. . T• --
KZN-D6 •T.- •T . .T • . - - .
KZN-D7 •A . •TC• .- • T • •C.T • .TATTAG•
KZK- D9 •1'.. • :rc • - C.. •G. •C.T• . TGTTAG•
KZN-D1O •A . • TAC• .- • T . . :rc • .-- .
KZN- B1 .rc, - : . CT . . T • --
KZN-B1O •A . C.T:rc • •C •C• .AAT.-- •
KZK- B14 •:rc . - •G• •CT . . T • .- - .
KZN- B20 •A . C. TIC • •C • C• .AAT--G•
KZN-B23 •A. C.T:rc • •C .c . .AAT .-- •
KZN-L1 • :rc.T • .- •T • .T.T.-- •
PNF216 1 . A. .zc. T . •T. •C. A • - -- .
RlO291 . A . •:rc . T • •T. . A • •C. G. .- •G. .T• .-- .
HGVC964 . A . • :rc . T• •T • .ft. •C. G. - •G.· • . T • 0 '-- '
KZN-D1 •:rc . T • • A. •C.A• - •T • •C• •G• . TA • •T-- •
KZN- D3 •A • •TC. T• •T • •CT.C.G. - .TT • •A-- •
KZN-B30 •A .ATC . TT.T • •C.TC.G. - . T . .TT • •T-- •
KZN-B31 . A. •TC. T• •T• •C.A. .- •C• •G• •TT • .T-- •
KZN- L12 . A . •TC. T• •T . •C• •C. A. - , . T • .-- .
GBV-c (l:A ) . A. •:rc . T •... •A. AC• •C. A. .- . T. T.-- •
KZN-DS . A . •:rc . T • •T. •A • CC• •C. A . .- . T. T . -- •'.
GSI SS . A. .TC . T . . T . •A •C. A• .- C.T.T .-G•
GTZ30 . A. . TC. T• . T. .A CCT.C.A. .- , .A •C. .T • .-- .
GOSBD •A. •:rc • T • •T. •T • .A• •A C. T .C .A• - . T .T .-- .
KZN-B2 . A . • :rc . T • •T . . AC• .- • T . •C• . C• 0' -- '
KZN-B3 .A. •:rc . T • •T • •A • :rc • .- . T • • T • •A • .T -G •
KZN- B4 . A . •TC. T• •T . •AC• - •C• . AAT. -- •
KZN- BS . A . •:rc . T• •T . •A . :rc • .- • T • .AAT.-- •
KZN-B 6 . A. •:rc . T• •T • •A •:rc • - • T • • T • .AG .T-G•
KZN-B7 •A. •:rc . T• •T • •l\C . - . C• .Al\C.-- .
KZN-BS •A • •TC. T• •T • •A •TC• .- •C• . T• 0 ' - - '
KZN-B9 . A . •:rc . .. T • •T • •1'. . TC. - • T • • T • .T-G•
KZN-B11 •A • •TC. T• •T • •A C• •l\C . - • T • -. .A.eA-G•
KZN-B1 2 . A . •TC. T • •T . •l\C • .- • C• . AAT. - - •
KZN- B13 . A . .rc. T• •T . •Y• • ' . • :rc • .- . CT • --
KZK- B1S . 1'.• • TC. T . . T . .. . 'l •• •:rc • - . CT • --
KZN-B1 6 . A. • :rc . T• •T . •l\C • - •C. T • .AAT.-- •
KZN-B17 .A. • :rc. T• .T . •A •TC• .- . 'l . .T-G.
KZN-B1S . A . •TC. T • •T • •A •TC• - •T • .C . T- G•
KZN- B19 •A . •:rc • T • •T • •l\C. - •C. T • .AAT .-- •
KZN- B21 . A . •TC. T • •T . .. •A .TC • .- • T • • T • . T- G•
KZN- B22 . A . • :rc . T• •T • •l\C. .- •C• .AAT.-- •
KZN- B24 •A • •TC. T • •T • •l\C . - •C• . AAT. - - •
KZN- B2S . 1'.. •TC. T • •T . .. •l\C. - ••T • . l\C • .. .-- .
KZN-B26 . A • • :rc . T. •T . '. ' •A . :rc • - •T • • T• .AG.T-G•
KZN-B27 . A . .rc , T• •T . •l\C. .- .T . •C• .C • 0 ' - - '
KZN-BZS .A. • :rc. T. •T • •l\C . .- •G. .C • .AAT.-- •
KZN-B29 . A • •TC. T. •T . . T. •l\C . .- •T. . C• .. . C• 0 '--'
KZN- 04 . A. • :rc. T • •T • •l\C. .- •C• . AAT . - - •
KZN-DS •A • • :rc . T • •T • •l\C. .- •G. . C. T• .AAT.-- •
KZN- D11 •A • •:rc . T • •T • •l\C . .- •C• .AA • . - - .
KZN-L2 •A • •:rc . T• •T • .. •l\C . .- •C• . AAT. -- •
KZN-L3 •A• •:rc . T. •T • •A . TC• .- •C• .T • • -G •
KZN-L4 •A. •TC. T • . T • •A •TC. - .C • •C• •G• .TT .TT-- •
KZN-LS •A. .!C. T• •T . •1'. • :rc . .- .C • .C • •G• .TT .TA-- •
KZN- L 6 •A • . !C . T. . T • •1'. •TC. - •G• . T• •A • . A- G•
KZN- L7 .A• . !C . .. T • •T . •l\C . - '" .C . .AAT .-- •KZN-LS •1'.• . !C . T . . T • •A •TC• - •C. . T • .-G•
KZN-L9 . A • . !C. T • •T. •1'. . rc , .- .G . .eAC.TG•
KZN- L1 O •A . . TC. T• •T . •A C• •l\C. - .T • . A . eA- G•
KZN-L11 • A. • TC. T • •T . • l\C • .- . C• . AAT . - - •
Fig. 1. (Continued)
ported by 88% of bootstrap replicates (Fig. 2).
Eleven isolates clustered as group 1, with a boot-
strap support of 90%. Six additional isolates clus-
tered as group 2 variants, five of which grouped
with 2a (bootstrap support of 91%) and one
(KZN D5) with 2b (bootstrap support of 87%).
Although this analysis did not strongly support
the groupings of groups 2a and 2b sequences
(58% of replicates), this analysis included the
group 3 isolate HGVC 964 which has previously
been shown to cluster with group 2 isolates upon
phylogenetic analysis of the 5'NCR (An et al.,
1997; Muerhoff et al., 1997; Smith et al., 1997).
Analysis of nucleotide 1-201 in this alignment
but excluding HGVe 964 produced very similar
results except that the bootstrap support for
group 2 isolates was increased to 75% (data not
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GBV-C GGCGAG:rIGA CAAGGACCAG TGGGGGCCGG GCGGGAGGGG GAAGGACCCC - CACCGCTGC CCTTCCCGGG GAGGC-GGGA AATGCATGGG GCCACCC
CG12LC .- .G . T.T.- . ~ - . CA. A. .GAR.-.
KZN-02 •AG. •ACT-. CAGTG-. . GA• - .T . . A•
KZN-06 - - .A .
KZN-07 . G. •C- . - . G• .GA. - . A.
KZN-09 . G. •C- . -. GT. .ACT . .CiA. .-. . A•
KZN-OIO •AA.-A. T.p. ·- TCTT. •T. .G.A.- . . A.
KZN-Bl . AG. •CT-.A. •T CAGTG-. • GA. - . T. . A• . A
KZN-BIO . G . GG. . T-. -. . A. . G• .-. . ACH
KZI'-B14 •AG. . CT-.C . •G -. .G. . GA. .-. .. .A •
KZN-B20 •G .G • ...•T-. •T -. . A• •G. .GC. . A•
KZN-B23 .G . G. . T• . T- . . T - . A• .G . •GC. . A•
KZN- Ll . A- . •T -. TT. . GA. - . A. .A
?NF216 1 •G.CT- T . .A .G. . T . M GT.-. C. •T .G.C.- .
RIC291 . G:rIT. T. M. .-. •C . GAC.- • .'.
HGVC964 •GTTTTT . M. ..-. ; •C . GAC .- .
KZN-Ol •G.TT .T . - A. Il.. C. •T . GA• - . A.
KZN-D3 . G. TC. T. -AGA. C. . C .G .C . - • . A.
KZN-B30 . G. TT.T . - Il.. A. C. •C . GAC.- . . A.
KZN-B31 . G.TC-T. . A . G. •T. M G. .-. . T . G. C. - • .A •
KZI'-L12 . G.CT-t . MGT. - . . T .G .C .- . . A. .MG
GBV-C(EA) ,G.T . -.A. . T CTeA.C . '! T . G. A. - .
KZN-OS .CiAC. - . C.G. .-. T .G.A. -. . A.
GSlBS . T.CC-Il.. -TGT.Il.• . T .G . . T- .
GT2aO . G. . T . •C-A . - 1'G"t• .T . GA. T- • . A.
GOSBO" •AC. T.A. . G. .T - . CGT. . T . GT. T- • • T.
KZI'- B2 . G . G. . G. CA- . CTGT. - . •GT. - .R . . AC.M
KZN- B3 .G . G. T. - . C. •T.- . •GA• T- • .A .
KZN-B4 •G .G . •G.CP.- • CTGT.-. : GT. - . A.
KZN- BS . A. . G. C. - • •A. . T. C.GT.- , •GA.T - . . A. . ACH
KZI'- B6 . G . A• .G .T A-. • G. CT.T . - . . GA.T-. .R. .ACH
KZI'-B 7 •G . G. . G. CA-. CTGT.- .C . . GT. - . R. . ACH
KZN- BB •G . G• . G.T. - . C• . T.- . . GA.T- . .A .
KZN-B9 . G . G. T.- . C• •T. - . . GA.T-. .R • .AMA
KZN-Bll •A. . G. CIl.- . CTG.T - . .GT .T - . . A.
KZN-B12 . G •G. •G. CA- . CTGT. - .C . . GT. - . R• .AC
KZN-B13 •AG. . G. T. •T. C• .-. .GA. .-. .ACMGM
KZN-B IS . AG. . G.T. .T . y ' .-. .GA. - .x ,
KZN-B16 . G . G. . G. CA- . CTGT. -. . G! . .-. •G . A.
KZN-B17 •G . G. T. - . C• . T.-. . GA.T - • .Il.•
KZN- BIB •G .A . •GCT.-. -.CATe. .GA.T- . . A.
KZN- B19 . G •G. •G.CA- • CTGT. - . . G!. - . G .x,
KZN- B21 • G . A• . G. T. - . crr .e- . . GA. - . A.
KZN-B22 . G .G • . G. CA- . CTGT.-. . GT. - .x,
KZN-B24 • G .G • . G. TA-. CTG. •- . C. . GT. - . Il.• . A
KZN-B25 . A. . G . G. . G. CA- . CTGT. - . . GT. - . A.
KZN-B26 . G . A• . G. TA- . CT.T . -. . GA.'l'- . .Il..
KZN- B27 •G •G• . G. CIl.- • CTGT. - . .GT. .-. .A •
KZN-B2B •G •G• . G.CP.- • CTGT.- . C. . G!. - .A.
KZN-B29 •G . G• . G. CP.- • CTGT. - . . GT. .- . .A •
KZN-IJ.4 . G .G • AG. 0 '-' C. CG.- . . GT. - . A.
KZN-DB •A.G . AG.CA- • •T. CTGT. - Te . .GT . - . A.
KZI'-Dll •G . G. . G. CA- . . Il. •T . CTGT. - . . G! . .-. . A.
KZN-L2 • G .G . AG.CP.- • CTG! .TAC. . GT. .-. . A. . A
KZN-L3 •G •G. . G.T.G• . A. - . A. C . .GA. T-. . Il.
KZN-L4 . G . G• CG.CA- • CTGT. - G. . GA.T - . .A
KZN- L5 •G •G• CG.CP.- • CTGT.-G. . GA. T- . .A. . ACH
KZN-L6 . G . A. .G .T • -.CP. . C. •T. .GA. T- • .x, . 1\
KZN- L7 •G •G• .G .CP.- • CTGT.- . .G!. .-. . A. .A
KZN-LB •G . G. . G. T.G • A. -. . A.C . . G. .GAAT- . . A
KZN-L9 .G .T . - • •A. .T. T.CA . C. . GA.'l'-. . A. . A
KZN-LIO . A. .G . CA. CTG.T- . •T. . GA.T- • .A. .1\
KZI'- Lll •G . G. AG. CP.- . . T . CTGT.-TC • . G!. .-. . A
Fig. 1. (Continued)
with that of isolate G05BD grouped separately
from sequences of group 1 and the new South
African sequences (bootstrap support 90%). None
of our isolates clustered with group 3 isolates
described from Southeast Asia. There was a high ,
degree of overlap in the ranges of distances be-
tween and within groups (data not shown). GBV-
CfHGV infects all racial groups in the province of
KwaZulu Natal, South Africa. The new variant of
GBV-CfHGV' seems to be more prevalent
amongst Africans than amongst Indians , Whites
or 'Coloureds' (Table 1).
4. Discussion
Several groups have examined the genetic varia-
tion in GBV-C/HGV by comparing sequences
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Race GBV-CjHGV groups
a 'Coloureds' : persons of mixed origin.
Table I
GBV-CjHGV groups according to race
provide an accurate guide to the relationship of
complete genome sequences. HGVC 964 is a
group 3 isolate based on the analysis of the com-
plete genome sequence (Takahashi et al., 1997)
'. but groups with group 2a isolates when analysis is
confined to the 5'NCR (An et al., 1997; Muerhoff
et al., 1997; Smith et al., 1997). Similarly, the
isolate G05BD appears to represent a distinct
phylogenetic group by analysis of the complete
genome sequence (Takahashi et al., 1997) but
groups with groups 2 and 3 sequences upon anal-
. ysis of the 5'NCR sequence (Simmonds and
Smith, unpublished results). In addition, the anal-
ysis of complete genome sequences do not provide
any evidence for the groupings as suggested by
our analysis of the 5'NCR sequences (Smith and
Simmonds, unpublished data) . Finally, the high
degree of overlap in the ranges of sequence dis-
tances between and within groups (data not
shown) does not permit the establishment of 'cut-
off' distances that define different groups or sub-
groups . Confirmation that the novel South
African variants described here comprise a new
grouping of GBV-CjHGV will require sequence
analysis of complete virus genomes.
Current information suggests that diversity
amongst African isolates of GBV-CjHGV is
greater than amongst the other major groupings,
consistent with the possibility that this virus may
have emerged in Africa (Tanaka et al., 1998).













from different segments of the GBV-C/HGV
genome. Analysis of complete genome sequences
suggests that GBV-C/HGV can be classified into
three groups based on pairwise distances greater
than 0.12 over the entire genome (Okamoto et al.,
1997) or into four or five groups based upon the
phylogenetic analysis of complete genome se-
quences (Takahashi et al., 1997). However, studies
with NS3, NS5A and envelope regions have been
unsuccessful or contradictory in defining groups
of GBV-CjHGV isolates (Kao et al., 1996; Muer-
hoff et al., 1997; Pickering et al., 1997; Viazov et
al., 1997; Lim et al., 1998). In contrast, analysis of
regions within the 5'NCR allows the discrimina-
tion of three major groupings that correlate with
the geographic origin of the isolates and with the
analysis of complete genome sequences (Muerhoff
et al., 199?, 1997; Smith et al., 1997). Based on
this assumption, phylagenetic analysis of the
5'NCR of our isolates identified three variants of
GBV-C/HGV in KwaZulu Natal, South Africa
with group 1 which is found predominantly in
West and Central Africa; group 2 which is found
in Europe and North America but also including
isolates from Pakistan, Japan and East Africa,
arid a new group of variants whose sequences are
different from all other known HGV jGBV-C se-
quences published to date. This new group is
supported by bootstrap analysis (88% of repli-
cates) and although they cluster with group 1
sequences (bootstrap value of 90%) they are dis-
tinct from any previously described African group
1 isolates (Muerhoff et al., 1996, 1997; Smith et
al., 1997).
These new South African variants were also
distinct from other GBV·CjHGV groups when
phylogenetic analysis was based on a shorter re-
gion of the 5'NCR previously shown to reproduce
the groupings observed for the complete genome
sequences (Smith et al., 1997) (data not shown).
However, recent evidence suggests that phyloge-
netic analysis of the 5'NCR may not always
Fig. 2. Ph~logeneti.c tree of GB.V-CjHGV 5'NCR sequences. A neighbour joining tree was constructed from p-distances between
representative published nUc1eotld~ sequences (GenBank{EMBL; accession numbers in parentheses) and from South African isolates
(KZN-KwaZulu Natal, South Afnca; KZN DI-Dll for haemodialysis patients, KZN Ll-Ll2 for CLD patients, KZN B1-B31 for
blood donors). Bootstrap values greater than 75% are indicated (500 replicates).
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the recent discovery of a virus closely related to
GBV-CjHGV infecting wild-caught chimpanzees
(Adams et al., 1998; Birkenmeyer et al., 1998). It
is possible that sequences detected in the current
study are a further reflection of the extensive
human population diversity in the southern area
of Africa.
Phylogenetic analysis of the 5'NCR sequences
of our isolates suggests that at least three groups
(groups 1, 2 and a new variant) of GBV-CjHGV
are present in the province ·of KwaZulu Natal,
South Africa.
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Phylogenetic analysis of GBV-C/hepatitis G virus
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Comparison of 33 epidemiologically distinct GBV-C/hepatitis G virus complete genome sequences
suggests the existence of four major phylogenetic groupings that are equally divergent from the
chimpanzee isolate GBV-Cuo and have distinct geographical distributions. These four groupings are
not consistently reproduced by analysis of the virus 5'-noncoding region (5'-NCR), or of individual
genes or subgenomic fragments with the exception of the E2 gene as a whole or-of 200-600
nucleotide fragments from its 3' half. This region is upstream of a proposed anti-sense reading
frame and contains conserved potential RNAsecondary structures that may be capable of directing
the internal initiation oftranslation. Phylogenetic analysis ofthis region from certain South African
isolates is consistent with previous analysis of the 5'-NCR suggesting that these belong to a fifth
group. The geographical distribution of virus variants is consistent with a long evolutionary history
that may parallel that of pre-historic human migrations, implying that the long-term evolution of
this RNA virus is extremely slow.
Introduction
The similarity in genome organization between GB virus-
Cjhepatitis G virus (GBV-CjHGV) and hepatitis C virus
(HCV) has led to the naive expectation that variation of these
closely related and persistent flaviviruses might also be similar.
However, our limited understanding of the causal reasons for
virus variability is underscored by the increasing evidence that
these viruses vary in quite different ways. Although both
viruses have a similar rate of nucleotide substitution during
persistent infection [0'4- 1'9 x 10-3 for HCV (Major et al.,
1999; Smith et al., 1997a; Okamoto et al., 1992; Ogata et al.,
1991), 0'4-2'4 x 10-3 for HGV (Khudyakov et al., 1997 ;
Nakao etal., 1997)], GBV-CjHGV lacksa hypervariable region
comparable to that present at the NH2 terminus of the HCV E2
I
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protein (Takahashi et al., 1997a; Nakao et al., 1997) and
observed ratios of synonymous to nonsynonymous sub-
stitution are higher for GBV-CjHGV (30 :1) than within HCV
subtypes (9 :1) although the latter are less divergent (Muerhoff
et al., 1997 ; Smith et al; 1997b). In addition, while different
genotypes of HCV differ by more than 30 %, the most extreme
GBV-CjHGV variants differ by only 14%. Previous studies
have identified three (Suzuki etal., 1999 ; Okamoto etal.. 1997),
four (Charrel et al; 1999) or five (Takahashi et 11.1., 1997b )
phylogenetic groupings of GBV-CjHGV, although some of
these groupings are weak and inconsistent between different
studies. However, whereas HCV genotypes can be dis-
tinguished by phylogenetic analysis of a variety of subgenomic
regions as smallas 222 nt, variants of GBV-CjHGV cannot be
reliably identified in this way. Systematic analysis of six
complete GBV-CjHGV genome sequences revealed that
congruent phylogenetic relationships were obtained for only a
minority of 300, 600 and 1200nt fragments, and that the
optimal region was all or part of the 5' -noncoding region (5' -
NCR) (Muerhoff et al., 1997; Smith et al. . 1997b).
At present 33 epidemiologically unrelated GBV-C HGV
-
complete virus genome sequences are available, including
three of group 1 and several isolates of uncertain relationship
to previously defined groupings. In addition, the recent
discovery of closely related chimpanzee viruses (Adams et al.,
1998) and the availability 0'£ a complete genome sequence
(GBV-Ctro) (Birkenmeyer et al., 1998) allows phylogenetic
trees to be constructed using a more appropriate outgroup. We
have therefore undertaken a re-analysis of the phylogenetic
relationships of GBV-CjHGV complete genome sequences,
the extent to which these can be reproduced by analysis of
subgenomic regions and the implications of virus geographical
variation for theories about its evolutionary history.
Methods
• Nucleotide sequences. Nucleot ide sequences were obtained from
GenBank and manipulated and aligned using Simmonic 2000 software (P.
Simrnonds. unpublished ). Nucleotide positions of aligned sequences are
numbered relative to the AUG codon at the beginning of the El gene
of the prototype isolate GBV-C (U36380 ; Leary et al.. 1996b). The 32
other epidemiologically unrelated complete genome sequences were
AB00328S-ABOO3293 (Takahashi et al.. 1997b), ABo13500 (Saito et aI.,
1999), AF104403 (Charrel et al., 1999), AB013501 (Konomi etal., 1999 ),
AF031829 (Bukh et al; 1998), D87255 (Shao et al., 1996), D90600,
D90601 (O karnoto et al.. 1997), U44402, U45966 (Linnen et aI., 1996 ),
U63715 (Erker et aI., 1996), AB008342 (Kaneko et aI., 1998), AF006500
(L. Lu et al., unpub lished), D87263 (Nakao et al., 1997), D8 nOS-D87715
(Katayama et al., 1998), U75356 (Y. S. Zhou and H. T. Wang unpub-
lished), U94695 (Wang etal..1997), AB01866 7 and AB02128 7 (H. Naito
& K. Abe, unpublished ), together with the outgroup AF070476 (GBV-
C,ro; Birkenmeyer et al., 1998). The partial sequence (positions -396 to
6118) of an additional isolate from Thailand (K-lO) was made available by
Sirirrug Songsivilai (personal communication), The boundaries between
genes were as given in Charrel et aI. (1999).
• Serum samples. Sera were collected from individuals from Papua
New Guinea, Sudan and The Gambia as part of population-based
hookworm or malaria surveys, from pregnant women in the Democratic
Republic of Congo (Mokilietal; 1999)and from blood donors from Saudi
Arabia. Sera from South Africa were as described previously (Sathar etal;
1999).
• PCR amplification of GBV-C/HGV genomes. RNA was ex-
tracted from plasma using a proteinase K-SDS lysis buffer (larvis et al;
1994). The 5' -NCR was detected by nested RT-PCR amplification using
the outer primers 5' TGCCA.CCCGCCCTCACCCGAA 3' (positions
-21 to -41) and 5' AGGTGGTGGATGGGTGAT 3' (- 443 to
-426), and the inner primers S' GGRGCTGGGTGGCCYCATG-
CWT 3' (- 76 to -97) and 5' TGGTAGGTCGTAAATCCCGGT
3' (- 415 to - 397). Amplification reactions were 30 cycles for each
round and consisted of 94 °C for 36 s, 55°C for 42 s and 72 °C for 90 s.
For samples that were PCR positive for the 5'-NCR [7/ 74 (9'4 %)
Papua New Guinea, 2/66 (3%) Sudan, 3/ 74 (4%) The Gambia and 1/48
(2%) Saudi Arabia], the E2 region was reverse transcribed and amplified
from RNA purified in a combined reaction using a standard buffer system
(Access PCR, Promega) according to the manufacturer 's instructions.
Two sets of primers were used to amplify adjoining regions of the E2
gene . Set 1 consisted of outer primers 5' GCCTCHGCCAGCTT.
CATCAGRTA 3' (1682- 1660) and 5' GGYAAYCCGGTGCGGTC.
VCCCYTGC 3' (1255- 1279), and inner primers 5' AAAYACAA.
-
ARTCCARVAGCARCCA 3' (1650-1627) and 5' TCCTACRCCA-
TGACCAARATCCG 3' (128&-1310). Amplification conditions were
30 cycles of 94°C for 18 s, 55°C for 21 s and 72 °C for 90 s. Set 2 con-
sisted of outer primers 5' ARCTYYGAACACCRSCGVACCAG 3'
(1499-1477) and 5' GCCASYTGYACCATAGCYGC 3' (979-998), and
inner primers 5' ACCCRAACGTYCCRGTBGGAGGC 3' (1375- 1353)
and 5' GTNGYBGAGCTSTYCGAGTGGGG 3' (1027- 1046).
The region of NS5A where duplications are observed in some isolates
(Tanaka et al., 1998) was amplified for 5'-NCR·PCR positive samples
from the Democratic Republic of Congo (n = 7), The Gambia (n = 4),
Sudan (n = 2) and Papua New Guinea (n = 8) using outer primers 5'
CACAATAGGCTGTATGGTTCTGG 3' (positions 6736-6714) and 5'
CCATCGCCWGCACTWATCTCGG 3' (positions 6409-6430), and
inner primers 5' TACRGARAGRGCCACRTTGAAGAC 3' (positions
6573-6550) and 5' ACNGAGAGCA:GCTCAGATGAG 3' (positions
6433-6453). Amplifications were started at 80 °C followed by 30 cycles
of 94 °C 18 s, 52 °C 21 s and 72 °C 90 s. The size of amplified DNA
fragments was assessed by electrophoresis through 4% Metaphor
agarose gels, with expected sizes of 140 or 180 bp for fragments with and
without a duplication.
• Nucleotide sequencing and phylogenetic analysis. Nucleo-
tide sequences of amplified fragments were obtained by direct sequencing
of amplified genome regions using Thermosequenase (Amersham) in
reactions containing 33P-labelled dideoxynucleotides. Potential RNA
secondary structures were investigated using Rt"lADraw version 1.0
(Matzura, 1995).
Complete coding region sequences were analysed by three different
methods . (1) Distances were estimated using an F84model of substitution
(Felsenstein. 1984), which allows for unequal transition/transversion
rates and unequal base frequencies. 100 bootstrapped datasets, distance
matrices, neighbour joining trees and a consensus tree were produced
using SEQBOOT, DNADIST, NEIGHBOR and CONSENSE, all part of
the PHYLIP package (Felsenstein. 1993). (2) Synonymous and non-
synonymous distances were estimated using Method I of Nei & Gojobori
(1986) for 200 datasets produced by bootstrapping codons (D. Haydon,
unpublished). Neighbour joining trees and a consensus tree were
produced as above. (3) Distances were estimated using a Tamura & Nei
(1993) model of substitution, a more general form of the F84 model that
also allows for unequal transition rates between purines and pyrimidines,
together with rate heterogeneity modelled as a proportion of invariable
sites plus eight rates taken from a discrete gamma distribution using
parameters estimated from the data. 100 bootstrapped datasets were
produced using SEQBOOT, and distance matrices calculated' with the
programs PUZZLE version 4.0.2 (Strimrner & von Haeseler, 1996) and
PUZZLEBOOT version 1,01 (Holder & Roger. 1999) using parameters
estimated from the dataset. Trees with the lowest least-squares deviation
were produced using the program FITCH applying global search, and a
consensus tree produced using CONSENSE. Phylogenetic trees of
subgenomic regions were produced with MEGA (Kumar et al; 1993)
using the Kimura 2-parameter model of substitution on datasets of 100
bootstrap replicates.
In order to determine which GBV-C/HGV group was closest to the
outgroup GBV·C,ro(AF070476l, we used a reduced dataset consisting of
three sequences from each group (Group 1. HGU36380, AB003291,
ABO13500 ; Group 2. AB013501. U44402, U63715 ; Group 3, AB003288.
D90601, U94695 ; Group 4. AB003292, AB018667, AB021287). We
estimated the likelihood of the outgroup clustering with each of the four
group s under four different models of nucleotide substitution : (i) an F84
model. (ii) an F84 model allowing for rate variation modelled using a
discrete gamma distribution with eight categories ; (iii) as for (ii), but
allowing for different transition/transversion ratios , different base
frequencies, different rates and different levels of rate heterogeneity for
each gene ; and (iv), as for (ii) but allowing parameters to differ for each
codon position. These models were fitted and the bootstrap support for
each cluster compared using the fast approximate bootstrap procedure of
Kishino & Hasegawa (1989) as implemented in the PAML version 2.0
package (Yang, 1999). Similar analyses of amino acid sequences were
carried out using Phylip 3.57c (Kimura substitution matrix), or RELL
[Jones et al. (1992) substitution matrix)] assuming gamma rate het- "
erogeneity.
Results
Complete genome sequences .
Phylogenetic analysis of the coding region of 33 epi-
demiologically unrelated complete GBV-CjHGV genome
sequences yielded evidence for four distinct phylogenetic
groupings each of which was supported by high levels of
bootstrap support (Fig. 1). These groupings correspond to the
three groupings previously identified from the analysis of
complete genome sequences (Okamoto et al., 1997) together
with an additional group consisting of an unclassified Japanese
sequence (Takahashi et al., 1997b) and three sequences from
Thailand (1(-10 ; Sirirrug Songsivilai, unpublished results),
Vietnam (AB018667) and Myanmur (AB021287). Similar
groupings and levels of bootstrap support were obtained when
the analysis was confined to either synonymous or non-
synonymous sites, or to amino acid substitutions, if com-
parisons were extended to include the entire virus genome, or
if the chimpanzee isolate GBV-~ro was used as an outgroup
(data not shown).
Although subgroupings of groups 1, 2 and 3 have been
distinguished by phylogenetic analysis of subgenomic regions
(Muerhoff et al., 1996 ; Takahashi et al., 1997a; Muerhoff et al;
1997) there was only limited evidence from the analysis of
complete genome sequences for subgroupings . Three group 3
isolates from China (U75356, U94695 and AF006500)grouped
together with high bootstrap support, while the isolates

















Fig. 1. Phylogenetic tree of GBV-C/HGV complete coding region sequences. Maximum likelihood distances between sequences
were calculated With Phylrp DNADIST (ts :tv = 2. assuming no :ate variation between sites) . and used to produce a neighbour
jOln.lng tree Wl~ Phylrp NEIGHBOR. Bootstrap values (100 replicates ) were obtained with the SEQBOOT and CONSENSE
options of Phylip . The tree was produced using Treeview version 1.5. ,
I-
0.20
Fig. 2. Frequency distribution of pairwise evolutionary distances between
GBV-C/HGV complete coding region sequences . Distance were calcu lated
as in Fig. 1.
group 2 isolates (group 2a) and isolate AB003292 from Japan
was relatively divergent from other group 4 isolates. How-
ever, analysis of pairwise distances between GBV-C/HGV
sequences revealed a distribution with only two overlapping
peaks (Fig. 2). corresponding to comparisons between
sequences belonging to different groups (distances of
O'131-D'171) or within one of the four phylogenetic groups
(0'076--0'137). The overlap between these two distributions
comprised 18/528 pairwise comparisons (3'5 %), more than
half of which involved a divergent group 2 isolate from South
America (AB013501).
A previous study suggested that certain group 1 isolates
containing a duplicated region within NS5A (e.g. isolate
AB003291) were ancestral to other GBV-C/HGV isolates
relative to GBV-A (Tanaka et al., 1998). However, this was
not confirmed when the analysis was extended to complete
genome sequences (Suzuki et al., 1999), or when we in-
vestigated the relative likelihood with which the more
closely related GBV-~ro isolate clustered with three repre-
sentatives from each group (Table 1). Under four different
Subgenomic regions
Next, we investigated the extent to which subgenomic
regions of GBV-C/HGV bear the same phylogenetic relation-
ships as do entire virus genomes. Analysis of individual virus
genes failed to produce congruent phylogenetic trees with the
sole exception of the E2 gene (Fig. 3). Similar analysis of
subgenomic fragments of 2000, 1000 or 500 nt produced
congruent trees only for fragments including the COOH-
models of substitution, clustering with group 1 could be
rejected at the 5 % level. Although clustering with group 2
gave the best fit to the data for the models which included rate
heterogeneity, differences between genes in transition/
transversion ratios, rate heterogeneity and base frequencies
were relatively small (results not shown), and the bootstrap
support for this clustering was not high enough to be
conclusive. The best fit to the data were obtained with the
model in which parameters could vary according to position
within codons, reflecting the strong bias against non-
synonymous substitution. Bootstrap resampling analysis using
simpler models of substitution at synonymous or non-
synonymous sites supported group 4 as being ancestral, while
analysis of amino acid sequences supported either groups 1 or
3 as being ancestral depending on the substitution matrix used.
Hence, our analysis does not consistently place anyone of the
four human GBV-C/HGV groups as being ancestral.
Furthermore, the duplicated region may be derivative
rather than ancestral since this requires fewer evolutionary
steps (Suzuki etal., 1999). Most isolates that lackthe duplication
have instead an 8 nt direct repeat (ACCCCGTC, positions
6457-6464 and 6487-6494) flanking a sequence with the
potential to form a structure with an 11 nt stem and .a 3 nt
loop. The formation of this stem-loop during RNA synthesis
could lead to slippage and mispairing between the direct
repeats resulting in the duplication of the hairpin loop and the
direct repeat. We did not detect the duplication in NS5A
amongst other isolates from Africa (n = 13) or Papua New
Guinea (n = 8) or other NS5A sequences available in GenBank
(n = 94).
. . .






Table 1. Log likelihood and approximate bootstrap support for the clustering of the outgroup GBV-Ctro with groups
1-4 under different models of substitution
Log likelihood for clustering (bootstrap support)
Model of substitution Group 1 Group 2 Group 3 Group 4
F84
F84 with rate variation
F84 with rate variation gene specific





- 47139'032 (0'5 %)
- 54035'720 (10'60 %)
-49038'439 (59'52 %)
-49014'258 (67'18%)
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Fig. 3. Congruence between phylogenet ic analysis of complete genomes and subgenomic fragments. The level of bootstrap
support for phylogenet ic groupings 1-4 is indicated by the degree of shading for different genes and subgenom ic fragments .
terminal region of the E2 gene. Analysis of the entire 3'-
terminal half of the virus genome or any of its subfragments
failed to produce congruent trees.
In most cases, sequences that grouped aberrantly were not
consistently associated -with a particular group. The only
exception was the group 4 sequence AB0021287 that grouped
with group 2 sequences for subgenomic fragments encompass-
ing the NH2 terminus of the NS2 gene or the CO OH-terminal
half of the NS5B gene. Even if the assumption is made that this
isolate is a recombinant between isolates of group 4 and 2 [the
major GBV-C/HGV groups found in this geographical region
(Naito etal., 1999)], the only additional subgenomic region that
then produces a congruent phylogenetic tree is a 1000 nt
fragment encompassing the COOH terminus of the E2 gene
and most of the NS2 gene.
Since a 500 nt fragment of the E2 gene could reproduce the
phylogenetic relationships of the complete genome sequences,
we next analysed this region in more detail (Figs 4 and 5).
Congruent phylogeneric trees were produced using a region
as small as 200 nt (positions 1344-1543). The shortest region
that gave a congruent tree with more than 98 % bootstrap
support for each group was the 600 nt region from positions
994-1594. This region also produced a congruent tree when
analysed at synonymous sites (> 85 % support) but not at
nonsynonymous sites.
Previous studies have suggested that the phylogenetic
relationships of GBV-C/HGV complete genome sequences
can be reproduced by analysis of the whole or part of the 5'-
NCR (Muerhoffetal., 1996; Smith etal., 1997 b;Muerhoff etal..
1997). The extreme 5'-terminal sequence is available for only
a single group I and none of the group 4 isolates, so an
adequate analysis can only be carried out from positions - 388
to - 1. Analysis of this region and of various subfragments
failed to produce congruent phylogenetic trees (Fig. 6), with
- I
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Fig . 4 . Congruence of phylogenetic
relationships produced using fragments
of the E2 gene. The extent to which
phylogenetic groupings observed from
analysis of complete genome sequences
are supported by comparison of
fragments of the E2 gene is indicated by
the level of shading . The number of
groups supported by more than 70% of
bootstrap replicates is indicated. The
minimum degree of bootstrap support is
given for selected examples . Also
indicated are the posit ion of an anti-
genome reading frame (Kondo et 0/.,
1998) , a region where synonymous
substitutions are suppressed (Simmonds
& Smith, 1999) and regions where the
presence of covariant nucleotide
substitutions suggests the presence of
RNA secondary structures (Simmonds &
Smith, 1999).






two sequences responsible for the majority of aberrant
groupings ABO13500, an extreme group 2 isolate from Bolivia,
groups with group 3 isolates for the 5'-NCR and some
subgenomic fragments in the 3' half of the genome, although
the 5'-NCR is atypical. Similarly, U75356, an unpublished
group 3 isolate from China, has a S'-NCR sequence similar to
but distinct from those of group 1 isolates. This sequence also
has a frameshift within NS5A and an unusual sequence at the
3' terminus (Smith et al.. 1997b).Hence, it is uncertain whether
these isolates represent recombinants (An et al., 1997) or
divergent variants with unique 5'-NCR sequences. If these two
sequences are excluded from the dataset, a congruent tree is
obtained when the region - 388 to - 1 is analysed. However,
subfragments of this region, including those previously
identified as reproducing the phylogenetic relationships of
group 1 and 2 isolates (Smith et al., 1997b), provide < 70%
bootstrap support for either groups 3 or 4.
-
Evidence for additional groupings from the analysis of
subgenomic regions
Having identified a region within the El gene that
consistently reproduces the phylogenetic relationships of
complete genome sequences, we compared published
sequences of this region for evidence of additional GBV-
CjHGV groups. Of 16 additional sequences for the region
994-1594 (accession nos U87653-U87664, AF063827,
AF0638l8, AF063830, AF017533), 14 (from USA, Jamaica,
Greece, UK and Egypt) grouped with group 2, and one each
with groups 1 (USA) and 3 (Hong Kong) ( > 99% support for
all groups ; data not shown). Similarly, nine additional
sequences of the region 1414-1693 from Italian patients
(AF015842-AF015862) clustered with group 2, although as
expected from the analysis of complete genome sequences
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Fig . 5. South African isolates form an addit ional E2 phylogenetic grouping. A phylogenetic tree was constructed by neighbour
joining using lukes-Cantor distances for the region 1146-1496 for selected South African isolates and for the corresponding
region from complete genome sequences. Bootstrap values (500 replicates) for branches are indicated where they were
greater than 70 %.
sequences for the 350 nt region 1146-1495 of five GBV-C
variants from South Africa with unusual 5'-NCR sequences
(Sathar et al., 1999) formed an additional group (Fig. 5), while
other South African isolates with 5' -NCR sequences that
clustered with groups 1 (n = 3) or 2 (n = 2) clustered with
groups 1 or 2 respectively. Isolates from Papua New Guinea
had E2 sequences that clustered with group 2 (n = 2) or group
4 (n = 2), while an isolate from Sudan (n = 1) clustered with
group 2.
Similaranalysis of 5'-NCR sequences is complicated by the
large number of sequences available within this region (1409
accessions) and the inconsistent phylogenetic relationships of
all but the largest fragments (Fig. 6). Visual examination for
motifs distinct from those typical of groups 1, 2, 3 and 4
revealed a small number of unusual sequences, but of these
only the variants from South Africa (Sathar et al; 1999)
described above, and isolates from Spain (Lopez-Alcorocho et
al., 1999) grouped separately from the 5'-NCR sequences of
-
-550 -500 -450 -400 -350 -300 -250 -200 -150 -100 -50 AUG
Excluding U75356 (group 3) and ABOO13500 (group 2)
No Groups 1 Group 2 Groups 3 Groups All Groups
Fig. 6. Congruence of phylogenetic
relationships produced using fragments
of the 5'-NCR. The extent to whic h
phylogenetic groupings observed from
analysis of complete genome sequences
are supported by compar ison of
fragments of the 5'-NCR is indicated by
the level of shading. Groupings were
considered to be supported if they were
observed in > 70% of bootstrap
replicates.
complete genome sequences for the region - 388 to -l.
These later isolates could represent recombinants since they
have motifs typical of group 3 sequences between positions
-489 and -459 but the remainder of the 5'-NCR is similar
to, although distinct from, that of group 2 isolates.
Discussion
Identification of phylogenetic groups
This analysis of complete genome sequences of GBV-
CjHGVidentifies four main phylogenetic groupings (Fig. 1).
The existence of the fourth group had been suggested from the
analysis of 5'-NCR sequences of Southeast Asian isolates
(Naito et al., 1999). A previous phylogenetic analysis of
complete genome sequences also proposed four groups in
which groups 1 and 4 were combined and group 3 was split
into two (Charrel et al., 1999), but the published bootstrap
analysis did not support these groupings. Similarly, an analysis
based upon genetic distances identified five groups with group
1 split into two (Takahashi et al.. 1997b), but our analysis
suggests that phylogenetic groups cannot be defined using
pairwise distances (Fig. 2).
-
An unexpected findingof this study is that the phylogenetic
relationships of complete GBV-CjHGV sequences (but not
subgroupings) can be reproduced by short COOH-terminal
fragments of the E2 gene (Fig. 4). Previous studies of smaller
numbers of sequences have shown that phylogenetic relation-
ships are inconsistent when comparisons are made for
individual genes (Takahashi et al., 1997b) or subgenomic
fragments (Smith et al., 1997 b). Although three (Cong et al.,
1999) or four (Urn et al., 1997) phylogenetic groupings are
observed when fragments larger than 1500 nucleotides
including the E2 gene are compared, interpretation of these
studies is complicated by idiosyncratic labelling, the absenceof
group 4 isolates and the failure to assess the robustness of
groupings. We show here that analysis of a 200 nt fragment
from the centre of the E2gene (positions 1344-1543) provides
> 75%bootstrap support for all four phylogenetic groupings,
while a 600 nt region (positions 994-1594) provided> 98%
support . This is in stark contrast to other coding regions: all
subgenomic fragments of 2000 nt or less that did not contain
this region of E2 failed to produce congruent trees with the
sole exception of a 2000 nt fragment encompassing the
remainder of the E2 gene, NS2 and the NH2-terminal half of
NS3 (Fig. 3).An important unresolved question is the extent to
which some complete genome sequences represent recom-
binants between different groups . Inconsistent relationships
were observed for some sequences between the 5'-NCR and
coding regions or between different coding regions. However,
the aberrant groupings were typically weak and inconsistent
suggesting that these do not represent simple recombinants.
Our analysis helps to clarify previous conflicting studies on
the extent to which subgenomic regions can be used to
identify GBV-CjHGV phylogenetic group ings. Mo st early
studies of virus diversity concentrated on a 118-135 nt
fragment within NS3 that was the first part of the genome to
be sequenced (Simons et al., 1995; Masuko et al., 1996;
Heringlake et al., 1996 ; Kao et a/., 1996; Berg et al. , 1996;
Schreier et al; 1996; Tsuda et al., 1996; Schrnidt et al.. 1996 ;
Muerhoff etal.. 1997; Pickering etal.. 1997; Ibanez etal; 1998).
However, the phylogenetic conclusions of these studies appear
to be unreliable since analysis of even the entire NS3 gene fails
to produce congruent groupings. Inconsistent phylogenetic
group ings have also been observed for the NH2 terminus of E2
(Urn etal., 1997; Muerhoff etal., 1997), 354 nt of NS5AjNS5B
(Viazov etal., 1997) or 279 nt of NS5B (Muerhoff et al., 1997).
Finally, although analysis of a 2600 nt fragment containing
both NS5A and NS5B produced a congruent tree for 12
isolates from groups 1, 2 and 3 (Khudyakov et al., 1997),
comparison of this region from the 33 complete genome
sequences gave aberrant groupings of some isolates with only
marginal support for groups 1 and 4 (data not shown).
The inconsistent phylogenetic relationships of GBV-
CjHGV subgenomic coding regions contrasts with that
observed for HCV where analysis of a variety of subgenomic
regions reproduces the phylogenetic relationships of complete
genomes (Simmonds et al., 1994; Tokita et al., 1998). This
difference could arise if different regions of the GBV-CjHGV
genome were subject to different evolutionary processes in
which case combining these regions could produce a less
reliable reconstruction than the analysis of individual regions
(Bull et al., 1993). However, the validity ofthe analysis based
on complete genome sequences is supported by the correlation
between their phylogenetic relationships and their geographi-
cal origin. An alternative explanation is that the amino acid
sequence of the GBV-CjHGV polyprotein is well conserved
(dN:ds 0-033, divergence < 11%) relative to HCV subtypes
(dx :ds 0'09 4, divergence < 10%). Phylogenetic groupings of
GBV-CjHGV therefore rely more on variation at synonymous
sites, many of which are invariant or saturated, possibly
because of the presence of extensive RNA secondary structures
within the GBV-CjHGV genome (Simmonds & Smith, 1999).
Consequently, GBV-CjHGV isolates with a common evol-
utionary origin may share only a small number of poly-
morphisms and analysis of subgenomic regions could often fail
to produce congruent phylogenetic trees.
There are several potential explanations for our observation
that analysis of the E2 gene or specific subfragments produces
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Fig. 7. Potent ial RNA secondary st ructures upstream of a potential anti-
sense reading frame. Potential hairpin loops formed by the nucleotide
sequence of the antisense strand corresponding to positions 1279-12 13
of the sense strand are indicated. Covariant nucleot ide subst itutions
observed amongst sequences from phylogenetic groups 1, 2 and 3 are
indicated in upper case, while substitutions that disrupt the proposed
structures are indicated in lower case. The conserved AUG codon at the
beginning of the anti-sense reading frame is indicated by bold lettering.
phylogeneti c trees congruent with those observed for com-
plete genome sequences. First, since E2 is the most variable
part of the GBV-CjHGV polyprotein (Katayama etal; 1998; .
Erker et al., 1996), the phylogenetic relationships of complete
genome sequences could depend entirely on substitutions in
E2. However, identicalgroupings are observed if E2 is excluded
and most amino acid substitutions occur at the NH2 terminus
of E2 (Urn etal., 1997; Katayama et al., 1998; Cong et al., 1999),
whereas it is only the central and 3' regions that produce
congruent phylogenetic trees, and then only for synonymous
rather than nonsynonymous substitutions. A second potential
explanation is that this region of the genome encodes an open
reading frame on the anti-sense strand (nucleotides 870-1226,
Fig. 4), possibly encoding a nucleocapsid protein (Kondo et al.,
1998). This would constrain the accumulation of substitutions
and so retain evidence of phylogenetic relationships. However,
although synonymous substitutions are suppressed in this part
of the genome (Muerhoff et a/., 1997; Simmonds & Smith,
1999), phylogenetic analysis of the anti-sense reading frame
fails to produce a congruent tree (Fig. 4). Another potential
source of constraint in this region of the genome would be if
translation of the anti-sense reading frame was dependent on
an upstream internal ribosome entry site. Indeed, substitut ions
in this region of the genome are frequently covariant and
associated with potential RNA secondary structures
(Simmonds & Smith, 1999) (Fig. 7), while RNA folding
predictions for representatives of groups 1-3 identify
structures with free energies one standard deviation below
those of random sequences of the same base composition.
However, these RNA structures were not observed in
sequences from group 4 isolates, and the anti-sense reading
frame is 10 residues longer in some group 3 isolates and lacks
the initial AUG codon in GBV-~ro'
-
Geographical distribution and origin of GBV-C HGV
isolates
The distinct geographical distribution of GBV-C/HGV
variants is consistent with their. eo-evolution with humans
during pre-historic migrations. Group 1 and 5 isolates are
African and have relatively diverse S'-NCR sequences
(Muerhoff et at 1997 ; Smith et al; 199 7 b; Naito et al.. 1999 ;
Sathar et at 1999), while the remaining groups correspond to
the three main waves of human migration from Africa to
Europe (group 2), northern Asia (group 3) and southern Asia
(group 4). In addition, the presence of group 3 variants
amongst nat ive populations in South America (Pujol et al.,
1998 ; Gonza lez-Perez et al., 199 7) is consistent with the first
colonization of this continent from northern Asia via the
Bering Strait. Although Japanese isolates have been found
belonging to groups 1- 4 (Takahashi etal.. 199 7 b, Okamoto et
at 199 7), most are group 3 suggesting that the presence of
other groups represents recent introductions.
Finally, since a virus related to GBV-C/HGV is present in
chimpanzees (Adams et al.. 1998; Birkenmeyer et al., 1998 ),
while New World monkeys harbour more distantly related but
species-specific variants (Bukh & Apgar. 1997 ; Leary et al.,
1996a ) it is possible that GBV-C/HGV has been continuously
present in human populations since speciation. In this case the
virus appears to have evolved at an overall rate of less than
10-5 per site per year (Suzuki et al., 199 9 ; Simmonds & Smith,
1999), although its rate of sequence evolution measured in
longitudinal studies is similar to that of other RNA viruses.
Further sequence analysis of the E2 region from GBV-C/HGV
variants isolated from different geographical regions may help
to clarify the origins of this unusual virus.
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Summary. GB Virus C and Hepatitis G Virus (GBV-C/HGV) are positive,
single-stranded ftaviviruses. GBV-C and HGV are independent isolates of the
same virus. Transmission via the blood-borne route is the commonest mode,
although vertical and sexual transmission is well documented. GBV-C/HGV
is distributed globally; its prevalence in the general population is 10 fold
higher in African countries than in non-African countries. High prevalences of
GBV-C/HGV have been found in subjects with frequent parenteral exposure
and in groups at high risk of exposure to blood and blood products. The
clinical significance of human infection with GBV-C/HGV is currently unclear.
The virus can establish both acute and chronic infection and appears to be
sensitive to interferon. Only some 12-15% of chronic Non-A, B, C hepatitis
cases are infected with GBV-C/HGV. A direct association with liver pathology
is still lacking and it is not yet clear as to whether GBV-C/HGV is indeed a
hepatotropic virus. Current evidence suggests that the spectrum of
association of GBV-C/HGV infection with extrahepatic diseases ranges
from haematalogical diseases, aplastic anaemia, human immunodeficiency
virus (HIV)-positive idiopathic thrombocytopenia and thalassemia, through to
common variable immune deficiency and cryoglobunemia.
Keywords: Flavivirus, PCR, Anti-E2, hepatitis, liver disease, clinical features
Introduction
Discovery of GBV-C and HGV
The first successful transmission of viral hepatitis from
humans to nonhuman primates was achieved by
Demhardt et al. (Deinhardt et al. 1967), when serum
from a 34-year-old surgeon (whose initials were GB)
Correspondence; M. A. Sathar, University of Natal , Faculty of
Medic ine , Department of Medicine, PO Box 7, Congella, 409 1,
South Africa.
© 2000 BlackwelJ Science Ltd. lnt, J . Exp. Path. (2000), 81, 305-322
with acute hepatitis was inoculated into tamarins
(Saguinus spp.). Animals inoculated with GB serum
developed hepatitis, as did animals inoculated with sera
of tamarins with GB serum-induced hepatitis. GB Virus
C (GBV-C).was identified in the serum of a human in
West Africa that contained recombinant nonstructural
proteins of two other novel flaviviruses, designated
GBV-A and GBV-B (Simons et al. 1995a). These viruses
were cloned from the serum of a tamarin inoculated with
the GB agent (Deinhardt et al. 1967)and are now known
to be of animal origin. Using degenerateprimers derived
from the homologous sequences shared by GBV-A,
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Figure 1. HGV (PNF2161) genome . Proteolytic processing and functions of the structural and non-structural proteins (nt =
nucleotide; UTR = untranslated region; E = envelope; NS = nonstructural).
GBV-B, and HCV from the NS3/helicase region of these
viruses, amplification products were obtained from
immunoreactive sera whose sequence was different
from the other viruses . The new virus was named
GBV-C (Simons et al. 1995b; Leary et al. 1996).
Independently, in an effort to identify additional agents
for post-transfusion non-A-non-B hepatitis (NANB),
Linnen et aJ. (Unnen et al. 1996) performed molecular
cioning with plasma from a patient with presumed NANB
hepatitis, and a virus like RNA sequence was identified
and designated Hepatitis G Virus (HGV).
Genomic organization of GBV-C/HGV
The genomic organization of GBV-C/HGV and HCV is
similar and both viruses belong to the family of
Flaviviridae. They are both linear, positive single-
stranded RNA molecules composed of about 9500
nucleotides (nt)(Figure 1).
The viral polyprotein is preceded by a 5' untranslated
region (UTR), followed by a long open reading frame
(ORF) terminating with 3' UTR (Figure 1)(Linnen et al.
1996). The polyprotein is cleaved into smaller fragments
with different funct ions by host-encoded signal pepti-
dases and viral proteases. These fragments include the
envelope proteins (E1 and E2) at the amino or N-
terminal end followed by nonstructural (NS) proteins
(NS2, NS3, NS4, and NS5) at the carboxyor C-terminal
end (Figure 1). The GBV-C/HGV genome is unusual in
that the region between the 5' UTR and the envelope
proteins is absent or truncated (Simons et al. 1995a;
Leary et al. 1996; Linnen et al. 1996). This region
normally encodes the nucleocapsid/core protein that
encases the viral genome. The 5' UTR conta ins an
intemal ribosome entry site (lRES) that is capable of
directing CAP-independent translation of the polyprotein
(Simons et al. 1996). Sequence comparisons of the two
prototype isolates, HGV and GBV-C , show that they
have 86% and 95% homology at the nucleotide and
amino-acid levels, respectively. They are therefore
cons idered to be independent isolates of the same
virus (Leary et al. 1996; Linnen et al. 1996).
Phylogenetic analysis of GBV-eIHGV
Comparisons of 33 epidemiologically distinct complete
or near complete genomic sequences of GBV-C/HGV
suggest the existence of four major phylogenetic groups
that are equally divergent from the chimpanzee isolate,
GBV-Ctrop (Birkenmeyer et al. 1998), and have distinct
geographical distribution (Figure 2) (Smith et al. 2000).
Group 1 includes isolates from Ghana, West Africa and
a single Japanese isolate; Group 2 includes isolates
from Europe, North and South America and Japan;
Group 3 includes isolates from Japan and China and the
fourth group consists of isolates from South-east Asia
(Figure 2) (Smith et al. 2000). With the sole exception of
E2 gene segments, phylogenetic analysis of individual
Qenes and subgenomic regions have failed to consis-
tently produce congruent phylogenetic trees of the four
major groups that correlate with the geographical origin
of the isolates (Smith et al. 2000). Recently , a new
variant of GBV-C/HGV whose sequences of the 5' NCR
were different from all other known GBV-C/HGV
sequences was identified in the province of Kwazulu
Natal (KZN) , South Africa (Sathar et al. 1999a).
Phylogenetic analysis of the E2 gene segment from
certain KZN isolates is consistent with previous analysis
of the 5' NCR(Sathar et al. 1999a; Smith et al. 2000),
suggesting that these belong to a fifth group (Smith et al.
2000)(Figure 3).The spread of geographically distinct
GBV-C/HGV groups has been associated with human
migration (Smith et al. 2000).The greater diversity
amongst Group 1 African isolates compared to the
306 © 2000 Blackwell Science Ltd, International Journal of Experimental Pathology, 81, 305-322
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Figure 2. Phylogenetic tree of GBV-C/HGV complete coding region sequences (with permission, Smith et al. 2000).
other major groups, and the confirmation of a fifth group
in South Africa (Smith et al. 2000), is consistent with the
possibility that GBV-C/HGV may have emerged in Africa
(Tanaka et al. 1998) and evolved together with its
human host during their prehistoric migration.
Detection of GBV-CIHGV
GBV-CIHGV MA
The reverse-transcription polymerase chain reaction
(RT-PCR) is the only diagnostic tool available to detect
currentGBV-C/HGV infection. Initially, primers from the
NS3 region of the genome were used to detect viral RNA
(Simons et al. 1995b; Linnen et al. 1996). Degenerate
primers to the NS region have also been shown to be
sensitive in detecting GBV-C/HGV RNA (Yoshiba et al.
1995). Primers from the NS5A (Linnen et al. 1996) or 5'
UTR (Schlueter et al. 1996) have been shown to be
more reliable; the latter region appears to be more
sensitive and more widely used in this respect (Kao et al.
1997a). Detection of PCR products can be accom-
plished by the relatively simple procedure of agarose gel
electrophoresis and staining the gel with ethidium
bromide, or alternatively, by a single tube assay based
on RT-PCR amplification of the 5' UTR, followed by
oligomer hybridization. Detection employs a microparti-
cle immunoassay in the automated LCx system (Mar-
shall et al. 1998). While RT-PCR remains the 'gold
standard' for detecting GBV-CIHGV, its sensitivity is not
fully resolved.
GBV-CIHGV Antibodies
An antibody response to GBV-C/HGV directed against
the envelope glycoprotein, E2, has been detected
following its expression as a recombinant protein in
Chinese hamster ovary cells (Pilot-Matias et al. 1996;
Tacke et al. 1997a). The secreted E2 protein has been
purified and used in a solid phase enzyme-linked
immunosorbent assay (ELlSA) for the detection of anti-
E2 (Dille et al. 1997). Interestingly, almost all sera
© 2000 Blackwell Science Ltd. International Journal of Experimental Pathology, 81, 305-322 307
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Figure 3. South African isolates (KZN) form an additional E2 phylogenetic grouping (Group 5) (with permission, Smith et al. 2000).
positive for anti-E2 are negative for viral RNA, and vice
versa, implying that anti-E2 is associated with virus
clearance and is perhaps, protective or neutralizing
(Pilot-Matias et al. 1996; Tacke et al. 1997a). Testing for
anti-E2 greatly extends the ability of RT-PCR to define
the epidemiology of GBV-C/HGV(Sathar et al. 1999b).
However, the specificity for anti-E2 has not been
established.
Routes of GBV-C/HGV transmission
Since the discovery of GBV-CIHGV, attempts have been
made to clarify its principle mode of transmission. In
non-African countries the predominant route of trans-
mission of GBV-C/HGV is parenteral. High prevalences
of GBV-C/HGV have been found in subjects with
frequent parenteral exposure and in groups at high risk
308 © 2000 Blackwell Science Ltd, International Journal of Experimental Pathology, 81, 305-322
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of exposure to blood and blood products, including
intravenous drug abusers' (IVDA), patients on mainte-
nance haemodialysis, multitransfused individuals and
haemophiliacs. The high prevalence in blood donors
worldwide suggests that the principle route of transmis-
sion is via contaminated blood and blood products.
However, maintenance of the virus at high levels in
blood donors and the general population requires an
effective nonparenteral route of transmission. Blood
donors, however, are not representative of the general
population since they are highly selective.
Various studies have pointed to the important role of
sexual exposure as a likely route of transmission of
GBV-C/HGV, in both non-HIV infected subjects without
the risk for parenteral transmission (IVDU and multi-
transfused individuals including haemophiliacs)(Kao
et al. 1997b; Scallan et al. 1998; Sawayama et al.
1999) and HIV-infected individuals with the risk for
parenteral and sexual transmission (homosexuals,
heterosexuals and prostitutes)(Bourlet et al. 1999;
Nubling et al. 1997; Ibanez et al. 1998; Nerurkar et al.
1998). Infection with GBV-C/HGV appears to be more
frequent in patients with a sexual risk than those with
parenteral exposure (Bourlet et al. 1999; Ibanez et al.
1998). In a study of 600 antenatal patients there was an
overall prevalence (GBV-C/HGV RNA and/or Anti-E2
positive) of 11.8%. Since this group represents a young,
sexually active population, the authors concluded that
sexual or close contact might play a role in the
transmission of GBV-C/HGV (Skidmore & Coilingham
1999). Rubio et al. (Rubio et al. 1997) reported a GBV-
C/HGV prevalence of 21.7% among heterosexual
partners of 150 index cases. Stark et al. (Stark et al.
1996) found GBV-C/HGV prevalence of 10.9% among
non-drug injecting homosexual and bisexual men.
Scallan et al. (Scallan et al. 1998) found a high
prevalence of markers for GBV-C/HGV in non-intrave-
nous drug using prostitutes (40%) and male homosex-
uals (47%). A positive" correlation was demonstrated
between GBV-C/HGV infection in prostitutes and the
number of years of prostitution (Kao et al. 1997b;
Sawayama et al. 1999) and the high frequency of paid
sex (Wu et al. 1997). The near absence of GBV-C/f:iGV
infection among heterosexual men (4%) and the
comparatively higher prevalence among heterosexual
women (15%) suggests that, as in HIV infection, the
receptive partner is at high risk for acquiring GBV-CI
HGV (Nerurkar et al. 1998). lnterspousal transmissions
of GBV-C/HGV have been reported (Kao et al. 1997c;
Sarrazin et al. 1997). Although the role of semen in the
transmission of GBV-C/HGV is controversial (Semprini
et al. 1997; Hollingsworth et al. 1998), recent reports
have suggested that human saliva may contribute to the
spread of GBV-C/HGV RNA (Seemayer et al. 1998;
Chen et al. 1997). Tucker et al. (Tucker et al. 2000) did
not detect GBV-C/HGV replicative intermediaries in the
cadaver biopsies of salivary glands and the gonads of
.GBV-C/HGV positive patients, implying that the virus
may be present in the saliva and semen of infected
individuals, but not transmitted by these routes. Despite
the evidence for increased frequencies of GBV-C/HGV
infection in association with sexual exposure, the
mechanism of transmission remains unclear.
There is a higher risk of mother to infant transmission
in high risk groups (Feucht et al. 1996; Fischler et al.
1997; Viazov et al. 1997; Zanetti et al. 1997; Wejstal
et al. 1999). However, it is not clear whether co-infection
with HCV, HIV-1 (or both) , or IVDU are the underlying
cause for transmission of GBV-C/HGV from mother to
infant. Nor is it clear as to whether transmission of GBV-
C/HGV is influenced by breastfeeding or by the mode of
delivery (Viazov et al. 1997; Zanetti et al. 1997; Wejstal
et al. 1999). Although the rate of perinatal transmission
of GBV-C/HGV exceeds that of HCV, in most studies
GBV-C/HGV did not induce liver disease in the infants
studied (Wejstal et al. 1999; Zanetti et al. 1997).
Among 220 cases of needle-stick injuries, GBV-CI
HGV RNA was detected in 21 (9.5%) donors (Shibuya
et al. 1998). At the time of injury none of the 21
recipientswere positive for GBV-C/HGV RNAor anti-E2;
only 1/14 (7.1%) recipients was positive for GBV-C/HGV
RNA which persisted for approximately 3 years without
any evidence of Jiver disease (Shibuya et al. 1998). It
has been suggested that iatrogenic infection with GBV-
C/HGV could possibly occur through insufficient ster-
ilization of needles and syringes (Ohshima et al. 2000).
Confirmation that GBV-C/HGV is indeed an occupa-
tional hazard in hospital employees (Gartner et al. 1999;
Schaade et al. 2000) will require more comprehensive
longitudinal studies.
Prevalence of GF3V-C/HGV infection
The prevalences of GBV-C/HGV infection in selected
groups of subjects from some published studies are
listed in Tables 1-4. The frequency of positivity for RNA
or anti-E2 varies among groups, depending on the
subjects' origins and the methods used to detect GBV-
C/HGV markers. Generally, infection with GBV-C/HGV
is significantly associated with a history of IVDA,
exposure to blood transfusions, dialysis and with HCV
infection. There is a: higher prevalence of GBV-C/HGV
RNA in blood donors and the general population of
African countries (10-19%) compared to non-African
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Table 1. Reported prevalences of GBV-C/HGV RNA in blood donors in some published studies
Continent Country n RNA + (0/0) References
N America USA 769 13(1.7) (Linnen et al. 1996)
S America Brazil 11 2(1.8) (Lampe et al. 1997)
Africa Egypt 82 16(12.2) (EI-zayadi et al. 1999)
South Africa 248 32(12 .9) (Mphahlele et al. 1998)
South Africa 249 26(10.4) (Tucker et al. 1997)
South Africa 167 21(12.6) (Lightfoot et al. 1997)
South Africa 532 59(11 .1) (Castelling et al. 1998)
South Africa 232 44(18 .9) (Sathar et al. 1999b)
Caribbean Martinique 221 9 (4.1) (Cesaire et al. 1999)
Asia Japan 448 4(0.9) (Masuko et al. 1996)
China 205 2(1) (Wang et al. 1997b)
Thailand 69 3(4.3) (Raengsakulrach et al. 1997)
Vietnam 890 11(1.2) (Kakumu et al. 1998)
Nepal 181 4(2) (Shrestha et al. 1997)
Mongolia 121 8(6.6) (Kondo et al. 1997)
Australia 120 5(4) (Moaven et al. 1996)
Europe Austria 92 3(3) (Schlueter et al. 1996)
Germany 1048 14(1.34) (Roth et al. 1997)
Germany 106 59(4 .7) (Heringlake et al. 1996)
UK 125 4(3.2) (Jarvis et al. 1996)
Italy 100 1(1) (Fiordalisi et al. 1996)
Spain 200 6(3) (Saiz et al. 1997) .
countries (1-6%) (Table 1). The high prevalence in
commercial blood donors (5-26%) (Table 2) is probably
due to the increased risk of parenteral acquisition in this
group. The prevalence of GBV-C/HGV anti-E2 anti-
bodies in healthy individuals ranges from 3-15.1 %
(Table 4).
The simultaneous detection of Anti-E2 greatly extends
the ability of RT-PCR to define the epidemiology of
GBV-C/HGV (Table 4). For example, in non-African
countries, 1-2.5% of blood donors is GBV-C/HGV RNA
positive. Using Anti-E2 assays, the same population of
blood donors showed 3-9% seroprevalence. The over-
all prevalence of GBV-C/HGV in non-African blood
donors was 4-16%, compared to 20-30% in Africa
(Table 4). In the high risk group of patients the overall
prevalence of GBV-C/HGV infection ranged from 20 to
89% (Table 4). The combined overall prevalence of
GBV-CIHGV infection is higher in African countries than
in non-African countries (Table 4). The simultaneous
detection of GBV-C/HGV RNA and Anti-E2 may
represent the seroconversion state.
Thus, the total exposure to GBV-C/HGV should take
into account both the number of PCR-positive samples
(Le. viraemic/RNA positive) and anti-E2 positive sam-
ples (Le. previously infected but cleared) in a given
population. GBV-C/HGV infection appears to be a
common infection globally. The reason for the high
prevalence of GBV-C/HGV in blood donors worldwide
and the basis for the racial differences in GBV-C/HGV
infection in blood donor populations are not known.
Whether socio-economic factors are associated with
prevalence of GBV-C/HGV is not known for certain,
although a relationship was noted between GBV-CI
HGV infection and the lack of water-borne sewage
(Tucker et al. 1997). The differences in the prevalence
of detecting GBV-C/HGV infection (Tables 1-4) may
be due to the differences in the sensitivity of the
various PCR protocols and primers (derived from
various regions of the genome) used by various
investigators, and preselection of patients in terms of
status for other viral markers as well as different
patient histories. Further investigations are required to
determine whether genetically distinct isolates from
different geographical regions of the world escape
detection by current PCR methods and anti-E2
assays.
GBV-CIHGV Anti-E2: A protective/neutralizing antibody
and a marker for recovery
Analysis of serial samples for both RNA and anti-E2
suggests that GBV-CIHGV infection follows one of two
paths: acute infection followed by recovery(appearance
of GBV-C/HGV E2 antibody), or acute infection progres-
sing to chronicity (persistence of GBV-C/HGV RNA).
Follow-up of 16 post-transfusion patients for up to
16 years revealed that individuals who develop an anti-
E2 response become GBV-C/HGV-RNAnegative, while
310 © 2000 Blackwell Science Ltd. International Journal of Experimental Pathology. 81. 305-322
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(EI-Zayadi et al. 1999)
(Sathar et al. 1999b)
(Lampe et al. 1997)
(Wang et al. 1997)
(Lamballerie et al. 1996)
(Masuko et al. 1996)
(Tsuda et al. 1996)
(Jarvis et al. 1996)
(Unnen et al. 1996)
(Geroiami et al. 1997)
(Kinoshita et al. 1997)
(Gonzales-Prez et al. 1997)
(Castelling et al. 1998)
(Anastassopoulou et al. 1998)
(Dille et al. 1997)
(Gutierrez et al. 1997)
(Shev et al. 1998)
(Unnen et al. 1996)
(Tacke et al. 1997a)
(Aikawa 1996)
(Roth et al. 1997)
(Dille et al. 1997)
(Pilot-Matias et al. 1996)
(Gutierrez et al. 1997)
(EI-Zayadi et al. 1999)
(Shrestha et al. 1997)
(Scallan et al. 1998)
(Wu et al. 1997)
(Scallan et al. 1998)
(Schlueter et al. 1996)
those who do not develop anti-E2 are persistently
infected (Tacke et al. 1997b). The presence of anti-E2
and the subsequent loss of viraemia have been
confirmed by other investigators (Dille et al. 1997;
Gutierrez et al. 1997; Hassoba et al. 1997). Anti-E2
appears to be long-lasting, circulating antibodies and
once acquired generally tends to persist (Masuko et al.
1996; Lefrere et al. 1997)
In chronic HCV infection the co-existence of E21NS1
antibody and viraemia suggests that anti-E2 is not a
neutralizing/protective antibody, but serves as a marker
of active HCV replication (Yuki et al. 1996). GBV-C/HGV
Anti-E2 on the other hand, has been described as a
marker of viral clearance (recovery/past) and is con-
sidered to be protective against GBV-C/HGV reinfection.
In 54 recipients who underwent orthotopic liver trans-
plantation (OLT), the presence of anti-E2 pre-transplant
was associated with a relatively low rate (15%) of post-
transplantation GBV-C/HGV infection compared to 46%
in anti-E2 negative (pre-transplant) patients (Hassoba
et al. 1998). Post-transplantation immune suppression
apparently had only a minor effect on the prevalence of
anti-E2 in patients who were anti-E2 positive prior to
transplantation (Hassoba et al. 1998). A negative
association between the presence of GBV-C/HGV
RNA and the presence of anti-E2 was found in all
patients tested pre- and post-transplantation, suggesting
viral clearance (Hassoba et al. 1998). Anti-E2 appearsto
be a neutralizing antibody whose presence at the time of
liver transplantation protects against acquisition of GBV-
C/HGV infection post-OLT (Bizollon et al. 1998; Has-
soba et al. 1998; Silini et al. 1998; Tillmann et al. 1998).
No new GBV-C/HGV infections were noted among
subjects with anti-E2, despite ongoing drug use (Tho-
mas et al. 1998).
Site(s) of replication
The site of GBV-C/HGV replication has been an area of
intense interest and remains uncertain. A true hepato-
tropic virus replicates in the liver. GBV-C/HGV is a
positive-stranded f1avivirus whose genomic organization
is similar to HCV, as such replication should proceed via
a negative-strand RNA intermediate, the detection of
which should be possible in the liver. GBV-C/HGV RNA
was detected by RT-PCR in washed hepatocytes of 9/58
(15%) children with chronic viral hepatitis (Lopez-
Alcorocho et al. 1997). Madejon et al. (Madejon et al.
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(Linnen et al. 1996)
(EI-zayadi et al. 1999)
(Sugai et al. 1997)
(Alter et al. 1997a)
(Mphahlele et al. 1998}
(EI-Zayadi et al. 1999)
(SChleicher et al. 1996)
(Francesconi 1997)
(Sugai et al. 1997)
(Yashina et al. 1997)
(Saiz et al. 1997)
(Hwang et al. 1997)
(Alter et al. 1997a)
(Mphahlele et al. 1998)
(Nakatsuji et al. 1996)
(Alter et al. 1997a)
(Wang & Jin 1997)
(Nakatsuji et al. 1996)
(Yashina et al. 1997)
(Dawson et al. 1996)
(Tsuda et al. 1996)
(Shrestha et al. 1997)
(Sathar et al. 1999b)
(Nakatsuji et al. 1996)
(Linnen et al. 1996)
(Fiordalisi et al. 1996)
(Kanda et al. 1997)
(Nishiyama et al. 1999)
(Tangkijvanich et al. 1999)
(Cao et al. 1998)
(Brechot et al. 1998)
(Lightfoot et al. 1997)
(Yoshiba et al. 1995)
(Kanda et al. 1997)
(Heringlake et al. 1996)
(Haydon et al. 1997)
(Sallie et al. 1996)
(Munoz et al. 1999)
(Liu et al. 1999)
Table 4. Reported prevalences of GBV-CIHGV RNA and Anti-E2 antibodies in some published studies
Clinical Group Country n RNA+ (%) Anti-E2+ (%) Exposure (%) References
Blood Donors Japan 200 2(1) 10(5) 12(6) (Tanaka et al. 1998)
Germany 200 5(2.5) 7(9) 33(16.5) (Tacke et al. 1997a)
US 199 3(1.5) 9(4.5) 11(5.5) (Gutierrez et al. 1997)
US 100 1(1) 3(3) 4(4) (Dille et al. 1997)
Spain 200 5(2.5) 28(14) 32(16) (Tacke et al. 1997b)
Sou1h Africa 248 32(12.9) 30(12.1) 52(21.1) (Mphahlele et al. 1999)
Sou1h Africa 232 44(18.9) 35(15.1) 74(31.9) (Sathar et al. 1999b)
Commercial Donors US 711 93(13 .1) 195(27.4) 288(40.5) (Gu1ierrez et al. 1997)
Plasmapheresis Donors US 50 13(26) 17(34) 30(60) (Dille et al. 1997)
West Africa 30 10(33.3) 4(13.3) 14(46.7) (Dille et al. 1997)
IVDU Germany 99 38(38) 41(41) 75(75) (Tacke et al. 1997a)
US 27 1(3.7) 23(85 .2) 24(88.9) (Dille et al. 1997)
US 102 15(14.7) 76 (74.5) 91(89.2) (Gutierrez et al. 1997)
Haemophiliacs Spain 62 22(34%) 20(32) 33(53) (Tacke et al. 1997b)
France 92 16(17.4) 33(35) 47(51) (Gerolami et al. 1997)
Haemodialysis South Africa 70 17(24.3) 18(25.7) 33(47 .1) (Sathar et al. 1999b)
Renal Transplant Germany 221 31(14) 89(40) 118(53) (Stark et al. 1997)
Chronic liver disease South Africa 98 12(12.2) 32(32 .7) 33(47.1) (Sathar et al. 1999b)
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1997) and Saito et al. (Saito et al. 1997) detected GBV-
C/HGV antigenomic RNA in'12113 livers and peripheral
blood mononuclear cells (PBMCs) of one of the same 13
patients examined. Because hepatocytes and PBMCs
are bathed in blood, it is possible that the PCR signal
noted may be due to cell-bound virus rather than active
replication occurring in these cells (Laras et al. 1999).
Using RT-PCR with tagged primers and southem blot
analysis, antigenomic GBV-C/HGV RNA was detected
in 4/6 liver specimens; using in situ hybridization in two
such specimens GBV-CIHGV infection was restricted to
hepatocytes (Seipp et al. 1999). Hepatotropism of GBV-
C/HGV has been demonstrated by in vitro infection of
PBMC and cells of human hepatoma cell lines (Ikeda
et al. 1997; Fogeda et al. 1999; Seipp et al. 1999).
Hepatocytes may not be the only site of viral replication;
antigenomic GBV-CIHGV RNA was also detected in the
mononuclear cell infiltrates in the portal areas of the liver
(Kobayashi et al. 1999). These results suggest that
GBV-C/HGV replicates in the liver.
Using RT-PCR with tagged primers and in vitro
derived templates, Melior et al. (Melior et al. 1998)
were unable to detect antigenomic GBV-C/HGV RNA in
either liver biopsies or in the PBMCs of 20 GBV-C/HGV
infected individuals. Radkowski et al. suggested that
PBMCs may not be the replication site of GBV-C/HGV
(Radkowski et al. 1998). In 5/17 patients undergoing
liver transplantation, GBV-CIHGV RNA was detected in
sera and not in the liver on repeated testing for viral RNA
from different portions of the liver (Fan et al. 1999). In
patients co-infected with GBV-CIHGV and HCV, the
hepatotropism of HCV and not GBV-C/HGV was
consistently proven (Kudo et al. 1997; Laskus et al.
1997; Pessoa et al. 1998). These findings suggest that
GBV-C/HGV is not a hepatotropic virus and that neither
the liver nor PBMCs may be the actual site of GBV-C/
HGV replication.
In their study of six cadaver biopsies from one GBV-C/
HGV positive patient co-Infected with HIV, Mushahwar
et al. (Mushahwar et al. 1998) detected glyceraldehyde-
3-phosphate dehydrogenase (GAP-DH) mRNA and
GBV-C/HGV RNA only in the liver, which was localized
to individual hepatocytes. In multiple cadaver autopsies
of 12 patients (four with AIDS, six HIV positive and two
with end-stage liver disease) (Laskus et al. 1998;
Radkowski et al. 1999), GBV-C/HGV RNA intermedi-
aries were consistently demonstrated in the bone
marrow and spleen. However, these results are difficult
to interpret in immunocompromised patients. In a
preliminary study of 23 cadaver biopsies from four
GBV-C/HGV positive patients who were HIV negative,
the spleen and bone marrow biopsies were uniformly
positive for both negative- and positive-strand GBV-C/
HGV' RNA (Tucker et al. 2000). The authors (Tucker
et al. 2000) concluded that GBV-C/HGV is a Iympho-
tropic virus that replicates primarily in the spleen and
bone marrow. These findings require confirmation using
in situ hybridization and immunohistochemical staining.
Strand-specific detection of RNA is fraught with
problems such as false priming of the incorrect strands
or self-priming related to RNA secondary structure. All of
the strand-specific studies used methods to reduce
false-priming and ·self-priming events viz. chemical
modification of the 3' ends (Madejon et al. 1997; Saito
et al. 1997); conducting cDNA synthesis at high
temperature with the thermostable enzyme (Tth) (Las- .
kus et al. 1997; Tucker et al. 2000); using in vitro derived
templates (Laskus et al. 1997; Melior et al. 1998; Tucker
et al. 2000); using 'tagged' primers (Melior et al. 1998;
Seipp et al. 1999); in situ hybridization of liver biopsies
(Kobayashi et al. 1999; Seipp et al. 1999) and in vitro
infection of human hepatoma cells with GBV-C/HGV
monoinfected serum (Seipp et al. 1999). Only Laskus
et al. (Laskus et al. 1997) and Melior et al. (Melior et al.
1998) qualified their reactions using in vitro derived
templates and provided end point titration data.
GBV-C/HGV infection and liver disease
Most GBV-C/HGV infections appear to be asympto-
matic, transient, and self-limiting, with slight or no
elevation of alanine aminotransferase (ALT) (Alter et al.
1997a; Alter et al. 1997b). Co-infection with GBV-C/
HGV does not alter the clinical course of community-
acquiredhepatitis A, B or C (Alter et al. 1997a; Alter et al.
1997b). Most of these subclinical cases resolve after
loss of serum GBV-C/HGV RNA with a concomitant
appearance of anti-E2 (Dille et al. 1997; Gutierrez et al.
1997). Figure 4 depicts a typical clinical picture of a
patient with acute post-transfusion GBV-C/HGV infec-
tion. To evaluate the clinical course of GBV-CIHGV
infection, patients who were infected with GBV-CIHGV
only were studied by Wang et al. (Wang et al. 1996).
Among 25 such patients who acquired GBV-C/HGV
infection by transfusion, 20 patients who were followed
up at 2-4 week intervals over six months maintained
normal ALT activities. The other five patients showed
only moderate elevations in ALT « 124 IUn) over the
first six months, with no further elevations in the
subsequent follow-up period of two years. In these five
patients, there were no other clinical signs of liver
disease. Jaundice was absent in the 25 patients,
whereas it was present in two out of the seven patients
with HCV co-infection (Wang et al. 1996). GBV-C/HGV
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Figure 4. Clinical picture of a patient with acute post-
transfusion GBV-C/HGV infection (with permission, Hwang
et al. 1999).
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is capable of inducing persistent infection in about 5-
10% of infected individuals. Masuko et al. (Masuko et al.
1996) retrospectively followed eight haemodialysis
patients with GBV-C/HGV infection for 7-16 years. In
two patients, the virus was present at the start of
haemodialysis. One had a history of transfusion, and
GBV-C/HGV RNA persisted over a period of 16 years,
the other cleared GBV-C/HGV RNA after 10 years. In
five patients, GBV-C/HGV RNA was first detected 3-
20 weeks after blood transfusion and persisted for up to
13 years. No elevations in serum ALT or signs of active
liver disease were found in these patients. It would
appear that in many patients infected with GBV-C/HGV,
virus replication could occur without detectable damage
to the liver. GBV-C/HGV transmission to chimpanzees
and tamarins resulted in infection without elevation in
ALT (Bukh et al. 1998). On the contrary, GBV-C/HGV
infection in macaques (Cheng et al. 2000) produced
mildly elevated ALT levels with mild hepatitis and
positive antigenic expression in hepatocytes, suggesting
that GBV-CIHGV may be pathogenic to primates.
A strong association between GBV-C/HGV and
fulminant hepatitis has been suggested (Yoshiba et al.
1995; Heringlake et al. 1996) which may be associated
with a specific strain of GBV-C/HGV (Heringlake et al.
1996). However, these studies did not clearly define
whether GBV-C/HGV was transmitted by the transfu-
sions they received prior to the onset of fulminant
hepatitis. Additional studies by Yoshiba et al. (Yoshiba
et al. 1996) showed that only a few of the fulminant
hepatitis patients studied had received a blood transfu-
sion prior to the onset of fulminant hepatitis. In a similar
study, GBV-C/HGV RNA was detected in 3/15 (20%)
patients with HBV infection and in 3/25 (12%) patients
without markers of hepatitis A-E infection (Tameda etal.
1996). Of the six patients with GBV-C/HGV RNA, only
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three had a history of transfusion and all of these
patients were co-infected with HBV. According to
Tameda et al. (Tameda et al. 1996) these results
indicate a role of GBV-C/HGV in inducing fulminant
hepatitis either by itself or in concert with other hepatitis
viruses. Using real time detection polymerase chain
reaction (RTD-PCR), GBV-C/HGV RNA was measured
serially in the sera of three Japanese patients with non
A-E fulminant hepatitis, none of whom received any
therapeutic transfusions before admission (Inoue et al.
1999). Serum ALT levels paralleled GBV-C/HG RNA in
all three cases and sequence analysis revealed that the
same GBV-C/HGV strain infected the patients during
their entire clinical course, despite plasma exchange
therapy. In one patient, hepatocyte destruction contin-
ued with persistent viraemia, although ALT levels
decreased. The authors (Inoue et al. 1999) concluded
that their assumption of an association of GBV-C/HGV
with fulminant hepatitis in these three patients was
further strengthened by the disappearance or persis-
tence of GBV-C/HGV RNA in serum which appeared to
be linked to the prognosis. However, several other
studies have provided no evidence of an association of
GBV-C/HGV with fulminant hepatitis (Hadziyannis
1997). The discrepancies in the association of GBV-C/
HGV with fulminant hepatitis may be influenced by the
sensitivity of the detection system and the differences in
the GBV-C/HGV infection rates in the different popula-
tions studied. The role of GBV-C/HGV in the aetiology of
fulminant hepatitis remains controversial.
Some investigators have reported histological fea-
tures in liver biopsies of GBV-C/HGV-infected indivi-
duals. Among six chronic hepatitis patients with GBV-C/
HGV RNA only, the histology of the liver samples
revealed chronic active hepatitis in one patient and
chronic persistent hepatitis in five others (Fiordalisi et al.
1996). All patients with chronic hepatitis had elevated
ALT levels between 89 and 478 UJI. In contrast, among
the 11 acute hepatitis cases positive for GBV-C/HGV
RNA, the ALT levels varied between 615 and 2477 U/I.
Colombatto et al. (Colombatto et al. 1997) studied GBV-
C/HGV in 67 patients with liver disease without any
markers for hepatitis A-E. They reported an association
between nonspecific inflammatory bile duct lesions and
elevated cholestatic enzymes (gamma glutamyl trans-
peptidase and alkaline phosphatase) in 50% of patients.
Ross et al. (Ross et al. 1997) showed that GBV-C/HGV
infection might affect the clinical course and outcome
after orthotopic liver transplantation (OLT) by the
development of severe cholestasis , which could result
from bile duct damage and bile duct loss. In a
preliminary study, an association between recurrent or
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de novo GBV-C/HGV infection and severe post-trans-
plant cholestasis and ductopenia was also observed in
the grafts of GBV-C/HGV-positive liver organ transplant
patients (Dhillon et al. 1996). However, in many studies
no correlation between GBV-C/HGV infection and
elevation of cholestatic enzymes were noted. Further
investigations are needed to substantiate these findings.
Manolakopoulos et al. (Manolakopoulos et al. 1998)
found an association between GBV-C/HGV and HCV-
viremia and portal and periportal inflammation. They
reported that the duration of HCV/GBV-C/HGV eo-
infection may be an important factor in the progression
of liver disease and that inflammation with necrosis in
the portal and periportal tracts was significantly higher in
patients with combined viremia compared to those with
HCV infection alone. The authors suggested that GBV-
C/HGV in patients with HCV infection might accelerate
liver injury toward more severe fibrosis in patients with
dual infection. Diamantis et al. (Diamantis et al. 1997)
reported that mild fibrosis correlated with GBV-C/HGV
whilst Francesconi et al. (Francesconi et al. 1997)
observed subtleties in histological appearance in HCV
co-infected patients. However, numerous studies have
shown that in HCV eo-infected individuals, GBV-C/HGV
does not affect HCV replication, HCV RNA concentra-
tion, and liver disease (Tanaka et al. 1996; Bralet et al.
1997; Enomoto et al. 1998; Pawlotsky et al. 1998; Petrik
et al. 1998; Slimane et al. 2000).
During OlT, pre-transplant GBV-C/HGV has been
reported to be associated with post-transplant viraemia
(Fried et al. 1997;·Feucht et al. 1997; Haagsma et al.
1997). In the absence of HBV or HCV in liver transplant
recipients, the prevalence of GBV-C/HGV infection has
no influence on the graft (Haagsma et al. 1997). Berg
et al. (Berg et al. 1996) found a significantly higher
percentage of hepatocellular carcinoma in patients with
pre-Ot,T GBV-C/HGV co-infection compared with
patients with HCV infection alone (5/6 vs. 16/68;
P < 0.01). Bizollon et al. (Bizollon et al. 1998), on the
other hand, showed that the prevalence of hepatocel-
lular carcinoma was not different in patients with pre-
transplantation GBV-C/HGV co-infection or with HCV
infection. In addition, GBV-C/HGV co-infection did not
seem to have a significant impact on the course of HCV
infection after transplantation.
Hepatocarcinogenecity of GBV-C/HGV
GBV-C/HGV RNA was detected in 11/111 (10%) of
cases of hepatocellular carcinoma (HCC) (Kanda et al.
1997). The authors concluded that GBV-C/HGV was
unlikely to be a major aetiological agent of non-B non-C
HCC. In a large series of 503 patients with HCC in
Europe, Brechot et al. (Brechot et al. 1998) demon-
strated a major impact of HBV (19% positive) and HCV
(40%) but not GBV-C/HGV (7%) in HCC. In a study of
167 Black South Africans with HCC and 167 matched
controls, Lightfoot et al. (Lightfoot et al. 1997) showed
that patients infected with GBV-C/HGV did not have an
increased relative risk of developing HCC. In addition,
co-infection with GBV-C/HGV did not further increase
the risk of HCC in patients chronically infected with HBV
and HCV. In a retrospective study of GBV-C/HGV in
formalin-fixed, paraffin-embedded (FFPE) tissues of
HCC patients from various geographical areas (Japan,
Spain, Korea, United States, Japanese Americans in
Hawaii), GBV-C/HGV was neither detected nor was
there any evidence of any association of GBV-C/HGV
with HCC (Abe et al. 1998). In this study HCV genotype
11/1 band HBV were significantly associated with HCC.
In a population-based study of non-Asian patients with
HCC and community controls in Los Angeles, California,
Yuan et al. concluded that GBV-C/HGV infection may
account for approximately 8% of HCC (Yuan et al.
1999). GBV-C/HGV RNA was detected in 12/144 (8.3%)
non-Asian patients with HCC and 5/225 (2%) community
controls. The presence of GBV-C/HGV RNA was
associated with a statistically significant 5.4 fold risk,
which was independent of the effects of HBV and HCV
infections (Yuan et al. 1999). In a hospital-based case-
controlled study the relative risk factor suggested a fair
association between GBV-C/HGV infection and HCC
(Tagger et al. 1997). However, GBV-C/HGV did "not
seem to be a major aetiological agent of HCC because
the population-attributable risk was lower (4%) than
those for HbsAg (52%), HCV RNA (36%) and excessive
alcohol intake (52%) (Tagger et al. 1997). Among
subjects with GBV-C/HGV exposure (RNA and anti-E2
positive) a greater proportion of cases (40%) than
controls (14%) had a transfusion history (Tagger et al.
1997). Hepatocarcinogenicity of GBV-C/HGV is an
important key question that remains controversial.
Extrahepatic manifestations of GBV-C/HG infection
Hepatitis-associated aplastic anaemia is a rare but well-
documented phenomenon, unlikely to be caused by any
of the known hepatitis viruses (Byrnes et al. 1996;
Brown et al. 1997a). In some cases of hepatitis-
associated aplastic anaemia, GBV-C/HGV was the
only aetiological agent detected, even if the patients
had not received any transfusions before diagnosis
(Crespo et al. 1999; Kiem et al. 1997; Zaidi et al. 1996).
Moriyama et al. (Moriyama et al. 1997) detected GBV-CI
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HGV RNA in 5/18 (27.7%) patients with aplastic
anaemia who receiveo blood transfusions before diag-
nosis but not in eight patients who did not receive
transfusions. Similarly, Brown et al. (Brown et al. 1997b)
detected GBV-C/HGV RNA in 26.3% and 23.1% of
patients with aplastic anaemia and multi-transfused
control patients, respectively. Kiem et al. (Kiem et al.
1997) detected GBV-C/HGV RNA in 26.1% of patients
with hepatitis-associated aplastic anaemia and idio-
pathic aplastic anaemia who did not receive transfu-
sions. The authors concluded that although transfusions
are a major source of GBV-C/HGV infection, the high
prevalence in those who did not receive transfusions
suggests an association of GBV-C/HGV with aplastic
anaemia, whether associated with hepatitis or not.
Further studies in serial serum samples and meticulous
evaluation of the disorders associated with the infection
will be needed to prove or disprove a causal association
of GBV-C/HGV and aplastic anaemia.
It is interesting to note that GBV-C/HGV replication
has been consistently shown in bone marrow and
spleen, and not in the lymph nodes and tonsils (Laskus
et al. 1998; Radkowski et al. 1999; Tucker et al. 2000),
suggesting a haematological cell tropism. Because the
genomic organization, structural and biological charac-
teristics of GBV-C/HGV are similar to that of HCV, GBV-
C/HGV has been investigated as a possible aetiological
agent in the development of haematological disorders.
Ongoing GBV-C/HGV infection was detected in 29 of 60
(48%) multi-transfused patients with haematological
malignancies (Skidmore et al. 1997). GBV-C/HGV
prevalence in patients with B-cell non-Hodgkin's lym-
phoma was significantly higher than in healthy controls
(Zignego et al. 1997; Ellenrieder et al. 1998). All patients
were asymptomatic and without clinical or sonographic
signs of chronic liver disease (Ellenrieder et al. 1998).
GBV-C/HGV prevalence in lymphoma or cryoglobuline-
mia patients do not support the hypothesis that this virus
also may play a major role in Iymphomagenesis or in the
production of mixed cryoglobulinemia (Cacoub et al.
1997; Nakamura et al. 1997; Ellenrieder et al. 1998).
Pavlova et al. (Pavlova et al. 1999) investigated two
groups of patients, one with clonal stem cell disease with
long latency period (myelodysplasia, myeloproliferative
disease) and one with malignant haematological dis-
eases (Hodgkin's lymphoma, non-Hodgkin's lymphoma,
acute leukaemia, multiple myeloma). The prevalence of
GBV-C/HGV RNA in the group of oncological cases
(72%) was significantly higher (P = 0.02) than in the
patients with clonal stem cell diseases (28%). A
correlation could not be confirmed between GBV-C/
HGV and liver enzyme levels, blood transfusions,
chemotherapy, or viral co-infection (Pavlova et al.
1999). GBV-C/HGV infection in these patients is most
likely to have originated from exposure to blood
products, and to persist because of deficient immune
surveillance. However, the clinical significance of these
findings with respect to liver dysfunction is not yet clear.
The pathogenetic consequences of GBV-C/HGV infec-
tlon in Iymphoproliferative disorders must be conclu-
sively proven in additional studies.
Viral infections are presumed to trigger auto-immune
processes. Heringlake et al. (Heringlake et al. 1996)
observed that the prevalence of GBV-C/HGV in auto-
immune hepatitis (AIH) type I-Ill was higher (9.8%) than
in blood donors (4.7%). In contrast, patients with viral
hepatitis S, C, and D were more frequently infected with
GBV-C/HGV (16%, 20%, 36%, respectively). In con-
trast, Tribl et al. (Tribl et al. 1999) found a significantly
increased prevalence of GBV-C/HGV in patients with
AIH (11%), HBV.(16%), and HCV (21%) than in healthy
controls (2%). However, it remains unclear whether
infection with GBV-C/HGV has an impact on the course
of disease in patients with AIH. Persistent GBV-C/HGV
RNA detected in 7/36 (19.4%) thalassemic patients was
not associated with significant biochemical evidence of
liver damage (Zemel et al. 1998). Patients with common
variable immunodeficiency (CVID) are prone to unex-
plained chronic hepatitis whilst patients with X-linked
agammaglobulinemia (XLA) who have a similar primary
antibody deficiency are not prone to hepatitis (Morris
et al. 1998). In their study of 78 CVID and 28 XLA
patients, Morris et al. (Morris et al. 1998) concluded that
the high prevalence of GBV-C/HGV viremia is due to the
long-term exposure to blood products and that GBV-C/
HGV does not cause chronic hepatitis in immunocom-
promised XLA patients. In addition, the authors sug-
gested that, in the majority of CVID patients, GBV-C/
HGV is not the cause of chronic non-B or -C hepatitis. In
Japanese leprous patients the prevalence of GBV-C/
HGV was higher (5.2%) than in blood donors (1%)
(Egawa et al. 1996).Tucker et al. (Tucker et al. 1998)
suggested an association with glomerulonephritis, hint-
ing that virus replication may occur in the kidney.
Interferon (IFN) treatment of GBV-CIHGV infection
There are conflicting reports conceming the sensitivity of
GBV-C/HGV to interferon (IFN) therapy. In some studies
it seems to be similar to HCV (Berg et al. 1996; Tanaka
et al. 1996; Orito et al. 1997; Jarvis et al. 1999), but in
others it appears to be independent (McHutchison et al.
1997; Nagayama et al. 1997; Umlauft et al. 1997).
However, the response may be different (Saiz et al.
316 © 2000 Blackwell Science Ltd. International Journal of Experimental PathOlogy, 81, 305-322
Current Status Review
GB virus C/Hepatitis G virus (GBV-CIHGV)
1997). DuringlFN-a therapy, serum GBV-C/HGV RNA
levels decrease in most patients treated, and it may
become undetectable (Tanaka et al. 1996; Martinot et al.
1997; Nagayama et al. 1997; Saiz et al. 1997;
Brandhagen et al. 1999; Jarvis et al. 1999). In only a
small percentage of patients the response is sustained,
and in most cases the GBV-C/HGV RNA concentration
returned to pre-treatment levels after therapy was
stopped (Berg et al. 1996; Tanaka et al. 1996;
Karayiannis et al. 1997; Martinot et al. 1997; Saiz et al.
1997; Pawlotsky et al. 1998). Genotype, viral load, IFN
dose, and the amino acid substitutions in the NS5A
region (designated as the interferon sensitivity determin-
ing region (ISDR)) are considered to be some of the
predictors for the efficacy of IFN therapy on HCV
(Shiratori et al. 1997). However, most researchers
detect no influence of GBV-C/HGV infection in response
to IFN-a in patients with chronic HCV (Tanaka et al.
1996; Martinot et al. 1997; Orito et al. 1997; Saiz et at.'
1997; Kato et al. 1999). No correlation between the
amino acid sequence in the GBV-C/HGV NS5A region
and response to IFN therapy was found, indicating that
the GBV-C/HGV NS5A region.does not act as the ISDR
(Kato et al. 1999). A sustained response is predictable in
patients with a low pre-treatment GBV-C/HGV viral load
(Nagayama et al. 1997; Onto et al. 1997; Saiz et al.
1997; Enomoto et al. 1998; Jarvis et al. 1999).
Conclusions
GBV-C and HGV are closely related Flaviviruses of
human origin. The detection methods for GBV-C/HGV
need to be standardized and subjected to repeated
quality control studies. GBV-C/HGV has a relatively high
prevalence in the general population and a higher
prevalence in certain high-risk groups. Transmission
by blood transfusions, parenterally, sexually and from
infected mothers to tt}eir new-born infants has been
documented, and can induce persistent viraemia in
humans. Most studies on GBV-C/HGV tropism have
been limited to PBMCs and liver biopsies. Clearly,
additional tissues from different organs of non-immuno-
compromised patients need to be studied using highly
specific techniques to resolve the site(s) of replication
for GBV-C/HGV. The role of GBV-C/HGV in human
pathology needs to be examined more thoroughly in the
absence of co-infection with other viruses. More
information about its immune responses against the
viral antigens and the virus pathogenicity is needed to
better understand the clinical significance of G8}i:-C/
HGV. However, some findings suggest that GBV-CI
HGV is involved with some cases of acute and chronic
hepatitis; that GBV-C/HGV may be pathogenic to
primates considered to be appropriate non-human
hosts for viral hepatitis studies; and that GBV-C/HGV
does indeed replicate in human liver. It would be
premature to screen blood donors for GBV-C/HGV and
.exclude a large proportion of blood donors from the
donation pool without solid evidence that GBV-C/HGV is
indeed pathogenic to humans.
Current evidence suggests that other viral agents or
other factors may be responsible for a large majority of
post-transfusion or community-acquired non-A-E hepa-
titis. A new pathogen, namely, Transfusion Transmis-
sible Virus (TTV) has become a new focus of viral
hepatitis research. This DNA non-enveloped virus has
numerous similarities to GBV-C/HGV. Several indepen-
dent studies have cast doubts on the pathogenicity of
TTV. More recently, a novel hepatitis virus code named
SEN-V has been isolated. SEN-V is considered by some
leading researchers in hepatitis, to be the 'best
candidate virus to account for previously unexplained'
hepatitis.' However, no data on SEN-V (The New York
Times, 20th July 1999) has been presented in peer-
reviewed publications.
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It was assumed initially that analysis of the 5' NCR
allowed the discrimination of three major groups that
correlated with the geographic origins of the isolates
and with the analysis of the complete genome sequ-
ences. Based on this assumption, sequence and phylo-
genetic analysis of the 5' non-coding region (5' NCR) of
GBV-C/HGV isolates from the Western and Eastern
Cape Provinces [Tucker et al ., 1999] and the province of
KwaZulu Natal [Sathar et al., 1999] of South Africa
demonstrated the presence of new variants of GBV-C/
HGV in South Africa. Unlike Tucker et al. [1999]
neither major deletions nor additional bands to the
predicted 344bp PCR fragment were observed in any of
the isolates from KwaZulu Natal [Sathar et al., 1999].
Recent evidence suggests that phylogenetic analysis
of the 5'NCR may not always provide an accurate guide
to the relationship of complete genome sequences
[Smith et al. , 2000]. In their thorough analysis of 33
epidemiologically distinct complete or near complete
genomic sequences of GBV-C/HGV, Smith et al . [2000]
provided evidence of the existence of four major
geographically distinct phylogenetic groups that were
equally divergent from the chimpanzee isolate, GBV-
Ctrop [Birkenmeyer et .al ., 1998]. Group 1 included iso-
lates from Ghana, West Africa, and a single Japanese
isolate; Group 2 included isolates from Europe, North
and South America, and Japan; Group 3 included
isolates from Japan and China; and Group 4 included
isolates from southeast Asia [Smith et al., 2000].
Analysis of 5' NCR (positions -388 to 71) and
subfragments of this region, including those previously
identified as reproducing the phylogenetic relation-
ships of group 1 and 2 isolates, provided <70% boot-
strap support for either groups 3 or 4 [Smith et al.,
1997]. However, the variants from KwaZulu Natal
grouped separately from the 5'-NCR sequences of
complete genome sequences for the region -388 to -1
[Smith et al. , 2000]. When 5' NCR sequences of
complete genome sequences for the region 143-442
were analyzed, Group 3 (bootstrap support 83%) and
Group 4 (bootstrap support 71%) isolates are not clearly
differentiated by the phylogenetic analysis of this
© 2001 WILEY-LISS, INC.
region; only the South African isolates grouped sepa-
rately (Fig. 1). In contrast, analysis of a 200-nt
fragment from the center of the E2 gene (positions
1,344-1,543) provides>70% bootstrap support for all
four phylogenetic groupings, while a 600-nt region
(position 994-1,594) provided >98% bootstrap support.
GBV-C/HGV isolates from KwaZulu Natal form an
additional fifth group when E2 sequences for the 350 nt
region (positions 1,146 to 1,495) are compared with the
corresponding region from the complete genome
sequences of all four phylogenetic groups [Smith et al.,
2000]. With the sole exception ofE2 gene, phylogenetie'
analysis of individual genes and subgenomic regions,
including the 5' NCR, failed to consistently produce
congruent phylogenetic trees of the four major groups
that correlate with the geographic origin of the isolates
[Smits et al. , 2000]. Phylogenetic analysis of the E2
gene segment of KZN isolates was shown to be con-
sistent with previous analysis of the 5' NCR [Sathar
et al., 1999], suggesting that these belong to a fifth
group [Smith et al., 2000].
In their proposal that South African GBV-C/HGV
isolates be classified as "Genotype 5," Tucker and
Smuts [2000] did not make reference to the findings of
Smith et al. [2000] nor did they include in their analysis
GBV-C/HGV isolates from the province of KwaZulu
Natal, South Africa [Sathar et al., 1999]. Phylogenetic
analysis of 5'NCR sequences of the "novel" South
African GBV-C/HGV isolates from the provinces of
the Western, and Eastern Cape (excluding the dele-
tants) [Tucker et al. , 1999] and from KwaZulu Natal
[Sathar et al ., 1999], grouped South African isolates as
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Fig. 1. Consensus phylogenetic tree of 5/NCR sequences of GBV-CI
HGV isolates from South Africa and representative published
sequences from GenBanklEMBL. Phylogenetic analysis was carried
out on a 311-bp fragment, positions 143-442 in the GBV-C prototype
isolate (U36380). Maximum likelihood distances between sequences
were calculated using Phylip DNADIST (ts :tv = 3, assuming no rate
an additional fifth group (Fig. 1). The inclusion of
GBV-C/HGV isolates from KwaZulu Natal in the
proposal made by Tucker and Smuts [2000] that South
African isolates be classified as Group 5 or Genotype 5,
will be more representative of isolates from South
Africa.
It would certainly be interesting to obtain the E2 seq-
uences of additional South African isolates. However,
the complete sequence of one or more of the novel
South African isolates would indeed settle the question
of whether or not this is in fact a new phylogenetic
variant.
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variation between sites), and used to produce a neighbour joining tree
using Phylip NEIGHBOR. Bootstrap values (lOO replicates) were
obtained with the SEQBOOT and CONSENSE options of Phylip. The
tree was produced using Treeview version 1.5. KZN= KwaZulu Natal;
A-H= 8 geographical health regions of KwaZulu Natal.
REFERENCES
Birkenmeyer LG, Desai SM, Muerhoff AS, Leary TP, Simons IN,
Montes CC, Mushahwar IK. 1998. Isolation of a GB virus-related
genome from a chimpanzee. J Med VlTOl 56:44-5l.
SatharMA, Soni PN, Pegoraro R, Simmonds P, Smith DB, DhillonAP,
Dusheiko GM. 1999. A new variant of GB virus Clhepatitis G
virus (GBV-C/HGV) from South Africa. Virus Res 64:151-160.
Smith DB, Guceanu N, Davidson F, Jarvis LM, Mokili JLK, Hamid S,
Ludlam CA, Simmonds P. 1997. Discrimination of hepatitis G
viruslGBV-C geographical variants by analysis of the 5' non-
coding region . J Gen Virol 78:1533-1542.
Smith DB, Basaras M, Simon F, Haydon D, Cuceanu N, Prescott L,
Kamenka C, Millband D, Sathar MA, Simmonds P. 2000. Phyla-
genetic analysis of GBV-C/Hepatitis G virus. J Gen Virol 81:769-
780.
Tucker TJ, Smuts H. 2000. GBV-C/HGV Genotypes: Proposed
nomenclature for Genotypes 1-5. J Med Viml 62:82-88.
Tucker TJ, Smuth H, Eickhaus P, Robson SC, Kirsch R. 1999.
Molecular characterisation of the 5' non-eoding region of South
African GBV-C/HGV isolates: major deletion and evidence of a
fourth genotype. J Med Virol 59:52-59.
193
REFERENCES
Abbas, AK, Murphy, KM, Sher, A (1996). Functional diversity of helper T lymphocytes .
Nature 383, 787-793.
Abe, K, Edamoto, Y, Park, YN., Nomura, AM., Taltavull, T.C., Tani, M. and Thung, S.N.
(1998) In situ detection of hepatitis B, C, and G virus nucleic acids in human hepatocellular
carcinoma tissues from different geographic regions. Hepatol. 28, 568-572.
Adams, N.J., Prescott, L.E. , Jarvis, L.M., Lewis, lC.M, McClure, MO., Smith, D.B. and
Simmonds, P . (1998) Detection in chimpanzees of a novel flavivirus related to GB virus
C/hepatitis Gvirus. J. Gen. Virol. 79, 1871-1877.
Aikawa, T., Sugai, Y and Okamoto, H. (1996) Hepatitis C infection indrug abusers with
chronic hepatitis C. N EngL J. Med. 334, 193-194.
Alberti, A, Chemello, 1, Cavaletto, D., Tagger, A , Dal Canton, A , Bizzaro, N., Tagarello, G.
and Ruol, A (1991) Antibody to Hepatitis C virus and liver disease in volunteer blood donors.
Ann. Intern. Med. 1141010-1012.
AlIen, J.P., Litten, RZ., Anton, RF. and Cross, G.M. (1994) Carbohydrate-deficient
. transferrin as a measure of immoderate drinking.Alcohol. Clin. Exp. Res. 18 799-812.
194
Alter, H'J, and Bradley, D.W. (1995) Non-A, non-B hepatitis unrelated to the hepatitis C virus .
(non - ABC). Sem. Liv. Dis. 15, 110-120.
Alter, M.l, Gallagher, M., Morris, T.Y., Moyer, L.A, Meeks , EL., Krawczynski, K., Kim,
IP., Margolis, H. and for the Sentinel Counties Viral Hepatitis Study Team. (1997a) Acute
non-A-E Hepatitis in the United States and the role ofHepatitis G Virus infection. N Eng. J.
Med. 336, 741-746.
Alter, H.l , Nakatsuji, Y., Melpolder, r, Wages, r, Wesley, R, Shih, lW.-K. and Kim, lP.
(1997b) The incidence of transfusion-associated hepatitis G virus infection and its relation to
liver disease. N EngI. J. Med. 336, 747-754.
An, P., Wei, x., li, N., Wu, o.s., Yuhki, land Winkler, C. (1997) Evolutionary analysis of
the 51-terminal region of hepatitis G virus isolated from different regions of China. J. Gen.
Viral. 78,2477-2482.
Anastassopoulou, e.G. , Paraskevis, D., Sypsa, v., Psichogiou, M., Katsoulidou, A ,
Tassopoulos, N., Skoutelis , A , Malliori, M. and Hatzakis, A (1998) Prevalence patterns and
genotypes ofGB Virus ClHepatitis G Virus among imprisoned intravenous drug users. J. Med.
Viral. 56, 246-252.
Anonymous. From the Centers for Disease Control. (1991) Self-induced malaria associated
with malariatherapy for Lyme disease-Texas. J. Am. Med. Ass. 265, 317-318.
195
Arankalle, V.A, Chadha, M.S ., Tsarev,S.A, Emerson, S.u., Risbud, AR, Banerjee, K. and
Purcell, RH (1994) Seroepidemiology of water-borne hepatitis in India and evidence for a
third enterically-transmitted hepatitis agent Proc. Natl. Acad. Sci. USA 91, 3428-3432.
Bengtsson A (2001) The role ofCD30 in atopic disease. Allergy . 56,593-603.
Berg, T., Naumann, U; Fukumoto, T., Bechstein , W.O., Neuhaus, P., Lobeck, H , Hohne, M.
Schreier, E. and Hopf, U. (1996a) GB virus C infection in patients with chronic hepatitis B
and C before and after liver transplantation. Transplan t. 62, 711-714.
Berg, T., Dirla, u, Naumann, u ,Heuft, HG, Kuther, S., Lobeck, H , Schreier, E. and Hopf,
U. (1996b) Responsiveness to interferon alpha treatment in patients with chronic hepatitis C
coinfected with hepatitis Gvirus. J. Hepatol. 25, 763-768.
Bhardwaj, B., Qian, K., Detmer, 1., Mizokami, M., Kolberg, I.A, Urdea, MS., Schlauder,
GG, Linnen, I.M., Kim, IP., Davis, G.L. and Lau, YN. (1997) Detection of GB virus
C/Hepatitis G Virus RNA in serum by reverse transcription polymerase chain reaction.J. Med.
Virol. 52, 92-96.
Birkenmeyer, L.G., Desai, S.M., Muerhoff, AS., Leary, T.P., Simons, i.N., Montes, C.C. and
Mushahwar, IK. (1998) Isolation of a GB virus-related genome from a chimpanzee. J. Med.
Virol. 56, 44-51.
196
Bizollon T., Guichard, S., Ahmed, S.AS., Chevallier, P., Ducerf, C., Sepetjan, M. Baulieux, I
and Trepo, C. (1998) Impact of hepatitis G virus on the course of hepatitis C virus infection
before and after liver transplantation. J. Hepatol. 29, 893-900.
Bourlet, T., Guglielminotti, C., Evrard, M., Bertelot, P., Grattard, F., Fresard, A, Lucht, F.R.
and Pozzetto, B. (1999) Prevalence of GBV-C/Hepatitis G Virus RNA and E2 antibody
among subjects infected with human immunodeficiency virus Type 1 after parenteral or sexual
exposure. J. Med. Virol. 58,373-377.
Bralet, M-P., Roudot-Thoraval, F., Pawlotsky, I .-M., Bastie, A, van Nhieu, IT. , Duval, I,
Dhumeaux, D. and Zafarani, E.-S. (1997) Histopathologic impact of GB virus C infection on
chronic hepatitis C. Gastroenterol. 112, 188-192.
Bradley, D.W., Maynard, lE., Popper, H, Cook, E.H., Ebert, I.W., McCaustland, K.A,
Schalde, C.A and Fields, H.A (1983) Posttransfusion non-A, non-B hepatitis: physico-
chemical properties oftwo distinct agents . J. Infect. Dis. 48254-265.
Brechot, C., Nalpas, B., Courouce, AM., Duhamel, G., Callard , G., Camot, F., Tiollais, P. and
Berthelot, P. (1982) Evidence that hepatitis B virus has a role in liver-cell carcinoma in
alcoholic liver disease. N. Eng. J. Med. 23, 1384-1387.
197
Brechot, C., Degos, F., Lugassy, C., Theirs, v.,Zafarani, E.-S., Franco, D., Bismuth, H. and
Trepo, C., Benhamou, I.P. ,Wands, I. Isselbacher, K ,Tiollas,P.and Berthelot, P. (1985)
Hepatitis B Virus DNA in patients with chronic liver disease and negative tests for hepatitis B
surface antigen. N.Eng. J. M~d. 312, 270-276.
Brechot, c.,Nalpas, B. and Feitelson, M.M. (1996) Interactions between alcohol and hepatitis
viruses in the liver. Hepatitis and chronic liver disease. Clin. Lab . Med. 16 273-287.
Brechot, C., Jaffredo , F., Logorce, D., Gerken, G., Meyer zum Buschenfelde, K ,
Papakonstontinou, A , Hadziyann is S.J., Romoeo, R Colombo, M., Rodes, I., Bruix, J.,
Williams, Rand Naoumov, N. (1998) Impact of HBV, HCV and GBV-C/HGV on
hepatocellular carcinomas in Europe: Results ofa European concerted study. J. HepatoL 29,
173-183 .
Brillanti , S., Barbara, L., Miglioli, M. and Bonino, F. (1989) Hepatitis C virus: a poss ible
cause ofchronic hepatitis in alcoholics. Lancet 1, 1390-13 91.
Brown, D., Powell, A , Morris, A , Rassam, S., Sherlock, S., McIntyre, N., Zukerman, AI.
and Dusheiko, G.M. (1992) Improved diagnosis of chronic Hepatitis C Virus infection by
detection of antibody to multiple epitopes : Confirmation by antibody to synthetic
oligopeptides. J. Med. Virol. 38 167-171.
Brown, K E., Tisdale, 1 , Barrett, J., Dunbar, C.E. and Young, N.S. (1997a) Hepatitis-
associated aplastic anaemia. N Eng. J. Med. 336, 1059-1064.
198
Brown, K. E., Wong, S. and Young, N.S. (1997b) Prevalence of GBV-C/HGV, a novel
"hepatitis" virus in patients with aplastic anaemia. Br. J. Haematol. 97,492-496.
Bukh, land Apgar, CL. (1997) Five new recently discovered (GBV-A) virus species are
indigenous to New World monkeys may constitute a separate genus ofthe Flaviviridae. Viro!.
229,429-436.
Bukh, r. Kim, lP., Govindarajan, S., Apgar, cr., Foung, S.K., Wages, J.Jr., Yun, A.I.,
Shapiro, M , Emerson, S.u. and Purcell, RH. (1998) Experimental infection of chimpanzees
with hepatitis Gvirus and genetic analysis ofthe virus. J. Infect. Dis. 177,855-862.
Byrnes , Ll., Banks, A.T., Piatack, M and Kim, lP. (1996) Hepatitis G associated with
aplastic anaemia. Lancet 348, 472.
Cacoub, P., Frangeul, L. and Musset, L. (1997) Hepatitis G and mixed cryoglobulinemia.Ann.
Intern. Med. 126, 1022.
Cantaloube, IF. , Charrel, RN., Attoui, H., Biagini, P., De Micco, P. and Lamballarie, X.
(1997) Evaluation of four PCR systems amplifying different genomic regions for molecular
diagnosis of GB Virus C infections. J. Virol. Meth. 64, 131-135.
Cao, K., Mizokami, M., Orito, E., Ding, X , Ueda, R, Chen, G., Yu, S.Z. and Tokudome, S.
.(1998) GB virus C/hepatitis G virus infection among patients with hepatocellular carcinoma in
the inshore area ofthe Yangtze River, China. J. Gastroenterol. Hepatol. 13,1241-1248.
199
Castelling, A., Song, E., Sim, 1., Blaauw, D., Heyns, A., Schweizer, R, Margolius , L., Kuun,
E., Field, S., Scoub, B. and Vardas, E. (1998) GB Virus C prevalence in blood donors and
high risk groups for parenterally transmitted agents from Gauteng,in South Africa.
JMed. Virol. 5, 103-108.
Cesaire, R, Martial , J., Maier, H., Kerob-Bauchet, B., Bera, 0., Duchaud, E., Brebion, A and
Pierre-Louis, S. (1999) Infection with GB virus C/hepatitis G virus among blood donors .and
hemophiliacs in Martinique, a Caribbean island. J. Med. Virol. 59, 160-163.
Charrel, RN., Attoui, H., Demicco, P. and Delamballerie, X. (1999) The complete coding
sequence ofa European isolate ofGBV-C hepatitis Gvirus. Biochem. Biophys.Res.Commun.
255,432-437.
Chen, M., Sonnerborg, A., Johansson, B. and Sallberg, M. (1997) Detection of hepatitis G
virus (GB virus C) RNA in human saliva. J. Clin. Microbiol. 35, 973-975.
Cheng, Y., Zhang, W. -Z., Li, J., Li, B., Zhao, J. -M., Gao, R Xin, S. -J., Mao, P. -Y. and Cao,
Y. (2000) Serological and histological findings in infection and transmission ofGBV-C/HGV
to Macaques. J. Med. Virol. 60,28-33.
Choo, Q.L., Kuo, G., Weiner, AJ., Overby, L.R, Bradley, D.W. and Houghton, M (1989)
Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome.
Science 244, 359-364.
200
Colombatto, P ., Randone, A , Civitico, G., Monti Gorin, G., Dolci , L., Medaina, N., Calleri,
G., Oliveri, F., Baldi, M , Tappero, G., Volpes, R , David , E., Verme, G., Smedile, A , Bonino,
F. and Brunetto, M.R (1997) A new hepatitis C virus-like flavivirus in patients with
cryptogenic liver disease associated with elevated GGT and alkaline phosphatase serum levels .
J. Viral. Hepat. 4, 55-60.
Cong, 'M.E., Fried, M.W., Lambert, S., Lopareva, E.N., Zhan, M.Y., Pujol, F.H., Thyagarajan,
S.P., Byun, K.S., Fields, H.A and Khudyakov, YE. (1999) Sequence heterogeneity within
three different regions ofthe hepatitis Gvirus genome. Virol. 255,250-259.
Coutsoudis, A , Pillay, K., Spooner, E., Kuhn , L., Coovadia, H.M. and for the South African
Vitamin A Study group (1999) Influence of infant-feeding patterns on early mother-to-child
transmission ofIDV-1 in Durban, South Africa: a prospective cohort study. Lancet 354,471-
476 .
Craxi, A and Almasio, P. (1996) Diagnostic approach to liver enzyme elevation. J. Hepatol.
25,47-51.
Crespo, J., de las Heras. , Rvero, M., Lozano, I .L., Fabrega, E. and Pons-Romero, F. (1999)
Hepatitis G virus infection as a poss ible causative agent of community-acquired hepatitis and
associated aplastic anaemia. Postgrad. Med. J. 75,159-160.
Dabis , F. and Ekpini, E.R (2002). IDV-l/AIDS and maternal and child health in Africa.
Lancet. 359,2097-2104.
201
Dawson, G.J., Chan, K.H., Cabal, C.M., Yarbough, P.D., Reyes, G.R and Mushahwar, IK. .
(1992) Solid-phase enzyme-linked immunosorbent assay for Heaptitis E virus IgG and IgM
antibodies utilising recombinant antigens and synthetic peptides . J. Virol. Meth. 38, 175-186.
Dawson, G'L, Schlauder, GG, Pilot-Matias, T.l, Thiele, D., Leary, T.P., Murphy, P.,
Rosenblatt, lE., Simmons, J.N., Martinson, F.E.A, Gutierrez, RA, Lentino, lR, Pachucki,
C., Muerhoff, AC., Widell, A, Tegmeier, G, Desai, S.M. and Mushahwar, IK. (1996)
Prevalence studies of GB Virus C infection using reverse transcriptase-polyrrierase chain
reaction. J.Med. Virol. 50,97-103.
Deinhardt, F., Holmes , A W., Capps, RB. and Popper, H. (1967) Studies on the transmission
of human viral hepatitis to marmoset monkeys. Transmission of disease, serial passage and
description ofliver lesions . J. Exp. Med. 125,673-687.
Deinhardt, F., Peterson, D., Cross, G and Wolfe, L., Holmes, A W. (1975) Hepatitis in
marmosets. Am. J. Med. Sci. 270, 73-80.
Deka, N., Sharma, M.D. and Mukerjee, R (1994) Isolation of the novel agent from human
stool samples that is associated with sporadic non-Anon-B hepatitis. J. Virol. 68, 7810-7815.
De Lamballerie, X, Charrell, RN. and Dussol, B. (1996) Hepatitis GB virus C in patients on
haemodialysis. N. Eng/. J. Med. 334, 1549.
202
Dhillon, AP., Savage, K, Kim, IP., Yun, A, Burroughs, AK, Rolles, K and Dusheiko,
G.M. (1996) Hisopathology of hepatitis G virus infection. IX Triennial International
Symposium on viral Hepatitis and Liver Disease, Rome (Abstract)
Diamantis, I.D., Kouroumalis, E., Koulentaki, M., Falserkan, E., Schmd, P.A, Hirsch, HH,
Buhler, H., Gyr, K and Battegay, M. (1997) Influence ofHGV infection on liver disease. Eur.
J. Clin. Microbiol. Infect. Dis. 16,916-919.
Diehl AM. (1989) Alcoholic liver disease. Med. Clin. North. Am. 73, 815-830.
Dille, B.I, Surowy, T.K, Gutierrez, RA, Coleman, P.F., Krigge, M.F., Carrick, RI, Aach,
RD., HoUinger, F.B., Stevens, C.E., Barbosa, L.H, Nemo, G.J., Mosely, W.M., Dawson, G.I
and Mushahwar, I.K (1997) An ELISA for detection of antibodies to the E2 protein of GB
. Virus C. J.Infect.Dis. 175,458-461.
Dusheiko , G.M., Brink, B.A, Conradie, ID., Marimuthu, T. and Sher, R (1989) Regional
revalence of hepatitis B, delta and human immunodeficiency virus in Southern Africa:a large
population survey. Am. J. Epidemiol. 129, 138-145.
Egawa, K, Yukawa, T., Arakawa, S., Nakao, H, Inoue, T., Tanaka, T., Tsuda, F., Okamoto,
H., Miyakawa, Y. and Mayumi, M. (1996) Infection with GB Virus C in leprous patients in
Japan. J. Med. Virol. 49, 110-114.
203
El-Zayadi, AR, Selim, 0., Naito, H , Hess, G. and Ahdy, A (1999) Prevalence of GBV-
C/hepatitis Gvirus viraemia among blood donors, health care personnel, chronic non-B non-C
hepatitis, chronic hepatitis C and hemodialysis patients in Egypt. J.Virol. Meth.80, 53-58.
Ellenrieder, v.. Weidenbach, H, Frickhofen, N., Michel, D., Prummer, 0. , Klatt, v.,Bemas,
0 ., Mertens, T., Adler, G. and Beckh, K. (1998) HCV and HGV in B-cell non-Hodgkin's
lymphoma. J.Hepatol. 28,34-39.
Enomoto, M., Nishiguchi, S., Fukuda, K., Kuroki, T., Tanaka, M., Otani, S., Ogami, M. and
Monna, T. (1998) Characteristics of patients with Hepatitis C Virus with and without GB
Virus C/Hepatitis G Virus eo-infection and efficacy of interferon Alfa. Hepatol. 27, 1388-
1393.
Eparza J and Bhamarapravani N. (2000). Accelerating the development and future viability of
:mv-1 vaccines: why, when , where, and how. Lancet. 355, 2061-2066.
Erker, le., Simons, IN., Muerhoff AS., Leary, T.P., Chalmers, ML., Desai, S.M and
Mushahwar, IK. (1996) Molecular cloning and characterization ofa GB virus C isolate from a
patient with non-A-E hepatitis. J. Gen.Virol. 77,2713-2720.
Esteban, J.L., Esteban, R , Viladomiu, L., Lobez-Talavera, lC., Gonzales, A, Hemandez,
J.M. and Roget, N. (1989) Hepatitis C virus antibodies among risk groups in Spain. Lancet 2,
294-297.
204
Eugenia, Q.R, Ana, Q.R., and Carmen, M. (2001) Investigation of saliva, faeces, urine or
semen samples for the presence ofGBV-C/HGVRNA Eur. J. Epidemiol. 17,271-274.
Fan , X, Xu, Y., Detre, K and Bisceglie, AD. (2002) Direct evidence ofGB Virus C/Hepatitis
G Virus (GBV-C/HGV) superinfection. Elimination of resistant viral strain by donor strain in
a patient undergoing liver transplant. J. Med.Virol. 68, 76-81.
Fan, x, Xu, Y., Solomon, H., Ramrakhiani, S., Neuschwander-Tetri, RA and Di Bisceglie,
AM.. (1999) Is hepatitis G/GB virus-C virus hepatotropic? Detection ofhepatitis G/GB virus-
C viral RNA in liver and serum. J. Med. ViroL 58, 160-164.
Fanson, RG., Osmack, P. and Bisceglie, M (2000) A comparison between the phenol-
chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of
Hepatitis C and GBV-C/hepatitis Gviral RNA from serum. J. Virol. Meth. 8923-27.
Fattovich, G., Vinannte, F., Giustina, G. et al (1996) Serum levels ofsoluble CD 30 in chronic
hepatitis B virus infection. Clin. Exp. Immunol. 103,105-110.
Felsentein, J. (1993) PHYLIP Inference package 3.5 . Department of Genetics, University of
Washington, Seattle:
205
Feray, c., Zignego, AL., Samuel , D., Bismuth, A, Reynes, M, Tiollais, P., Bismuth, H and
Brechot, C. (1990) Persistent hepatitis B virus infection of mononuclear blood cells without
concomitant liver function: the liver transplantation model. Transplant. 49, 1155-1158.
Feucht, HR., Zollner, B., Polywka, S. and Laufs, R. (1996) Vertical transmission of hepatitis
G. Lancet 347,615.
Feucht, HH, Zollner, B., Polywka, S., Knodler, B., Schroter, M. , Nolte, H and Laufs, R.
(1997a) Distribution of Hepatitis G Viraema and antiody response to recombinant proteins
with special regard to risk factors in 709 patients. Hepatol. 26,491-494.
Feucht, H-H, Fischer, L., Sterneck, M ., Knodler, B., Broelsch, C.E. and Laufs, R (1997b) GB
virus C infection and liver transplantation: increased risk of transfusion-transmitted infection.
Blood 63,1695-1697.
Fiordalisi, G., Zanella, I, Mantero, G., Bettinardi, A, Stellini, R, Paraninfo, G., Cadeo, G.
and Primi, D. (1996) High prevalence of GB virus C infection in a group of Italian patients
with hepatitis of unknown etiology. J. Infect. Dis. 174, 181-'183.
Fischler, B., Lara, C., Chen , M., Sonnerborg, A, Nemeth, A and Sallberg, M . (1997) Genetic
evidence for mother-to-infant transmission of hepatitis Gvirus. J. Infect. Dis. 176,281-285.
206
Fogeda, M., Navas, S., Martin, J., Casqueiro, M.., Rodriguez, E., Arocena, C. and Carreno, V.
(1999) In vitro infection of human peripheral blood mononuclear cells by GB virus
C/Hepatitis Gvirus. J. Virol. 73,4052-4061.
Fogeda, M., Lopez-Alcorocho, J.M, Bartolome, J., Arocena, C., Martin, M.G. and Carreno,
V. (2000) Existence of distinct GB Virus C/Hepatitis G virus variants with different tropism.
J. Virol. 747936-7942.
Francesconi,R, Giostra,F., Ballardini,G., Manzin,A, Solforosi,L., Lari,F., Descovich,C.,
Ghetti, S.,Grassi,A, Bianchi,G., Zauli,D.,Clementi,Mand Bianchi,F.B. (1997) Clinical
implications of GBV-C/HGV infection in patients with "HCV-related" chronic hepatitis. J.
Hepatol. 26, 1165-1172.
Fried, M.W., Khudyakov, YE. , Smallwood, G.A, Congm, M.-E., Nichols, B., Diaz, E.S.P.,
Gutekunst, RD., Gordon, R .D., Boyer, T.D. and Fields, H.A (1997) Hepatitis G virus eo-
infection in liver transplantation recipients with chronic hepatitis C and non-viral chronic liver
disease. Hepatol. 25, 1271-1275.
Fujisawa, T., Horiike, N., Michitaa, K. and Onji, M. (2000) Influence ofRNA titre and amino
acid changes in the NS5A region of GB virus C/hepatitis G virus on the effectiveness of
interferon therapy. J. Gastroenterol. Hepatol. 15632-639.
207
Gallian, P., Rodrgues , v., Canataloube, IF., Dessein, H., deMicco, P., Dessein, Al and
deLamballerie, X. (1998) High prevalence of GBV-C/Hepatitis G Virus in a Brazilian
population with Helminth infection. J. Med. Virol. 56, 310-315.
Gartner, RC., Kaul, H., Neutzling, AG., Sauter, M., Mueller-Lantzsch, N. and Kohler, H.
(1999) High prevalence ofhepatitis G virus (HGV) infections in dialysis staff Nephrol. Dial.
Transplan t. 14,406-408.
Gerolami, v.,Haflon, P., Chambost, H., Sicardi, F., Thuret, 1, Planells, R , Halimi, G., Fossat,
C; Michel , G. and Cartouzou , G. (1997) Prevalence of hepatitis G virus RNA in a
monocentric population ofFrench haemophiliacs. Br. J. Haematol. 99,209-214.
Gimenez-Barcons , M., Ibanez, A, Tajahuerce, A , Sanchez-Tapias, IM., Rodes, I , Martinez,
MA and Saiz, le. (1998) Genetic evolution of hepatitis G virus in chronically infected
individual patients. J. Gen. Viral. 79,2623-2629.
Gimenez-Barcons , M , Sanchez-Fueyo, A., Ampurdanes, S., Puig-Basagoiti, F., Guilera, M,
Ibanez, A , Clotet, B., Martinez, M.A, Rodes , J., Saiz, lC. and Sanchez-Tapias, l M. (2000)
Genetic evolution of GB virus C/hepatitis G virus (GBV-C/HGV) under interferon pressure.
Antivir. Res. 46 157-170.
Gonzales-Prez, M.A, Norder, H., Berstrom, A , Lopez, E., Visona, K.A and Magniu, L.O.
(1997) High prevalence of GB Virus C strains genetically related to strains with Asian origin
in Nicaraguan haemophil iacs. J. Med. Virol. 52, 149-155.
208
Goubau, P., Liu, H.F., Goderniaux, E. and Burtonboy, G (1999) Influence of CD4+
lymphocyte counts on GB Virus C/hepatitis G virus carriership in IDV positive individuals . J.
Med. Virol. 57,367-369.
Greentree LB. Malariotherapy and cancer. Med. Hypoth. 7,43-49.
Guilera, M., Saiz, le., Lopez-Labrador, F.X., Olmedo, E., Ampurdanes, S., Forns, x., Bruix,
L, Pares, A, Sanchz-Tapias, IM, Jimenez de Anta, M.T. and Rodes, I (1998) Hepatitis G
virus infection in chronic liver disease. Gut 42 107-111.
Gutierrez, RA, Dawson, GJ., Knigge, M.F., Melvin, S.L., Heyden, C.A, Kyrk, C.R, Young,
C.E., Carrick, RI., Schlauder, GG., Surowy, T.K, Dille, B.I., Coleman, P.F., Thiele, D.L.,
Lentino, J.R, Pachucki, C. and Mushahwar, lK (1997) Seroprevalence of GB Virus C and
persistence ofRNA and antibody. J. Med. Virol. 53, 167-173.
Haagsma, E.B., Cuypers, H..T.M., Gouw, AS.H., Sjerps, M..C., Huizenga, IR, Slooff
MJ.H. and Jansen, P.L.M. (1997) High prevalence of hepatitis G virus after liver
transplantation without apparent influence on long-term graft function. J. HepatoL 26, 921-
925.
Hadziyannis S.J. (1997) Fulminant hepatitis and the new GBV-C flavivirus. J.Viral.Hepatol.
5,15-19.
209
Handa, A and Brown, KE. (2000) GB VlfUS c/hepatitis G virus replicates m human
haematopoietic and vascular endothelial cells. J. Gen. Virol. 81,2461-2468.
Hassoba, HM., Terrrault, N.A, El-Gohary, A , Scheffel, c, Jou, C.K, Brackett, J., Hunt, J.,
Lou, S.C. and Wright, T.L. (1997) Antibody to GBV-C second envelope glycoprotein (Anti-
GBV-C E2):Is it a marker of immunity? J. Med. Virol. 53,354-360.
Hassoba, HM., Pessoa, M.G., Terrrault, N.A, Lewis , N.J., Hayden, M., Hunt, lC., Qiu, X ,
Lou, S.C. and Wright, T.L. (1998) Antienvelope antibodies are protective against GBV-C
reinfection: Evidence from the liver transplant model. J. Med. ViroL 56,253-258.
Haydon, G.H, Jarvis, L.M, Simpson, Kl, Hayes , P.C. and Simmonds, P. (1997) The clinical
significance ofthe detection of hepatitis GBV-C RNA in the serum ofpatients with fulminant,
. presumed viral, hepatitis. J. Viral. Hepatol. 4; 45-49.
Haynes BF. Panteleo G et al (1996). Towards understanding of the correlates of protective
immunity to mvinfection. Science 271, 342-348.
Heimlich, Hl, Chen , XP., Xiao, B.Q., Liu, S.G., Lu, YH, Spletzer, E.G., and Yao,lL.
(1997) . Malariotherapy for mvpatients. Mech. Age. Dev . 93,79-85.
Heringlake, S., Osterkamp, S., Trautwein, c, Tillmarm, HL., Beker, K, Muerhoff S.,
Mushahwar, IK., Hunsmann, G. and Manns , M.P. (1996a) Association between fulminant
hepatic failure and a strain ofGB virus C. Lancet 348, 1626-1629.
210
Heringlake, S., Ti11mann, H.L., Cordes-Temme, P., Trautwein, C., Hunsmann, G. and Manns,
M.P. (1996b) GBV-CIHGV is not the major cause of autoimmune hepatitis. J. Hepatol. 25,
980-984.
Heringlake, S., Ockenga, I, Tillmann, HL., Trautwein, C; Meissner, D., Sto11, MH.I, Jou,
C., Solomon, N., Scmidt, RE. and Manns, M.P. (1998) GB Virus ClHepatitis G Virus
infection: a favorable prognostic factor in human immunodefeciency virus-infected patients?
JiInfect. Dis. 177, 1723-1726.
Higgins, D.G., Bleasby, Al and Fichs, R (1992) Clustal V: improved software for multiple
sequence alignment. CABIOS. 8, 189-191.
Hijikata, M , Shumizu, YK, Kato, H , lwamoto, A, Shih, lW., Alter, HI, Purcell, RH and
Yoshikura, H. (1993) Equilibrium centrifugation studies of hepatitis viruses : Evidence of
circulating immune complexes. J. Virol. 67 1953-1958.
Hino, K , Moriya, T., Ohno, N., Takahahsi, K, Hoshino, H, Ishiyama, N., Katayama, K,
Yoshizawa, Hand Mishiro, S. (1998) Mother-to-infant transmission occurs more frequently
with GB virus C than hepatitis C virus. Arch. Viral. 143, 65-72.
HoIlingsworth, RC., Jameson, L., Minton, J.E., Crowe, M., Curran, R, Rowe, T., Grabowska,
AM., Pillay, D., Irving, W.L. and Ball, lK (1998) GBV-C/HGV coinfection in nrv-i
positive men: Frequent detection ofviral RNA in blood plasma but absence from seminal fluid
plasma. J. Med. Viral. 56,321-326.
211
Hwang, S.l, Lu, RH.., Chan, e.Y, Wang, YJ., Wu, le. and Lee, S.D. (1997) The role of
hepatitis G virus infection in patients with acute posttransfusion hepatitis in Taiwan.
Gastroentero/. 112,1260-1264.
. .
Hwang, S.l, Lu, RH., Chan, C.Y, Chang, F.Y and Lee, S.D. (1999) Detection ofantibodies
to E2-protein of GB virus-C/hepatitis G virus in patients with acute posttransfusion hepatitis.
J. Med. Virol. 57,85-89.
Thanez, A , Gimenez-Barcons, M, Tajahuerce, A, Tural, C., Sierra, G., Clotet, B., Sanchez-
Tapias, J.M., Rodes, L, Martinez, M.A and Saiz, le. (1998) Prevalence and Genotypes of
GB Virus C/Hepatitis G Virus (GBV-CIHGV) and Hepatitic C Among Patients infected with
Human Immunodeficiency Virus: Evidence of GBV-C/HGV sexual transmission. J. Med.
Virol. 55, 293-299.
lkeda, M., Sugiyama, K, Mizutani, T., Tanaka, T., Tanaka, K, Shimotohno, K and Kato, N.
(1997) Hepatitis G virus replication in human cultured cells displaying susceptibility to
hepatitis C virus infection. Biochem. Biophys. Res. Commun. 235, 505-508.
Inoue, K, Yoshiba, M., Sekiyama, K and Kohara, M.. (1999) Possible association between
serum GB virus C RNA level and disease activity in fulminant hepatitis type G. J. HepatoL
30,801-806.
212
Jarvis, L.M, Davidson, F., Hanley, I.P., Yap, P.L., Ludlam, C.A and Simmonds, P. (1996)
Infection with Hepatitis G Virus among recipients of plasma products. Lancet. 348, 1352-
1355 .
Jarvis , L.M., Bell, H , Simmonds, P., Hawkins, A., Hellum, K, Harthug, S., Maeland, A,
Ritland, S., Myrvang, B., von der Lippe, B., Raknerud, N. and Skaug, K. (1999) The effect of
treatment with alpha-interferon on hepatitis G/GBV-C viraemia. The CONSTRUCT Group.
Scand. J. Gastroenterol. 33, 195-200.
Kabelitz, D. and Wesch, D. (2001) Role ofT-lympocytes inHIV infection. Eur. J.Med. Res. 6
169-174.
Kakimi, K , Guidotti, L.G., Koezuka, Y., Chisari, F.V. (20000). Natural killer T cell activation
inhibits hepatitis B virus replication in vivo. I. Exp. Med. 192,921-930.
Kakumu, S., Sato, K, Morishita, T., Anh, T.K, Binh, N.H, Vu Dien, B., Chinh, D.H, Phuc,
N.H, Thinh, N.V., Trinh, L.T. , Yamamoto, N., Nakao, Hand Isomura, S. (1998) Prevalence
of Hepatitis B, Hepatitis C, and Hepatitis GB Virus CIH~patitis G Virus Infections in liver
disease patients and inhabitants in Ho Chi Minh, Vietnam. J. Med. Virol. 54,243-248.
Kanda, T., Yokosuka, 0., Irnzeki, F., Tagawa, M., Ehata, T., Saisho, H. and Omata, M. (1997)
. GB virus C RNA in Japanese patients with hepatocellular carcinoma and cirrhosis. J. Hepatol.
27,464-469.
213
Kao, IR., Ghen, P.I, Hsiang, S.C.,Chen, W. and Chend, D.S. (1996) Phylogenetic analysis
of GB Virus C: Comparison of isolates from Africa, North America, and Taiwan. J. Infect.
Dis. 174,410-413 .
Kao, J.R., Chen, P.I, Chen, W., Hsiang, C.S., Lai, M.Y. and Chen, D.S. (1997a)
Amplification of GB virus-C /hepatitis G virus RNA with primers from different regions of
the viral genome. J. Med. Viral. 51,284-289.
Kao, IR., Chen, W., Chen, P.I, Lai, M.Y., Lin, R Y. and Chen, D.S. (1997b) GB Virus-
C/hepatitis G virus infection in prostitutes: Possible role of sexual transmission.J. Med. Viral.
52,381-384.
Kao, IR., Liu, C.l, Chen, P.l, Chen, W., Hsiang, S.C., Lai, M.Y. and Chen, D.S. (1997c)
Interspousal transmission of GB virus C/hepatitis G virus: comparison with hepatitis C. J.
Med.Viral. 53,348-353.
Karayiannis, P., Petrovic, L.M., Fry, M., Moore, D., Enticott, M., McGarvey, M.I., Scheuer,
P.J. and Thomas, R.c. (1989) Studies ofGB hepatitis agent in tamarins. Hepatol. 9, 186-192.
Katayama, K., Kageyama, T., Fukushi, S., Hoshino, F.B., Kurihara, C., Ishiyama, N.,
Okamura, H. and Oya, A. (1998) Full - length GBV-C/HGV genomes from nine Japanese
isolates:characterisation by comparative analyses. Arch. Viral. 143, 1063-1075.
214
Kato, T., Mizokami, M., Orito, S., Ohba, K., Nakno, T., Kondo, Y., Tanaka, Y., Ueda, R.,
Mukaide, M ., Yasuda, K. & lino, S. (1999) Amino acid substitutions in NS5A region of GB
Virus C and response to interferon therapy. J. Med. Virol. 57,376-382.
Kato, T., M izokami, M., Nakano, T., Orito, E. et al (1998) Heterogeneity in E2 region of
GBV-C/Hepatitis G Virus and Hepatitis C Virus. 1. Med. Virol 55, 109-17.
Kew, M.C. (1996) Progress towards the comprehensive control ofhepatitis B in Africa: a view
from South Africa . Gut 38, S31-S36.
Kew, M.C., Yu, M.C., Kedda, M.A, Coppin, A, Sarkin, A and Hodkinson, 1. (1997) The
relative roles of hepatitis Band C viruses in the etiology of hepatocellular carcinoma in
southern African blacks. Gastroenterol. 112,184-187.
Kew, M.C. (2001) Hepatitis Band C viruses and hepatocellular carcinoma. Clin. Lab. Med.
16,395-406.
Kiem, H .P., Myerson, D. , Storb, R. ., McDonaldG.B., Spurgeon, c.L. and Leisenring, W.
(1997a) Prevalence of hepatitis G virus in patients with aplastic anaemia. Blood 90, 1335-
1336 .
Kiem, HP., Strob, R. and McDonaldG.B. (1997b) Hepatitis -associated aplastic anaemia. N.
Eng. J. Med. 337,424-425.
215
Kim, J.P., Linnen, J., Zhang-Keck, Z.-Y, Beltaev, A , Zhang, Y , Fung, K , Krawczynski, K , '
Alter, M., Lim, M., Hadlock, K , Young, L., Hoover, c., Femandez, 1., Piatack, M , Chong, S.,
Karayiannis, P., Thomas, H.C., Hadziyannis S1., Hess , G, Bradley, D.W., Foung, S.KJ.,
Margolis, H , Shih, J,W., Alter ID. and Fry, K.E. (1997) Viral hepatitis and liver disease. In:
Rizzetto, M., Purcell, RHG1.L. and Verme, G, (Eds.) Viral Hepatitis and Liver Disease, pp.
340-346. Turin: Edizioni Minerva Medica.
Kim, J.P. and Fray, KE. (1998) Structure and molecular virology og HGV (GBV-C). In:
Zuckerman, A1. and Thomas, HC., (Eds) Viral Hepatitis, Second edn . Pp. 417-425. London
Edinburugh Philadelphia Sydney Toronto: Churchill Livingstone
Kinoshita, T , Miyake, K, Nakao, H , Tanaka, T., Tsuda, F., Okamoto, H , Miyakawa, Y and
Mayumi, M. (1997) Molecular investigation of GB Virus C infection in haemophiliacs in
Japan. J. Infect. Dis. 175,454-457.
Kobayashi, M., Tanaka, E., Nakayama, 1., Furuwatari, c., Katsuyama, T, Kawasaki, S. and
Kiyosawa, K. (1999) Detection of GB Virus C/Hepatitis G Virus genome in peripheral blood
mononuclear cells and liver tissue. J. Med. Virol. 57, 114-121.
Kondo, Y , Mizokami, M. and Nakao, TE.A (1997) Prevalence and molecular epidemiology
ofGB virus C/hepatitis Gvirus infection in Mongolia. J. Med. Virol. 52, 143-148.
Kudo , T., Morishima, and Shibata. (1997) Hepatitis G Infection. N. Eng. J. Med. 337, 276-
277.
216
Kumar, S., Tamura, K. and Nei, M. (1993) 1.0. :MEGA: Molecular Evolutionary genetics
Analysis. PA,USA: Pennsylvania State University.
Kunkel, U; Hohne,M, Berg, T., Hopf U., Kekule, U.H, Frosner, G., Pauli, G. and Schre ier,
E. (1998) Quality control study on the performance of GB virus Clhepatitis G virus PCR J.
Hepatol. 28, 978-984.
Kuo, G., Choo, Q.L., Alter, H.J., Gitnick, G.L., Redeker, AG., Purcell, RH., Miyamura, T.,
Dienstag, J.L., Alter, M.l , Stevens, C.E., Tegtmeier, G.E., Bonino, F., Colombo, M., Lee, W.-
S., Kuo, c. Berger, K., Shuster, IR, Overby, L.R, Bradley, D.W., and Houghton, M. (1989)
An assay for circulating antibodies to a major etiologic virus ofhuman non-A, non-B hepatitis.
Science 244, 362-364.
. Kwok, S. and Higuchi, R (1989) Avoiding false positives with PCR Nature 3391, 237-238.
Lampe, E., Saback, F.L., Yoshida, C.F. and Neil, C. (1997) Infection with GB virus
Clhepatitis G virus in Brazilian haemodialysis and hepatitis patients and asymptomatic
individuals. J. Med. Virol. 52,61-67.
Laras, A, Zacharakis, G. and Hadziyannis, S.l (1999) Absence of the negative strand of
GBV-C/HGV RNA from the liver. J. Hepa toL 30,383-388.
217
Laskus, T , Radkowski, M., Wang, L.F., Vargas, H. and Rakela, 1. (1997) Lack ofhepatitis G
virus replication in the livers of patients coinfected with hepatitis C and Gviruses.J. Virol. 71,
7804-7806.
Laskus, T , Radkowski, M , Wang, L.F., Vargas, H. and Rakela, 1 (1998) Detection of
hepatitis G virus replication sites by using highly strand-specific Tth-based reverse
transcriptase PCR J. Virol. 74,3072-3075.
Lau, D.T, Miller, KD., Detmer, J., Kolberg, 1, Herpin, R , Metcalf, lA, Davey, R T and
Hoofnagle, J'H, (1999) Hepatitis G virus and human immunodeficiency virus coinfection:
response to interferon-alpha therapy.J. Infect. Dis. 180, 1334-1337.
Lazdina, D., Hultgren, C., Chen, M , Fischler, B., Weiland, 0 ., Mushahwar, I.K and Sallberg,
M (2000) Humoral and Cellular immune responses to the GB Virus ClHepatitis G Virus
envelope 2 protein. J. Med. Virol. 62,334-344.
Leary, TP., Muerhoff AS., Simons, J.N., Pilot-Matias, r.r, Erker, lC., Chalmers, M.L.,
Schlauder, G.G., Dawson, G.J., Desai, S.M and Mushahwar, IK (1996a) Consensus
oligonucleotide primers for the detection of GB virus C in human cryptogenic hepatitis. J.
Virol. Meth. 56,119-121.
218
Leary, T.P., Muerhoff, AS., Simons, I.N., Pilot-Matias, T.J., Erker, r.c., Chalmers, M.L.,
Schlauder, G.G. and Dawson, G.J. (1996b) Sequence and genomic organisation ofGBV-C: A
novel member of the Flaviviridae associated with human non A-E hepatitis. J. Med. Viro/. 48,
60-67.
Lefrere, J.I., Loiseau, P., Maury, J., Lasserre, J., Mariotti, M., Ravera, N., Lerable, J., Lefevre,
G., Morand-Joubert, L. and Girot, R. (1997) Natural history of GBV-C/hepatitis G virus
infection through the follow-up of GBV-C/hepatitis G virus-infected blood donors and
recipients studied by RNA polymerase chain reaction and anti-E2 serology. Blood 90,3776-
3780.
Lefrere, 1.1., Roudot-Thoraval, F., Morand-Joubert, L., Petit, J.e., Lerable, J., Thauvin, M. and
Mariotti, M. (1999) Carriage of GB Virus C/Hepatitis G Virus RNA Is associated with a
slower immunological, virological, and clinical progression to Human hnrnunodeficiency
virus disease in coinfected persons. .J. Infect. Dis. 179, 783-789.
219
Lefrere, J.J., Lerable, J., Mariotti, M., Bogard, M., Thibault, v., Frangeul, L., Loiseau, P.,
Bouchardeau, F., Laperche, S., Pawlotsky, J.M., Cantaloube, J.F., Biagini, P., de Lamballerie,
X, Izopet, J., Defer, C, Lepot, 1, Poveda, J.D., Dussaix, E., Gerolami, v., Halfon, P., Buffet-
Janvresse, c., Ferec, C., Mercier. B., Marcellin, P., Martinot-Peignoux, M., Gassain, M.
(2000a) Lessons from a multicentre study ofthe detectability ofviral genomes based on a two-
round quality control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain
reaction assay. J. Virol. Meth. 85, 117-124.
Lefrere, J., Sender, A, Mercier, B., Mariotti, M, Pernot, F., Soulie, J., Malvoisin, A, Berry,
M , Gabai, A, Lattes, F ., Galiay, J., Pawlak, C., de Lachaux, v., Chauveau, v., Hreiche, G.,
Larsen, M., Ferec, C., Parnet-Mathieu, F., Roudot-Thoraval, F. and Brossard, Y. (2000b) High
rate of GB virus type CIHGV transmission from mother to infant.possible implications for the
prevalence of infection in blood donors. Transj. 40,602-607.
Lelbach, W.K. (1975) Quantitative aspects of drinking in alcoholic liver cirrhosis. In: Khanna,
J.M, Israel, Y. and Khalant, H, (Eds .) Alcohol liver pathology, pp. 1-18. Toronto: Addiction
Research foundation of Ontario
Lightfoot, K., Skelton M., Kew, M.C., Yu, M.C., Kedda, M.A, Coppin, A and Hodkinson, J.
(1997) Does hepatitis GB virus C infection cause hepatocelluar carcinoma in black Africans?
Hepatol. 26, 740-742.
220
Linnen, I, Wages, I, Zhang-Keck, Z.Y, Fry, KE. , Krawczynski, KZ., Alter, H, Koonin, E.,
Gallagher, M., Alter, M., Hadzivannis, S., Karaviannis, P., Fung, K , Nakatsuji, Y , Shih,
IW.-K, Young, L., Piatak, M., Hoover, K , Femandez, I, Chen, S., Zou, I.-C., Morris, T.,
Hyams, KC., Ismay, S., Lifson, J.D., Hess, G., Foung, S.KH, Thomas, HC., Bradley, D.,
Margolis, Hand Kim, IP. (1996a) Molecular cloning and disease association of hepatitis G
virus: A transfusion transmissible agent 'Science 271, 505-508.
Linnen, J., Wages, I , Zang-Keck, Z.Y, Fry, KE. , Krawczynski, K , Alter, H, Koonin, E.,
Gallagher, M, Alter, M, Hadziyannis, P., Fung, K , Nakatsuji, Y , Shih, W.-K, Young, L.,
Piatak, M., Hoover, c., Fernandez, I , Chen, S., Zou, I-C., Morris, T., Hyarns, KC., Ismay,
S., Lifson, J.D., Hess, G., Foung, S.KJ., Masuko, K , Mitsui, T., Iwano , K., Yamazaki, C.,
Okuda, K , Meguro, T., Murayama, N., Inoue, T., Tsuda, F., Okamoto, H., Miyakawa,Y and
Mayumi, M. (1996b) Infection with Hepatitis GB Virus C in patients on maintenance
haemodialysis.N.Engl.J.Med. 23, 1485-1490.
Lisitsyn, N., Lisitsyn, N. and Wigler M (1993) Cloning the differences between two complex
genomes. Science 259,946-951.
Liu, c.r, Kao, IH, Lai, MY, Chen, P.l, Chu, IS., Chen, W. and Chen, D.S. (1999)
Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in
Taiwan. J. Gastroenterol. Hepatol.14, 352-357.
221
Liu, Z.X., Govindarajan, S., Okamoto, S., Dennert, G. (2000). KK cells cause liver injury and
facilitate the induction ofT cell-mediated immunity to a viral liver infection. J. Immunol. 164,
·480-6486.
Lopez-Alcorocho, J.M., Millan, A, Garcia-Trevijano, E.R., Bartolome, J., Ruiz-Moreno, M.,
Otero, M and Carreno, V. '(1997) Detection of hepatitis GB virus type C RNA in serum and
liver from children with chronic viral hepatitis Band C. Hepatol. 25, 1258-1260.
Madejon, A Fogeda, M., Bartolome, J., Pardo, M. Gonzales , C., Cotonat, T. and Carreno, V.
(1997) GB virus C RNA in serum, liver and peripheral blood mononuclear cells from patients
with chronic hepatitis B, C, and D. Gastroenterol. 113, 573-578.
Manolakopoulos, S., Morris, A, Davies, S., Brown, D., Hajat, S. and Dusheiko, G.M. (1998)
Influence of GB virus C viraemia on the clinical, virological and histological features of early
hepatitis C-related hepatic disease. J. Hepatol. 28, 173-178.
Marshall, R.L., Cockerill, J., Friedman, P., Hayden, M., Hodges, S., Holas, C., Jennings, C,
Jou, C.K., Kratohvil, J.L.T. , Lewis, N., Scheffel, C., Traylor, D. and Wang, L.S.N. (1998) R.
Detection of GB virus C by the RT-PCRLCx system. J. Virol. Meth. 73,99-107.
Martinot, M., Marcellin, P., Boyer, N., Detmer, J., Pouteau, M. Castelnau, C., Degott, C.,
Auperin, A Collins, M. Kolberg, J., Wilber, 1., Benhamou, lP. and Erlinger, S. (1997)
Influence of hepatitis G virus infection on the severity of liver disease and response to
interferon-alpha in patients with chronic hepatitis C. Ann. Intern. Med. 126,874-881.
222
Masuko, K., Mitsui,T., lwano, K., Yamazaki, C., Okuda, K., Meguro, T., Murayama, N. and .
Mayumi, M. (1996) Infection with Hepatitis GB Virus C in patients on maintenance
haemodialysis. NEngl.J.Med. 23, 1485-1490.
McHutchison, J., Nainan , O.v., Alter, MJ ., Sedghi-Vaziri, A , Detmer, J., Collins , M. and
Kolberg, I. (1997) Hepatitis C and G eo-infection : Response to interferon therapy and
quantitative changes in serum HGV-RNA Hepatol. 26,132-1327.
MelIor, J., Haydon, G., Blair, C; Livingstone, W. and Simmonds, P. (1998) Low levels or
absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral
blood mononuclear cells. J. Gen. Virol. 79,705-714.
Melvin, S.L., Dawson, G.I., Garrick, RI., Schlauder, G.G., Heyden, C.A and Mushahwar,
IK. (1998) Biophyscical characterisation of GB virus C from human plasma. J. Virol. Meth.
71147-157.
Mills, P.R, Pennington, T.R., Kay, P., MacSween, RN.M and Watkinson, G. (1979)
Hepatitis Bs antibody in alcoholic cirrhosis. J. Clin. Pathol. 33, 778-782.
Miyamoto, R. , Okamoto, R., Sato, K., Tanaka, T. and Mishiro, S. (1992) Extraordinarily low
density of hepatitis C virus estimated by sucrose density gradient centrifugation and the
polymerase chain reaction. J. Gen. Virol. 73, 715-718.
223
. Moaven, L.D., Hyland, C.A, Young, IF., McCaw, R, Mison, L. and Locamini, S.A (1996)
Prevalence ofhepatitis G in Queensland blood donors. Med.JAustralia 165,369-371.
Mohsen A Het al (2002). Hepatitis C Virus and mv-1 eo-infection, Gut 51, 601-608.
Moriyama, K, Okarnura, T. and Nakano, S. (1997) Hepatitis GB virus C genome in the serum
of aplastic anaemia patients receiving frequent blood transfusions. Br. J. Haematol. 96, 864-
867 .
Morris A, Webster, AD., Brown, D., Harrison, T.I and Dusheiko, G. (1998) GB virus C
infection in patients with primary antibody deficiency. J. Infect. Dis. 177, 1719-1722.
Mosier D E and Chisari F V. (2002). GB Virus C and mortality from mv infection. N Eng J
Med (Letter to the Editor) 346, 377 .
Mphahlele M.I, Lau, G.KK and Carman, W.F. (1998) HGV: the identification, biology and
prevalence ofan orphan virus . Liver 18,143-155.
Mphahlele, M.I, Aspinall, S., Spooner, R and Carman, W.F. (1999) Age related prevalene of
hepatitis Gvirus in South Africans. J. Clin. Pathol. 52, 752-757.
224
Mukaide, M., Mizokami, M.,Orito, E., Ohba, K-I. et al (1997) Three different GB virus
C/hepatitis G virus genotypes.Phylogenetic analysis and genotyping assay based on restriction
fragment length polymorphism. FEBS Lett. 407 , 51-58.
Munoz, S.l, Alter, Hl, Nakatsuji, Y., Shih, J.W., Reddy, RK, Jeffers, L., Schiff, E.R, Reid,
AE., Marrone, A, Rothstein, K, Manzarbeitia, C. and Liang, T.l (1999) The significance of
hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of
unknown etiology. Blood 94,1460-1464.
Muerhoff, AS., Leary, T.P., Simons , IN., Pilot-Matias , T.l, Dawson, G.l, Erker, lC.,
Chalmers, M.L. , Schlauder, G.G., Desai, S.M. and Mushahwar, I.K. (1995) Genomic
organisation ofGB viruses A and B: two new members ofthe Flaviviridae associated with GB
agent hepatitis. J. Virol. 69, (5621):5630.
Muerhoff, AS., Simons, J.N., Leary, T.P., Erker, J.C., Chalmers, M.L., Pilot-Matias, T.J.,
Dawson, G.J., Desai, S.M. and Mushahwar, IK (1996) Sequence heterogeneity within the 5'-
terminal region ofthe hepatitis GB virus C genome and evidence for genotypes. J.Hepatol. 25,
379-384.
Muerhoff, AS., Smith, D.B., Leary, T.P., Erker, J.C., Desai, S.M. and Mushahwar, I.K
(1997) Identification of GB virus C variants by phylogenetic analysis of 5' unstralated and
coding region sequences. J.Virol. 71, 1533-1542.
225
Murthy, RV.R, Muerhoff, AC., Desai, S.M., Natov, S.N., Bouthot, RA, Ruthazer, RR,
Schmid, c.H., Levey, AS. and Mushahwar, IK (1998) Predictors ofGBV-C infection among
patients referred for renal transplantation. Kidney Int. 53, 1769-1774.
Mushahwar, IK Erker, lC., Muerhoff, AC. and Desai, S.M. (1998) Tissue tropism of GBV-
C and HCV in immunocompromised patients and protective immunity of antibodies to GB
virus C second envelope (GBV-C E2) glycoprotein . Hepatol. Clin. 6,23-27.
Mushahwar, IK and Zuckerman IN. (1998) Clinical implications of GB virus C. J. Med.
Virol.56,1-3.
Nagayama, R, Miyake, K and Okamoto, H. (1997) Effect of interferon on GB virus C and
hepatitis C virus in hepatitis patients with the eo-infection. J. Med. Virol. 52, 156-160.
Naito, Hand Abe, K(2001) Genotyping system of GBV-C/HGV type 1 to type 4 by the
polymerase chain reaction using type-specific primers and geographical distribution of viral
genotypes. J. Virol. Meth. 91, 3-9.
Naito, H., Win, KM. and Abe, K (1999) Identification of a novel genotype of hepatitis G
virus in Southeast Asia.J. Clin. Microbiol. 37, 1217-1220.
226
Naito , Hand Abe, K(2001) Genotyping system of GBV-CffiGV type 1 to type 4 by the
polymerase chain reaction using type-specific primers and geographical distribution of viral
genotypes. J. Virol. Meth. 91, 3-9.
Nakamura, S., Takagi, T. and Matsuda, T. (1997) Hepatitis G virus RNA in patients with B-
cell non-Hodgkin's lymphoma. Br. J. HaematoL 98, 1051-1052.
Nakao, H., Okamoto, H, Fukuda, M , Kishimoto, I, et al (1997) Mutation rate of GB Virus
C/hepatitis G virus over the entire genome and in the subgenomic regions Virol. 233,43-50.
Nakatsuji, Y, Shih, W.-K, Tanaka, E., Kiyosawa, K, Wages, J., Kim, IP. and Alter, HI.
(1996) Prevalence and disease association of hepatitis G virus infection in Japan. J. Viral.
Hepat. 36,307-316.
Nalpas, B., Berthelot, P., Thiers, v., Duhamel, G., Courouce, AM., Tiollais, P. and Brechot,
C. (1985) Hepatitis B virus multiplication in the absence ofusual serological markers: a study
of 146 chronic alcoholics. J. Hepatol. 1,89-97.
Nei, J., Matsuda, Y and Yakada, A (1983) Chronic hepatitis induced by alcohol. Dig. Dis.
Sei. 28,207-215.
227
Nerurkar, V.R, Chua, P.K., Hoffinann, P.R, Dashwood, W.M., Shikuma, CM. and
Yanagihara, R (1998) High prevalence of GB Virus C/Hepatitis G Virus infection among
homosexual men infected with Human Immunodeficiency Virus Type 1: Evidence for sexual
transmission. J. Med. Virol. 56, 123-127.
Nishiyama, Y, Hino, K. Sawada, N. and Tsuda, F. (1999) Little contribution ofGB virus C to
the development ofprimary hepatocellular carcinoma in Japan. J. GastroenteroL 34, 494~97:
Nubling, CM. and Lower, J. (1996) GBV-C genomes in a high risk group, in plasma pools,
and intravenous immunoglobulin. Lancet 347,68.
Nubling, CM., Bialleck, H., Fursch, AI., Scharrer, 1, Schramm, W., Seifried, E., Schmidt, .
U; Staszewski, S. and Lower, J. (1997) Frequencies of GB Virus C/Hepatitis G Virus
genomes and specific antibodies in German risk and non-risk populations. J. Med. Virol. 53,
218-224.
Nunnari G, Nigro L, Palmero F., Berger, A, Doerr, H.W.,Russo, R, et al. (2002). Slower
progression of mv-1 infection in HGV eo-infected individuals correlates with an intact T-
Helper-l cytokine profile. Abstract presented at the 9th Conference on Retroviruses and
Opportunistic Infections, Feb 24-28, Seattle, WA
Ockenga, J., Tillmann, H.L., Trautwein, C., Stoll, M., Manns, M.P. and Schmidt, RE. (1997)
Hepatitis Band C inmv infected patients: prevalence and prognosis value. J. Hepatol. 27 18-
24.
228
Ohshima, S., Komatsu, M., Nakane, K., Meng, X.W., Goto, T., Fujii, T., Yoneyama, K.,
Wada, Y., Tobori, F., Mukaide, M , Masamune, O. and Watanabe, S. (2000) Iatrogenic GB
virus C/hepatitis G virus infection in an area endemic for hepatitis C virus. J. Hosp. Infect 44,
179-185.
Okamoto, H., Nakao, H.~ Inoue, T., Fukuda, M., Kishimoto, J. , Lizuka, H., Tsuda, F.,
Miyakawa, Y. and Mayumi, M. (1997) The entire nucleotide sequences of two GB virus
C/hepatitis Gvirus isolates ofdistinct genotypes from Japan. J.Gen.Virol. 78, 737-745.
Orito, E., Mizokami, M, Yasuda, K., Sugihara, K., Nakamura, M., Mukaide, M, Ohba, K.,
Nakano, T., Kato, T., Kondo, Y., Kumada, T., Yeda, R and lino, S. (1997) Interferon-alpha
therapy in patients dually infected with hepatitis C virus GB Virus C/hepatitis C virus-
virological response to HGV and pretreatmentHGV viraemia level. J. Hepatol. 27,603-612.
Orrego, H., Blake, I.E., Blendis, L.O.M., Kapur, B.M. and Israel, Y. (1979) Reliability of
assessment of alcoholic intake based on personal interviews in a liver clinic. Lancet 2, 1354-
1356.
Pares, A, Barrera, I.M., Caballeria, I., Ercilla, G., Bruguera, M, Caballeria, L., Castillo, R
and Rodes, I. (1990) Hepatitis C virus antibodies in chronic alcoholic patients: association
with severity ofliver injury. Hepatol. 12, 1295-1299.
229
Parks, W.P.I and MeInick, I L. (1969) Attempted isolation ofHepatitis viruses in marmosets. .
J. Infect. Dis. 120,539-547.
Pavlova, B.G., Heinz, R , Selim, U , Tuchler, H., Pittermann , E. and Eder, G. (1999)
Association ofGB virus C (GBV-C)/hepatitis Gvirus (HGV) with haematological diseases of
different malignant potential. J. Med. Virol. 57,361-366.
Pawlotsky, J.-M., Roudot-Thoraval, F., Muerhoff, AS., Pellerin, M., Gennanidis, G., Desai,
S.M, Bastie, A , Darthuy, F., Remire, J., Zafarani, E.-S., Soussy, C.-I, Mushahwar, IK. and
Dhumeaux, D. (1998) GB Virus C (GBV-C) infection in patients with chronic hepatitis C.
Influence on liver disease and on hepatitis virus behaviour: Effect of interferon alfa therapy. J.
A/ed. Virol. 54,26-37.
Pessoa, M.G., Temault, N.A, Demter, r, Kolberg, r, CoIlins, M , Hassoba, H.M. and Wright,
T.L. (1998) Quantification ofHepatitis G and C viruses in the liver: Evidence that hepatitis G
virus is not hepatotropic. Hepatol. 27,877-880.
Petrik, 1 , Guella, L., Wight, D.G.D., Pearson, G.M, Hinton, 1 , Parker, H., Allain, I-P. and
Alexander, G.IM. (1998) Hepatic histology in hepatitis C virus carriers coinfected with
hepatitis G virus. Gut 42, 103-106.
230
Pickering, IM., Thomas, HC. and Karayannis, P. (1997) Genetic diversity between hepatitis
G virus isolates: Analysis ofnucleotide variation in the NS3 and putative 'core' peptide genes.
J. Gen. Viral. 78, 53-60.
Pilot-Matias, T.I, Muerhoff, AS., Simons, IN., Leary, T.P., Buijik, S.L., Chalmers, M.L.,
Erker, lC, Dawson, G.J., Desai, S.M. and Mushahwar, IK. (1996a) Identification of
antigenic regions in the GB hepatitis viruses GBV-A,GBV-B and GBV-C. J. Med. Viral. 48,
329-338.
Pilot-Matias, T.I, Carrick, RI, Coleman, P.F., Leary, T.P., Surowy, T.K., Simons, IN.,
Muerhoff AS., Bujik, S.L., Chalmers, ML., Dawson, G.l, Desai, S.M. and Mushahwar, I.K.
(1996b) Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector
system and its utility as a serologic marker. Viral. 225,282-292.
Pujol, F.H, Khudyakov, YE., Devesa, M., Cong, M.E., Loureiro, CL., Blitz, L., Capriles, F.,
Beker, S., Liprandi, F. and Fields, H.A (1998) Hepatitis Gvirus infection in Amerindians and
other Venezuelan high-risk groups. J.ClinMicra. 36,470-474.
Radkowski, M., Wang, L.F., Vargas, H, Rakela, I and Laskus, T. (1998) Lack of evidence
for GB virus C/hepatitis G virus replication in peripheral blood mononuclear cells. J. Hepatol.
28,179-183.
231
Radkowski, M, Wang, L.F., Cianciara, I, Rakela, I and Laskus, T. (1999) Analysis of
hepatitis G virus/GB virus C quasi species and replication sites in human subjects. Biochem.
Biophys. Res. Commu. 258,296-299.
Raengsakulrach B., Ong-Aj-Yooth, L. and Thaiprasert, T. Nilwarangkur, S., Ong-aj-yooth, S.,
Narupiti, S., Thirawuth, v.. Klungthong, C., Snitbhan, R, Vaughn, D.W. (1997) High
prevalence of hepatitis G viraemia among kidney transplant patients in Thailand. J. Med.
Viral. 53,162-166.
Ramshaw lA and Ramsay Al. (2000). The prime boost strategy: exciting prospectives for
improved vaccination. Immunol, Today 21,163-165.
Reyes, G.R, Purdy, M.A, Kim, IP., Luk, K.C., Young, L.M., Fry, K.E. and Bradley, nw
(1990) Isolation ofa cDNA from the virus responsible for enterically transmitted non-A, non-
B hepatitis. Science 247, 1335-1339.
Rey, D., Fraize, S., Vidinic, I, Meyer, P., Fritsch S., Labouret, C., Schmitt, C., Lang, IM. and
Stoll-Keller, F. (1999) High prevalence of GB Virus C/Hepatitis G Virus RNA in patients
infected with Human Immunodeficiency Virus. J.Med. Viral. 57, 75-79.
Ross , RS., Viazov, S., Kruppenbacher, lP., Elsner, S., Sarr, S., Lange, R, Eigler, F.-W. and
Roggendoef, M. (I997) GB Virus C infection in patients who under went liver transplantation.
Liver 17, 238-243.
232
Ross, RS., Viazov, S., Schmitt, D., Schmolke, S., Tacke, M , Ofenloch-Hehnle, B., Holtmann,
M., Muller, Da Villa, G., Oliveira, I.M., Szabo, A , Paladi , N., Kruppenbacher, IP., Philipp,
T.H.. and Roggendorf, M. (1998) Distinct prevalence of antibodies to the E2 protein of GB
Virus C/Hepatitis G Virus in.different parts of the world. J. Med. ViroI..54, 103-106.
Roth, W.K., Waschk, D., Marx, S., Tschander, S., Zeuzems, S., Bialleck, H., Weber, H. and
Siefield, E. (1997) Prevalence of hepatitis G virus its strain variant, the GB agent, in blood
donations and thei r transmission to recipients. Transf 37, 651-656.
Rubio , A , Rwy, C., Sanchez-Quijano, A , Leal, M., Pineda, lA, Lissen, E. & Hess , G. (1997)
Is hepatitis Gvirus transmitted sexually? J. Am. Med. Assoc. 277,532-533 .
Sabin, C.A, Devereux, H., Kinson, Z., Griffioen, A., Brown, D., Dusheiko, G. and Lee, C.A
(1998) Effect of eo-infection with hepatitis G virus on IllV disease progression infection in
hemophiliac men. J. Acquir. Immune. Defic. Syndr. Hum. Reterovirol. 19, 546-548.
Saito, T., Tanaka, K., Kondo, M , Morita, K., Kitamura, T., Kiba, T., Numata, K. and
Sekihara, H. (1997) Plus-and Minus stranded Hepatitis G Virus RNA in liver tissue and in
peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 237,288-291.
Saiz, I.C ., Ampurdanes, S., Olmedo, E., Lopez-Labrador, F.x., Foms, X, Guilera, M.,
Tassies, D., Costa, I, Sanchez-Tapias, IM, Jimenez de Anta, M.T. and Rodes, J. (1997)
Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to
interferon therapy. J. Hepatol. 26,787-793 .
233
Salapuro, M. (1999) Carbohydrate-deficient transferrin as compared to other markesr of
alcoholism: a systematic review. Alcohol 19, 261-271 .
Sallie, R , Shaw, 1. and Mutimer, D. (1996) GBV-C virus and fulminant hepatic failure.
Lancet 347,68.
Sarrazin, c., Roth, W.K. and Zeuzems, S. (1997) Heterosexual transmission of GB virus-
C/hepatitis Gvirus infection. Eur. J. Gastroenterol. Hepatol. 9, 1117-1120.
Sathar, M.A, Soni, P.N., Fernandez-Costa, F., Wittenberg, D.F. and Simjee, AB. (1994)
Racial differences in the prevalence of hepatitis A virus in KwaZululNatal, South Africa. J.
Med. Virol. 44, 9-12 .
Sathar, M.A, Soni, P.N., Naicker, S., Conradie, J., Lockhat, F. and Gouws, E. (1999a) GB
Virus C/Hepatitis G Virus infection in KwaZulu Natal, South Africa. J. Med. Viro!. 59,38-44.
Sathar, M.A, Soni, P.N., Pegoraro, R, Simmonds, P., Smith, D.B., Dhillon, AP. and
Dusheiko, G.M. (1999b) A new variant of GB virus C/hepatitis Gvirus (GBV-C/HGV) from
South Africa. Virus Res. 64, 151-160.
Sathar, M.A, Soni, P.N. and York, D. (2000) GB Virus C/Hepatitis GVirus (GBV-C/HGV):
still looking for a disease. Int. J. Exp. Pathol. 81,1-18.
Sathar, MA and D.F.York. (2001) Group 5: GBV-C/HGV isolates from South Africa. J Med.
Viro!. 65,121-122.
234
Sato, K, Tanaka, T., Okamoto, H., Miyakawa, Y and Mayumi, M. (1996) Association of
circulating hepatitis G virus with lipoproteins for a lack of binding with antibodies. Biochem.
Biophys. Res. Comm. 229, 719-725 .
Sawayama, Y, Hayaashi, J., Etoh, Y, Urabe, H., Minami, K and Kashiwagi, S. (1999)
Hetrosexual transmission ofGB Virus C/Hepatitis G Virus infection to non-intravenous drug-
using female prostitutes in Fkuoka, Japan. Dig. Dis. Sci. 44, 1937-1943.
Scallan, M.F., Clutterbuck, D., Jarvis, L.M, Scott, G.R and Simmonds, P. (1998) Sexual
transmission ofGB Virus C/Hepatitis G Virus. J. Med. Virol. 55,203-208.
Schaade, L., Platzer, C.A, Kleines, M. and Ritter, K (2000) GB virus/hepatitis G virus
infection in medical staff J. Hosp. Infect. 44, 153-154.
Schaluder, GG, Dawson, GJ., Simons, J.N., Pilot-Matias, T.J., Gutierrez, RA, Heynen,
C.A, Knigge, M.F., Kurpiewski, GS., Buijk, S.L., Leary, T.P. Muerhoff, AS., Desai,
S.Mand Mushahwar, lK (1995) Molecular and serologic analysis in the transmission of the
GB hepatitis agents. J. Med. Virol. 46, 81-90.
Schleicher, S., Chaves, RL., Dehmer, T., Gregor, M., Hess, G and Flehming, B. (1996)
Identification of GBV-C hepatitis G RNA in chronic hepatitis C patients . J. Med. Virol. 50,
71-74.
235
Schlueter, V., Schmolke, S., Stark, K., Hess, G., Ofenloch-Haehnle,B. and Engel, AM.
(1996) Reverse transscription-PCR detection ofhepatitis Gvirus. J. Clin. Microbiol. 34,2660-
2664.
Schmidt, u., Kom, K. and Fleckenstein, B. (1996) Molecular evidence for the transmission of
hepatitis Gvirus by blood tranfusion, Lancet 347,909.
Schreier, E., Hohne, M., Kunkel, u., Berg, T. and Hopf, U. (1996) Hepatitis GBV-C
sequences in patients infected with HCV contaminated anti-D immunoglobulin and among i.v.
drug users in Germany. J. Hepatol. 25,385-389.
Schroter, M., Polywka, S., Zollner, B., Schafer, P., Laufs, R. and Feucht, H.-H. (2000)
Detection of TT Virus DNA and GB Virus Type CIHepatitis G Virus RNA in Serum and
Breast Milk: Determination ofMother-to-Infant Transmission. J. Clin. Microbiol. 38745-747.
Schwan, A, Sjolin, S., Trottestam, U and Aronosson, B.(1984).Relapsing Clostridium difficle
enetrocolitis cured by rectal infusion ofnormal faeces. Scand. 1 Infect. Dis. 16,211-215.
Sciammas, R. and Bluestone, lA (1999) TCR cells and viruses. Microbes and Infection 1,
203-212.
Seemayer, C.A, Viazov, S., Philipp, T. and Roggendoef, M. (1998) Detection of GBV-
CIHGV RNA in saliva and serum, but not in urine of infected patients. Infection 26, 39-41 .
236
Seipp, S., Scheidel, M, Hofmann, W.J., Tox, H., Theilmann, L., Goeser, T. and Kallinowski,
B. (1999) Hepatotropism of GB virus C (GBV-C): GBV-C replication in human hepatocytes
ofhuman hepatoma cell lines. J. HepatoL 30, 570-579.
Semprini, AE., Perisco, T., Theirs, v., Oneta, M, Tuveri, R, Serafini, P., Boschini, A ,
Giuntelli, S., Pardi, G. and Brechot, C. (1997) Absence of hepatitis C virus and detection of
hepatitis G virus/Gls virus C RNA sequences in the semen of infected men. J.Infect.Dis. 177,
848-854.
Shev, S., Bjorkman, P., Norkrans, G., Foberg, A, Lindh, G., Lindholm, Weiland, O. and
Widell, A (1998) GBV-CIHGV infection in Hepatitis C Virus-infected differed Swedish
blood donors. J. Med. Virol. 54,75-79.
Shibuya, A , Takeuchi, A, Sakurai, K. and Saigenji, K. (1998) Hepatitis G virus infection
from needle-stick injuries in hospital employees. J. Hospt. Infect. 40,287-290.
Shimanaka, K., Tsutsumi, M., Sawada, M ., Tsuchishima, M., Urashima, S., Ueshima, YK.H.
and Takase, S. (1999) Clinocopathological study ofchronic hepatitis induced by alcohol with
and without hepatitis G virus. Alcohol. Clin. Exp. Res. 23, 29S-32S.
Shimizu, YK., Hijikata, M ., Kiyohara, T., Kitamura, Y and Yoshikura, H. (1999) Replication
ofGB virus C (hepatitis G virus) in interferon-resistant Daudi cells. J. Virol. 73, 8411-8414.
237
Shiratori,Y, Kato, N., Yokosuka, 0 ., Irnzeki, F., Hashiomoto, E., Hayashi, N., Nakamura, A,
Asada, M., Kuroda, H, Tanaka, N., Arakawa, Y , Omata, M and for the Tokyo-Chiba
Hepatitis Research Group. (1997) Predictors for the efficacy of interferon therapy in chronic
hepatitis C virus infection. GastroenteroL 13, 558-566.
Shrestha, S.M., Shrestha, S., Tsuda, F., Sawada, N., Tanaka, T., Okamoto, H., Miyakawa, and
Mayumi, M. (1997) Infection with GB virus C and hepatitis C virus in drug addicts, patients
on maintenance hemodialysis, or with chronic liver disease in Nepal. J. Med. Virol. 53, 157-
161.
Silini, E., Bell., L., Alberti, AB., Asti, M, Cerino, A, Bissolati, M., Rondinara, G., De Carlis,
L., Forti, D., Mondelli, M.D. and Ideo, G. (1998) HGV/GBV-C infection in liver transplant
recipients: antibodies to the viral E2 envelope glycoprotein protect from de novo infection. J.
HepatoL 29, 533-540.
Simmonds, P., Smith, D.B., MCoMish, F., Yap, P.L., Kolberg, 1., Urdea, M.S. and Holmes,
E.C. (1994) Identification of genotypes of hepatitis C virus by sequence comprisons in the
core, El and NS-5 regions. J. Gen. Virol. 75,1053-1061.
Simmonds, P. and Smith, D.B. (1999) Structural constraints on RNA virus evolution. J.Virol.
73, 5787-5794.
238
Simons, IN., Desai, S.M and Mushahwar, IK (1996) The GB Viruses: Isolation,
characterisation, diagnosis and epidemiology. Viral Hepatitis 2, 229-246 .
Simons, IN., Desai, S.M. and Mushahwar, IK (2000) The GB Viruses. Curr. Topics Micro.
Immuno. 242,341-375.
Simons, IN., Pilot-Matias, T.I , Leary, T.P., Dawson, G.I, Desai, S.M, Schlauder, G.G.,
Muerhoff AS., Erker, IC., Buijik, S.L., Chalmers, ML., Van Sant, C.L. and Mushahwar,
IK (1995a) Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc.
Natl. Acad. Sci. USA 921, 3401-3405.
Simons, IN., Leary, T.P., Dawson, G.I, Pilot-Matias, T.J., Muerhoff AS., Schlauder, G.G.,
Desai, S.M. and Mushahwar, IK (1995b) Isolation of novel virus-like sequences associated
with human hepatitis. Nature Medicine 1, 564-569.
Simons, IN., Desai,.S.M., Schultz, D.E., Lemon, S.M. and Mushahwar, K (1996) Translation
initiation in GB viruses A and C: Evidence for internal ribosome entry and implications for
genome organisation. J. Virol. 70,6126-6135.
Skidmore, S.J., Collingham, KE., Harrison, P., Neilson, J.R, Pillay, D. and Milligan, D.W.
(1997) High prevalence ofhepatitis G virus in bone marrow transplant recipients and patients
treated for acute leukemia. Blood. 89,3853-3856.
239
Skidmore, S.J. and Collingham, E. (1999) Prevalence of GB Virus - C/Hepatitis G Virus
infection in an antenatal population. J. Med. Viral. 57,235-237.
Slimane, S.B., Albrecht, J.K., Fang, lW.S., oodman, Z., Mizokami, M, Qian, K., Lau, Y.lN.
and the Hepatitis Interventional Therapy Group (2000) Clinical, virological and histological
implications of GBV virus-C/hepatitis G virus infection in patients with chronic hepatitis C
virus infection: a multicentre study based on 671 patients. J. Viral. Hepatol. 7,51-55.
Smith, D.B., Guceanu, N., Davidson, F., Jarvis, L.M, Mokili, IL.K., Hamid, S., Ludlam, C.A
and Simmonds, P. (1997a) Discrimination of hepatitis G virus/GBV-C geographical variants
by analysis ofthe 5' non-coding region. J . Gen. Viral. 78, 1533-1542.
Smith, D.B., McAllister, J., Casino, C. and Simmonds, P. (1997b) Virus "quasispecies" :
making a mountain out ofa molehill? J Gen Viro178, 1511-1519.
Smith, D.B., Basaras, M., Simon, F., Haydon, D., Cuceanu, N., Prescott, L., Kamenka, C.,
Millband, D., Sathar, MA and Simmonds, P. (2000) Phylogenetic analysis of GBV-
C/Hepatitis G virus. J. Gen. Viral. 81, 769-780.
Sobue, S., Higashi, K., Nakao, H, Takahashi, Y., Itoh, M and Nakajima, K. (1998) Hepatitis
G virus infection in patients with alcoholic liver disease. Alcohol. Clin. Exp. Res. 22, 156S-
160S.
240
Soni, P.N., Tait, D.R., Kenoyer, D.G., Fernandez-Costa, F., Naicker, S., Gopaul, W. and
Simjee, AE. (1993) Hepatitis C virus antibodies among risk groups in a South African area
endemic for hepatitis B virus . J. Med. Viral. 40, 65-68 .
Soni, P.N., Tait, D.R., Gopaul, W., Sathar, M.A and Simjee, AE. (1996) Hepatitis C virus
infection in chronic liver disease in Natal. S. Afr. Med. J. 86, 80-83 .
Sorenson, T.I.A, Orholm, M, Bentsen, K, Hoybye, G., Eghoje, K and Christoffersen, P.
(1984) Prospective evaluation ofalcohol abuse and alcohol liver injury in men as predictors of
development ofalcohol liver injury. Lancet 2,241-244.
Stark, K, Bienzle, u., Hess, G., Engel, AM.., Hegenscheid, B. and Schluter, V. (1996)
Detection of the hepatitis G virus genome among injecting drug users, homosexual and
bisexual men, and blood donors. J. Infect. Dis. 174,1320-1323.
Stark, K, Meyer, C.G., Tacke, M, Schwarz, A, Braun, c., Huzly, D., Engel, A.M., May, 1.
and Bienzle, U. (1997) Hepatitis G virus RNA and hepatitis G virus antibodies in renal
.
transplant recipients: prevalence and risk factors. Transplant. 64,608-612. Stark, K, Doering,
C.D., Bienzle, U; Pauli, G., Hamouda, 0., Engel, AM. and Schreier, E. (1999) Risk and
clearance of GB virusC/hepatitis G virus infection in homosexual men: A longitudinal study.
J. Med. Viral. 59,303-306.
Strimmer, K and von Haeseler, A (1999) Puzzle. Maximum likelihood analysis for
nucleotide, amino acid, and two-state data. 4.02.
241
Sugai, Y , Nakayama, H., Fukuda, M , Sawada, N., Tanaka, T., Tsuda, F., Okamoto, H.,
Miyakawa, Y and Mayumi, M (1997) Infection with GB virus C in patients with chronic
liver disease. J. Med. Virol. 51,175-181.
Susuki , Y , Katayama, K, Fukushi, S., Kageyama, T., Oya, A , Okamura, H., Tanaka, Y ,
Mizokami, M . and Gojobori, T. (1999) Slow evolutionary rate ofGB virus C hepatitis Gvirus.
J. Mol. Evol. 48,383-389.
Tacke, M, Kiyosawa, K., Stark, K , Schlueter, v., Ofenloch-Haehnle, B. and Hess, G. (1997a)
Detection ofantibodies to a putative hepatitis Gvirus envelope protein. Lancet 349,318-320.
Tacke, M , Schmolke, S., Schlueter, v., Sauleda, S., Esteban, J.I, Tanaka, E ., Kiyosawa, K , .
Alter, H.J., Schmitt, U; Hess, G., Ofenloch-Haehnle, B. and Engel, AM. (1997b) Humoral
Immune response to the E2 protein of the Hepatitis G Virus is associated with long-term
recovery from infection and reveals a high frequency of Hepatitis G Virus exposure among
healthy blood donors. Hepatol. 26, 1626-1633.
Tagger, A , Donato, F., Ribero, M.L., Chiesa, R , Tomasoni, v., Portera, G., Gelatti, U;
Albertini , A , Fasola, M , Nardi, G. and and the Brescia HCC Group . (1997) A case-control
study on GB virus C/hepatitis G virus infection and hepatocellular carcinoma. Hepatol. 26,
1653-1657.
242
Takahahsi, K , Kishimoto, 1., Yoshizawa, H, Okamoto, H , Yosahikawa, A. and Mishiro, S.
(1992) p26 Protein and 33-nm particle associated with nucleocapsid of hepatitis C virus
recovered from the circulation of infected hosts. Virol. 191,431-434.
Takahahsi, K , Hijikata, M., Hino, K and Mishiro, S. (1997) Entire polyprotein-ORF
sequences of Japanese GBV-CIHGV isolates: implications for new genotypes. Hepatol. Res.
8, 139~148 .
Tameda, Y, Kosaka, Y , Tagawa, S., Takase, K, Sawada, N., Nakao, H, Tsuda, F., Tanaka,
T., Okamoto, H , Miyakawa, Y and Mayumi, M. (1996) Infection with GB virus C (GBV-C)
in patients with fulminant hepatitis. J. Hepatol. 25, 842-847.
Tamura, K and Nei, M . (1993) Estimation of the number of nucleotide substitutions in the
control region ofmitochondrial DNA in human and chimpanzee. Mol. Bio. Evol. 10, 512-526 .
Tanaka, T., Kato, N., Cho, M.J. and Shimotonho, K (1995) A novel sequence found at the 3'
terminus ofhepatitis C virus genome. Biochem. Biophys. Res. Commun. 215, 744-749.
Tanaka, E., Alter, H.J. and Nakatsuji, Y (1996) Effect of hepatitis G virus infection on
chronic hepatitis C. Ann. Intern. Med. 125, 740-743 .
Tanaka, Y , Mizokami, M, Orito , E., Ohba, K , Kato, T., Kondo, Y , Mboudjeka, 1, Zeneng,
L., Kaptue, L., Bikandou, B., Mpele, ·P., Takehisa, 1., Hayami, M.Y., Suzuki, M. and
Gojobori, T. (1998) African origin ofGB virus C/hepatitis G virus. FEBS Lett. 423, 143-148.
243
Tangkijvanich, P., Hirsch, P., Theamboonlers, A, Nuchprayoon, 1. and Povorawan, Y. (1999) .
Association of hepatitis viruses with hepatocellular carcinoma in Thailand. J. GastroenteroL
34,227-233.
Taylor J, Trimachi C "etal (1991). Efficacy studies on a canarypox rabies recombinant virus.
Vaccine 9,190-193.
Theirs, v., Nakajima, E., Kremsdorf, D., Mack, D., Schellekens, H., Driss, F., Goudeau, A ,
Wands , J., Sninsky, J. and Tiollais, P. (1988) Transmission of hepatitis B from hepatitis B -
seronegative subjects. Lancet 1, 1273-1276.
Thomas, D.L., Vlahov, D., Alter, HI., Hunt, r.c., Marshall, R, Astemborski, I. and Nelson,
K.E. (1998) Association of antibody to GB Virus C (Hepatitis G Virus) with viral clearance
and protection from reinfection. J. Infect. Dis. 177, 539-542.
Tillmann, H.L., Heringlake, S., Trautwein, C., Meissner, D., Nshan, RI.HJ., Kratochvil, I.,
Hunt, J., Qiu, X, Lou, S.c., Pichlmayr, R and Manns, P. (1998) Antibodies against the GB
Virus C envelope 2 protein before liver transplantation protect against GBVirus C de novo
infection. Hepatol. 28,379-384.
Tillmann, HL., Heiken, H, Knapik-Botor, A , Heringale, S., Ocenga, J., Wilber, J.C.,
Goergen, R , Detmer, J., McMorrow, M, 8to11, M., Schmidt, RE. and Manns, MP. (2001)
Infection with GB Vrus C and reduced mortality among Hl'V-infected patients. N. Eng. J.
Med. 345,715-724.
244
Toyoda, H., Fukuda, Y., Hayakawa, T., Takamatsu, J. and Saito, H. (1998) Effect ofGB Virus
ClHepatitis G Virus eoinfection on the course of mv infection in Hemophilia patients in
Japan. J. Acquir. Immune. Defic. Syndr. Hum. Reterovirol. 17,209-213.
Tran, A , Hastier, P., Longo, F., Yang, G., Ouzan, D., Durant, J., Follana, R , Buckley, M.,
Saint-paul, M.C., Doglio,A, Rampal, P. and Benzaken, S. (1998) Lack of influence of
Hepatitis G virus infection on alcohol-related hepatic lesions . Scand. J. Gastroenterol. 33,
1209-1212.
Tribl, B., Schoniger-Hekele, M., Peterman, D., Bakos, S., Penner, E. and Muller, C. (1999)
Prevalence of GBV-C/HGV RNA, virus genotypes, and Anti-E2 antibodies in Autoimmune
Hepatitis .Am. J. Gastroenterol. 94,3336-3340.
. Tseng, C-T. Mikovsky, E., Houghton M , Klimpel , G.R, (2001). Characterisation of liver T-
cell receptor yr/ T-cells obtained from individuals chronically infected with hepatitis C virus
(HCV): evidence for these T cells playing a role in the liver pathology associated with HCV
infections. Hepatol. 33,312-1320.
Tsuda, F., Hadiwandowo, S., Sawada, N., Fukuda, M., Tanaka, T., Okamoto, H., Miyakawa,
Y. and Mayumi, M. (1996) Infection with GB virus C (GBV-C) in patients with chronic liver
disease or on maintenance hemodialysis in Indonesia. J. Med. Virol. 49, 248-252.
245
Tucker, Tl, Louw, S.J., Robson, S.C., Isaacs, S. and Kirsch, R (1997) High prevalence of
GBV-C Hepatitis G Virus infection in a rural South African Population. J. Med. Virol. 53,
225-228.
Tucker, Tl, Smuts, RE.M., Kirsch, K.E., Eickhaus, P., Robson, s.c. and Swanepoel, C.
(1998) The hepatitis G virus/GBV-C is associated with glomerulonephritis. S. Afr. Med. J. 88,
285-286 .
Tucker, TJ., Smuth, R , Eickhaus, P., Robson, S.C. and Kirsch, R (1999) Molecular
characterisation of the 51non-coding region of South African GBV-C/HGV isolates: Major
deletion and evidence ofa fourth genotype. J. Med. Virol. 59, 52-59.
Tucker, TJ. and Smuts, H.E. (2000) GBV-C/HGV Genotypes:Proposed nomenclature for
Genotypes 1-5. J. Med. Virol. 62, 82-83 .
Tucker, r .r. Smuts, RE. , Eedes , C., Knobel, G.D., Eickhaus, P., Robson , S.C. and Kirsch,
RE. (2000) Evidence that the GBV-C/hepatitis G virus is primarily a lymphotropic virus. J.
Med. Virol. 61 , 52-58.
Umlauft, F., Wong, D.T, Underhill, P.A, Oefner, P.l, Jin, L., Urbanek, M., Gruenewald, K.
and Greenberg, H.B. (1997) Hepatitis G virus infection in haemodialysis patients and the
effects ofinterferon treatment. Am. J. Gastroenterol. 92, 1986-1991 .
246
Viazov, S., Rifileman, M., Khoudyakov, Y, Fields, H, Varenholz, C. and Roggendoef M.
(1997a) Genetic heterogeneity of hepatitis Gvirus isolation in different parts of the world. J.
Gen. Virol. 78,577-581.
Viazov, S., Riffelmann, M., Sarr, S., Ballauff, A, Meisel, Hand Roggendorf M. (1997b)
Transmission ofGBV-C/HGV from drug-addicted mothers to their babies. J. Hepatol. 27, 85-
90.
Wands, J.R and Blum, HE. (1991) Hepatitis Band C viruses and alcohol-inducd liver injury.
Hepatol. 14, 730-732.
Wang, J.-T., Tsai, F.-C., Lee, C.-Z., Chen, P.-J., Sheu, r-e, Wang, T.-H and Chen, D.-S.
(1996) A prospective study oftransfusion-transmitted GB virus C infection: Similar frequency
but different clinical presentation compared with hepatitis C virus. Blood. 88, 1881-1886.
Wang, Y, Chen, HS., Fan, M.H, Liu, HL., An, P., Sawada, N., Tanaka, T., Tsuda, F. and
Okamoto, H (1997a) Infection with GB Virus C and Hepatitis C Virus in hemodialysis
patients and blood donors in Beijing. J. Med. Virol. 52, 26-30.
Wang HL. and Jin, D.Y (1997b) Prevalence and genotypes of hepatitis G virus in Chinese
professional blood donors and hepatitis patients. J. Infect. Dis. 175,1229-1233.
247
Wang, H.L. , Hou, YD. and Jin, D-Y. (1997c) Identification ofa single genotype ofhepatitis G
virus by comparison of one complete genome from a healthy carrier with eight from patients
with hepatitis. J. Gen. Virol. 78,3247-3253.
Watt, G. Kantipong, P., Jongsakul, K., de Souza, M.and Burnoff, T. (2001) Passive transfer of
scrub typus plasma to patients with ADIS: a descriptive clinical study. Q.J.M 94,599-607.
Watt, G., Kantipong, P., de Souza, M., Chanbancherd, P ., Jongsakul, K. et al (2000) IllV-1
suppression during acute scrub-typhous infection. Lancet. 356,475-479.
Wejstal, R , Manson, AS., Widell, A and Norkrans, G. (1999) Perinatal transmission of
hepatitis G virus (GB Virus type C) and hepatitis C virus infection-A comparison. Clin. Infect.
Dis. 28,816-821.
Westaway, E.G., Brinton, M.A, Gaidamovich, S.Y., Horzinek, M.C., Igarashi, A , Kaariainen,
L., Lvov, D.K., Poterfield, IS., Russel, P.K. and Trent, D.W. (1985) Flaviviridae. Intervirol.
24 183-192.
White, P.A, Li, Z and Rawlinson, W.D. (1999) Sequence diversity in the 5 UTR region ofGB
virus C/hepatitis G virus assessed using sequencing, hetroduplex mobility analysis and single-
strand conformation polymorphism.1 Virol. Meth. 83, 91-101 .
248
Woitas, RP., Lechmann, M, Jung, G., Kaiser, R ,Sauerdruch, T andSpengler, U. (1997)
CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T
lymphocytes. J. Immunol. 159,1012-1018.
Woitas, RP., Rockstroh, 1.K., Beier, I , Jung, G., Kochan, B., Matz, B., Brackmann, HH,
Sauerbruch, T. and Spengler, U. (2001) Antigen-specific cytokine response to hepatitis C virus
core epitopes in HIV/hepatitis C virus-coinfected patients. AIDS 13 1313-1322.
Wong, S.B.J., Chan, S.H and Ren, E.E.C. (1999) Diversity of GB Virus C/Hepatitis G Virus
isolates in Singapore: Predominance of Group 2A and the Asian Group 3 variant. J. Med.
Virol. 58, 145-153 .
Woolley, I., Valdez, H, Walker, C., Landay, A , Zdunek, D., Hess, G. and Lederman, MM.
(1998) Hepatitis G Virus RNA is common in AIDS patients' plasma but is not associated with
abnormal liver function tests or other clinical syndromes. J. Acquir. Immune. Defic. Syndr.
Hum. Reterovirol. 19,408-412.
Worobey M and Holmes EC (2001) Homologous recombination in GB Virus Hepatitis G
virus Mol. Bioi. Evol. 18:254-261 .
Wright, T.L., Mamish, D., Combs, c, Kim, M., Donegan , E., Ferrel, L., Lake, 1., Roberts , 1.
and Ascher, N.L. (1992) Hepatitis B virus and apparent fulminant non-A, non-B hepatitis .
Lancet 339952-955.
249
Wu IC., Sheng, W.Y, Huang, YH., Hwang, S.l and Lee, S.D. (1997) Prevalence and risk
factor analysis ofGBV-C/HGVinfection in prostitutes. J. Med. ViroL 52,83-85.
Xiang, I , Klinzman, D., McLinden, I , Schmidt, W.N., LaBrecque, D.R, Gish, Rand
Stapleton, IT. (1998) Characterization of hepatitis G virus (GB-C virus) particles: evidence
for a nucleocapsid and expression of sequences upstream ofthe El protein. J. Virol. 72,2738-
2744.
Xiang, I , Daniels, K.J., Soli, D.R, Schmidt, W.N., Labrecque, D.R. and Stapleton, IT. (1999)
Visualization and characterization of GB virus-C particles: evidence for a nucleocapsid. J.
Viral. Hepa t. 1, 16-22.
Xiang, J., Wunschmann, S., Schmidt, W., Shao, I and Stapleton, J.T. (2000) Full length GB
Virus C {Hepatitis G Virus) RNA transcripts are infectious in primary CD4-positive T cells. J.
Virol. 74,9125-9133.
Xiang, I , Wunschmann, S., Diekema, D.I, Klinzman, D., Patrick, K.D., George, S.L. and
Stapleton, IT. (2001) Effect of coinfection with GB Virus C on survival among patients with
HIV infection. N. Engl. J. Med. 345, 707-714.
Yashina, T.L., Favorov, M.O., Khudyakov, Y E.,Fields, H.A, Znoiko, 0 .0., Shkurko, T.V.,
Bonafonte, T., Sevall, IS., Agopain, MS. and Peter, lB. (1997) Detection ofhepatitis Gvirus
{HGV) RNAclinical characteristics ofacute HGV infection. J. Infect Dis. 175, 1302-1307.
250
Yeo, AE.T., Matsumoto, A, Hisada, M, Shih, 1.W., Alter, HI, Goedert, 1.1. and of the .
Multicenter Hemophilia Chorot Study (2000) Effect of Hepatitis G virus infection on
progression ofmY infection in patients with Haemophilia. Ann. Intern. Med. 132,959-963.
Yoshiba, M., Okamoto, M. and Mishiro, S. (1995) Dtection of the GBV-C hepatitis virus
genome in serum from patients with fulminant hepatitis of unknown etiology. Lancet 346,
1131-1132.:
Yuan, IM., Govindarajan, S., Ross, RK. and Vu, M.C. (1999) Chronic infection with
hepatitis G virus in relation to hepatocellular carcinoma among non-Asians in Los Angeles
County, California. Cancer 86,936-943 .
Yuki, N., Hayashi, N., Kasahara, A, Hagiwara, H, Mita, E., Ohkawa, K., Katayama, K.,
Fusamoto, H and Kamada, T. (1996) Quantitative analysis of antiody to hepatitis C virus
envelope 2 glycoprotein in patients with chronic hepatitis C virus infection. Hepatol. 23,947-
952.
Zaidi Y., Chapman, C.S. and Myint, S. (1996) Aplastic anaemia after HGV infection. Lancet
348,471-472.
Zanetti, AR, Tanzi, E., Romano, L., Principi, N., Zuin, G., Minola, E., Zaparoli, B., Palmieri,
M, Martin, A , Ghisotti, D., Friedman, P., Hunt, 1. and Laffler, T. (1997) The Lombardy
Study Group on vertical/perinatal hepatitis viruses transmission ofGBV-C virus.JMed.Virol.
54, 107-111.
251
Zarski, I .P., Bohn, B., Bastie, A, Pawlotsky, JM., Baud, M., Bost-Bezeaux, F., Tran van
Nhieu, J, Seigneurin, I.M., Buffet, C. and Dhumeaux, D. (1998) Characteristics of patients
with dual infection by hepatitis Band C viruses. J. Hepatol. 28,27-33.
.Zemel, R, Dickman, R, Tamary, H., Bukh, J, Zaizov, R and Tur-Kaspa, R (1998) Viremia,
genetic heterogeneity, and immunity to hepatitis G/GB-C virus in multiply transfused patients
with thalassemia. Transfus. 38,301-306.
Zetterman RK. (1990) Autoimmunity and alcoholic liver disease. Am. J. Med. 89,127-128.
Zhang, Z.x., Milich, D.R, Peterson, D.L., Birkett, A, Schvarcz, R, Weiland, o. and Sallberg,
M (1997) Interferon -alfa traetment induces delayed CD4+ proliferative responses to the
hepatitis C virus non strustural 3 protein regardless of the outcome of therapy. J. Infect. Dis.
1751294-1301.
Zignego, AL., Foschi, M., Laffi, G., Monti, M., Careccia, G., Romanelli, RG., De Majo, e.,
Mazzanti, R, Buzzelli, G., La Villa, G. and Gentilini, P. (1994) "Inapparent" Hepatitis B virus
infection and Hepatitis C virus replication in alcoholc subjects with and without liver disease.
Hepatol. 19577-582.
Zignego, AL., Giannini, C., Gentilini, P., Bellesi, G., Hadziyannis, S. and Ferri, C. (1997)
Could HGV infection be implicated in lymphomagenesis? Br. J. Haematol. 98, 778-779.
Zuckerman, AJ (1977) Chronicle ofVIRAL hepatitis. Bull. Hyg. Trop. Dis. 54, 113.
Zuckerman, AJ. (1996) Alphabet of hepatitis viruses. Lancet 347,558-559.
252
